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Abstract
Aims This thesis investigated the health and supportive care needs of surgical lung cancer
patients to address gaps in the evidence base and inform future service developments. Addi-
tionally, the prognostic significance of smoking behaviour was investigated.
Methods Semi-structured interviews were conducted with 29 surgical (VATS and thoraco-
tomy) lung cancer patients to explore health, functioning, smoking, satisfaction with recovery
and preferences for a tailored rehabilitation programme. Interviews were analysed using frame-
work approach. Systematic literature searches were conducted to review evidence of the asso-
ciation between smoking history or continued smoking after diagnosis and prognosis. Survival
estimates were combined where possible using a random effect inverse variance model.
Results Most participants experienced difficulty during recovery. Breathlessness and pain
emerged as dominant health challenges. Participants were open to being offered smoking ces-
sation support. From 78 and 10 studies, preliminary evidence was found that both smoking
history and continued smoking are associated with prognosis, respectively. Analyses indicated
that smoking-associated increased risk may be mediated through cancer-related pathways.
Conclusions Many surgical lung cancer patients’ supportive care needs are not being met.
Well developed treatments and services for management of breathlessness, pain and smoking
cessation may improve quality of life and health outcomes after lung cancer surgery, and require
further testing.
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CHAPTER
ONE
INTRODUCTION
1.1 Thesis aims and outline
The aim of this thesis is to investigate key issues surrounding the health and supportive care
needs of lung cancer patients treated with surgery for curative intent. It has been recognised
that lung cancer receives less research attention than other cancers,[1] and there are gaps in
the evidence base regarding the supportive care needs of this population. The investigations
reported in this thesis were conducted with the intention of addressing some of these gaps, and to
aid tailoring of supportive care to the needs of this patient group in future service developments.
Within other areas of medicine, rehabilitation programmes form an important part of supportive
care, for example cardiac, stroke or pulmonary rehabilitation.[2–4] In addition to describing
the health and supportive care needs of patients during the first year after surgery, patients’
attitudes towards health behaviour change and also preferences regarding the content and format
of a tailored rehabilitation programme are also explored. Although the causal role of smoking
in the development of lung cancer is well known, there is no consensus regarding prognostic
significance of smoking history, or of continued smoking after diagnosis. As understanding the
22
CHAPTER 1. INTRODUCTION
prognostic significance of smoking is relevant to patient counselling and rehabilitation, this was
also investigated by means of two systematic reviews of the evidence relating to these areas.
I will now summarise the aim and content of each chapter of this thesis to help orientate the
reader, and to explain how I have addressed these issues of investigation.
The aim of Chapter 1 is to introduce the broad topics that this thesis refers to. Using the
latest available statistics, the current epidemiological profile of lung cancer is presented, along
with predictions for growth of the lung cancer survivor population over the next three decades.
A brief overview of the processes involved in thoracotomy and video assisted thoracic surgery
(VATS) is presented, along with treatments that are commonly used in conjunction with surgery.
Next, I present an overview of what is already known regarding specific issues that underpin
the investigations presented in this thesis, namely health and functioning of surgical lung cancer
patients and health behaviours with a focus on smoking. I then summarise some of the landmark
developments that have occurred within cancer services over the past two decades and describe
key activities that have been ongoing as a result of government strategy to improve the care
of cancer survivors in general. Finally, I outline the rationale for developing supportive care
services for surgical lung cancer patients and summarise the thesis aims.
Chapter 2 - 4 presents a qualitative interview study conducted with surgical lung cancer patients
recruited from Birmingham Heartlands Hospital. This study had four aims. First, participants’
experiences of health and functioning during the first year after surgery are explored, in order
to understand the main challenges that these patients face during this time and identify potential
needs to be addressed by supportive care services. Second, participants’ attitudes towards smok-
ing and smoking cessation, and the role of the NHS in providing support for smoking cessation
as part of the cancer care pathway is investigated. Third, with participants that received standard
care, attitudes towards recovery, supportive care received and preferences for the content and
format of a tailored rehabilitation programme are explored. Fourth, with those who participated
in a rehabilitation programme that was being piloted at the time of the qualitative interview
study, attitudes towards recovery, supportive care received as part of the programme and design
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changes needed to improve tailoring are explored. The interview findings related to each of
these aims are discussed in the context of other relevant published studies and suggestions for a
rehabilitation programme are presented.
Chapter 5 investigates the relationship between smoking history and the prognosis of lung can-
cer by means of a systematic review, meta-analysis and meta-regression using longitudinal ob-
servational data. There are many studies that have reported observational data on the relation-
ship between smoking history and prognosis, but results are mixed and a review is warranted.
Longitudinal observational studies are the best evidence available to consider this relationship,
although allow inference of association only rather than confirmation of a causal link. It is
biologically plausible that smoking history may confer a greater risk of disease progression,
cancer-related death or death due to co-morbid disease. Mediation of risk through pathways re-
lated or unrelated to cancer is investigated along with the importance of recency and heaviness
of smoking history.
Chapter 6 aims to investigate the case for smoking cessation support as an integral part of
surgical lung cancer patient care. Specifically, based on similar methods to the review reported
in chapter 5, the association between continued smoking and prognosis is investigated by means
of a systematic review with meta-analysis. This review has been published by the BMJ in
January 2010. In the absence of randomised controlled trials of smoking cessation interventions
with lung cancer patients that measure prognostic outcomes, this relationship is also investigated
using data from longitudinal observational studies. Indications that smoking cessation even
at this late stage could be beneficial to prognosis would be an important message to give to
patients, and would strengthen the case for smoking cessation support to be an integral part of
cancer care.
Finally, the aim of chapter 7 is to bring together the findings of the studies reported in chapter 2
- 6 to draw overarching conclusions and make recommendations for future research.
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1.2 How cancer develops
Cancer is initiated by critical changes to the genome of an individual cell.[5] Once initiated,
these pre-neoplastic lesions are understood to move through distinct phases in which a tumour
mass develops and then spreads to colonise other parts of the body, a process known as metas-
tasis.[6] The biological processes involved from genetic change through to development of the
neoplastic and metastatic phenotypes are many and diverse, and not completely understood.
However, rapid advances in research and technology are leading to ever more detailed under-
standings, and driving forward development of more effective treatments.[7]
In 2000, Hanahan and Weiberg published a seminal peer-reviewed work proposing that in or-
der to develop and spread a tumour must acquires six functional capabilities, the so called ‘six
hallmarks of cancer.’[8] Although different tumour types may gain these capabilities through
different mechanisms, tumour survival and development is dependent on these capabilities of
evading apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals, sus-
tained angiogenesis, limitless replicative potential and tissue invasion & metastasis.[8]
Genetic drivers of lung cancer development are thought to primarily involve mutation of genes
that encode for the epidermal growth factor receptor (EGFR) and K-Ras proteins. Mutations
of genes coding for EGFR are more commonly associated with non-smoking related lung tu-
mours,[9] and are thought to lead to over-expression or activation of the EGFR receptor.[10]
Activation of the EGFR pathway plays an important role in cell proliferation, apoptosis, an-
giogenesis and invasion.[9] The ras gene family encodes for membrane bound GTPase binding
proteins that regulate cell growth, differentiation and apoptosis, and mutations may lead to
deregulation of these processes.[11, 12] Other frequent mutations associated with lung cancer,
as well as other tumours, are of genes encoding the tumour suppressor protein p53 and the
vascular endothelial growth factor (VEGF) signal protein.[13]
25
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1.3 Epidemiology of lung cancer
1.3.1 Incidence and histological classification of lung tumours
In the UK, the annual incidence of lung cancer is second only to breast cancer, and in 2010 ac-
counted for over 42 000 new cancer diagnoses.[14] Histological classification of lung tumours
fall into two main categories; non-small cell lung cancer (NSCLC) and small cell lung can-
cer (SCLC). NSCLC accounts for around 85% of incident lung tumours,[15, 16] and can be
sub-divided into three main histological types: squamous cell carcinoma (35-45% of NSCLC
tumours), adenocarcinoma (35-40% of NSCLC tumours) or large cell carcinoma (around 10%
of NSCLC tumours).[17] Generally, squamous cell tumours arise from cells that are located
within the central bronchi, whereas adenocarinoma and large cell tumours are located periph-
erally.[18] Small cell carcinoma arises from neuroendocrine cells located more centrally within
lung tissue and is the most aggressive histological type of tumour.[19] Historically, incidence
rates have been highest for squamous cell carcinoma.[18] However, during the 1970s and 1980s,
the incidence of squamous cell carcinoma began to decrease whereas incidence of adenocarci-
noma increased.[20, 21] It is thought that this change in trend may have been partly due to the
introduction of porous wrapping paper and perforated filters for manufactured cigarettes which
allowed deeper inhalation of smoke.[18, 22, 23] Other rarer histological types of lung cancer
include adenosquamous, sarcomatoid, carcinoid and salivary gland lung tumours.[17, 24]
1.3.2 Risk factors for the development of lung cancer
Smoking is the main risk factor for lung cancer, increasing risk of developing all main histo-
logical sub-types.[25, 26] In countries which have seen a high prevalence of smoking, currently
around 90% of lung cancer diagnoses are attributable to smoking.[27] Smoking is most strongly
associated with the development of small cell carcinoma and squamous cell carcinoma, fol-
lowed by large cell and adenocarcinoma.[26] The risk of lung cancer associated with smoking
26
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has most commonly been studied in terms of lung cancer death, rather than lung cancer inci-
dence.[23, 28–31] Over the past 50 years, the age-adjusted risk of death from lung cancer in
men and women who smoke has increased as successive cohorts have started to smoke earlier
in their lifetime, and people have developed more regular and heavier smoking behaviours.[23]
The earliest evidence regarding the size of increased risk came from men, as smoking behaviour
became established earlier in men than in women.[32] In the past there has been uncertainty as
to whether the risk of death is as great for women who smoke as it is for men, as women were not
yet demonstrating the same burden of risk.[23] However, a recent US study found that women
have now ‘caught up’ with men in terms of risk. Age-adjusted estimates based on current smok-
ers aged 55 years and above between 2000-2010 showed that men had a 27 fold increased risk
of dying from lung cancer and for women the increased risk was 26 fold compared to never
smokers (men RR 27.32 (24.30, 30.70), women RR 26.18 (23.65, 28.98)).[23]
Other environmental risk factors for the development of a lung tumour include exposure to as-
bestos, ionising radiation and air pollution.[27] Although these environmental factors increase
the risk of developing a lung tumour, host susceptibility has also long been recognised as being
important.[33] Not all who are exposed to risk factors develop lung cancer, and evidence from
case-control and cohort studies show that family history of lung cancer predicts risk.[27, 34]
Racial disparity of incidence relative to smoking prevalence is particularly notable for African-
American males, and it is thought that this group may carry genetic susceptibility to the car-
cinogenic effects of tobacco smoke.[27, 35]
1.3.3 Temporal trends of lung cancer incidence
Lung cancer incidence has changed dramatically within demographic strata over the 20th cen-
tury, largely based on changes in smoking prevalence 20-30 years previously.[27, 36, 37] In
the first two decades of the twentieth century lung cancer was a rare disease. However, inci-
dence began to rise sharply in men in the 1930s until the 1950s, after which it began to steadily
fall. Females followed with a rise in incidence that began in the 1960s and as yet, continues to
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climb.[27] Currently, more men than women develop lung cancer: in 2010, a total of 23 175
men were diagnosed with a lung tumour whereas 18 851 female cases were recorded in the
UK.[14] It is predicted that over the coming years incidence in women will begin to outstrip
incidence in men.[27, 38]
The rise in incidence seen since the 1930s has mainly been in the older age groups.[39] In-
cidence rate remained relatively low for people in their 40s and 50s. However, incidence in
people diagnosed above 60 years of age increased.[39] Over the past decade, there has been a
marginal decrease in incidence rates in men for most age groups, apart from those age 70-79
years who have seen a more marked decline. Today, incidence is highest in age 80 or above
(see figure 1.1).[14] For women, every 10-year birth cohort from age 60 upwards has seen a
steady increase in incidence over the past decade, most markedly so in those aged 60-69 and
80+. Again, incidence is highest in women aged 80 or above (see figure 1.2).[14]
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Figure 1.1: European age-standardised incidence rates per 100,000 population in males by age in Great
Britain. [Source: Cancer research UK, cancer statistics]
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Figure 1.2: European age-standardised incidence rates per 100,000 population in female by age in Great
Britain. [Source: Cancer research UK, cancer statistics]
1.3.4 Predicted future prevalence of lung cancer survivors
1.3.5 Survival rates
Lung cancer is the largest cause of cancer death, accounting for 22% of all cancer deaths in
the UK in 2010.[41] Unlike other cancers, 5-year survival rates in the UK have shown only
marginal improvement over the past four decades, and survival rates are lower than most other
European countries as well as Australia and Canada.[42, 43] Of the 21 most common cancers,
lung cancer has the second lowest survival rate, with around 30% of patients surviving for one
year and 8% for 5 years.[41]
Histological cell types of lung tumour grow at different rates, and faster growing tumours have
poorer survival rates.[18] A lung tumour is thought to be detectable after 30 cell division cy-
cles. However, symptoms usually arise later than this and diagnosis is often delayed. Fatality
occurs after 40 cycles.[39] Small cell tumours are the fastest growing tumour, doubling monthly
whereas squamous cell tumours double every 3 months and adenocarcinoma doubles every six
29
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Figure 1.3: Population pyramid for England and Wales, mid 2011. [Source: Office for National
Statistics][40]
months.[39] As such, small cell tumours progress from being detectable to causing death within
6 months - 1 year, whereas this occurs within 1-2 years and 2-4 years for squamous cell and
adenocarcinoma tumours respectively.[39]
Treatment with surgery, radiotherapy or chemotherapy significantly increases survival.[44] Cur-
rently, over 70% of lung cancer tumours are diagnosed at an advanced stage and are unable to
receive curative treatment.[14] However, around 20-30% of NSCLC tumours are diagnosed at
a stage eligible for surgery, and the 5-year survival of this group can be as high as 73%.[45]
In addition to tumour stage, a number of other factors are taken into account before surgical
treatment is decided upon, such as a patients’ age, co-morbidity and performance status (see
section 1.4).[46, 47] Not all patients with potentially operable tumours are fit for surgery, and
on average 14% of lung cancer patients in Great Britain and Northern Ireland underwent radical
surgery in 2010.[48] Most cases of small cell lung cancer are diagnosed in advanced stages.
Treatment with chemotherapy or radiotherapy can extend survival for those in early stages.
However, given the aggressive nature of the disease the prognostic benefit is small.[46]
Looking in more detail at lung cancer survival rates within demographic stratum some patterns
can be seen, particularly for age and socio-economic group. In 2010, 5-year age-standardised
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Figure 1.4: Five-year relative survival rates by age and gender.
(Average relative survival for years 2005-2009, data for females aged 15-39 not available. [Source:
Cancer research UK, cancer statistics])
survival rates for men and women in the UK were both low at 6%. When looking at men
and women combined, relative survival rates decrease with increasing age (see figure 1.4).[49]
Relative survival takes into account deaths from other causes, as the survival rate is calculated
relative to the number of deaths that would be expected in corresponding demographic strata in
the general population. Therefore, this difference represents an excess risk of death due to lung
cancer rather than being explained by normal age-related increased risk of death.[50, 51]
Inequalities in survival by socio-economic status have also been reported, particularly in men.
A recent UK population-based study reported a significant 1.4% difference in relative survival
between men in the highest and those in the lowest strata of deprivation, who were diagnosed
between 1986 and 1990.[52] Although this number is small, given the large number of men
who are diagnosed with lung cancer each year this results in an important rise in the number of
deaths within more deprived groups.[49] The deprivation gap between women was smaller and
non-significant.[52] Socio-economic inequalities in survival may be due to a number of factors,
including later presentation [44], lower probability of receiving timely active treatment [53] and
lower rates of use of the NHS in deprived groups.[54, 55]
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1.3.5.1 Lung cancer staging systems
Treatment is strongly indicated by stage at diagnosis, which describes the extent to which a
tumour has developed and spread. A patients’ tumour may be staged based on clinical ob-
servations, for example using imaging or bronchoscopic investigations or on pathological in-
vestigation.[46] There have been a number of iterations of the classification system of tumour
stage.[45] Classification of a NSCLC tumour is based on assessment of T (tumour), N (node)
and M (metastasis) components, and tumours are further classified into five stage groups based
on the size and positioning of the tumour, extent of metastasis to regional lymph nodes and to
distant sites (see table 1.1 for description of TNM classifications, and table 1.2 for description
of stage grouping). This staging system has some applicability to SCLC, but often a tumour is
simply classed as being of ‘limited’ or ‘extensive’ stage.[56] Survival differs by stage at diag-
nosis. A recent study based on more than 81 000 patients from 19 countries reported survival
rates based on clinical or pathological staging. For NSCLC, five year survival rates ranged from
43 - 73% for patients diagnosed with a stage I tumour, 25-46% for patients diagnosed in stage
II, 7-9% for patients diagnosed in stage III and ranged from 2-13% for patients diagnosed with
a stage IV tumour.[45] In contrast, 25% of patients diagnosed with limited stage SCLC survive
for 2 years, and less than 5% of patients survive for 5 years with extensive SCLC.[41]
1.3.6 The prognostic significance of smoking exposure for surgical lung
cancer patients
The single most important arbiter of prognosis is receipt of curative treatment, which is largely
determined by tumour stage at diagnosis.[57] The main stay of curative treatment for lung
cancer is surgery.[46, 47] Although successful surgery increases survival, rates are still lower
than in corresponding demographic strata of the general population.[58] Some studies have de-
scribed the risk of various causes of death after lung cancer surgery. It is likely that risk of
death after surgery remains higher than the general population due to risk of disease relapse and
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Table 1.1: Definitions for T, N and M descriptors: International Associations for the Study of Lung
Cancer (IASLC) lung cancer staging classification
TX Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial
washings but not visualized by imaging or bronchoscopy
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour 3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of
invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)
T1a Tumour 2 cm in greatest dimension
T1b Tumour 2 cm but 3 cm in greatest dimension
T2 Tumour 3 cm but 7 cm or tumour with any of the following features (T2 tumours with these features are classified
T2a if 5 cm) Involves main bronchus, 2 cm distal to the carina. Invades visceral pleura associated with atelectasis or
obstructive pneumonitis that extends to the hilar region but does not involve the entire lung
T2a Tumour 3 cm but 5 cm in greatest dimension
T2b Tumour 5 cm but 7 cm in greatest dimension
T3 Tumour 7 cm or one that directly invades any of the following: chest wall (including superior sulcus tumours),
diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumour in the main bronchus 2 cm distal to
the carina but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire
lung or separate tumour nodule(s) in the same lobe
T4 Tumour of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal
nerve, oesophagus, vertebral body, carina; separate tumour nodule(s) in a different ipsilateral lobe
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including
involvement by direct extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular
lymph node(s)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Separate tumour nodule(s) in a contralateral lobe; tumour with pleural nodules or malignant pleural (or pericardial)
effusion
M1b Distant metastasis
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Table 1.2: TNM stage groupings based on IASLC classification
Occult tumour TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1a, b N0 M0
Stage IB T2a N0 M0
Stage IIA T1a, b N1 M0
T2a N1 M0
T2b N0 M0
Stage IIB T2b N1 M0
T3 N0 M0
Stage IIIA T1,T2 N2 M0
T3 N1, N2 M0
T4 N0, N1 M0
Stage IIIB T4 N2 M0
Any T N3 M0
Stage IV Any T Any N M1a, b
cancer related death, although studies indicate that up to half of patients treated with surgery die
from co-morbid disease.[59–64] Complications after surgery also elevate the risk of death, and
in particular surgical lung cancer patients are at an increased risk of dying from major infec-
tions.[65] The causal role of smoking in the development of lung cancer is widely recognised,
but it is also possible that smoking exposure (i.e. smoking history or continued smoking af-
ter diagnosis) may be associated with prognostic outcome after lung cancer surgery by either
increasing the risk of disease progression and death from cancer, or by increasing the risk of
non-cancer related death due to co-morbid disease.[31, 61] Smokers are also more likely to
develop complications after lung cancer surgery.[66] However, the prognostic significance of
smoking exposure for surgical lung cancer patients has not been reviewed. Chapter 5 and 6
of this thesis report two systematic reviews that sought to investigate the relationship between
smoking exposure and prognosis, focusing on prognostic significance of smoking history and
of continued smoking after diagnosis, respectively.
1.4 Lung cancer treatment
1.4.1 Curative treatment
The mainstay of curative treatment for lung cancer is surgery. Radical surgery is considered
firstline treatment for patients with NSCLC who are diagnosed between stage I-IIIa.[46, 47]
Patients with stage IIIa NSCLC tumours may also undergo surgery with curative intent, al-
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though this is often supplemented with adjuvant therapy.[44, 47] Patients with limited-stage
SCLC (T1-2a, N0, M0) may be considered for surgery. However, it is rare that SCLC tumours
have not developed beyond this stage at presentation.[46] Depending on the stage and position
of the tumour, surgery can involve removal of a small section of lung tissue (wedge resection,
or segmentectomy), a whole lung lobe (lobectomy) or a whole lung (pneumonectomy).[67]
An alternative curative treatment to surgery is radical radiotherapy. This is offered to patients
who are too unwell to undergo surgery and have an unacceptable risk of post-surgical compli-
cations.[46, 47] It may also be offered to patients who are unwilling to undergo surgery, or who
have an early stage tumour which is inoperable. [68]. During radical radiotherapy treatment,
ionizing radiation is delivered to affected areas of the body by an external beam.[69] Conven-
tionally, direction/coverage of the beam has been determined from 2-D imaging. Advances have
led to an improvement in the precision of the delivery of external beam radiation, notably using
sterotactic techniques which involved 3-D imagining.[70, 71] Radical radiotherapy treatment
regimes occur over a shorter period of time than radiotherapy given as an adjuvant palliative
treatment. Radiation may be delivered as daily treatment for up to 7 weeks, or a more intensive
regime of continuous hyper–fractionated accelerated radiotherapy (CHART) delivered over the
period of 12 days.[68, 69, 71] Even though this treatment is considered to be curative, in general
survival rates are lower that those seen after radical surgery. [68, 72] However, advances such
as stereotatic techniques promise to lead to improvements in survival.[70, 73, 74]
Given that the aims of this thesis are to consider the supportive care needs of lung cancer sur-
vivors (i.e. of patients treated curatively rather than palliatively), it would be relevant to explore
both patients treated with radical surgery and radiotherapy. However, I have been unable to
collect or use data from patients treated with radical radiotherapy. This was due to difficulties
during recruitment to the qualitative interview study (for details see section 2.3.2 ). Similarly, no
studies included in the systematic reviews of the effect of smoking history or continued smok-
ing after diagnosis were conducted on patients who received radical radiotherapy (for details
see section 5.4.1 and 6.4.1). Therefore, this thesis has concentrated on assessing the supportive
35
CHAPTER 1. INTRODUCTION
care needs and the prognostic significance of smoking for surgically treated lung cancer patients
only.
1.4.1.1 Surgical treatment
Surgical procedures Surgery for lung cancer can either be performed via thoracotomy or
thoroscopically (video assisted thoracic surgery, VATS).[46] Thoracotomy involves a 15-25cm
incision between the 5th and 6th ribs, cutting through skin and all layers of intercostal muscle
(figure 1.5a). Depending on the location of the tumour, entry to the thoracic cage may be
made under the arm (axillary), from the back to the side (posterolateral) or under the breast
(anterolateral). In order to gain sufficient access necessary to resect lung tissue, ribs are spread
using metal retractors or sometimes excised (figure 1.5b).[75] VATS does not require retraction
of the rib cage, and involves small 2.5 cm incisions for the insertion of a camera and surgical
tools (figure 1.6a and 1.6b).[76] The tumour mass is palpated (thoracotomy) or located (VATS)
(figure 1.5c and 1.6c). Ligamentous attachments are dissected. Significant blood vessels and
bronchial tubes are isolated, ligated and transected, to free the lung tissue and interrupt the
vascular supply to the area for resection (figure 1.5d, 1.5e). Transection of larger vessels is
performed using a stapling device (figure 1.5f and 1.6d), eventually freeing the lung tissue for
resection (figure 1.5h). In the case of a VATS procedure, the resected lung tissue is bagged and
removed through one of the openings to the thoracic cavity (figure 1.6e and 1.6f). If necessary,
lymph nodes are dissected (figure 1.6g). To prevent air leakage, the remaining lung tissue is
stitched together (figure 1.5h). In order to prevent the build up of air (pneumothorax) and fluid
(pleural effusion) within the intrathoracic space, a chest drain is inserted for a few days after
surgery after both thoracotomy and VATS (figure 1.6h).[77]
Assessment for suitability for surgery Guidelines for deciding patient suitability for surgi-
cal treatment are published by the British Thoracic Society[47] and the National Institute for
Health and Clinical Excellence (NICE).[46] In order to identify patients at high risk of perioper-
ative death, a cardio-vascular event or unacceptably high levels of post-surgical breathlessness,
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Figure 1.5: Lung lobe resection via thoracotomy. Source:
http://www.youtube.com/watch?v=OJbgWFt1jWg]
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Figure 1.6: Removal of lung lobe via VATS procedure. [Source:
http://www.youtube.com/watch?v=SlG8Mf5RdCY]
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these guidelines recommend that several tests are performed to assess patients’ fitness before
decisions about surgical treatment are made. These include a range of respiratory function
tests and exercise tolerance tests to test cardio-pulmonary fitness. Tests used to assess respi-
ratory function include those that measure ventilation, including spirometric measures such as
FVC (forced vital capacity), FEV1 (force expiratory volume in 1 sec) and FVC/FEV1 ratio and
those that test gaseous exchange such as oxygen saturation tests and CO2 transfer (DLCO).
The shuttle walk test and cardio-pulmonary exercise tests are also recommended as a func-
tional assessment and to assess cardio-pulmonary fitness. 1 In addition, guidelines recommend
the calculation of the thoracoscore which indicates risk of perioperative mortality,[78] and is
based on age, gender, American Society of Anaesthesiologists (ASA) score (classifies extent
of systemic disease), performance status classification (measures extent to which patients’ day
to day activities are effected by disease symptoms), MRC breathlessness score, priority for
surgery (elective/emergency), extent of resection, malignant/benign disease and number of co-
morbidities.
As a general guideline, in order to tolerate lobectomy or pneumonectomy, patients must demon-
strate an (FEV1) of >1.5L or >2L respectively.[79] A post-operative predicted FEV1 of ≥ 30%
is generally considered to be the cut off for those at low or medium/high risk of developing post-
surgical breathless.[46, 47] However, the latest British Thoracic Society (BTS) and NICE guide-
lines have a more permissive stance on acceptance for surgery than previous guidelines.[46, 47]
Cut off levels for acceptable scores on fitness for surgery tests have remained the same, or in the
case of thoracoscore are not given, but guidelines stress that patients must be informed about
level of risk of adverse post-surgical outcomes and then be given the choice as to whether to
proceed or not. Therefore, it is possible that in the future, greater numbers of patients of bor-
derline fitness may undergo surgery, with the consequence of more patients experiencing high
levels of post-surgical breathlessness.
1During a shuttle walk test, patients walk around two cones placed 10m apart to the pace of auditory beeps.
The pace is gradually increased and exercise tolerance/breathlessness are assessed.
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1.4.2 Adjuvant treatment
For many years, it has been standard practice to supplement surgery with adjuvant chemother-
apy regimes for other tumours, but there has not been sufficient evidence to recommend this
for lung tumours.[44] However, over the past decade strong evidence has emerged to recom-
mend adjuvant chemotherapy for patients after resection of early NSCLC [80]. Current BTS
guidelines recommend offering a cisplatin-based combination therapy regimen to patients with
T1-3N1-2M0 NSCLC, and recommend also considering this treatment for patients with a T2-
3N0M0 NSCLC tumour >4 cm diameter.[46, 47] The role of adjuvant radiotherapy after lung
cancer resection has also been controversial over past decades, with mixed evidence of its effec-
tiveness.[81, 82] Currently, radiotherapy is not indicated for patients with complete resection of
early stage tumours, but is recommended when microscopic evidence of disease spread is found
within the resected tumour margins. For patients with T1-4N0-M0 limited stage SCLC tumours,
chemotherapy and radiotherapy are both indicated. Chemotherapy and radiotherapy are recom-
mended to run concurrently for those patients with good performance status, or sequentially for
those who would not tolerate combined treatment.[46, 47]
1.5 Health and functioning of lung cancer patients during
the first year after surgery
It has been noted that there is a lack of research outlining the ‘natural history’ of cancer sur-
vivorship in terms of health experiences (see section 1.7.2). The first aim of the qualitative
interview study that is documented in chapters 2 to 4 of this thesis was to explore patients’ ex-
periences of health and the effect of health on functioning during the first year after surgery for
lung cancer. Previously published literature in this area was reviewed before commencing the
qualitative interview study in order to help with construction of the interview guide (see table
2.2). An overview of what is already known about the health and functioning of lung cancer
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patients after surgery is presented below.
1.5.1 Quantitative quality of life (QOL) studies
Historically, research exploring QOL has focused on patients surviving childhood cancers.
However, during the past decade there has been an increasing focus on the QOL of adult sur-
vivors.[83] Even so, the survivorship experience of lung cancer patients has been studied less
than patients with other cancers.[83, 84] There have been a variety of tools developed to assess
QOL, some of which have been developed specifically to capture lung cancer specific issues and
have been validated in this patient group. A review published in 2012 found that the most widely
used validated tools in lung cancer are the European Organisation for Research and Treatment
of Cancer quality of life questionnaire (EORTC QLQ C-30), a generic tool for assessing health
related quality of life in cancer patients, and the EORTC QLQ LC-13 which is a lung cancer
specific quality of life tool.[85] The C-30 questionnaire contains 30 questions and is used to
calculate five functional scales (physical, role, cognitive, emotional, and social), eight symp-
toms (fatigue, pain, nausea and vomiting, dyspnoea, loss of appetite, insomnia, constipation
and diarrhoea), a global health status / QOL scale and perceived financial impact of the disease.
The LC-13 questionnaire contains 13 questions regarding lung cancer specific symptoms. Other
generic QOL tools, such as the SF-36, have been used to assess QOL in lung cancer patients
which calculates scores for vitality, physical function, bodily pain, general health, physical role,
emotional role, social role functioning and mental health.
During preparations for conducting the qualitative study, twelve studies [86–97] measuring
QOL in surgical patient populations were identified that had been published between 1995 and
2009. For a summary of these studies see table 1.3. All twelve studies showed that patients
experience reduced QOL in comparison to baseline scores in various domains as well as lung
cancer specific symptoms for at least 1 month after surgery. However, there was mixed evidence
on the amount of functional impairment, severity of symptoms, and the length of duration of
impairment/ symptoms. In particular, studies indicated that physical, role and social function
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can remain impaired and that patients may also experience prolonged breathlessness, pain and
fatigue for twelve months or more. Generally, impairment/symptoms were found to be greater
and endure longer for those undergoing pneumonectomy compared to lobectomy or wedge re-
section,[87, 88] for thoracotomy compared to VATS procedure [86] and for those experiencing
disease progression.[93] Lung cancer QOL has also been shown to be worse compared to pa-
tients with other cancers [98] and the general population.[90, 92] Most of the studies (7/9) were
conducted in samples smaller than 150 patients, and no studies had taken account of differences
in baseline characteristics when comparing groups. However, these studies indicate some of
the most prevalent quality of life issues facing lung cancer patients during their first year after
surgery.
Given the differences reported in these scores, recruitment of patients to the interview study
reported in chapters 2 - 4 aimed to represent both patients who had undergone thoracotomy and
those who had undergone VATS as well as those who had received more or less conservative
tissue resection. Other sub-groups were also represented in the sample (see section 2.3.4).
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1.5.2 Specific symptoms reported by surgical lung cancer patients
1.5.2.1 Breathlessness
One commonly reported sequelae of pulmonary resection is breathlessness.[99] There is mixed
evidence regarding the length of time after surgery that patients continue to experience breath-
lessness based on quantitative QOL studies. Some studies found that breathlessness returns to
baseline scores within 3 months after surgery and others report continuing breathlessness a year
after surgery (see table 1.3). There is also data to suggest breathlessness can be reported for up
to five years for a significant proportion of patients. Sarna et al. investigated the presence of res-
piratory symptoms in lung cancer survivors 5 or more years after surgery. Among 142 patients,
63% reported breathlessness and 10% were unable to leave the house due to breathlessness.
These authors also reported that breathlessness significantly predicted physical functioning,
physical role and social functioning scores.[100]
There has been little published research examining the causes of breathlessness after surgery
for lung cancer or of effective treatments. The ventilatory processes involved in breathing have
two main functions, moving air in and out of the lungs and secondly gaseous exchange be-
tween the airspace of alveoli and the blood.[39] Respiratory control is complex, and requires
highly co-ordinated orchestration of several conscious and autonomic processes that detect oxy-
gen saturation levels in the blood and regulate the mechanical processes of breathing.[101] It
is possible that surgical incision and damage to intercostal muscles may result in decondition-
ing.[102] Clearly, surgery also removes lung tissue, reducing the surface area for exchange
of oxygen and carbon dioxide which may also contribute to breathlessness.[103] Post-surgical
reduction in forced expiratory volume in one second (FEV1) has been shown to be directly
related to the amount of lung resected in those who have undergone surgery for lung cancer,
with a 15% reduction seen in lobectomy patients six months after surgery in comparison to a
35% reduction after pneumonectomy.[104] However, it is well known that self reported levels
of breathlessness do not always correlate with spirometric measures of respiratory function, or
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Table 1.4: The modified Borg scale
Grade Degree of breathlessness related to activities
0 Nothing at all
0.5 Very, very slight (just noticeable)
1 Very slight
2 Slight
3 Moderate
4 Somewhat severe
5 - 6 Severe
7 - 8 Very severe
9 Very very severe (almost maximal)
10 Maximal
Table 1.5: The MRC breathlessness scale
Grade Degree of breathlessness related to activities
1 Not troubled by breathlessness except on strenuous exercise
2 Short of breath when hurrying on the level or walking up a slight hill
3 Walks slower than most people, stops after a mile or so, or stops after 15 minutes walking
at own pace
4 Stops for breath after walking 100 yards or after a few minutes on level ground
5 Too breathless to leave the house, or breathless when undressing
other physiological tests such as oxygen saturation and arterial blood gases.[105] Guidelines
recommend that spirometric measures should not be used in isolation to determine respiratory
function, but rather should be used in conjunction with patient self report.[47]
Measures of breathlessness that form part of QOL tools are single items that rate breathless-
ness on a Likert scale. These tools have been developed for clinical trials rather than clinical
care.[85] Two of the most widely used, generic clinical tools for measuring breathlessness are
(1) The modified Borg scale and (2) The MRC breathlessness scale. The Borg scale is a measure
of perceived breathlessness that quantifies severity on a scale from 0-10, where 0 represents ‘no
breathlessness at all’ and 10 represents ‘maximal breathlessness’.[106] The MRC breathless-
ness scale does not quantify the severity of breathlessness, but rather classifies the associated
limitation in function on a scale of 1 to 5.[107] The descriptions of each of these scores can be
found in table 1.4 and 1.5.
Qualitative explorations of patients’ experiences of breathlessness have been conducted in pa-
tients with end stage disease receiving palliative care.[108] However, the experience of breath-
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lessness and effect on function has not been qualitatively explored in lung cancer patients who
have undergone surgery. In chapter 3 - 4, patients’ experiences of breathlessness are explored,
and interpreted in the light of the MRC breathlessness scale and Borg scales.
1.5.2.2 Pain
Thoracotomy is recognised as being one of the most painful surgical procedures, akin to limb
amputation.[109, 110] Surgical damage to skin, soft tissue, bone and muscle results in an in-
flammatory response, and pain signals are transmitted through the intercostal nerves. Intercostal
nerves themselves may also be damaged during the surgical procedure, and in addition constant
motion due to breathing continually aggravates the area.[111] The International Association
for the Study of Pain (ISAP) has stated that pain after thoracotomy is “characterised by an
aching sensation in the distribution of the incision that usually resolves in the two months fol-
lowing the surgery.” [112] Although in the past it was thought that persistent pain was only
experienced in the case of tumour recurrence, it is now recognised that a proportion of patients
do develop persistent pain independently of tumour recurrence, or post-thoracotomy pain syn-
drome (PTPS).[111] PTPS has been described as persistent pain which has an aching, burning
dysaesthesia and/or a pleuritic component.[113, 114] The merriam-webster medical dictionary
defines dysaethesia as ‘impairment of sensitivity, especially to touch.’ Pleuritic is defined as “of,
relating to, or affected with pleurisy”, which is a condition in which the lining of the pleural
cavity of the lungs becomes inflamed and is associated with sharp, shooting pains on inhala-
tion. Shoulder pain is also common after thoracotomy although the reasons for this are not
completely understood.[87]
Dajczman et al published the first data in a small group of patients demonstrating the existence
of chronic post-thoracotomy pain in disease free patients, in 1991.[115] Fifty-six patients were
interviewed between 2 months and 5 years post-thoracotomy. In this group, 73% of patients
were still experiencing pain after two years and 30% reported pain at 5 years. Since then
other studies have confirmed the existence of chronic post-thoracotomy pain, but estimates of
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incidence range from 11% to 80%.[111] There are mixed reports in QOL studies of the length
of time that patients continue to experience pain (see table 1.3), with some studies reporting that
pain scores return to baseline within the first three to six months after surgery and others finding
evidence of pain persisting for twelve months after surgery. It has been estimated around 5%
of patients continue to experience pain that is incapacitating 12 months after surgery.[113, 116,
117]
Control of post-surgical pain is important not only from a QOL point of view, but pain can also
prevent patients from mobilising, can inhibit coughing and can cause shallow breathing.[118,
119] These factors increase the risk of atelectasis and retention of secretions which can lead
to hypoxaemia, hypercapnia and respiratory failure. In addition, immobilisation increases the
risk of deep venous thrombosis and pulmonary embolism.[120] As such, the goal of acute pain
control after thoracotomy is for patients to be able to move, breathe deeply and cough without
experiencing high levels of pain.[119, 120] The World Health Organisation developed what
is commonly referred to as the ‘three-step analgesic ladder’ as a guide to the management of
cancer-related pain.[121] The first step includes simple analgesics such as paracetamol and non
steroidal anti-inflammatory drugs (NSAIDs). If pain persists or increases, other treatment is
added. The second step of treatment adds weak opioids, for example tramadol or codeine, and
then the third step adds strong opioids such as morphine or pethidine. Non-pharmacological
interventions may also be used such relaxation, hypnosis and acupuncture.[122]
Prediction of those who will experience greater pain related to thoracic surgery is complex,
as the cause of pain is multi-factorial. Pain experiences may differ due to variation in the
surgical technique used, positioning of the incision and patient specific anatomical differences,
responses to analgesia and psychological responses to pain.[120] Some studies have shown
that experience of acute post-surgical pain predict PTPS.[123–125] The aetiology of PTPS is
not known, however pain descriptions are consistent with intercostal nerve damage, and this is
considered to be an important cause.[111]
There are no measures that have been developed to specifically describe patient reported post-
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thoracotomy pain. Similar to breathlessness, pain experience is captured within QOL scales us-
ing a single item scale. Other studies have generally used generic visual analogue scales, Likert
scales and/or tools such as the McGill pain questionnaire (MPQ) to describe post-thoracotomy
pain.[114, 115, 117, 126] The MPQ allows patients to identify words that described their pain
that fall into three classes of description: sensory, affective and evaluative. The words used to
describe pain denote the intensity and are associated with a score. In addition, patients rate their
present pain intensity on a 5 point scale. This questionnaire had been used to interpret descrip-
tions of pain experiences reported by interview participants in the qualitative study reported in
chapter 2 - 4. The MPQ can be found in appendix A.1.
1.5.3 Prevalence of co-morbidities in lung cancer survivors
Multi-morbidity is likely to be high in lung cancer patients due to the association of this tu-
mour with both age and smoking. This issue is important not only for predicting prognosis but
also has implications for the planning of services, clinical decision making and patient man-
agement.[127, 128] One US study including patients that had received curative or non-curative
treatment described the prevalence of 56 co-morbidities in 1 155 lung cancer patients.[129]
Prevalence within this sample was highest for chronic obstructive pulmonary disease (COPD)
(29%), connective tissue disease (22%) and peripheral vascular disease (10%). Another study
conducted in the US found that 30% of patients had co-morbid cardio-vascular disease, 36%
hypertension and 37% had co-morbid respiratory disease. The stage at diagnosis and treatment
received by patients in this study was not reported.
Two known studies have described prevalence of co-morbidity in surgically treated lung cancer
patients. One study conducted in Spain described the frequency of 5 specific co-morbid dis-
eases in 2 992 consecutive patients and found that 50% of patients had an additional diagnosis
of COPD, 16%, 13% and 10% of patients had atrial hypertension, cardiac disease or periph-
eral vascular disease, and 9% of patients had diabetes.[130] The second study was conducted
in the US with 451 patients who had undergone surgery for pathological stage I NSCLC.[60]
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Co-morbidity was measured using the Kaplan-Feinstein Index. This measure classifies co-
morbidity as absent, mild, moderate or severe based on the number of individual diseases
present and the extent to which the disease is advanced. Thirty three percent did not have a
co-morbid condition at diagnosis with lung cancer, whereas 33%, 26% and 10% were described
as qualifying for mild, moderate or severe KFI score. However, the authors did not describe
the prevalence of individual co-morbid diseases. Although more studies are needed to describe
the prevalence of co-morbidities in lung cancer patients treated in the UK, it is likely that a
significant minority, if not the majority, are affected by at least one co-morbid disease.
1.6 Health behaviours of lung cancer patients after surgery
The second aim of the qualitative interview study documented in this thesis was to describe
patients’ health behaviours after surgery and explore their attitudes towards behaviour change.
This was with a particular view to exploring patients’ preferences for the inclusion of support
for health behaviour change within a rehabilitation programme. The role of health behaviours in
improving patient health, management of treatment sequelae and improving disease outcomes
for cancer survivors has received increasing attention over the past few years.[131] However, the
majority of research has focused on survivors of breast, prostate and colorectal cancers.[132] A
previous review of the evidence relating to the health behaviours of lung cancer patients, and the
relationship between post-diagnosis behaviours and health outcomes found no research regard-
ing exercise, diet or alcohol consumption.[133] However, some studies regarding post-diagnosis
smoking behaviour and health outcomes were reported and showed that smoking cessation may
lead to both short term benefits (e.g. shorter length of hospital stay[134], better quality of life
[135] and lower levels of reported pain[136]) and longer term prognostic benefits,[137] (see
chapter 6 for a review of the evidence for prognostic benefits of smoking cessation).
Given the lack of evidence surrounding health behaviours other than smoking, the following
sections will focus on some of the key issues that inform incorporation of smoking cessation
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into a rehabilitation programme for surgical lung cancer patients. First, it is important to know
the prevalence of current smoking at the time of diagnosis and how many continue to smoke
after diagnosis. It may be that many patients with a smoking history have already quit by this
stage or quit as a reaction to their diagnosis. However, even if a minority of patients continue to
smoke, it is worth investigating patients’ attitudes towards their smoking and towards being of-
fered smoking cessation support. Second, there has been considerable debate in the literature as
to the optimum timing of smoking cessation before surgery in terms of post-surgical pulmonary
complications. Despite mounting evidence that smoking cessation may lead to improved out-
comes in both the short and the long term, there has been a concern that quitting immediately
before surgery may cause a paradoxical increase in risk of surgical complications. If patients
express a preference for being offered support to quit smoking, it is important to understand
the optimum time for quitting before surgery. These two topics are discussed in the following
sections.
1.6.1 Prevalence of smoking in patients diagnosed with lung cancer
Eight known studies have described the prevalence of smoking in surgical lung cancer patients
(see table 1.6).[138–145] Three of the eight studies retrospectively questioned patients about
their smoking status at diagnosis and found that at least 85% had a history of smoking and be-
tween 44 and 100% were smokers at diagnosis. The study reporting 100% current smokers had
selected patients based on their smoking behaviour, therefore this prevalence is not representa-
tive of surgical lung cancer patients in general at diagnosis. On average, patients were surveyed
between two and ten years after diagnosis and between 13 and 46% were smoking at follow
up. Two of these retrospective cohorts[138, 140] relied on self report of smoking status only,
and the third included biochemical validation of smoking status at the time of interview.[139]
Biochemical validation is considered the gold standard in confirming smoking abstinence, and
is considered stronger evidence than self report only.[146] These studies provide weak evidence
of the prevalence of smoking at diagnosis and continued smoking after diagnosis, but indicate
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that smoking behaviour is still relevant to lung cancer patients at and beyond diagnosis.
Five studies used a prospective cohort design to capture smoking behaviour during the first
year after diagnosis, providing stronger evidence.[141–145] However, biochemical validation
of smoking status was only used in two studies.[141, 145] As with the retrospective studies,
the prospective cohort studies reported that around 90% of patients diagnosed with lung cancer
had a history of smoking and that a significant number still smoked at diagnosis. Two of these
studies were conducted in the US more than twenty years ago and it is possible that smoking
prevalence has changed since this time.[142, 143] Gritz et al. reported smoking behaviour in
840 patients by combining data from three clinical trials of adjuvant therapy which recruited
patients between 1977 and 1987.[143] All patients had been diagnosed with NSCLC and were
treated with surgery. This study found a high prevalence of smoking at diagnosis, at 60%.
However, only 4% were reported as current smoking at an average of 4 years after diagnosis. It
is not clear from this study how many patients were lost to follow up due to death and in addition
smoking status was ascertained by self report. Dresler et al. recruited 363 surgical lung cancer
patients between 1992 and 1996.[142] This study reported that just under half of patients were
smoking at diagnosis and 13% of patients were smoking at longest follow up, which on average
was one and a half years after surgery.
Three more recent studies were also conducted in the US.[141, 144, 145] One of these stud-
ies[145] recruited patients between 2001 and 2005 but included only patients who were smokers
at diagnosis and therefore prevalence could not be assessed. This study reported that 80% were
biochemically confirmed as quit one year after surgery. Cooley et al followed up 94 stage I-
IIIA patients 1, 2 and 4 months after they had undergone surgery between 2002 and 2006.[141]
Thirty seven percent of patients were smoking at time of diagnosis. Some patients who had quit
before diagnosis relapsed after treatment and were smoking at 4 months follow up, along with
others who had been smokers at diagnosis such that 48% were smoking at follow up. Logistic
regression modelling showed that young age, less than high school education, quitting fewer
than 6 months before diagnosis and high pain scores were predictive of smoking at follow up in
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this study. Finally, Park et al published the largest cohort study to date in lung cancer patients.
However, only around half of the sample had undergone surgery.[144] Overall, 38% of patients
were found to be smokers at diagnosis and 13% were smoking at 5 months follow up. In a
univariate logistic regression, those who had surgery were found to be 36% less likely to smoke
at 5 months follow up than those who had not had surgery (OR 0.64 (95%CI 0.45-0.90)).
In summary, three retrospective and five prospective cohort studies have provided evidence of
a falling prevalence rate of current smoking amongst surgical lung cancer patients over the
past decades, but that currently over a third of patients may smoke at diagnosis. A significant
minority of these patients may continue to smoke after treatment. The proportion of contin-
ued smokers reported in previously published studies has varied, but this is likely to be due
to differences in follow up periods, bias introduced due to the study methodology and lack of
biochemical validation of smoking status. There was some indication that age, education and
performance status were related to the likelihood of continued smoking, and in particular those
who had quit within a year of diagnosis appeared to be at higher risk of relapse to smoking after
treatment than those who had quit more than a year before diagnosis. This picture of smoking
prevalence amongst surgical lung cancer patients confirms that smoking cessation support is
likely to be relevant to many patients and is potentially an important component of a rehabilita-
tion programme.
1.6.2 Optimum timing of smoking cessation for surgical lung cancer
patients
Smokers are at an increased risk of post-surgical complications compared to non-smokers.[147–
151] In particular, smoking has been associated with increased anaesthetic dosage, increased
risk for local wound complications, pulmonary and cardiac complications, post-surgical inten-
sive care admission and longer periods of hospitalisation compared to non smokers.[147, 152–
155] Patients who undergo pulmonary resection are most vulnerable to pulmonary complica-
tions including pulmonary infection, atelectasis, bronchospasm, and prolonged ventilation.[134,
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156, 157] It is thought that smoking may elevate risk of respiratory complications by decreasing
ciliary action, macrophage activity and small airways function, and causing an increase sputum
production.[147, 158]
Although it is advisable for patients to quit smoking before surgery, even if only temporarily
[159], there has been considerable debate in the literature as to how long before surgery a
patient must quit in order to see a reduction in risk of complications, and regarding the optimal
timing of smoking cessation before surgery.[160] Studies have compared risk within different
surgical populations, between different time windows of pre-surgical quitting, for several types
of complication, with mixed results. An in depth appraisal and discussion of all the literature
on this topic is outside the scope of this thesis. However, I will summarise some of the key
studies within this debate that are relevant to understanding the optimum time for quitting before
thoracic surgery.
One of the main issues of contention within the debate has been the safety of quitting smoking
within 2 months leading up to surgery.[134, 160, 161] Two studies conducted 20-30 years ago
in non thoracic surgery patients [162, 163] and one more recent study conducted in patients
undergoing lung surgery [164] found that quitting within this time window (<8 weeks before
surgery) was associated with an increased risk in complications. An additional study found
that smoking cessation may temporarily increase sputum production above the level produced
as a smoker,[165] thus indicating a potential mechanism by which those who quit immediately
before surgery may be at greater risk of pulmonary complications.[156, 161] Although many
additional studies have shown no increased risk, or a decrease in risk, concern still persists
amongst some surgeons and anaesthetists and some local surgical guidelines have recommended
that smokers do not quit within this time window.[161]
Several authors have published narrative reviews, or systematic reviews with meta-analyses
in this area.[147, 153, 156, 159–161, 166–170] The most up to date systematic reviews were
published in 2011 [168] and 2012 [169]. Myers et al, included two RCTs and seven observa-
tional studies that ‘allowed comparisons of post-surgical complications in patients who stopped
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smoking 8 weeks or less prior to surgery (recent quitters) with those who continued to smoke
(continuers). All types of post-surgical complications were considered from all specialities and
populations.’[168] Two of the studies included in the review were observational studies on pa-
tients that had undergone pulmonary resection.[158, 171] Relevant data from all studies were
pooled to assess risk of any complication or pulmonary complication which showed no sig-
nificant difference between recent quitters and continuers (Any complication RR 0.78 (95%CI
0.57, 1.07), Pulmonary complication RR 1.18 (95% CI 0.95, 1.46). Individual study estimates
for the two studies conducted on patients who had undergone pulmonary resection of risk of
any complication or risk of pulmonary complications did not show any significant difference.
However, a small number of patients were contributing to these analyses (Barrera, 2005 [158]
n= 52, Groth, 2009 [171] n= 39) Although this review found no cause of concern for quitting
before surgery in terms of an increased risk of complications, it combines data for all those who
quit at any point in the 8 weeks preceding surgery. In some studies patients had quit within two
weeks of surgery whereas others had quit six or eight weeks before. If risk was only elevated
for those who quit within 2 weeks, this may be masked by combining these data. Although this
review gives reassuring evidence, an elevated risk for those quitting more immediately before
smoking cannot be ruled out.
Wong et al [169] used similar inclusion criteria to Myers et al., but extended inclusion to studies
with participants who quit within 6 months rather than just 2 months before surgery. This re-
view included 25 studies in total (2 RCTs, 7 prospective cohort studies, 16 retrospective cohort
studies). Five of the studies had been conducted on patients who had undergone pulmonary
surgery,[66, 158, 164, 171, 172] which includes the 2 studies found by the Myers review. Sim-
ilar to Myers et al, data in this review are combined for all types of surgery. However, rather
than comparing those who quit any time within 8 weeks to those who continued to smoke,
this review compared five categories of smoking behaviour (current smoker, quit <2 weeks, 2-4
weeks, >4-8 weeks and >8 weeks before surgery).
Compared to those who continued to smoke, the risk of respiratory complication was found to
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not significantly differ for those who quit <2 weeks (RR 1.20 (95% CI 0.96, 1.50; 3 studies,
559 ppts) or 2-4 weeks before surgery (RR 1.14 (95% CI 0.90, 1.45; 3 studies, 2210 ppts) and
was significantly reduced for those who quit >4 weeks - 8 weeks (RR 0.77 (95% CI 0.61, 0.96;
4 studies, 5659 ppts) and >8 weeks before surgery (RR 0.53 (95% CI 0.37, 0.76; 5 studies,
1426 ppts). When directly comparing risk in those who quit <2 weeks before surgery with
those who quit between 2 and 4 weeks, no significant difference was found (RR 1.04 (95% CI
0.83, 1.30; 3 studies, 2170 ppts). This indicates that quitting at any point within 4 weeks of
surgery is associated with the same level of risk as for those who continue to smoke. However
significant decreases in risk of pulmonary complications were found for those who quit >4
weeks compared to <4 week (RR 0.65 (95% CI 0.46, 0.93; 3 studies, 5592 ppts) and for those
who quit >8 weeks compared to those who quit <8 weeks before surgery (RR 0.47 (95% CI
0.29, 0.74; 5 studies, 1309 ppts). Similarly, those who quit smoking >3-4 weeks before surgery
had a lower risk of developing wound complications than those who quit smoking <3-4 weeks
before (RR 0.74 (95% CI 0.56, 0.98; 7 studies, 845 ppts). This indicated that patients need
to quit at least 4 weeks before surgery in order to reduce their risk of complications, and for
those who quit even earlier the benefits are greater. However, the authors state that the findings
should be interpreted with caution because many of the studies did not score highly on quality
measures. Many studies posed a possible risk of bias because smoking status was based on
self report and outcome assessor was not blinded to smoking status. Out of 17 studies that
contributed to the estimates quoted here, 13 reported differences in baseline characteristics and
in two these characteristics were not assessed. In addition, crude rates of complication were
included in the meta-analyses which may be subject to confounding.
No review has conducted sub-group analyses combining studies that have been performed on
patients undergoing pulmonary surgery only. Of the 5 studies that have been identified by
systematic reviews that have been carried out in this population, four recruited a total of 300 pa-
tients or fewer and only a proportion of these patients quit smoking within the time window of
interest to this discussion. However, one study conducted in adult patients undergoing primary
resection for lung cancer [66] was large (n = 7990) and is worthy of note. In this study, data
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regarding risk of the occurrence of pulmonary complication (prolonged ventilation >48hr post-
surgical, need for reintubation, atelectasis requiring bronchoscopy, tracheostomy, pneumonia
and development of acute respiratory distress syndrome) were prospectively obtained. Smok-
ing behaviours were split into 5 categories: current smokers (n= 1595) and those who quit >14
d-1 months (n = 404), 1-12 months (n = 940), >12 months (n4026) before surgery and those
who never smoked (n= 1025). Data were derived from several hospitals. The authors report a
significant difference in the distribution of age, gender, BMI, zubrod score (tool for assessing
performance status), spirometry measures and resection type between the 5 smoking behaviour
groups. However, the methods of assessing differences was not described, and post-hoc tests
did not ascertain which groups differed. Crude measures of risk of pulmonary complications
showed a trend of decreasing risk for increasing periods of cessation before surgery (current
smoker = 6.9%, quit >14d-1m = 6.2%, quit 1-12m = 6.4%, quit >12m =5.8% and never smoked
= 2.6%). To account for baseline differences, the authors conducted a multivariable analysis us-
ing a non parsimonious mixed model with logit link which included 20 variables. As with other
reviews, the authors used never smokers as the reference category and found that both current
smokers and those who quit within a month surgery were at increased risk of complications
(current smoker OR 3.5 (95% CI 1.1, 11), >14d ays-1m OR 4.6 (1.2, 18). Indirectly compar-
ing current smokers to those who quit 2-4 weeks before surgery did not find any significant
difference (OR 1.31 (95% CI 0.26-6.7)
Taken together, these reviews and studies indicate that smokers who quit within a month before
surgery are not at an increased risk of pulmonary or wound healing complications. In addition,
quitting at least four weeks before surgery appears to be associated with risk reductions and
the longer the length of time a patient has quit before surgery the better. There is reasonably
strong evidence that this is also the case specifically for patients undergoing pulmonary surgery.
However, although some of the studies included in these reviews were relatively large (over
1000 patients), most did not score highly in quality measures and findings may be subject to
bias and uncontrolled confounding. Notwithstanding the limitations of data, reviews in the area
have concluded that surgeons should not be deterred from offering smoking cessation at any
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point up until surgery. These data provide a strong case that smoking cessation support should
be offered to patients as soon as possible before surgery.
1.7 Evolution of cancer services over the past two decades
1.7.1 The Calman-Hine report and The Cancer Plan
Over the past 2 decades, there have been marked changes in the way cancer services are or-
ganised and delivered. The Calman-Hine report,[173] published in 1995, was the first ever
comprehensive review of UK cancer services and recommended changes to national service
configuration and delivery. One of the driving factors that led to this comprehensive review
was the inequality in service provision and cancer outcomes that was apparent across the coun-
try.[173] In response to these difficulties, the Calman-Hine report set out what has been referred
to as seven innovative and ground breaking principles which heralded a more patient-centred
approach and equitable service:[174]
1. access to uniform high-quality care in the community or hospital
2. early identification of cancer and availability of national screen programmes
3. patients to be given clear information at all stages
4. services to be patient centred
5. centrality of primary care and effective communications
6. psychological aspects of care are important
7. cancer registration and monitoring of treatment and outcome are essential.[174]
The content of the Calman-Hine report underpinned ‘The Cancer Plan’ 2000, the first political
document of its kind to set out a comprehensive programme of service reforms that encom-
passed changes in prevention, diagnosis, treatment, care and research,[175] and this programme
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was updated in 2004 in ‘The NHS plan and the new NHS: providing a patient-centred ser-
vice’.[176] These documents have provided the vision and acted as a catalyst to many positive
developments within cancer care, including the formation of cancer networks (organisations
tasked with driving change and improvement in cancer services for the population of a spe-
cific geographic area), the integration of clinical expertise in the form of multidisciplinary team
(MDT) meetings in which individual cases are discussed and clinical decisions are made, the
emergence of national screening programmes to improve rates of early detection of tumour de-
velopment and the formation of cancer registries where data regarding diagnosis, treatment and
outcome of disease are systematically collected and recorded.[44]
Specific to lung cancer, as a result of these reforms and accompanying financial investments,
services have developed to centre clinical decision making around lung cancer MDTs, and lung
cancer clinical nurse specialists (CNS) are assigned to individual patients to provide tailored
support as they progress through the system. In addition, the evidence base for treatments has
improved and developments in technology have improved techniques for disease staging and
delivering treatments.[44] These developments have been incorporated into national guidelines
for the diagnosis and treatment or lung cancer.[46, 47]
1.7.2 The Cancer Reform Strategy and The National Cancer
Survivorship Initiative (NCSI)
Due to improvements that have been made in early detection, treatment and survival rates, along
with the ageing population, the prevalence of people living with cancer is now increasing.[177]
In 2008, it was estimated that there were 2 million cancer survivors living in the UK and that this
number is rising annually by an estimated 3.2%.[63, 178] Modelling of cancer prevalence has
predicted that by 2040 almost one quarter of people living in the UK who are aged 65 and above
will have received a cancer diagnosis, rising from one eighth of that age group in 2008.[178]
In recognition of this significant increase and the changing needs of this population, cancer
survivorship care has been placed more firmly on the agenda of cancer research and service de-
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velopment. Additional to improvements brought about by The Cancer Plan, the Cancer Reform
Strategy published in 2007 highlighted the need to develop services for those ‘living with and
beyond cancer’.[179] Previous care pathways had focused on detection, diagnosis, treatment
and palliation, but the needs of curatively treated patients have been largely overlooked.[177,
180]
The National Cancer Survivorship Initiative (NCSI), a partnership between the English DH and
Macmillian Cancer Support, and supported by NHS improvement, was set up to deliver the
aspirations set out by the Cancer Reform Strategy for those living with and beyond cancer. The
NCSI was launched in September 2008 with the explicit goal of taking “the necessary steps
to ensure that those living with and beyond cancer get the care and support they need to lead
as healthy and active a life as possible, for as long as possible”. Figure 1.7 demonstrates the
position and scope of survivorship care within the complete cancer care pathway.
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Figure 1.7: Complete pathway of cancer care, including survivorship [Source: NHS Improvement -
Cancer, 2011]. [181]
To fulfil this mandate, the NCSI commenced a stream of work that began with assessing and
filling gaps in the existing evidence base. In brief, this work confirmed that current care in
the UK was not addressing patients’ survivorship or supportive care needs.[182] A survey of
cancer services throughout England showed that care pathways were often ill defined after treat-
ment, and were focused on surveillance of disease rather than involving holistic assessment of
need. In addition, there was found to be a lack of co-ordination between primary and secondary
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care.[183] In their vision document published in January 2010, the NCSI set out 5 shifts that
were necessary to adapt to the needs of the cancer survivor population :[177]
1. a cultural shift in the approach to care and support for people affected by cancer to a
greater focus on recovery, health and well being
2. a shift towards assessment, information provision and personalised care planning. This is
a shift from a one-size fits all approach to follow up to personalised care planning based
on assessment of individual risks, needs and preferences
3. a shift towards support for self management. This is a shift from a clinically led approach
to follow up care to support self-management, based on individual needs and preferences
and with the appropriate clinical assessment, support and treatment
4. a shift from a single model of clinical follow up to tailored support that enables early
recognition of and preparation for the consequences of treatment as well as early recog-
nition of signs and symptoms of further disease
5. a shift from an emphasis on measuring clinical activity to a new emphasis on measuring
experience and outcomes from cancer survivors through routine use of Patient Reported
Outcome Measures (PROM) in after care services.[177]
During the lifetime of this doctoral study, significant strides forward have been made in defining
and testing new ‘risk stratified’ models of care for cancer patients. Building on the findings of
initial ground work, this pathway was tested within lung, breast, colorectal and prostate cancer
groups.[184] The lung cancer specific model was first described after I completed the interviews
that form part of the empirical work reported in this thesis (see chapter 2 - 4).[181] At the
foundation of this model, a personalised care plan is created with the patient and reviewed on
a regular basis. Based on patient need, follow up may take one of three levels of intensity:
self management, shared care or complex care. As the needs of patients change, they may
move between these levels of care. It was estimated that 15%, 60% and 25% of all lung cancer
patients would need each of the three levels of care respectively. The lung cancer risk stratified
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pathway is shown in figure 1.8 below.
The feasibility of implementing a risk stratified pathway was piloted with lung cancer patients
by two teams based at Hull and East Yorkshire Hospitals NHS trust and Brighton and Sussex
University Hospitals NHS trust, and the findings were published in September 2012.[184] In
brief, this involved piloting a health and wellbeing clinic to identify patient needs and referral
on to other services. Also, for patients still under outpatient care, a more flexible approach to
consultant led clinic appointments was trialled, including a pre-clinic telephone assessment one
week prior to clinic to allow for re-scheduling based on patient need. This work indicated that
all patients required some form of professional led care, but that also many could self manage
for periods during the pathway. Clinical support services that patients were most frequently re-
ferred to included physiotherapy/breathlessness clinics, nutritional and psychological services,
district nursing, occupational therapy/wheelchair services and home oxygen services. Pre-clinic
telephone calls resulted in around a quarter of appointments being cancelled and rescheduled.
Also, about one fifth of appointments were arranged at patient or professional request, and po-
tentially avoided emergency admissions. This work was geared towards lung cancer patients
with ‘active or advanced disease’, and therefore it is unknown how the findings relate to the
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needs of surgical lung cancer patients in particular. No estimation of the stratification of needs
for surgical lung cancer patients has been made.
In addition to defining and piloting new models of care, the NCSI research workstream have
made a series of recommendations for research emphasising that “the highest priority for re-
search in cancer survivorship is to understand the ‘natural history’ of survivorship and to create
risk stratification tools for all cancers and for survivors of all ages”.[185] Recent reports by the
NSCI and also the National Cancer Research Institute (NCRI) have noted a lack of research in
all areas of lung cancer research in particular. In 2011, Mick Peake, the National Clinical Lead
for lung cancer, explained “The issue of how best to follow up lung cancer patients is difficult.
This is because it is almost an evidence-free area, as has been recognised in the recently updated
NICE Lung Cancer Guidance.”[181] This includes a specific lack in a description of the natural
history of health experiences after treatment and investigations surrounding the supportive care
needs of lung cancer survivors.[1, 46, 182, 186]
1.8 Current and future supportive care for lung cancer
patients after surgery
1.8.1 Terminology used to describe models of after care
The concept of supportive care and rehabilitation within the NHS is not unprecedented. Reha-
bilitation programmes are offered as standard to patients with coronary heart disease,[2] stroke
[4] and COPD.[3] Throughout research literature, strategy and guideline documents, several
terms have been used to describe care for patients that is additional to primary treatment, in-
cluding ‘survivorship care’, ‘after care’, ‘rehabilitation’, ‘supportive care’, ‘follow up care’, ‘en-
hanced recovery’ and ‘palliative care’. There are various definitions for these terms, but many
overlap and the distinction between them is often blurred.[187] The NCSI/NHS Improvement
have not given a definition of supportive care as included in figure 1.8. Within the documen-
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tation arising from the work of these organisations, various terms have been used to describe
care, including survivorship care, after care, follow up care and supportive care.
Within this thesis, the terms rehabilitation and supportive care have been chosen to identify the
type of care that is being investigated. The term rehabilitation is used to refer to a programme
that is conducted for a finite period of time before, during and/or after discharge. The aim of
cancer rehabilitation is to:[188]
“help a person with cancer to help himself or herself to obtain maximum physi-
cal, social, psychological, and vocational functioning within the limits imposed by
disease and its treatment.”
The term supportive care is used as an umbrella term for the services that help support patients
(and their family), of which a rehabilitation programme may be one aspect. As such, this follows
the definition given by NICE:[189]
“helps the patient and their family to cope with cancer and treatment of it, from
pre-diagnosis, through the process of diagnosis and treatment, to cure, continuing
illness or death and into bereavement. It helps the patient to maximise the benefits
of treatment and to live as well as possible with the effects of the disease. It is given
equal priority alongside diagnosis and treatment.”
Although this definition of supportive care also includes aspects of palliative care (i.e. dealing
with the issues presented by terminal illness and death) and emphasises support given to family
as well as the patient, this thesis focuses on the needs of patients within the first year after
surgery only. In addition, it should be noted that although supportive care is denoted as being
separate to the risk stratified follow up care in figure 1.8 by the NCSI, for the purposes of this
thesis and based the NICE definition, supportive care includes the activities that form the risk
stratified area of this care pathway and is interchangable with the concept of survivorship care.
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1.8.2 Current supportive care - national guidelines
Current BTS guidelines[47] on the radical management of patients with lung cancer do not
include any recommendations regarding appropriate supportive care for surgical lung cancer
patients, and the only post-surgical considerations included relate to adjuvant chemotherapy
and radiotherapy. In order to minimise post-surgical complications and reductions in quality
of life, guidelines advocate the least invasive form of surgery possible, including using VATS
or muscle sparing thoracotomy procedures if possible. In addition, for patients with smaller
tumours and of borderline fitness, lung parenchymal-sparing surgery is advocated. More ex-
tensive resection is only indicated if this in the only means by which a clear surgical margin
around the tumour can be obtained. NICE guidance for the diagnosis and treatment of lung
cancer has acknowledged the importance of supportive care through every stage of the can-
cer care pathway.[46, 190] Within the section on ‘Palliative interventions and supportive and
palliative care’, this guidance advocates that services should follow recommendations given in
a related NICE guidance document for supportive and palliative care in cancer patients.[189]
Whilst these guidelines recommend that patients should receive holistic care, including access
to psychological, social, spiritual and rehabilitation support services, no specific recommenda-
tions regarding the supportive care needs of surgical lung cancer patients are detailed.
The 2005 NICE guidance for the diagnosis and treatment of lung cancer made further recom-
mendations for supportive care specific to lung cancer, but these were largely based on needs of
patients with advance disease (e.g. management of endobronchial obstruction, brain metastasis,
pleural effusion, spinal cord compression etc) although it was also recommended that “other
symptoms, including weight loss, loss of appetite, depression and difficulty swallowing, should
be managed by multidisciplinary groups that include supportive and palliative care profession-
als.” The updated version of this guidance published in 2011 has additional recommendations
that patients receive a specialist follow up appointment within 6 weeks of completing treatment
to discuss ongoing care and regular appointments thereafter, that patients with a life expectancy
greater than 3 months should also receive a follow up care led by a lung CNS, that patients are
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able to contact the nurse between their hospital appointments and that lung CNS appointments
should be scheduled by the hospital rather than relying on patients to book appointments when
they experience symptoms. In addition, the updated guidance includes recommendations re-
garding smoking cessation. Specifically, patients should be advised to stop smoking as soon as
a diagnosis of lung cancer is received as smoking increases the risk of pulmonary complications
after surgery, and patients should be offered support to quit including prescriptions of nicotine
replacement therapy (NRT) or varenicline. The guidance further advises that surgery should not
be postponed in order for patients to stop smoking.
These recommendations advocate the current gold-standard for supportive care after lung cancer
surgery. However, it is not known to what extent patients receive this support, or the quality of
the support given in standard care. Although increased support by a lung cancer specialist nurse
is advocated, the specific needs of surgical lung cancer patients have not been defined. In the
updated NICE guidance, additional recommendations regarding communication and enhanced
information were made, but none of these recommendations address patients’ informational
needs regarding the effects of surgery and what to expect during recovery. In addition, no
specific recommendations regarding rehabilitation have been made, rather this was highlighted
as a priority for further research. In particular, research regarding the effect of pulmonary
rehabilitation, optimisation of drug treatment and enhanced recovery programmes before and
after surgery on mortality, pulmonary complications, pulmonary function and quality of life
was recommended.[46]
1.8.3 Future rehabilitative care: tested programmes based on
pulmonary rehabilitation
As has been previously discussed (see section 1.5), there is evidence that lung cancer patients
experience a range of health challenges after surgical treatment. Given the respiratory involve-
ment, it has been hypothesised that post-surgical lung cancer patients may benefit from pul-
monary rehabilitation and NICE has recommended further research to measure these poten-
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tial benefits.[191–193] Pulmonary rehabilitation is a programme of tailored exercise and self
management education that was developed for patients with chronic obstructive and non ob-
structive pulmonary disease, and is routinely offered as part of treatment.[194] It is possible
that pulmonary rehabilitation may improve pulmonary function and reduce the risk of pul-
monary complications. In a cohort of 331 patients who underwent wedge resection, lobectomy
or pneumonectomy, predictive post-surgical FEV1 was shown to be the strongest indicator of
risk for development of post-surgical complications [195] and patients with COPD have also
been shown to be at an increased risk of pulmonary complications after lung cancer surgery
compared to patients without.[196]
Three rehabilitation programmes based around principles of pulmonary rehabilitation for COPD
have previously been piloted with lung cancer patients. Spruit and colleagues tested an 8-week
in-patient programme of exercise 3 months after surgery in an uncontrolled pilot trial. The trial
enrolled 10 patients, nine of whom had undergone surgical treatment. Exercise training was
conducted in a group setting along with COPD patients and consisted of daily cycling, treadmill
walking, weight training and stretching exercises. Pulmonary function (measured by FEV1), 6-
min walking distance and peak cycling load were measured before and after the programme.
No significant change in FEV1 was found, however patients showed a significant increase in
exercise capacity at the end of the programme compared to baseline.[191]
Similarly, Cesario et al. tested an inpatient programme with 25 surgical lung cancer patients.
The programme was offered to 211 eligible patients, but the majority declined to participate
and were treated as controls. The programme included five daily 3 hour supervised sessions
each week, up to a maximum of 20, during a hospital stay for the first month after surgery. Ses-
sions included 30 min of continuous cycling, abdominal muscle activities, inspiratory resistive
sessions, treadmill, upper and lower extremities training and full arm circling. Twice weekly
education sessions were also available coving the topics of pulmonary physiopathology, phar-
macology of medications, dietary counselling, relaxation and stress management techniques,
energy conservation principles, and breathing retraining. Those accepting the offer to partic-
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ipate in the trial had significantly worse baseline performance status and respiratory function,
and therefore direct comparison found that controls had better functional and respiratory func-
tion scores after one month. However, comparing one month scores to baseline within group,
borg scale on exertion, FEV1, distance walked and oxygen saturation after 6 minute walk test
all showed improvement for those who received treatment, and deterioration for controls.[192]
A pilot trial of outpatient pulmonary rehabilitation delivered before surgery has also been asso-
ciated with improvements. Bobbio et al. piloted a four week programme with 12 patients who
were eligible for lung cancer surgery, but showed evidence of obstructive pulmonary disease on
pre-surgical respiratory function tests and maximal oxygen consumption by a cardio-pulmonary
exercise test was found to be ≤15 ml/kg/min. The programme involved daily 1.5 hour hospi-
tal appointments, five days a week for four weeks. Patients were taught breathing exercises
and incentive spirometry, and participated in aerobic exercise in the form of stationary cycling
for 40 minutes. After four weeks, resting pulmonary function and diffuse lung capacity of pa-
tients was unchanged, however exercise capacity increased with a significant improvement in
maximal oxygen consumption of 2.8 ml/kg/min.[193]
These pilot trials have shown improvements in exercise capacity and breathlessness scores in the
short term but have been conducted in small groups of self selecting patients. These approaches
remain to be assessed in terms of patient acceptability and definitively tested for long term
effectiveness.
1.9 Rationale for investigating the health and supportive
care needs of surgical lung cancer patients
Of the 41 000 new lung cancer cases in 2008, it was estimated that 12 000 survived for at
least a year and were in need of rehabilitative care.[63] Most patients that survive for longer
than one year will have received curative treatment, the mainstay being surgery.[82] As has
been discussed previously (see section 1.3.4), although survival rates in lung cancer have only
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marginally improved over the past decades, there is an expected rise in incidence due to the
ageing population.[38] In addition, it is possible that in the future, more patients of borderline
fitness will be offered surgery as a result of changes in the national guidelines whose recommen-
dations are more permissive, and advocate greater patient choice in the decision to operate.[46,
47] Taken together, this indicates that the number of lung cancer patients undergoing surgical
treatment and potentially in need of supportive care is set to rise in the coming years.
It has been acknowledged that the current system of cancer care follow up is unsustainable and
does not meet the need of the growing population of cancer survivors.[177] In the first phase of
piloting pathways of care, led by NHS improvement, two medical teams in Hull and Brighton
were invited to test newly developed pathways of care for lung cancer. However, the focus was
to test a proactive management approach to those with active or advanced disease and did not
specifically focus on the needs for surgical patients.[181] Future work by the NCSI in defining
and piloting new pathways of care will be taken forward with breast, colorectal and prostate
cancer only, and is no longer going to focus on lung cancer. [182]
It has been noted that there is a lack of research detailing the ‘natural history’ and care needs of
lung cancer survivors, and these research areas have been identified as a priority by the NCSI,
NCRI and NICE.[1, 46, 186] Past studies using quantitative and qualitative methods to explore
the health experiences of lung cancer patients have mainly focused on those receiving palliative
care or survivorship issues 1-5 years after radical treatment. Although survey and quality of
life data indicate that surgical lung cancer patients often experience health challenges such as
breathlessness and pain after surgery, there are conflicting reports on the duration of these health
challenges. No qualitative exploration of recovery after lung cancer surgery has been published,
nor patients’ evaluation of or attitudes towards their recovery. Although some description of the
prevalence of health behaviours such as smoking, exercise and diet of cancer survivors exists,
again there has been little focus on lung cancer patients specifically and no previous study
has aimed to explore surgical patients views on health behaviours and behaviour change after
diagnosis. Some pilot trials of rehabilitation programmes designed for lung cancer patients
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based on pulmonary rehabilitation have been tested, and report on physiological outcomes.
Patients’ experience of the programme or attitudes towards their post-surgical supportive care
needs have not been explored.
Given the lack of evidence surrounding the health of surgical lung cancer patients and their
supportive care needs, coupled with the growing number of this patient group, an exploration
of these issues is warranted. The purpose of this thesis is to explore these issues in order to
contribute to the evidence base from which tailored services can be designed and tested in the
future.
1.9.1 Thesis aims
In brief, this thesis documents research activity that sought to investigate key health and support-
ive care issues for surgical lung cancer patients in order to contribute to future developments in
supportive care services for this patient group. Below are the specific aims of the investigations
of this thesis:
1. Describe patients’ experiences of health and functioning during the first year after surgery.
2. Describe patients’ health behaviours during the first year after surgery and explore atti-
tudes to health behaviour change.
3. Explore patients’ satisfaction with recovery and level of supportive care received.
4. Describe key design features (i.e. content and format) for a tailored rehabilitation pro-
gramme, based on patients’ needs and preferences.
5. Assess the strength of evidence that smoking history affects prognosis, and if risk of death
is mediated through pathways that are related or unrelated to cancer.
6. Assess the strength of evidence that continued smoking after a diagnosis of lung cancer
affects prognosis, and the likely contribution of cardiovascular risk and cancer-specific
risk.
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TWO
LUNG CANCER PATIENTS’ PERSPECTIVES ON
HEALTH AND SUPPORTIVE CARE NEEDS AFTER
SURGERY: A QUALITATIVE STUDY
2.1 Purpose and aims of the study
This qualitative interview study was conducted to inform the development of supportive care
services for surgical lung cancer patients, and identify important design features of a tailored
rehabilitation programme based on patients’ expressed needs and preferences. In line with these
purposes, the study aimed to explore the following, relating to the first 12 months after surgery:
1. Participants’ health experiences and effect on function.
2. Participants’ health behaviours, health behaviour change and NHS support to change be-
haviour.
3. With participants receiving standard care - attitudes towards recovery, supportive care re-
ceived and preferences for the content and format of a tailored rehabilitation programme.
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4. With participants enrolled on a pilot rehabilitation programme - attitudes towards recov-
ery, supportive care received and rehabilitation programme design change.
This chapter includes the introduction to this study, including the philosophical and method-
ological underpinning, justification for the methods used and a detailed account of the methods.
The subsequent two chapters document the results and the discussion/conclusion, respectively.
This study has been split over three chapters due to the volume of results.
2.2 Introduction
Meeting the needs of cancer survivors has become a focus of national service development since
publication of the Cancer Reform Strategy in 2007 (see section 1.7.2). The rationale for devel-
oping services for surgical lung cancer patients has been discussed in the main introduction (see
section 1.9). In order to develop tailored programmes, understanding the ‘natural history’ of the
patients’ health experiences and also patients’ attitudes regarding the content and design of ser-
vices is key.[186] These issues have not previously been qualitatively explored with surgical
lung cancer patients.
Qualitative exploration of patients’ perspectives is necessary for two main reasons. First, al-
though some quantitative instruments have been used to measure QOL and specific symptoms in
lung cancer patients, the ability of these instruments to capture the varied experience of surgical
patients is unknown.[177] Investigating participants’ experiences qualitatively may shed further
light on the nature of the multifaceted reality of health and functioning after lung surgery, and
indicate if commonly used instruments adequately represent these descriptions. Second, cur-
rent policy aimed at ‘modernising’ healthcare puts the patient ‘at the heart of the NHS’.[197]
Understanding patients’ attitudes towards/preferences for health care is therefore recognised to
be an essential component of developing services that meet their needs.[177, 197, 198]
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2.2.1 Ontological, epistemological and methodological stance:
identification and justification
Qualitative research began to flourish in the latter half of the 20th century (the so called post-
modern era) and past decades have seen the establishment of an array of different underlying
beliefs and approaches to this type of inquiry.[199] In particular, qualitative researchers may
differ regarding their beliefs about the nature/characteristics of reality and what is possible
to be known about it (ontology), how it is possible to know about the nature of reality and
what constitutes ‘knowledge’ (epistemology), and also by their approach used to attempt to
find knowledge regarding reality (methodology).[200, 201] Many have sought to formulate a
definition of qualitative research that, despite the diversity of beliefs and approaches, captures
its essence. A widely quoted definition was formulated by Denzin and Lincoln who explained
that qualitative researchers “study things in their natural settings, attempting to make sense of,
or to interpret, phenomena in terms of the meanings people bring to them.” [202] In addition
to this, Richie and Lewis suggested that qualitative methods are best used “to address research
questions that require explanation or understanding of social phenomena and their contexts.
They are particularly well suited to exploring issues that hold some complexity and to studying
processes that occur over time.”[200] Since its emergence, beliefs and approaches to qualitative
inquiry have evolved such that today, qualitative research is an umbrella term for a variety of
different approaches that may take different philosophical positions, guiding the actions of the
researcher.[203, 204]
It has been acknowledged that “there is no one, single accepted way to approach or carry out
qualitative research”[200]. Establishing a perspective is not a “clear-cut” exercise because dif-
ferent perspectives may be required.[199] However, before embarking on a line of qualitative
inquiry, it is necessary to identify which philosophical perspectives the researcher holds to, or
the paradigm that will be used to inform data collection, analysis and interpretation. Denzin and
Lincoln (1994) describe a paradigm (or world view) as the "net that contains the researcher’s
epistemological, ontological, and methodological premises". It is the philosophical stance that
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provides "a basic set of beliefs that guides action".[202] In the following sections, I will ex-
plain which philosophical positions and methodological approach I took, as well as the specific
methods that I used, in the context of some of the main alternatives, and justify why those I
have chosen are appropriate for pursuit of the aims of this study.
2.2.1.1 Ontology and epistemology
Positivist thinking dominated science from the renaissance until the 20th century, and it is from
this tradition that paradigms of qualitative inquiry have evolved. Ontologically, positivists hold
the belief that reality exists externally or independently to the observer, and is not formed
through the value that the observer or the observed places upon it, so called ‘realism’.[200]
Epistemologically, positivists believe that knowledge about these underlying truths or phenom-
ena can only be obtained through empirical methods of inquiry (i.e. observation through the five
human senses of sight, touch, hearing, smell, taste); deductive, hypothesis driven observation
and experimentation uncovers the ‘what’, ‘when’ , ‘why’ and ‘how many’ of a phenomenon
which is represented in numerical form.[204] The aim of the positivist researcher is to uncover
a single ‘objective truth’, distanced from bias or interpreted value that may skew the observa-
tion. Although this tradition remains active within quantitative approaches, challenges to this
paradigm began to arise at the end of the 19th century, particularly by researchers in the fields of
the social sciences.[199] In the second half of the 20th century, alternative ontological and epis-
temological positions have been advocated by qualitative researchers and the methods used to
gain knowledge based on these underlying beliefs have increasingly become accepted as having
an important role within the field of health research.[204]
Generally, qualitative inquiry could be described as interpretivist.[200] Unlike positivism, in-
terpretivism encompasses the belief that knowledge can be gained through other means than the
senses, specifically through the ‘interpretations’ or ‘constructions’ of individuals or groups of
people based on their experience and influenced by their cultural context. This epistemological
position is taken along side the ontological view that rather than there being one underlying re-
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ality which is objective, there may be several different versions of reality.[202] At the extreme
end of this ontological spectrum, some researchers believe that reality does not exist externally
but is solely the substance of people’s interpretations; that truth is entirely relative. This has
been referred to as ‘relativism’ or ‘idealism’.[199, 200] The most conservative of qualitative
researchers maintain that some of the tenets of positivism can be applied to the social world
as well as the physical worlds (e.g. biological, mechanical, astrophysical worlds) within which
empirical methods were developed. However, moving on from conservative positivism they
believe that there could be more than one underlying reality depending on the perspective of the
observer, thus retaining “an ontological realism while accepting a form of epistemological con-
structivism and relativism” and accepting the “possibility of alternative valid accounts of any
phenomenon” Maxwell, 2008 [199]). Regardless of where researchers place themselves on this
ontological spectrum, qualitative inquiry is considered to be more strongly suited to answering
‘why’ and ‘how’ questions, and to uncovering meaning.[203, 204]
In order to investigate the aims of this project, I have taken on the approach developed by the Na-
tional Centre for Social Research, namely Framework Approach.[200] This approach has been
developed over several decades specifically for use within the field of applied policy research,
and has been recommended and successfully employed within the field of health research.[198,
205, 206] It is based on ‘subtle realism’, as described by Hammersley [207], which posits that
the phenomena under investigation exist independently of participants’ interpretations. How-
ever, different perspectives (or realities) held by participants are acknowledged in the belief
that “different vantage points will yield different types of understanding”[200] and helps the
researcher to understand different ways in which reality has been experienced to convey a “full
. . . picture of the nature of that multifaceted reality.” [200] In other words, although the phe-
nomena that this project aims to investigate could be considered to exist on a purely biological
or practical level (i.e. health, health behaviour, functioning, health services), and measured
independently of participants’ interpretations to some degree, this project acknowledges that
different realities exist based on interpretation of those experiencing these phenomena (onto-
logical position) and seeks to understand the nature of these underlying phenomena from the
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perspective of individual patients (epistemological position), thereby gaining a greater under-
standing of patients’ attitudes towards these things.
2.2.1.2 Methodological approaches
There are a variety of methodological approaches to qualitative inquiry which are underpinned
by the philosophical positions outlined above. I will briefly describe three commonly used
methodologies, and then compare and contrast these approaches to the framework approach
which has been employed in this study. Here, I use the term methodology to refer to the ‘the-
ory’ behind method rather than the practical specifics of data collection and analysis itself (e.g.
interviewing, focus groups, case studies, coding, identification of themes etc.),[208] which I de-
scribe afterwards. The first approach is ‘constant comparison’, which has its roots in grounded
theory methodology developed by Glaser and Strauss [209], and more lately has developed to
include thematic analysis, naturalistic enquiry and interpretive description.[210] Qualitative in-
quiry that uses the constant comparative method proceeds by comparing newly collected data
with data that was collected previously. Instances of a phenomenon are compared within and
between participants to understand how it is the same or different. This method is concerned
with describing the range and patterning of manifestations of the phenomenon and what fac-
tors it might be related to. Often, particularly with grounded theory, no pre-existing theory
or structure is imposed on data collection; rather patterns and theories are formed through the
iterative process of data collection and constant comparison. This is often referred to as induc-
tive reasoning.[200] However, pre-existing theories or knowledge can also been applied using
these methods, particularly when using thematic analyses, which deductively lead to the ac-
quisition and exploration of the range and patterning of the phenomena/experience based on a
pre-existing hypothesis-driven framework.[208]
The narrative approach to qualitative research involves encouraging participants to ‘tell their
story’, normally in chronological order. Rather than comparing phenomena within and between
participants to identify patterns of experience, this approach typically focuses on one or a lim-
80
CHAPTER 2. QUALITATIVE INTERVIEW STUDY
ited number of participants to provide an in depth illumination of the phenomenon of interest.
Stories are viewed as a vehicle by which underlying lived experience can be represented and this
approach is concerned with how choice of language reveals the underlying lived experience and
reveals how people make sense of the phenomenon.[203] Discourse analysis, a type of narrative
approach, draws on the fields of sociolinguistics and cognitive psychology to understand what
is being communicated. It looks in more detail at not only the choice of language, but at the
way participants respond to questions (e.g. pauses, silences, avoidance etc.) and how societal
influences may bring meaning to phenomena through language.[211]
Phenomenological approaches to qualitative inquiry seek to uncover the essence of a phe-
nomenon by in depth study of several individuals, as opposed to only one or two as is the case
with narrative research. Ontologically, this approach appears to veer towards positivism, in that
it seeks to find the single essence of a universal phenomenon through lived experiences, for
example that of insomnia, grief, anger or undergoing a medical procedure.[203] Epistemologi-
cally, phenomenology asserts that reality is a function of consciousness and only exists through
the perceived meaning derived from lived experience. Using this approach, research attempts to
uncover, across many participants, a universal description of ‘what’ was experienced and ‘how’
they experienced it in order to give a detailed description of the phenomenon of interest.[212]
Framework approach, as used in this study, contains elements of these approaches, but most
closely resembles a constant comparative, thematic analysis approach.[200] As with the narra-
tive approach, participants are encouraged to ‘tell their story’ in chronological order as a means
of eliciting and understanding of the phenomena of interest. However, rather than focusing
on the choice of language within a limited number of individuals, participants ‘stories’ and
the instances of experiences/attitudes are compared and contrasted in order to understand the
range of experiences and attitudes that are exhibited, and to identify common themes. Although
framework approach takes interpretive ontological and epistemological positions (i.e. there are
many versions of reality, and knowledge is gained about these versions through the channel
of peoples’ interpretations ), aspects of positivism remain (hence the ‘subtle realism’ classifi-
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cation). Specifically, the researcher aims to be as neutral as possible and rather than learning
about the phenomenon under study by becoming part of the social world experiencing it, re-
mains an impartial observer of the interpretations of others. In addition, rather than taking a
purely inductive approach to understanding experience, experience can be deductively explore
based on preceding understandings and identified research priorities.
This qualitative study arose from pre-determined research priorities and in addition potential
areas of importance had been identified based on a search of published literature (see sections
1.5- 1.6). Based on the capacity to combine deductive and inductive analytical frameworks, the
pragmatic approach to data collection and the successful use by other studies exploring heath
and healthcare issues, the framework approach was considered the most suitable approach to
adopt for this study.
2.2.1.3 Data collection and analysis methods: Identification and justification
There are various options in terms of qualitative data collection approaches, ranging from the
more intensive approaches of ethnography where a researcher becomes part of the social world
understudy through to more time conserving approaches of conducting individual interviews
and focus groups.[203] Given the individual nature of the health experiences and that the aim
of the research was not to understand group influences on experiences, I decided to interview
patients on a one to one basis. A semi-structured interview format was chosen over structured
or unstructured interviewing as there were a range of specific topics that I wanted to address
with participants, but it also gave participants’ an opportunity to introduce areas of discussion
not dictated by the researcher. Richie and Lewis [200] described five interlinking processes to
data collection and analysis using framework approach:
1. Familiarisation with the data - immersion in a pragmatically selected portion of the data
2. Identifying a thematic framework - deductively identify a thematic framework/index for
analysis using the structure of the interview and inductively from findings in stage 1
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3. Indexing - apply all data collected to the identified thematic framework in textual form,
with iterative changes made to the index (and framework) as data collection progresses
4. Charting - summarising data under themes identified by the framework.
5. Mapping and interpretation - map the range and interpret the findings, including finding
associations and defining typologies.[15]
Reflections on the processes that have been involved in conducting this study have been dis-
cussed in section 4.2.
2.3 Methods
The following sections describe the methods used for the study, including data collection and
analysis. Interviewees are referred to as ‘patients’ until they consented to the study, after which
they are referred to as ‘participants’.
2.3.1 Funding/Collaboration
This study was funded by the National School of Primary Care Research (NSPCR). The funding
application and confirmation of funding letter can be found in appendix A.2. The University of
Birmingham acted as sponsor (see appendix A.3). A stipulation for being awarded funding was
to form a collaboration with another primary care department within the NSPCR. I collaborated
with the Healthtalkonline (HTO) team within Primary Care Health Sciences at the University
of Oxford, and arrangements were made to dovetail the aims of this project with a contribu-
tion to their website. The HTO website contains “a unique database of personal and patient
experiences through in-depth qualitative research into over 50 different illnesses and health
conditions.”[213] The HTO venture has been running for over a decade. Patients are inter-
viewed regarding their experiences of health and treatment, the interviews are video recorded,
and visual or audio clips from the videos are published on the website. At the time of this
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project, the HTO website did not include interviews conducted with lung cancer patients who
had undergone VATS. Three participants (HTO1, HTO2 and HTO3) who had undergone VATS
were interviewed following procedures in the HTO manual, and the interviews were video taped
in addition to an audio recording. Clips from the video recordings of interviews with HTO1 and
HTO2 are both posted on the HTO website.[214][215]
2.3.2 NHS recruitment sites
Prior to the commencement of this qualitative research project, the research team that I was
working with had an established collaboration with the thoracic surgery centre at Birmingham
Heartlands Hospital NHS trust (BHH). The idea for the project had been discussed with a tho-
racic surgeon at BHH, and the initial focus was set to be surigcally treated lung cancer patients.
However, as the project developed, it was decided that it would be a beneficial addition to also
recruit patients treated with radical radiotherapy. This was because survival rates are improved
after both of these curative treatments, and it was considered that in addition to surgical patients,
radical radiotherapy patients may also be in need of additional supportive care after treatment.
No previous study was identified that had qualitatively investigated the health and supportive
care needs of lung cancer patients treated with radical radiotherapy. As such, a collaboration
was set up with University Hospital Birmingham NHS Foundation Trust (UHB) who treat lung
cancer patients with curative radical radiotherapy, and a substantial amendment to recruit pa-
tients from this site was granted (see section 2.3.3).
There was one clinical oncologist at UHB that treated lung cancer patients with radical ra-
diotherapy. Unfortunately, although this oncologist agreed to facilitate recruitment of eligible
patients, I was only sent details of and recruited one patient treated this way. During the course
of the project, I made numerous attempts to engage the clinical oncologist, or enlist the help of
a secretary, to improve recruitment but was unable to make progress. As there was only one
radical radiotherapy patient recruited, it was decided that this patients would be excluded from
this analysis. Although this is not ideal as the patient had consented to having data taken and
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was expecting it to be used, I felt that this was the best course of action as it was not possible
to conduct a representative analysis of patients who had received this treatment. Therefore, this
project returned to a sole focus on surgically treated lung cancer patients.
2.3.3 Ethics and R&D approval
As this study involved NHS patients and their data, ethical approval to conduct the study was
sought from Birmingham, East, North and Solihull Research Ethics Committee. A favourable
opinion was given on the 11th March, 2009 (see appendix A.4). During the course of the study
I applied for approval of two substantial amendments. The first amendment involved a change
in the interview schedule, and the second was to extend recruitment to patients treated with
radical radiotherapy from an additional hospital trust, the University Hospitals Birmingham
NHS Foundation Trust. Favourable opinions were given on the 21st September 2009 and 9th
May 2011, respectively (see appendices A.5 and A.6). As patients were only identified by
the hospital trust, and interviews took place at patients’ homes rather than on the premises, it
was not necessary to apply for an honorary contract for each trust, but rather a letter of access
was granted by Heart of England NHS trust and the University Hospitals Birmingham NHS
Foundation Trust (see appendices A.7 and A.8).
The HTO project was granted ethical approval by Berkshire Research Ethics Committee on
22nd May, 2009 (see appendix A.12). Although I did not need to seek for ethical approval to
conduct interviews according to the HTO manual with HTO1, HTO2 and HTO3, I applied to
the Heart of England NHS trust for an additional letter of access to conduct these interviews
(see appendix A.13).
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2.3.4 Patient sample
Lung cancer patients were recruited from a tertiary referral thoracic surgery centre, based at
Birmingham Heartlands Hospital (BHH).1 A list of all patients that were eligible to take part
in the study was generated by a secretary attached to the thoracic surgery team at BHH from
the hospital computerised patient record system. Patients were recruited at interview between
February 2010 and November 2011, and a list was generated a number of times over the course
of recruitment to capture new patients that were becoming eligible. Criteria for eligibility were
as follows:
1. Diagnosis of non-small cell or small cell lung cancer
2. Removal of lung tissue via surgical procedure (VATS or thoracotomy)
3. Surgical procedure conducted between 3 and 12 months previous to the date of interview
4. No confirmed recurrent tumour
The rationale for recruiting patients between 3 and 12 months after surgery, rather than all at 12
months, was to contemporaneously explore patients experiences throughout this period. It was
anticipated that this would give a more reliable overall understanding of the diversity of health
experiences and health behaviours, by minimising recall bias. Although one year survival rates
after surgery are high at around 80%,[216–218] sampling patients at various points along the 12
month pathway also minimised any impact that survival bias may have on the representativeness
of the sample throughout the study period. The strengths and weaknesses of this approach have
been explored in the discussion to this study (see section 4.2).
Patients were purposively selected for initial contact from the list of eligible patients generated
by the secretary. Identification of patients and initial contact was carried out by the research
nurse/physiotherapist, under my direction. The aim of sampling was to recruit patients to rep-
1BHH thoracic surgery unit receives referrals from 11 individual hospitals in the West Midlands, Worcester-
shire, Herefordshire and Gloucestershire areas: BHH, Solihull Hospital, Good Hope Hospital, Walsall Manor, City
Hosptial, UHB, Sandwell General Hospital, Alexandra Hospital (Redditch), Hereford County Hospital, Worcester
Royal Infirmary and Cheltenham General Hospital.
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resent a range of characteristics that may affect the experience of recovery and views regarding
care including age, gender, primary incision procedure (VATS v thoracotomy procedure) and ex-
tent of resection (wedge resection v lobectomy v bilobectomy v pneumonectomy). As patients
were specifically selected for these characteristics, recruitment was not random or consecu-
tive.[219] Patients were not purposefully sampled based on smoking status, as their smoking
status was unknown before the time of the interview. However, a diverse range of behaviours
(i.e. never, former, current at diagnosis, and continued, relapsed or quit after diagnosis) were
represented in the sample (see section 3.1).
During the initial contact, the research nurse/physiotherapist briefly introduced the study, and
asked if patients would be willing for their contact details to be sent to a researcher at the
University of Birmingham who would tell them more about the study and set up an interview
time. In the brief introduction to the study, the research nurse/physiotherapist explained that the
purpose of the study was to talk about their recovery after surgery and about their experience of
and views regarding aftercare.
During the recruitment period for the interview study, a pilot trial of a rehabilitation pro-
gramme for surgical lung cancer patients (the ROC programme - Rehabilitation for Operated
lung Cancer) began recruiting patients who had been treated surgically at BHH (see section
2.3.4.1 for full details of the ROC programme). The thoracic surgery centre received patient
referrals from twelve different hospitals in the region. Patients who had been referred from
either by BHH, Solihull Hospital or Worcester Royal Infirmary (WRI) were eligible to take part
in the ROC programme. Eligible patients were identified at MDT meetings and were recruited
at their first visit to a thoracic surgery/respiratory clinic after the MDT meeting, before surgery.
The first patient was recruited onto the ROC programme on the 6th May, 2010. Patients who
were enrolled in the ROC programme were not excluded from the interview study, if they ful-
filled the interview study eligibility criteria. PID1-14 from the interview study had been identi-
fied for surgery in an MDT before the ROC programme began recruiting patients, and therefore
had not participated in the programme. PID15-31 and HTO1-3 were all identified at an MDT
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whilst the ROC programme was running, and some of these patients had been referred from
either BHH, Solihul Hospital or WRI and therefore had taken part in the ROC programme. Re-
cruiting both patients who had received and who had not received the ROC programme gave the
opportunity to compare the experiences and views of patients who had received these different
levels of care. The research nurse/physiotherapist who initially contacted patients for interview
did not have any prior knowledge of patients who had receive standard care, but were involved
in running the ROC programme and therefore had prior knowledge of some of the ROC patients.
The implications of this and have been discussed in section 4.2.
2.3.4.1 The ROC programme
The ROC programme was designed by a multidisciplinary team of health professionals involved
in surgical lung cancer patient care at BHH and WRI.The development of the programme was
led by Mr Babu Naidu, a thoracic surgeon. The aim of the programme was to modify risk
factors for post-operative pulmonary complications and to improve patient experience through
enhanced information giving and self management education. Modifiable risk factors were
identified based on previous published evidence from the team.[157] Specifically, it was de-
cided that the ROC programme would be designed to address COPD, BMI and smoking status.
Exercise-based rehabilitation programmes have been shown to be effective in optimising recov-
ery in other cancers,[221] cardiovascular disease[2] and have shown promise for lung cancer
patients specifically.[192, 193, 196] Based on this evidence, and coupled with clinical judgment
and expertise, the multidisciplinary team designed the ROC programme which was embedded
within pulmonary rehabilitation services for COPD patients being provided by BHH and WRI.
Participants that enrolled on the ROC programme joined physiotherapist-led pulmonary reha-
bilitation exercise training and education sessions and received additional enhanced informa-
tion sessions tailored to the needs of surgical lung cancer patients from a physiotherapist and
lung CNS. In addition, participants were assessed for nutritional and smoking status and if ap-
propriate were referred to a Macmillan dietician or specialist smoking cessation advisor. The
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programme was run locally at BHH hospital gym for participants referred for surgery from
BHH and within the community at Worcester for participants who had been referred for surgery
from WRI. Participants were encouraged to attend sessions twice a week for as many weeks
as possible prior to surgery. Surgery was not delayed in order for patients to participate in the
pre-surgery component of the programme. Participants were invited to return for a further six,
weekly supervised exercise and education sessions, four weeks after discharge. Sessions lasted
for two hours, with one hour for exercise and one hour for education.
Exercise and educational sessions were delivered in a group setting, although participants exer-
cised at their own pace and received individual feedback from physiotherapists. The content of
exercise and educational sessions are shown in Table 2.1.
Table 2.1: Exercise and education sessions received by participants enrolled in the ROC programme
Exercise session (1st hour) Educational sessions (2nd hour)
Participants were encouraged to engage in
all of the following exercises:
Lower body manoeuvres
Walking
Cycling
Step-ups
Marching on the spot
Sit to stand
Upper body manoeuvres
Upright wall press-ups
Ball bouncing
Backstroke
Upper body twists whilst sitting
Double arm lift with exercise ball
Pulley
Each education session focused on one of
the following topics:
Need for lifestyle change (smoking
cessation, healthy diet)
COPD and co-morbidities
Benefits of exercise
At home advice on exercise
How to deal with breathlessness
Chest clearance
Oxygen and inhalers
Participants received two additional one-to-one information sessions which were specifically
tailored to the needs of lung cancer surgical patients. The first was delivered at the point of
recruitment by a lung CNS, which occurred at the first clinic attendance after a patient was
identified as a candidate for surgery at the multidisciplinary team meeting (MDT). During this
session, a lung CNS explained in more detail what to expect before, during and after surgery,
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the surgical procedure, physical side effects of surgery and how their pain would be managed
whilst an inpatient and on discharge. In addition, participants were given lifestyle advice and
at this point participants who were smoking or had lost more than 10% of their weight over the
previous three months were referred for specialist smoking cessation and dietary intervention.
The second tailored information session was delivered by a physiotherapist during the hour
previous to the participant’s first pulmonary rehabilitation session. This session began with an
assessment of activity/fitness/limitations and health behaviours. Depending on the findings of
the assessment, the physiotherapist briefly covered the topics of the main educational sessions
(see table 2.1), and in addition gave a detailed explanation of lung physiology. Figure 2.1 gives
an overview of the ROC programme.
2.3.5 Recruitment
Patients were invited to participate in batches over the period of the study. The characteristics
of the included participants were monitored throughout this process to ensure maximum vari-
ation in the characteristics of interest (i.e. age, gender, primary incision procedure, extent of
resection and also type of supportive care (standard v ROC programme)). Patients who had
given consent for their details to be passed to a researcher after initial contact from the research
nurse/physiotherapist were contacted by myself, by telephone. More detail about the aims of
the interviews were given and patients were invited to participate in the study.
Patients who were undecided were sent a patient information sheet (PIS) (see appendix A.10)
in the post and given the option of thinking about their decision to participate for 1 week, after
which they were re-contacted for a decision. For those who agreed to be interviewed, I set up
an appointment time for the interview to take place at the patient’s home, and the PIS, along
with an appointment letter, were sent out to the patient’s address. Patients were given at least
48 hours after receiving the PIS before the interview occurred. Most patients did not request
further details about the interview, but some wanted to know more about the topics that would
be covered. In this case, I gave a verbal account of the information in the PIS (see appendix
90
CHAPTER 2. QUALITATIVE INTERVIEW STUDY
Eli
gib
le 
pa
tie
nt 
ide
nti
fie
d
at 
lun
g M
DT
RE
HA
BIL
IAT
IO
N P
RO
GR
AM
ME
 O
FF
ER
ED
 AT
 1S
T
CL
INI
C A
PP
OI
NT
ME
NT
 AF
TE
R M
DT
(1)
 Lu
ng
 CN
S a
sse
sse
s s
mo
kin
g s
tat
us
, b
mi
 an
d n
utr
itio
na
l st
atu
s
(2)
 Lu
ng
 CN
S d
eliv
ers
 ed
uc
ati
on
al 
int
erv
en
tio
n
(3)
 Da
te 
for
 fir
st 
pu
lon
ary
 re
ha
bili
tat
ion
 cla
ss 
co
nfi
rm
ed
 wi
th 
pa
tie
nt
PR
E-O
PE
RA
TIV
E P
UL
MO
NA
RY
 RE
HA
BIL
ITA
TIO
N
(1)
 Pa
tie
nt 
att
en
ds
 1 
ho
ur 
ea
rly
 be
for
e f
irs
t s
es
sio
n f
or 
tai
lor
ed
 1-
2-1
 in
for
ma
tio
na
l in
ter
ve
nti
on
 de
live
red
 by
 ph
ysi
oth
era
pis
t
(2)
 Pa
tie
nt 
co
nti
nu
es
 to
 at
ten
d p
ulm
on
ary
 re
ha
bili
tat
ion
 se
ssi
on
s (
1h
r e
xe
rci
se
 an
d 1
hr 
ed
uc
ati
on
) tw
ice
 a 
we
ek
 un
til s
urg
ery
.
(3)
 At
 fin
al 
se
ssi
on
 be
for
e s
urg
ery
, a
pp
oin
tm
en
t is
 m
ad
e t
o r
etu
rn 
to 
pu
lm
on
ary
 re
ha
bili
tat
ion
 se
ssi
on
s b
eg
inn
ing
 4 
we
ek
s a
fte
r s
urg
ery
.
PO
ST
-O
PE
RA
TIV
E P
UL
MO
NA
RY
 RE
HA
BIL
ITA
TIO
N
(1)
 Pa
tie
nt 
ret
urn
s f
or 
6 w
ee
kly
 se
ssi
on
s in
clu
din
g 1
hr 
ex
erc
ise
 an
d 1
hr 
ed
uc
ati
on
Cu
rre
nt 
sm
ok
er 
- re
fer
ral
 to
 lo
ca
l st
op
 sm
ok
ing
 se
rvc
e
Lo
st 
10
% 
or 
mo
re 
bo
dy
 we
igh
t - 
Re
fer
ral
 to
 M
ac
mi
llan
 di
eti
cia
n
Fi
gu
re
2.
1:
T
he
R
O
C
pr
og
ra
m
m
e
91
CHAPTER 2. QUALITATIVE INTERVIEW STUDY
A.10). Patients were informed that they could withdraw from the project at any time before,
during or at the end of the interview. HTO1, HTO2 and HTO3 were sent the HTO PIS (see
appendix A.15) in addition to the PIS developed for this project, and the potential that interview
material could be used for the HTO website was explained. As with other patients, interviews
were arranged at least 48 hours after receiving the study associated paper work.
2.3.6 Consent
On the day of interview, I checked that patients had read and understood the PIS. Patients who
had not read the PIS were given the opportunity to do so before consenting to take part. I also
gave patients the opportunity to ask questions about the study. Patients were then shown the
consent form and asked to read and sign. The consent form reminded patients of the rights to
withdraw from the study at any time, that relevant sections of their medical notes may be used by
researchers, that the interview would be recorded and that records would be kept confidentially.
HTO1, HTO2 and HTO3 signed additional consent forms that had been approved by Berkshire
REC (see appendices A.9 and A.14).
Although the aim of the interview was to focus on patients only, rather than to explore experi-
ences and views of partners or other family members, in some cases a third party was present
when I arrived at the patients’ home (see table 3.1). If participants requested that the third party
remained present at the interview, this was granted. Third parties did not fill out an additional
consent form but gave verbal consent to participate in the study. Third parties present in the
interview were not asked questions directly, but sometimes they added additional detail to de-
scriptions given initially by the participant. Additional data generated from participation of
third parties in an interview were transcribed along with the rest of the interview material, and
relevant data were included in the analysis whilst attributing the data to the third party.
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2.3.7 Interview
Before commencing, participants were reminded of the aims of the interview. Three possible
difficulties were anticipated and I sought to ameliorate their effect during the set up and deliv-
ery of the interview. Firstly, talking about cancer and treatment may have been upsetting. I
reminded participants that they could stop the interview at any time or decline to discuss partic-
ular topics. Secondly, due to the links between smoking and lung cancer, the topics of smoking
behaviour and treatment was raised sensitively. I aimed to convey a non-judgemental attitude
and encouraged participants to be honest about their smoking behaviour. Thirdly, it was pos-
sible that participant responses would be subject to social desirability bias. To overcome this,
before the interview commenced, I explained that patients could be frank about their experi-
ences and attitudes related to their health and treatment, and reminded them that the interview
findings would be anonymised and were being used to help improve services rather than being
used ‘against’ the NHS.
Interviews proceeded in a semi-structured fashion. To put the recovery experiences into context,
all interviews began with the question “So to start off with, can you tell me what first made
you think there was something wrong?” and participants were encouraged to tell their story
of diagnosis and treatment. Subsequently, several topics were addressed, although the order
and the wording of questions sometimes differed from participant to participant, depending on
how the interview had progressed. The interview topics and questions are found in table 2.2.
Although some closed questions were used, I generally aimed to use open ended, non-leading
questions.
After the interview, participants were given a leaflet signposting organisations which offer in-
formation and support to people who have been treated for lung cancer (see appendix A.11). All
interviews were recorded using a dictophone. The interviews were transcribed and anonymised
by a third party, and then edited for completeness and accuracy by myself. The transcribed
audio file of the interview was the only source of data used in the analysis.
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2.3.8 Post-interview data gathering
The research nurse completed a clinical information form for each participant interviewed from
information in their medical notes, detailing diagnostic and lung cancer surgery characteristics,
prescriptions for inhaled steroid or bronchodilators given on discharge, demographic informa-
tion, co-morbidities (history of COPD, ischaemic heart disease, cardiac failure, hypertension),
breathlessness and Eastern Cooperative Oncology Group (ECOG) performance status recorded
in the pre-operative clinic. Breathlessness was measured using the MRC breathlessness scale.
ECOG performance status included grade 0-5 of activity, with 0 being ‘fully active, able to carry
on all pre-disease performance without restriction’ and 5 being ‘dead’. For a full description of
these grades see section 1.5.2.1.
2.3.9 Interview pilots and iterative changes
The first two interviews were used as a pilot for the interview structure and delivery. Participants
were informed that their interview was a pilot and were asked to give feedback. Neither partici-
pant suggested changes, and felt that the interviews allowed them to express all information that
they felt was relevant. They did not find the content or tone of the interviews distressing. As
the number of interviews completed increased, I became more familiar with the subject area,
and made iterative changes to the preamble to the interview (increasing the directness of the
explanation of the focus and purpose of the interviews), wording of questions (used more terms
that were commonly used by participants, improved on construction of non-leading questions)
and simplified the interview schedule (see appendix A.16 for first version of interview script.
Final collection of questions that were used are found in table 2.2 ).
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2.3.10 Analysis
When conducting qualitative research, the stages of data collection and analysis inform each
other, and data collection undergoes iterative changes due to findings from concurrent analy-
sis.[200] In order to facilitate this, as interviews were completed, transcribed and checked, I
noted emerging themes. Data were managed using NVivo 9.2 (2011 QRS International) which
was developed in collaboration between QRS International and NatCen FrameWork software
developers, and for the first time includes the capability to construct framework matrices. Cod-
ing node trees were constructed, and each interview transcript was coded. Iterative changes
were made to the organisation of the coding tree as new themes emerged from interview data.
In addition, I began to construct framework matrices based on some of the main themes of the
interviews. This process allowed me to see what each participant had said about each theme, and
helped to identify areas that needed further clarification in future interviews. Interviews were
continued until it was considered that no new themes were emerging (saturation of themes)[208]
and the interview aims had been explored in full.
During the early stages of coding, five transcripts were coded independently by an experienced
qualitative researcher. Assignment of codes was found to correspond highly, but any differences
in coding were discussed and resolved. After all data had been collected and coded, and in order
to complete framework matrices, I carried out some additional data coding checks. This was
done by conducting broad context queries in NVivo to retrieve interview data regarding five
main themes of analysis: breathlessness, pain, fatigue & sleep, appetite & weight loss and
smoking. This retrieved all interview data that included the terms of the query along with
surrounding text. The query results were cross-checked with the coded data to ensure full
retrieval of relevant material and framework matrices were constructed based on the final coded
data. Queries were not carried out to check coding of participants’ views regarding attitudes to
recovery and supportive care due to lack of a finite list of key words that would identify these
data. Data were summarised along with illustrative quotes in the matrices for the overarching
themes and sub-themes listed in table 3.4.
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Types of experiences of breathlessness and pain were categorised based on commonly used clin-
ical tools to measure them (see table 3.6 and 3.9). Specifically, categorisation of breathlessness
experiences was based on the MRC breathlessness scale and the Borg Scale. Categorisation
of pain experience was based on the McGill Pain Questionnaire (MPQ) and descriptions of
post-thoracotomy pain syndrome (PTPS) given by the International Association for the Study
of Pain (IASP) (see section 1.5.2 for description of scales and PTPS). A typology of breathless-
ness and pain experience was constructed from patterns across several categories of experiences
that emerged whilst comparing accounts between participants, summarising the extent to which
participants were affected by these health challenges.
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QUALITATIVE INTERVIEW RESULTS
This chapter describes the characteristics of participants interviewed for the qualitative study,
the peri-surgical and post-surgical supportive care that participants received, the main topics
and themes for analysis and then presents the results for each of the four aims of the study (see
section 2.1).
3.1 Characteristics of participants
From the list of eligible patients generated by the medical secretary from computerised patients
records, a total of 46 patients were identified with the range of characteristics that had been
identified for sampling and were approached to participate in the study. From this a total of 34
participants were consented into the study and interviewed. One consented participant (PID2)
had undergone radical radiotherapy two years before removal of an additional tumour via tho-
racotomy at BHH. Searching the medical notes after interview, it became clear that there was
uncertainty over metastatic disease and this participant was excluded from the analysis (see
section 2.3.4). Two interviews (PID7 and PID8) were accidentally deleted from the dictaphone
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before they were saved onto a server, and one further interview (PID27) did not record suc-
cessfully due to technical failure of the equipment. One participant was recruited from UHB
after undergoing curative radiotherapy for a primary tumour (PID22). This participant was ex-
cluded from the analysis as I was unable to arrange other interviews with participants who had
received this treatment. Therefore, a total of 29 participants were included in the analysis, all
of whom had undergone radical surgery and represented a range of demographic and clinical
characteristics (see table 3.1 and 3.2, and figure 3.1).
In total, 14/29 participants were male and the mean age at interview was 70 years (range 39-82
years). . Twenty three participants’ primary procedure was thoracotomy, and 6 participants
had been resected via VATS. Twelve participants had undergone wedge resection (with one or
two wedges being removed) and fourteen participants underwent lobectomy (with one or two
lobes being removed). One participant had undergone a lobectomy with an additional wedge
resection and two participants had undergone a complete pnemonectomy.
There is no national data available regarding the demographics of surgically treated lung cancer
patients with which to compare the sample for representativeness. The 2011 National Lung
Cancer Audit (2010 patient cohort) gives a mean (SD) age of 71.4 (10.7) for all lung cancer
cases,[48] and this is consistent with the age range interviewed in this study. There is no data
on ethnicity or SES breakdown. The 2013 National Lung Cancer Audit (2012 patient cohort)
describes national figures for the number of patients receiving different types of surgical resec-
tion between 2008-2012.[222] During this period, 90% of patients received either lobectomy,
wedge resection, pnuemonectomy or bilobectomy. Therefore, as far as it is possible to tell, the
demographic and surgical characteristics of the patients interviewed are representative of these
characteristics in surgical lung cancer patients in general.
The goal was to recruit patients with confirmed lung cancer between 3 and 12 months after
surgery. Tumour histology was obtained from the medical notes for all but two of the partic-
ipants. Most participants had been diagnosed with non-small cell lung cancer (12 adenocari-
noma, 3 squamous cell, 1 large cell, 3 mixed NSCLC cell types), two participants had small
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PatientsNfullingNtheNinclusionNcriteriaNduringNstudyNperiod
nN=Nunknown
PatientsNapproachedNtoNparticipateNinNtheNstudyN
purposefullyNselectedNtoNrepresentNaNrangeNofN
characteristicsN
nN=N46
PatientsNrecruitedNintoNtheNstudy
nN=N34
RefusedNparticipationNdueNtoNunrelatedNillnessN(n=3)
SaidNtheyNwouldNcallNbackNwhenNtheyNwereNreadyN(n=2)
NotNinterestedN(n=4)
NoNanswerN(n=3)
NumberNofNpatientsNincludedNinNtheNanalysis
nN=N29
Didn'tNfulfillNinclusionNcriteriaN(n=2)
RecordingNerror/fileNdeletionN(n=3)
Figure 3.1: Flow chart of patient sampling
101
CHAPTER 3. QUALITATIVE INTERVIEW RESULTS
cell lung cancer, two participants had a carcinoid tumour and two participants had been diag-
nosed with a mixed non-small cell and small cell lung tumour. Again, these histological types
are representative of the range of histological diagnoses for lung cancer in general.[14] One
participant, however, was found to have no malignancy (PID23). In addition, all patients were
interviewed between 3 and 12 months after surgery apart from one who was interviewed at 14
months after surgery (PID 4). After consideration, PID23 and PID4 were included in the anal-
ysis. For PID23, this was based on the assumption that although his suspected lung cancer was
not confirmed, after surgery he would be phenotypically the same as other patients for whom
cancerous tissue had been removed via the same procedure. PID4 had confirmed lung cancer,
and although was interviewed at 14 months provided descriptions of her experiences during the
first 12 months which were relevant to the analysis.
Participants’ pre-surgical ECOG performance status[223] grade1 ranged from 0 (fully active,
able to carry on all pre-disease performance without restriction) to 3 (capable of only limited
self-care, confined to bed or chair more than 50% of waking hours), with a median score of 0.
Ten participants had been diagnosed with COPD before surgery and five of these participants
were prescribed inhaled bronchodilators and/or steroids on discharge. A further four partici-
pants were diagnosed with asthma and all were prescribed with inhaled bronchodilators and/or
steroids on discharge. Ten participants had been previously diagnosed with hypertension, four
had been diagnosed with ischaemic heart disease and one with chronic cardiac failure. MRC
breathlessness score ranged from 1 to 4, with a median of 1. MRC breathlessness score for
only participants diagnosed with COPD or asthma also ranged from 1-4, but participants had a
median score of 2 for COPD and 1 for asthma (for description of MRC breathlessness score see
section 1.5.2.1).
Most participants (26/29) had a history of smoking. At diagnosis, 11 were current smokers,
1Eastern cooperative oncology group (ECOG) performance status is a widely used measure to assess to what
degree patients are affected by disease. Grade 0 = fully active, able to carry on all pre-disease performance without
restriction, 1= restricted in physically strenuous activity but ambulatory and able to carry out work of a light or
sedentary nature, e.g. light house work, office work, 2 = ambulatory and capable of all self-care but unable to
carry out any work activities. Up and about more than 50% of waking hours, 3 = capable of only limited self-care,
confined to bed or chair more than 50% of waking hours, 4 = completely disables. Cannot carry on any self-care.
Totally confined to bed or chair, 5 = dead.
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15 participants had quit smoking between two months and 40+ years previously and three par-
ticipants were never smokers. The majority of ex-smokers had quit over 10 years before their
diagnosis.
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Table 3.3: Co-morbidity status
ID primary ECOG1 MRC2 COPD3 Asthma IHD4 CHF5 Hyper6 Prescribed inhaler TTH7
HTO1 VATS 0 1 0 0 0 0 0 None
HTO2 VATS 1 3 0 0 0 0 1 None
HTO3 VATS 1 3 1 0 0 0 0 Terbutaline, Seretide,
Tiotropium
PID9 VATS 0 1 0 1 0 0 0 Seretide
PID24 VATS 2 2 0 0 0 0 1 None
PID31 VATS 0 1 0 0 0 0 1 None
PID1 Thoracotomy 0 1 0 0 0 0 0 None
PID3 Thoracotomy 3 2 1 0 0 0 0 Salbutamol, Fluticasine,
Salmetarol
PID4 Thoracotomy 1 3 1 0 0 0 0 Salbutamol, Tiotropium
PID5 Thoracotomy 0 1 1 0 0 0 1 None
PID6 Thoracotomy 0 1 0 1 0 0 0 Salbutamol, Ipratropium,
Symbicort
PID10 Thoracotomy 0 1 0 0 0 0 0 None
PID11 Thoracotomy 1 2 1 0 0 0 0 Salbutamol, Seretide
PID12 Thoracotomy 1 1 1 0 1 1 0 None
PID13 Thoracotomy 1 2 0 0 0 0 0 None
PID14 Thoracotomy 0 1 0 0 0 0 0 None
PID15 Thoracotomy 0 1 1 0 1 0 1 None
PID16 Thoracotomy 0 1 0 0 0 0 0 None
PID17 Thoracotomy 0 2 0 0 0 0 0 None
PID18 Thoracotomy 0 1 0 0 0 0 1 None
PID19 Thoracotomy 0 1 1 0 1 0 1 None
PID20 Thoracotomy 0 1 0 0 0 0 1 None
PID21 Thoracotomy 1 1 0 0 0 0 1 None
PID23 Thoracotomy 1 3 1 0 0 0 0 Seretide, Salbutamol
PID25 Thoracotomy 2 4 1 0 1 0 0 None
PID26 Thoracotomy 0 2 0 0 0 0 0 None
PID28 Thoracotomy 2 1 0 0 0 0 1 None
PID29 Thoracotomy 2 4 0 1 0 0 0 Salmeterol, Beclometasone
PID30 Thoracotomy 1 1 0 1 0 0 0 Seretide, Salbutamol
1ECOG performance status score 0 to 5
2MRC breathlessness scale score 1 to 5
3Chronic obstructive pulmonary disease, 1 = present, 0 = absent
4Ischaemic heart disease, 1 = present, 0 = absent
5Chronic heart failure, 1 = present, 0 = absent
6Hypertension, 1 = present, 0 = absent
7TTH = to take home
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3.2 Description of peri- and post-surgical supportive care
received by interviewed participants
Participants who underwent thoracotomy were admitted for a median of 6 days (range 3-35)
and those who underwent VATS were admitted for a median of 4 days (range 1-8). Eighteen
participants received standard peri- and post-surgical supportive care (see below for descrip-
tion), and 11 participants were enrolled in a rehabilitation programme (for a full description of
the ROC programme see section 2.3.4.1).
Participants receiving standard care and the rehabilitation intervention were admitted on the
day of surgery, apart from PID3 who was admitted a week before with the aim of increasing
his fitness for surgery. As part of standard care, nurses/physiotherapists aimed to mobilise
participants on day one after surgery. Participants were medicated for pain control (including
intravenous morphine or epidural in cases of severe pain). To improve lung function and aid
expansion of the remaining lung tissue into the void created in the thoracic cavity after resection,
participants were taught breathing exercises by physiotherapists whilst inpatients. In addition,
they were given breathing exercise instructions and an incentive spirometer2 to be taken home
on discharge for continued use. In order to be considered fit for discharge, all participants had to
demonstrate ability to climb stairs, under the supervision of a physiotherapist. Participants were
assessed by a clinician before discharge and, along with other medications, were prescribed pain
medication as deemed necessary. Once discharged, participants receiving standard care were
followed up at an outpatient clinic at regular intervals with the primary aim of checking for a
second primary or recurrent tumour.
Participants of the ROC programme pilot received additional supportive care. Briefly this in-
volved twice weekly exercise sessions before surgery and six weekly sessions after surgery,
education sessions, and referral to the stop smoking service or a Macmillan dietician if neces-
2An incentive spirometer is a device which measures the strength of an exhaled breath. In order to achieve high
scores, a patient must breath in deeply and exhale strongly, thus exercising the lungs.
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sary (see section 2.3.4.1 for detailed description of the ROC programme).
3.3 Overarching topics and themes for framework analysis
To help orientate the reader through the following sections, a table of the main topics and
themes for analysis are shown in table 3.4. Main topics and themes were based on the interview
aims and areas of interest identified during the literature search (see sections 1.5 - 1.6). In
addition, some themes and also sub-themes emerged from interview. Although the second aim
was to explore health behaviours and behaviour change including smoking, diet and exercise,
diet and exercise have been omitted in the analysis. This is because although some participants
reported experiencing decreased appetite and weight loss, questions regarding diet and healthy
eating generated little data and was not a topic that was given priority by participants. Many
participants did report increasing their engagement in exercise, but this was discussed in the
context of recovery from breathlessness, or participation in the ROC programme, and as such
is referred to within the first and fourth main topics. Therefore, the second main analysis topic
focuses on smoking and smoking cessation only.
Dictated by the volume of data, six framework matrices were created for main topics or themes
to aid with data analysis (see table 3.4). Within each of the main topics and themes, qualita-
tive differences between key participant sub-groups were also considered. For the numbers of
participants belonging to key participant sub-groups, see table 3.5.
The conventions used for quotations throughout this results section are as follows
• An ellipsis (. . . ) is used to indicate a pause in the interview, or omission of words not
relevant to the quote
• () indicate a word that has been added to clarify the sense
• [] indicates anonymised words
• bold font indicates interviewer speaking
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Table 3.4: Main topics and themes for framework matrix analysis
Main topics Themes
Interview aim 1
Health and function
All participants (n= 29):
1. Breathlessness (framework matrix 1)
2. Pain (framework matrix 2)
3. Other health challenges (framework matrix 3)
Interview aim 2
Smoking
(framework matrix 4)
Participants with a smoking history only (n= 26):
1. Attitudes towards smoking and smoking cessation
2. Reasons for relapse to smoking after discharge
3. Views about NHS intervention for smoking cessation
Interview aim 3
Recovery, supportive care
received and rehabilitation
programme design
(framework matrix 5)
Standard care only (n= 18):
1. Satisfaction with recovery
2. Attitudes towards supportive care received
3. Preferences for the content and format of a tailored
rehabilitation programme
Interview aim 4
Recovery, supportive care
received and rehabilitation
programme design
(framework matrix 6)
ROC programme only (n= 11):
1. Satisfaction with recovery
2. Attitudes towards supportive care received
3. Suggested design changes for the ROC programme
Table 3.5: Number of patients belonging to key sub-groups
Standard care (n= 18) Enrolled in ROC programme (n= 11)
Extent of resection Thoracotomy
(n= 13)
VATS
(n= 5)
Thoracotomy
(n= 10)
VATS
(n= 1)
Pneumonectomy 2 0 0 0
Lobectomy 6 2 7 0
Wedge resection 5 3 3 1
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3.4 Main topic 1: health experiences and effect on function
Two health challenges dominated most participant interviews and arose largely without prompt-
ing: breathlessness and pain. Other health challenges described by participants included loss
of appetite, weight loss, altered sleep and fatigue. Individual health challenges often affected
specific activities and in many cases led to limitation of function. The following sections (3.4.1
- 3.4.4) explore accounts of breathlessness, pain and other less commonly reported health chal-
lenges. Each sub-section summarises the experiences of all consented participants, regardless
of clinical or treatment characteristics, after which qualitative differences between key partici-
pant sub-groups are considered. In addition, a typology of breathlessness and pain experiences
is presented (see table 3.7 and 3.10).
3.4.1 Main topic 1, theme 1: breathlessness
Post-surgical breathlessness was reported by 25/29 participants. Descriptions of experience
were complex and analysis revealed that there were seven dimensions (or sub-themes) of re-
ported breathlessness experience. Comparing interview accounts, categories of experience (or
sub-sub-themes) emerged within each dimension of breathlessness (see table 3.6). For two di-
mensions (5 - physical experience and 7 - other triggers) categories were discrete, and for the
remaining five dimensions categories lay on a continuum of severity. Where experiences lay on
a continuum, they are described from most favourable experience to the least favourable expe-
rience. Experiences are described using the dimension and category names found in table 3.6.
In the following sections, dimensions 1-4 are presented in combination, giving a description
of the extent to which breathlessness affected a participant. In order to help orientation of the
reader, this is done under the headings of the typology which was constructed from these ac-
counts, which is described in the section that follows these accounts (section 3.4.1.1.1). Finally,
dimensions 5-7 are discussed separately in light of this typology.
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Table 3.6: Categories of experience within seven dimensions of breathlessness
No Dimension Category name and description
(equivalence in Borg Scale (BS) and MRC breathlessness scale (MRC))
1 Level of severity Examples of descriptive words used to convey level of breathlessness:
1. ABSENT - no breathlessness (BS = 0–1)
2. LOW - mildly, somewhat, a little (BS = 1–2)
3. MEDIUM - quite, very (BS = 3-6)
4. HIGH - very, very or gasping (BS = 7–10)
2 Effect on function Activity level affected by breathlessness:
1. DEMANDING - strenuous activity such as sport and DIY (MRC = 1)
2. MODERATE - activities such as gardening, housework, shopping, carrying, climb-
ing the stairs and walking more than 1 mile (MRC = 2–4)
3. BASIC - activities of daily living such as talking, grooming, walking between
rooms on the same floor of the house (MRC = 5)
3 Duration Breathlessness resolved within:
1. SHORT - 2 weeks after surgery
2. MEDIUM - between 2 weeks and 3 months after surgery
3. LONG - was not resolved 3–12 months after surgery
4 Trajectory 1. IMPROVING - steady reduction in level of breathlessness over time
2. MAINLY IMPROVING - general trend of reduction over time, with setbacks
3. NO CHANGE - no improvement over time
4. DETERIORATION - Deterioration in breathlessness over time
5 Physical
manifestation
1. Rapid shallow breathing
2. Tightness
3. Reduction in lung capacity
6 Emotional
response
1. Pragmatic outlook, not distressed
2. Distressed
7 Other triggers 1. Smoking environments
2. Change in weather/temperature
3. Pain or fatigue
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3.4.1.1 Level of severity, effect on function, duration and trajectory (dimensions 1-4)
Most participants, regardless of pre-existing breathlessness due to infection or disease, reported
noticing a marked increase in breathlessness immediately after surgery. Almost without excep-
tion, participants described experiences in terms of the specific physical activities that provoked
an increased level of breathlessness. In addition, they gauged their progress in recovery by im-
provements, or otherwise, in the level of breathlessness experienced whilst engaging in these
activities and how long it took to improve. Thus level of severity, effect on function, duration
and trajectory of breathlessness were generally interconnected within participants’ accounts.
After comparison of participants’ accounts, the extent to which participants were affected by
breathlessness was found to lie on a continuum from those not affected to those severely af-
fected.
Not affected by breathlessness For a small number of participants, surgery was not accom-
panied by a noticeable increase in breathlessness and this health challenge did not feature in
their descriptions of recovery. For example, after being asked if they had suffered from breath-
lessness after surgery, two participants (PID19 - THORACOTOMY, LOBECTOMY, 6MPS; PID31 - VATS
, LOBECTOMY, 4MPS)3 stated that they experienced no breathlessness at all and one participant
(PID24- VATS, WEDGE RESECTION, 3MPS) described experiencing breathlessness that was so “light
weight” that she was not sure if it was real or imagined. PID9 (VATS, WEDGE RESECTION, 9MPS)
had suffered with TB as a child and reported having suffered with “chest weakness’’ all of her
life. She explained that although she experienced some breathlessness, she did not think that it
was “any worse now than it used to be” before surgery.
Mildly affected by breathlessness Some participants found that they experienced low4 lev-
els of breathlessness after surgery, but became breathless only when engaging in demanding
3MPS = months post-surgery at time of interview
4For definition of words use to describe level of severity, activity level affected, duration and trajectory of
breathlessness (e.g. low, medium, high level of severity, demanding, moderate, basic level of activity etc.) please
refer to table 3.6
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physical activities by the time of interview. For example, PID18 (THORACOTOMY, BILOBECTOMY,
3MPS) reported low levels of breathlessness associated only with playing tennis or walking up
hills using the words “slightly”, “a bit” and “somewhat”. He added:
PID18: “It’s never stopped . . . It’s not disappeared . . . it’s just probably gradually improv-
ing I should say, yes, it definitely is.”
He was a life-time non smoker and was the only participant who reported choosing to play sport
after surgery. Although his breathlessness had improved, he felt that he was still experiencing
more breathless then he would normally experience, and reported feeling 75% recovered at
interview.
PID26 (THORACOTOMY, LOBECTOMY, 7MPS) was a smoker at diagnosis, and continued to smoke
after his treatment. He explained that he was “surprised about how capable he felt” after
surgery. He had been able to manage the stairs easily in hospital and added:
PID26: “I was quite happy at how quick the recovery was, and in the first few weeks partic-
ularly on week 2 and 3 I was quite pleasantly surprised at how I could go for walks
in a morning.”
After seven months, he reported that he did not get breathless “in the general course of things”.
However, at the time of interview he was decorating his house and explained that he would need
to stop regularly due to breathless, when painting the ceiling for example.
A small number of participants reported experiencing medium levels of breathlessness provoked
by moderate activities after leaving hospital. However, the breathlessness improved over time
and resolved within the first three months after surgery. For example, HTO1 (VATS, LOBECTOMY,
3MPS), an ex-smoker of 11 years, found it easy to climb the stairs with the physiotherapists
whilst an inpatient. When he returned home, he went walking with his dog in a nearby park
on a daily basis which had made him feel breathless, but he noticed that over time the walking
was provoking lower levels of breathlessness. Three months after surgery, he reported that the
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breathlessness had disappeared:
HTO1: “When I first started walking up the hill, I was having to stop half way, then I found
that if I forced myself by striding out a bit stronger, I could get to the top. I was very
breathless when I got there, but it didn’t take long to recover, didn’t take long at all.
But now I can just stroll at one even pace . . . without having to stop at all”
Moderately affected by breathlessness The majority of participants reported medium or
high levels of breathlessness (‘quite’, ‘very’, ‘very very’, ‘gasping’) that were provoked by
moderate levels of activity (stairs, walking outside, housework etc.). After leaving hospital, all
of these participants described gradual improvements, although at different speeds. In addition
some participants reported setbacks in their recovery due to pulmonary complications (e.g. in-
fection, pulmonary embolism). For all of these participants, breathlessness was still present at
the time of interview to a certain extent.
Four participants (PID1, PID10, PID16, PID29) fitting this description were in employment
before they were diagnosed and three (PID10, PID16, PID29) were able to return to work.
All three participants who returned to work reported limitations in their ability to cope with
the physical demands due their health, and this was due to breathlessness for two (PID16 and
PID29). PID29 (THORACOTOMY, LOBECTOMY AND WEDGE RESECTION, 3MPS) was diagnosed with
asthma a number of years before her cancer diagnosis. She described experiencing a series of
chest infections before diagnosis, and had been given a rating of 4 on the MRC breathlessness
scale at a pre-surgical assessment. However, at interview she explained that, other than when
she had an infection, she had felt well before surgery. After surgery she noticed experiencing
an increased level of breathlessness. She explained that she had not felt 100% since the surgery
due to breathlessness, even when going back to work. Her work place had lightened her work
load to accommodate her needs, but she explained that she still found it difficult. She further
explained:
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PID29: “(I) can’t go shopping. I started to go around the shop, by the time I’d gone down
the first aisle, I had to say to my husband, take me back to the car. So I leave the
shopping, he takes me back to the car, he goes back and does the shopping. Then
there’s. . . when the grandkids come in. “Nanny, can you come down and do” “No,
darling I can’t get down there because I can’t get up. If I try to get up, it’s really
hard with my breathing” “Could you collect me from school”. . . “No, I can’t do that
darling, ‘cos I can’t get up you know”. . . So when you go to the shops, and you
need to go back to the car, in what way do you feel not well..? It’s because of the
breathlessness, I just couldn’t walk around, and we can’t always get wheelchairs. . .
they have set amount. And then if there isn’t one, you’re stuck.”
PID16 (THORACOTOMY, LOBECTOMY, 5MPS) was a smoker at diagnosis and continued to smoke
after surgery. She explained how since the surgery and going back to work she was “finding ev-
erything twice as hard physically” because of breathlessness. She particularly found it difficult
to climb the stairs which was something she couldn’t avoid at her workplace. She also noted
breathlessness when working in her garden, and was still experiencing these difficulties.
In contrast to those who had been able to return to work, PID1 (THORACOTOMY, WEDGE RESC-
TION, 11MPS) was unable to return to a manual labour job because of breathlessness and loss of
physical strength. Despite looking for other jobs, he had not been able to find anything at the
time of interview. On discharge from hospital, he started walking on a daily basis, sometimes
walking to the next town, and reported that 11 months after surgery this continued to provoke
medium levels of breathlessness:
PID1: “I walk everywhere. . . If I have to go to [the next town], I walk, I very rarely catch
the bus. And if I don’t have to pick up something then I’ll try and walk back . . .
you can walk slow . . . because there’s no rush . . . you get out of breath, but there
is always somewhere for you to sit down for five minutes and get your breath back
and have a rest and then get up and go and carry on.”
Other participants that continued to experience medium/high levels of breathlessness at the
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time of interview, provoked by moderate activities, had not been in employment before their
diagnosis, but had mostly led active lives. For example PID11 (THORACOTOMY, BILOBECTOMY,
4MPS), an ex-smoker of 10 years, had enjoyed fishing as a hobby. He had co-morbid COPD
and scored 2 on the MRC breathlessness scale on a pre-surgical assessment. He reported expe-
riencing increased levels of breathlessness after surgery, and that climbing stairs and walking
made him very breathless. Four months after his surgery, he reported a “slight improvement”,
but explained that the bronchodilator and corticosteroid inhalers that he had been prescribed for
COPD were helping. He had been unable to return to his hobby of fishing due to concerns about
breathlessness:
PID11: “I used to go fishing. Now I’m frightened of going any distance fishing. Why is
that? Because I’d be out of breath . . . I daren’t, I can’t even go on the rivers,
because I can’t walk with all them lumps . . . ”
PID4 (THORACOTOMY, WEDGE RESECTION, 12MPS) had led an active life visiting friends and go-
ing out socialising. She had been a lifelong smoker, although had quit two months before
surgery. Three months after returning home she relapsed to smoking 40 cigarettes per day,
although had begun a new quit attempt just prior to her interview. She had previously been
diagnosed with COPD and scored 3 on the MRC breathlessness scale in a pre-surgical assess-
ment. Twelve months after her surgery she was still struggling with breathlessness, although
was not housebound and was able to carry out activities of daily living: PID4 (THORACOTOMY,
WEDGE RESECTION, 12MPS) had led an active life visiting friends and going out socialising. She
had been a lifelong smoker, although had quit two months before surgery. Three months after
returning home she relapsed to smoking 40 cigarettes per day, although had begun a new quit
attempt just prior to her interview. She had previously been diagnosed with COPD and scored 3
on the MRC breathlessness scale in a pre-surgical assessment. Twelve months after her surgery
she was still struggling with breathlessness, although was not housebound and was able to carry
out activities of daily living:
119
CHAPTER 3. QUALITATIVE INTERVIEW RESULTS
PID4: “I mean it’s taken me a whole 12 months just to walk from here and get up to the
top. I’ve got to walk to the end of this road, go up a bit of a hill, come up [road1]
back where the shops are. It’s just when I hit [place2] . . . because it’s like that
[demonstrates a hill], I’m frightened for my breath. I mean I only do little steps
now, I can’t walk brisk like I used to, I can’t do none of that.”
Severely physically affected by breathlessness At the worst end of the spectrum, some par-
ticipants experienced high levels of breathlessness provoked by basic activities of daily living
and moving about in the house. For instance, PID20 (THORACOTOMY, PNEUMONECTOMY, 3MPS)
had been an active person who was smoking at diagnosis but had not smoked since that time.
He was a smoker until diagnosis, but had not previously been diagnosed with COPD. He was
one of two participants who had undergone a pnemonectomy. Unlike other participants, he
reported that he became progressively more breathless over time. Three months after surgery
he reported being housebound, and that basic activities of daily living and moving around the
house provoked high levels of breathlessness:
PID20: “How limited are you, would you say? Very limited. At the moment. Very limited.
I don’t do nothing, for myself . . . anything really strenuous, I have to get [wife] to
do it for me. As I say . . . I’d be out of breath by the time I get to the front room . . .
it takes me a good ten minutes to get upstairs at night, to get to bed. And I’m sitting
there gasping for another ten minutes, to try and get my breath before I can actually
get into bed and try and relax.”
PID3 (THORACOTOMY, WEDGE RESECTION, 10MPS) had been largely housebound for 10 months
since discharge from hospital. Before his surgery he had been working as a manual labourer,
although had experienced recurrent chest infections in the 3-4 years preceding his diagnosis. He
described himself as not experiencing breathlessness before his surgery, other than when he had
a chest infection. However, he was a lifetime smoker with a previous diagnosis of COPD and
was rated MRC breathlessness scale of rating of 2 (i.e. short of breath when hurrying or walking
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up a slight hill). He described experiencing an increase in breathlessness since his surgery, and
reported that he had not been able to continue working because of his health. He relapsed to
smoking after being discharged home. PID3 described how 10 months after surgery, walking
between two rooms on the ground floor of his house left him “gasping” for breath, as did his
morning and evening routines. He reported that over time his breathing had improved “a little,
not much’’.
PID3: “ What have been the main difficulties you have experienced since your oper-
ation? Difficulty breathing. Any kind of stress and getting up, getting dressed
[laughs] . . . Getting undressed. At night I’ll get ready for bed. Have a wash, brush
my teeth and whatever. Then I have to have what ten - fifteen minutes of oxygen
to clear my chest and then get into bed after that. And of a morning I’m coughing
continually for about half an hour, bring everything up and more oxygen.”
3.4.1.1.1 Typology of post-surgical breathlessness experiences In summary, the way in
which breathlessness affected participants varied by level of severity, effect on function, du-
ration and trajectory. Some participants were not affected by breathlessness. However, many
participants without a COPD diagnosis experienced breathlessness after surgery, and those with
COPD described a worsening of their experience of breathlessness after surgery. For many,
breathlessness limited their daily functioning for more than three months. In the most severe of
cases, participants found activities of daily living difficult and were largely housebound, or else
they were able to leave the house but still became breathless when engaging in moderate ac-
tivities such as walking, shopping, climbing stairs for example. Breathlessness prevented three
participants from returning to work, and made life difficult for others who did return to work.
Neither the MRC nor the Borg scales of breathlessness could describe breathlessness expe-
riences in their entirety. The MRC scale describes ‘effect on function’ but only describes a
small range of functions in which participants were limited. The Borg scale describes ‘level of
severity’ only.
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Building on these scales, a typology was constructed to represent emerging patterns of the extent
to which participants were affected by the experience of breathlessness (see table 3.7).
There were several clinical characteristics of participants that could have plausibly influenced
the extent to which participants were affected by breathlessness. These were:
1. Type of surgical procedure (thoracotomy v VATS)
2. Extent of resection (pneumonectomy v lobectomy v wedge resection)
3. Smoking behaviour (smoking v not smoking after treatment)
4. Inflammatory lung condition (present v absent)
5. Participation in the ROC rehabilitation programme pilot, which included physiotherapist
led gym sessions and educations about breathing and chest clearance.
Distribution of these participants characteristics within each level of the breathlessness typology
is described in table 3.8. There was a marked qualitative difference between the experiences of
those who had undergone thoracotomy compared with the six participants who had undergone
VATS. Two participants (PID24, PID31) who had undergone VATS reported no or negligible
breathlessness after surgery. A further two participants (HTO1, HTO2) described medium levels
of breathlessness, when walking for example, that had resolved within 3 months. The final two
participants (PID9, HTO3) experienced breathlessness before surgery due to pre-existing lung
conditions and reported breathlessness that was no worse or had improved after surgery. Thus,
all patients who had undergone VATS were examples of not affected or mildly affected by
breathlessness. Conversely, although some participants were not affected at all or were mildly
affected by breathlessness after undergoing thoracotomy, most reported being moderately or
severely affected by breathlessness.
It has previously been reported that extent of resection is associated with post-surgical spiro-
metric measures.[104] However, no obvious pattern of breathlessness experience was found
with resection type for participants who had undergone thoracotomy. Similarly, no pattern of
experience emerged based on smoking status, on pre-surgical MRC breathlessness score or on
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presence of inflammatory lung condition. Most of those enrolled the ROC programme pilot
were examples of being mildly or moderately affected, and none described being severely af-
fected. It is possible that participation in the rehabilitation programme changed the severity
of breathlessness experienced or increased speed of recovery although it was not possible to
investigate this using these data. Participants perceptions of how the rehabilitation programme
affected their breathlessness are discussed in section 3.7.1.
3.4.1.2 Description of the physical manifestation of breathlessness (dimension 5)
When describing breathlessness, some participants demonstrated being out of breath and found
it difficult to explain the experience in words. The demonstration was always of rapid shallow
breaths, and participants indicated that this was a necessary action to rectify the experience
of not having enough breath. All participants that gave this demonstration were people who
continued to be moderately affected by breathlessness at the time of interview. In addition, they
had all undergone thoracotomy. For example, PID14 (moderate - THORACOTOMY, BILOBECOTOMY,
5MPS)5 explained that although his breathlessness had improved, he still needed to take rapid
shallow breaths when walking:
PID14: “you feel as though something’s going to happen and you go <demonstrates quick,
shallow breathing in and out> like this all the time and I still get it now but not as
bad as it used to be . . . my wife makes me get up and have a walk around and by
the time I’m finished I’m sat down <demonstrates quick, shallow breathing in and
out> I’d have to do that, you know.”
Four participants (PID11, PID21, PID28, PID30) described a sensation of “tightness” that de-
veloped in response to physical activity or talking. Again, all participants who reported this
experience were examples of being moderately affected by breathlessness and had undergone
thoracotomy. PID11 (moderate - THORACOTOMY, LOBECTOMY, 4MPS) and PID30 (moderate - THORA-
COTOMY, BI-WEDGE RESECTION, 4MPS) were both ex-smokers and had a co-morbid inflammatory
5mild, moderate, severe refers to breathlessness typology category the participant belongs to
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lung condition. Along with preventative therapy (Seretide), they had been prescribed a bron-
codilator (Ventolin) and reported that acute administration helped:
PID11: “Tight, it goes tight. You can feel it. I can feel it myself when..I start to breathe and
anything like that you can feel, something inside, you know like tight.”
PID30: “it clears the tubes, piece of magic, absolute magic [signals to ventolin inhaler] . . .
talking takes my breath away but they are magic, I couldn’t do without them . . . You
feel it going all up like tightening here [points at the chest] and all the airwaves”
Finally, two participants (PID10 and PID20) described feeling that their lungs did not have the
physical capacity to take deep breaths as they felt necessary, or as they had been able to previous
to their surgery. PID10 (moderate - THORACOTOMY, BI-LOBECTOMY, 7MPS) explained:
PID10: “I can’t take a deep breath, it kind of just stops dead and that’s it . . . when I really
need to take a deep breath in I can’t do it, it just doesn’t happen.”
Similarly, PID20 (severe - THORACOTOMY, PNEUMONECTOMY, 3MPS) explained:
PID20: “I can’t seem to fill my lungs with air. And my lung . . . seems very shallow all the
time with the breathing”
In summary, necessity for rapid shallow breathing, tightness and limited lung capacity were
given as descriptions of the physical experience of breathlessness. All such descriptions were
given by participants who had undergone thoracotomy and had been moderately or severely
affected by breathlessness. There was no other discernible pattern indicating sub-group factors
that were associated with particular descriptions of the sensation of breathlessness, except it was
noted that participants describing limited capacity had both had 2 lobes of lung tissue removed
(PID10 = right bi-lobectomy, PID20 = left pneumonectomy).
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3.4.1.3 Emotional response to the experience of breathlessness (dimension 6)
When talking about breathlessness, some participants demonstrated a pragmatic, stoic outlook,
stating that it was an obvious consequence of lung resection and that it was something they had
to live with or get on with. For instance HTO1 (mild - VATS, LOBECTOMY, 3MPS) explained that in
the first weeks after his surgery he was breathless but felt that was “part and parcel of this type
of operation”. He added:
HTO1: “it does leave you a little breathless, which is something I can live with anyway, I
can live with that. But I’m getting better every day”
Some participants who had been moderately affected by breathlessness, were also pragmatic
about the experience, and did not seem overly distressed about it. For example, PID12 (moderate
- THORACOTOMY, LOBECTOMY, 5MPS) described not being able to walk up a hill. However, he
explained “I just accept the fact is what I can’t do, I can’t do.”
However, some participants described the physical experience of breathlessness as frightening.
For instance PID4 (moderate - THORACOTOMY, WEDGE RESECTION, 12MPS) described her emotional
response to becoming breathless when outside:
PID4: “I’m alright on the flat, but because it’s just up a bit, the way I walk [place2], I’m
frightened for my breath . . . It’s like being claustrophobic really because you’re
trying to get your breath because it comes on all of a sudden, well it’s not all of a
sudden I suppose. I think I’m stronger than I am and obviously I’m not.”
PID10 (moderate - THORACOTOMY, BILOBECTOMY, 9MPS), although nine months on from surgery,
described feeling scared about exercising or engaging in activities that would make her breath-
less. She described an acute episode of coughing whilst at dancing club with her daughter
which had been traumatic. She had felt that she was unable to breath properly, and a friend had
offered her the use of a ventolin inhaler which she reported had helped. She reported that she
was “getting used to things now” but still felt scared:
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PID10: “I’m scared to do a lot of things. I’m scared of getting out of breath . . . . I’m just
getting used to things now and slowly it will get better but I am scared to exercise. I
don’t know what the strength is there, I don’t know if I’m going to pull it. I’m scared
of over exerting myself at the moment.”
PID14 (moderate - THORACOTOMY, BILOBECTOMY, 5MPS) had been very breathless when discharged
from hospital, but gradually improved such that he could engage in activities of daily living
without becoming unduly breathless at the time of the interview. However, he described an
experience where his wife had encouraged him to take a trip to the local shops, but after half an
hour he had to come back home because he became severely breathless. Since that episode, he
had not had the confidence to go outside again:
PID14: “We was only out half an hour. And I came back, took me coat off, sat here and I
was like this [demonstrates shaking] and I was fighting for me breath wasn’t I? And
I thought well, if that’s going be the case, I’m not going to go out anymore. For the
time being anyway. But, uh, I haven’t been out since . . . it scares you, that’s what
scared me . . . when I came back from the walk, that’s what scared us, when I was
fighting for me breath. I was shaking like a leaf, I don’t know why.”
PID21 (moderate - THORACOTOMY, LOBECTOMY, 3MPS) had been housebound since discharge and
reported lacking confidence to leave the house. She explained that breathlessness was partly
responsible:
PID21: “What do you think knocks your confidence? [pause 8 sec] I don’t really know.
It’s just a mixture of like, will I be able to breathe if I walk far or um, am I going to
knock my side, am I going to get the shooting pains . . . it’s a mixture really.”
PID20 (severe - THORACOTOMY, PNEMONECTOMY, 3MPS) and PID3 (severe - THORACOTOMY, WEDGE
RESECTION, 10MPS) were both distressed by the level of breathlessness they continued to expe-
rience, and emphasised this with tone of voice and the words that they chose to describe their
breathlessness such as “gasping”, “really, really struggling” and “fighting” for breath. Both
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explained that they could not do most things for themselves anymore and they were depen-
dent on their wives. PID20 in particular seemed low in mood as he explained how his life had
changed since surgery:
PID20: “Oh I sold my car . . . 79 now, and I’ve been driving since I was 17. I’m not going
to drive again . . . I’ll probably surrender me licence next time . . . Fishing. That’s
all done . . . there’s no way I could do that now.”
In summary, there was a clear divide in terms of emotional response to breathlessness, based on
the extent to which participants were affected. Those who had been mildly affected and some
patients who had been moderately affected adopted a pragmatic, accepting attitude and were
not distressed. The remainder who were moderately and severely affected, were more likely to
report being distressed by the experience. Distress was mainly caused by the acute experience of
feeling breathless but also participants reported distress relating to reduced ability to function.
3.4.1.4 Other triggers of the experience of breathlessness (dimension 7)
Most descriptions of breathlessness were reported to be in conjunction with physical activ-
ity (see section 3.4.1.1). However, other triggers of breathlessness were also described. For
instance, two participants (HTO3 (moderate - THORACOTOMY, BI-WEDGE RESECTION, 4MPS), PID30
(moderate - THORACOTOMY, BI-WEDGE RESECTION, 4MPS)) reported that extra cold or hot tempera-
tures, windy weather conditions and dry heat from central heating affected their breathing. Both
of these participants had a co-morbid inflammatory lung condition.
For others, the experience of breathlessness was associated with pain and fatigue. For instance,
PID3 (severe - THORACOTOMY, WEDGE RESECTION, 10MPS) reported that whilst an inpatient he
found breathing difficult because of pain. In particular, he recounted an experience of not being
able to defecate “because (he) couldn’t breathe properly, because of pain”. PID13 (moderate -
THORACOTOMY, BI-WEDGE RESECTION, 5MPS) had co-morbid rheumatoid arthritis and found that
the pain associated with illness had lead to breathlessness on physical exertion, even before
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her lung resection. She did not specifically report breathlessness in conjunction with surgery
related pain, but found it difficult to distinguish changes in her experience of breathlessness
after surgery because of the breathlessness she had experienced in association with arthritic
pain before surgery. When reflecting on her experiences of breathlessness, PID10 (moderate -
THORACOTOMY, BILOBECTOMY, 9MPS) suggested that it contributed to tiredness, reporting that
“the two sort of go together”.
Finally, a small number of participants that smoked conceded that it was likely that their breath-
ing would be better if they were not smoking, or noticed that when they quit/relapsed their
breathing was affected (see section 3.5.2.1). Other participants who were non-smokers or ex-
smokers gave examples of finding it difficult to breath when being in a smoky atmosphere. For
example PID10 (moderate - THORACOTOMY, BILOBECTOMY, 9MPS) explained:
PID10: “I went to a really big . . . funeral about a month ago and literally as soon as we
came out . . . I think 90% of the people . . . lit a cigarette up . . . and I thought my
chest was going to explode. I just couldn’t get enough breath in you know”
Similarly, HTO1 (mild, VATS, LOBECTOMY, 3MPS) also reported experiencing breathlessness when
at a friend’s bonfire:
HTO1: “we were there for a couple of hours and . . . I couldn’t live with the smoke that
this bonfire was generating . . . I was getting lungfulls of the stuff . . . so we came
home. . . ”
In summary, breathlessness was mainly associated with physical activity, but was also reported
in association with hot, cold and dry temperature or weather conditions, pain, fatigue and smok-
ing/smoky atmospheres. These triggers were only described by participants that had undergone
thoracotomy. It is possible temperature or weather conditions triggering breathlessness may
be explained by presence of co-morbid COPD or asthma, although these participants noted an
increase in breathlessness after surgery.
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3.4.2 Main topic 1, theme 2: pain
Pain management was an integral part of post-surgical care, and participants described receiv-
ing analgesic pharmacotherapy via intravenous, epidural and/or oral routes of administration.
Although participants were largely unaware of the specifics of the analgesic pharmacotherapy
regime they had been prescribed, many mentioned that they received morphine as an inpatient.
In addition to pain management whilst in hospital, participants were often prescribed further
analgesic pharmacotherapy to use at home over the first few weeks after discharge. However,
no additional assessment or treatment of pain was pro-actively offered in standard care or as
part of the rehabilitation intervention.
Despite prescribed pharmacotherapy, 25/29 participants reported experiencing pain after surgery
at some point during the first 12 months. As with breathlessness, participant descriptions of pain
were complex, and they varied in seven dimensions (or sub-themes). Comparing participant ac-
counts, categories of experience (or sub-sub-themes) emerged within each dimension of pain
(see table 3.9). For three dimensions (severity, duration and emotional response), categories lay
on a continuum, whereas categories of effect on function, triggers and physical experience were
discrete. The level of pain experienced over time (trajectory) fluctuated for many participants,
possibly in part due to use of analgesia.
Due to differences in the level of surgical invasion during VATS and thoracotomy, experiences
are considered separately for these procedures. As with breathlessness, in the following sections
pain experiences are described using the dimension and category names found in table 3.9. In
order to help orientation of the reader, within both VATS and thoracotomy sub-sections, this is
done under the headings of a typology constructed from the combined findings from dimensions
1-5 (see table 3.10). Finally, dimensions 6-7 are discussed separately in light of the typology.
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3.4.2.1 Level of severity, effect on function, duration and trajectory (Dimensions 1-5)
Participants gave accounts of the pain that they experienced as an inpatient and also described
experiences and their duration after discharge. It was noted that there was correlation between
the level of pain experienced in hospital and that experienced after discharge. Those experienc-
ing no pain in hospital reported no pain or a low level of pain severity once discharged. Those
who had reported experiencing a low level of pain in hospital continued to experience low lev-
els of pain or the pain disappeared. All reporting high levels of pain in hospital continued to
experience high levels of pain when discharged. Pain after discharge lasted for varying lengths
of time, with some participants still experiencing moderate or high levels of pain at the time of
the interview.
3.4.2.1.1 Pain experiences after VATS
Not or mildly affected by pain Whilst in hospital and after discharge, all participants who
had undergone VATS reported experiencing either no pain or a low level of pain. For exam-
ple, PID9 (VATS, WEDGE RESECTION, 9MPS) was advised to undergo adjuvant treatment with
chemotherapy but she felt strongly that she did not want to accept it. Whilst describing her rea-
sons, she reported having experienced no pain so far throughout her whole patient journey and
she did not want to experience the side effects. HTO1 (VATS, LOBECTOMY, 3MPS), HTO3 (VATS,
WEDGE RESECTION, 4MPS) and PID24 (VATS, WEDGE RESECTION, 3MPS) all experienced low lev-
els of pain severity using the words “discomfort”, “a little pain’’ and “sore” whilst in hospital
which continued for a short period of time (up to three weeks) after discharge, after which it
disappeared. Both HTO1 and PID24 emphasised that the surgery had been nothing to worry
about. PID24 compared the experience to having tonsils removed:
PID24: “. . . I felt it, obviously, for a couple of days . . . to get out of the bed, whenever you
pulled it you could feel that area. I mean if you were to have your tonsils out, your
throat would be iffy for a couple of days, and this was no more.”
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PID31 (VATS, LOBECTOMY, 4MPS) reported not experiencing pain in hospital (note: he was only
in hospital for one night). However, he explained that “everything felt like a boulder, on the
way home in the taxi”. He added:
PID31: “The only time I knew I’d done it was if I turned . . . when I’d lie in bed at night . . .
it woke me up . . . but then, after a couple or three weeks it didn’t wake me up . . . I
had far more pain having my dentures fitted . . . the word is discomfort not pain you
occasionally get an ‘oops’ but not an ‘oh no, I can’t move!.’”
Similarly, HTO2 (VATS, WEDGE RESECTION, 4MPS) noted that when she came round from surgery
she was in no pain, but experienced some numbness. She reported that as the analgesia she had
been prescribed to take at home had “worn off” she began to feel soreness. Unlike participants
who had undergone VATS, she described how three months after surgery, she had developed
“sharp pains” at the site of the surgical incision which were still ongoing.
3.4.2.1.2 Pain after thoracotomy
Not affected by pain Two participants (PID5 (THORACOTOMY, WEDGE RESECTION, 6MPS) , PID15
(THORACOTOMY, LOBECTOMY, 5MPS)) that had undergone thoracotomy reported experiencing no
pain in hospital or after discharge.
Mildly physically affected by pain A few reported that their pain was initially well con-
trolled, but that they began to experience low level pain severity on reduction or removal of
analgesia either in hospital or after discharge. For example, PID12 (THORACOTOMY, LOBEC-
TOMY, 5MPS) reported waking up in no pain after surgery. However, he was being administered
with mechanically regulated intravenous morphine. A few hours after it was taken away, he
reported realising that he was still in pain and requesting for the medication to be restarted.
After discharge he reported experiencing medium level pain severity, particularly triggered by
breathing deeply or coughing, which gradually reduced. PID17 (THORACOTOMY, LOBECTOMY,
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5MPS) explained that after 6-8 weeks she began to experience “discomfort of the inner wound”,
which she attributed to “inner healing” taking place. PID11 (THORACOTOMY, BILOBECTOMY,
4MPS) reported experiencing “discomfort” that had continued when he was discharged home.
He explained that in his understanding the continuing pain originated from damage to his rib
cage:
PID11: “They said “the actual operation is nothing really . . . that will get better right away
. . . but your ribs always take a damn sight longer.” . . . And was that true? It was
true, but it wasn’t all that long. And you can’t say I had pain, it’s just discomfort at
times. So when you coughed, that was when the-? Only, that didn’t last long. But,
it’s only down here, by the side of the ribs. It didn’t last long at all.”
All of these participants were no longer in pain at the time of interview and had not experienced
pain for longer than two months.
Moderately physically affected by pain However, for some the pain lasted longer and they
reported low/medium level pain throughout their inpatient stay, which continued for up to six
months after discharge. For instance, PID13 (THORACOTOMY, BI-WEDGE RESECTION, 5MPS) noted
that it was painful when she did deep breathing exercises whilst in hospital, and this continued
after discharge although she reported not being in any pain at the time of interview. However,
she added that she was taking analgesic medication for arthritis and that this may have been
keeping the pain “under control”. PID14 (THORACOTOMY, BI-LOBECTOMY, 5MPS) described first
being aware of pain in hospital, and reported still being in “a bit” of pain at the time of inter-
view, and reported that pressure applied to the wound site triggered pain; for example, when
turning over in bed at night.
Other participants described experiencing high levels of pain in hospital, that continued after
discharge and gradually subsided to lower levels or had largely disappeared by the time of the
interview. For example, PID1 (THORACOTOMY, WEDGE RESECTION, 11MPS) was administered
with morphine whilst in hospital, and reported being sent home in a lot of pain with a weeping
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wound. His GP organised for him to be readmitted to a different hospital where he was treated
for the infection. He described being in a lot of pain until the infection had gone, which took
at least 3 weeks. After that, the scar began to heal and he reported having no further problems.
PID16 (THORACOTOMY, LOBECTOMY, 5MPS) explained that she had been experiencing high levels
of pain for up to six weeks after the operation. However, this was not associated with infection:
PID16: “I was in a lot of pain after the surgery . . . for a lot of weeks . . . . the pain was
really, really acute . . . I could hardly lift myself, . . . I was constantly having to take
painkillers . . . the pain’s just, it was just horrendous . . . it was really, really sharp.
Agonising pain. And was it constant? Or. . . Yes it was constant. The only thing
that helped was the painkillers. And that only dulled it, it didn’t get rid of it . . . it
was constantly there. But you’re not in pain now? No, I’m not in pain now. So
how did that happen? Gradually, yeah. It just went gradually over, I think it was
about like four weeks after I’d had surgery . . . Maybe longer than four. Four to six
weeks . . . it was a really long process pain wise.”
PID29 (THORACOTOMY, LOBECTOMY AND WEDGE RESECTION, 3MPS) explained that after surgery
if she laughed, took a deep breath or “had a good cough” she would have to support her chest
because of the pain. She added:
PID29: “you notice it less and less each time, unless you do something silly, like cough”
Severely physically affected by pain PID3 and PID19 both reported high levels of pain sever-
ity in hospital and after discharge which was associated with an infection of the wound. In both
cases, pain continued for many months after discharge and was associated with a reduction
in general activity levels. PID3 (THORACOTOMY, WEDGE RESECTION, 10MPS) explained that he
was in a “tremendous amount of pain” whilst in hospital which prevented him from being able
to cough when asked to do so by physiotherapists. Eventually he was able to cough with a
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rolled up towel under his arm to support his chest, in addition to local injections of morphine
around the wound site. Once he was able to cough, he reported producing black phlegm. After
discharge, he reported being in “absolutely agony” until he was referred by chance to a pain
management clinic by a chemotherapy nurse seven months after surgery. After eight days of
treatment he was pain free and the pain had not returned at the time of interview:
PID3: “I had a rolled up towel on there [signals to back of the arm chair] constantly, so
I could hold myself in whilst I coughed. Now I don’t need it . . . So basically I had
been suffering since the operation. Absolute agony. When I was coughing it was
literally doubling me up . . . ”
PID19 (THORACOTOMY, LOBECTOMY, 6MPS) described her wound site as “a gaping hole” that
was seeping fluid and that she was in a lot of pain whilst in hospital. She reported that the
dosage of her pain medication was increased in hospital, which had made her feel “lifeless”
and was in her understanding an overdose:
PID19: “they said to me that I could go home! . . . and I said, “But I’ve still got this hole . . .
I felt absolutely awful. In what way did you feel awful? Well . . . I just felt lifeless
. . . I was just in pain, uncomfortable and this was seeping stuff all the time.”
After discharge she was referred to the care of community nurses rather than readmitted to
hospital. The community nurses visited her everyday to “scrape the top off” the wound. After
a few weeks she saw the surgeon’s registrar who had performed her surgery. He told her that
the community nurses shouldn’t be scraping the wound and advised her to tell them to stop.
PID19 reported that although she relayed this information to the nurses, they disregarded it,
stating that “These surgeons and registrars, they don’t know what they’re talking about . . . All
they know about is cutting people open . . . they don’t know a thing about . . . getting closed
up again.” After many weeks of this continuing situation, she finally refused entrance to the
nurses and her wound began to heal. She reported that it took a long time for the wound to heal
(although didn’t specify a time on probing), and that she was in some pain but she wasn’t overly
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concerned about it and didn’t feel that she needed medication to control it.
PID10 (THORACOTOMY, BI-LOBECTOMY, 7MPS) reported that she experienced “horrendous”, “aw-
ful pain” in hospital. There was no evidence that this high level of pain was caused due to
infection. During the first month after discharge, she described not being able to move without
pain, and that despite being on pain killers she had to sit on the living room sofa with her arms
constantly propped up with pillows in order to avoid pain. Over time the pain subsided, but she
reported experiencing ongoing low level pain severity seven months after discharge:
PID10: “Later on in the day I don’t wear a bra because it swells all here, I just put . . .
the old kind of vest tops on. Because I get swelling like around it here [indicates
surgical wound site] and that gets quite tender still.”
Two participants (PID4, PID21) reported high levels of pain that had not subsided at the time of
the interview. There was no evidence that their continuing pain was associated with infection.
PID21 (THORACOTOMY, LOBECTOMY, 3MPS) reported experiencing a collapsed lung during a CAT
scan guided biopsy that was performed before her thoracotomy. She reported that the necessary
equipment to re-inflate her lung was not in the room where the biopsy had taken place, and she
explained:
PID21: “The result of that [no equipment immediately to hand] was that I had to have a
terrible procedure done, where they gave me no anaesthetic whatsoever, they took
me on a ward, and they held me down, actually physically held me down, and re-
inflated my lung by cutting me inside and putting a tube, a drain, into my lung . . . I
screamed the place down.”
She was subsequently diagnosed with cancer and underwent thoracotomy with lung resection,
but had to undergo a second surgery within the same admission period due to a second lung
collapse. She was receiving intravenous morphine drip whilst in hospital but described experi-
encing high levels of pain that continued when she was eventually discharged two weeks after
surgery. During the three months after her surgery, she had been housebound, partly due to pain
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and described why she was unable to exercise as she felt she ought:
PID21: “I lie down a lot because it’s easier, and I know I’m supposed to exercise but with
all the different pains I get, it’s difficult. I lie there and I think, I didn’t know I should
have pains here and . . . I’m numb down here but I’ve got pain here and I think how
can I . . . be numb and have pain at the same time?”
Finally, PID4 (THORACOTOMY, WEDGE RESECTION, 12MPS) described continuing pain although,
unlike any other participant, in addition to pain associated with the wound site, she described
that her bones “really, really ache”. She reported going to bed in pain and waking up in pain
and explained that she found this wearing. She had experienced aching before her surgery
associated with an accident where she had fallen out of her loft. However, she reported that the
aches and pains were much worse after her cancer treatment, and she particularly associated the
experience with radiotherapy treatment.
3.4.2.1.3 Typology of post-surgical pain experiences In summary, despite medication,
many participants experienced post-surgical pain, although at varying levels of severity and
lasting for varying amounts of time after surgery. High levels of pain were often reported by
participants who had an infected thoracotomy wound. Others experienced high levels of on-
going pain in the absence of infection, although this was associated with complications that
required additional surgery in the case of one participant. In general, participants were partic-
ularly aware of the pain when they were breathing, coughing or when pressure was applied to
the site of the wound. Some participants also reported that it was painful when lying in bed
or sitting in a chair, and those who experienced high level of pain severity reported that their
activity level was generally limited.
A typology was constructed to represent emerging patterns of the extent to which participants
were affected by the experience of pain (see table 3.10). The International Association for the
Study of Pain (IASP) define post-thoracotomy pain syndrome (PTPS) as pain that persists for
longer than 2 months. Most participants (n= 17) were moderately or severely affected by pain
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and therefore fitted this description.
As with breathlessness, there was a marked qualitative difference between the experiences of
those who had undergone thoracotomy compared with those who had undergone VATS, with
the latter being more likely to report no pain or mild pain and the former being more likely to
report moderate or severe pain. No other qualitative differences were noted for other sub-groups
based on participant or treatment characteristics (see table 3.11).
3.4.2.2 Physical experience of pain (dimension 5)
A range of different sensations of pain were described. Some participants described a clamp-
ing/tightening/pulling sensation that travelled along the incision scar. Although this sensation
was only reported by those who had undergone thoracotomy, it was experienced by those that
were mildly, moderately and severely affected by pain. These descriptive words for pain are
classified by the MPQ as constrictive pressure (group 5) and traction pressure (group 6) pain.
For instance, PID4 (severe - THORACOTOMY, WEDGE RESECTION, 12MPS)6 described this experi-
ence occurring regularly:
PID4: “I had this funny feeling when I was in hospital . . . it comes from the back all the
way round and I just put it down to the nerve endings . . . It’s like a clamp with the
pain but it sort of starts in the back where the scar is and then all of a sudden you
can feel it, it’s stiff . . . it goes hard . . . and you can feel it working its way around
and it stops about here [indicates front of the chest wall] . . . Are you feeling that
right now or?It’s stiff but not the pain. I get the pain in the morning mostly and
mostly on a night. And . . . if I sit in a certain way it comes on as well.””
PID25 (moderate - THORACOTOMY, WEDGE RESECTION, 3MPS) described the same experience, but
explained that “to be honest it’s been easier lately. It’s not so bad at all.” PID12 (moderate
- THORACOTOMY, LOBECTOMY, 5MPS) described a moving pain; however, it moved over several
6mild, moderate, severe refers to pain typology category that participants belong to
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weeks rather than happening daily. PID10 (severe - THORACTOMY, BI-LOBECTOMY, 7MPS) also
described experiencing a clamping sensation, but did not report any movement of the sensation:
PID10: “I still get ongoing pain around here [indicates wound site] and even at the end of
the day it feels as though my back on this side concertinas sort of thing like that,
you just want to go like that [demonstrates stretching].”
In addition, PID10 recounted a further similar experience:
PID10: “At one stage I had a lump come up here and I was in ever such a lot of pain with it..
what had happened was the nerves had got really agitated and pulled the diaphragm
up here . . . you could see it on the X-ray.”
Finally, PID14 (moderate - THORACOTOMY, BI-LOBECTOMY, 5MPS) reported a “clinging” sensation
“as if someone had grabbed him and pulled him down” around the wound site, although again
he did not report that this sensation moved along the scar.
Some participants described sharp, shooting pains which were described as “vicious” or “like
a butcher’s knife”. These descriptive words for pain are classified by the MPQ as spatial
(group 2), incisive pressure (group 4) and punishing (group 14) pain. For example, PID3 (se-
vere - THOROCOTOMY, WEDGE RESECTION 10MPS) described experiencing this sensation when he
coughed:
PID3: “When I was coughing it was literally doubling me up. What kind of pain was it?
Vicious . . . It was like. . . someone sticking a knife in-between my ribs.”
In addition, some participants reported that rather than feeling pain, they described sensations
of “numbness”, “feeling a bit funny”, “tingly” and “strange”. These descriptive words for
pain are classified within MPQ brightness (group 8) pain group.
Some participants reported that they experienced more than one type of pain. For example,
PID21 (severe - THORACOTOMY, LOBECTOMY, 3MPS) and PID3 (severe - THORACOTOMY, WEDGE RE-
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SECTION, 10MPS) explained:
PID21: “I’ve got three different types of pain . . . sometimes it’s like a nagging ache. Some-
times it’s shooting pains. And all the while continuing, it’s like I’ve got something
stuck between my ribs that’s there all the while.”
PID3: “It’s completely numb all the way down the centre, could stick a pin in it. But if I
press it, it hurts. Sometimes I get it like someone’s just stuck a branding iron on my
leg occasionally and that hurts”
Often participants noted that the site of the chest drain was particularly painful, more so than
the site of the lung resection. For instance, PID10 (severe -THORACOTOMY, BILOBECTOMY, 9MPS)
reported being in “utter pain’’ when she came round from surgery and further explained:
PID10: “. . . it was awful because I’d got two drains coming out of me with a big swing on
them as well . . . that was the worst pain from the drains. There was a big swing on
the drains like a constant pulling . . . and I was in utter pain.”
PID19 (severe - THORACOTOMY, LOBECTOMY, 6MPS) felt that the pain from the drains was worse
than giving birth:
“I couldn’t get over having the drains in, that was horrendous..I think it’s worse
than when I had two daughters. It’s horrible.”
In summary, it was noted that participants that had undergone a VATS procedure did not use
adjectives to describe their pain that belonged to any of the descriptive groups specified by
the MPQ. The only exception to this was HTO2 who developed shooting pains a few weeks
after discharge. The remaining participants used the words “discomfort” or “a bit of pain”. In
contrast, most participants who had undergone a thoracotomy, particularly those who had been
moderately or severely affected by pain, used adjectives recognised by the MPQ to describe their
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pain experiences. From the sample included in this study, there was no discernible pattern to the
manifestation of these sensations in terms of extent of resection or length of time since surgery.
Regardless of the level of pain reported, some participants noted that the site of the chest drain
(rather than the incision through which part of the lung was resected) was the most painful.
A number of participants described experiencing a cramping/tightening/pulling sensation that
moved along the incision scar. Movement of these sensations is not described by the MPQ.
3.4.2.3 Emotional response to pain (dimension 6)
There was a clear contrast between participants that reported not being affected or being mildly/
moderately affected by pain and those who were severely affected by pain. Generally, when de-
scribing experiences that fitted the mildly and moderately affected categories, participants spoke
pragmatically about their pain. For example HTO1 (mild - VATS, LOBECTOMY, 3MPS), PID13 (mod-
erate - THORACOTOMY, BI-WEDGE RESECTION, 5MPS), PID24 (mild - VATS, WEDGE RESECTION, 3MPS)
and PID29 (moderate - THORACOTOMY, WEDGE RESECTION AND LOBECTOMY, 3MPS) all explained
that it was “to be expected” and that they were not worried about it.
However, as would be expected, when participants experienced a high level of pain they found
it distressing whether it resolved quickly (moderately affected) or continued (severely affected).
This was reflected in their tone of voice and also choice of words to describe the pain such as
“tremendous”, “terrible’’, “awful”. A few participants reported that they had found it painful
to cough as an inpatient, or had found it difficult to mobilise themselves from their bed and
wash in the bathroom. Some participants felt that the staff had not been understanding of the
amount of pain that they were in. One participant (PID26 moderate - THORACOTOMY, LOBECTOMY,
7MPS) went as far as describing this as bullying:
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PID26: “in the first couple of days.. the physios . . . were getting me to cough . . . and it was
very painful from the wound sort of stretching and it felt like the wound was going
to burst open and they kept saying come on you need to try harder . . . and the pain
was excruciating and I was still trying, and I was thinking “this is bullying this is
because I’m in real pain here”’ . . . then at one point I just said “I’m not going to
do it any more so you might as well go away” and I was in tears, I was crying for
some reason.”
PID3 (severe - THORACOTOMY, WEDGE RESECTION, 10MPS) also recounted an experience which he
had found distressing as an inpatient, the day after his surgery:
PID3: “her and another nurse, frog marched me down to the bathroom, stood me in front
of the sink, no oxygen, nothing. She said have a wash, get yourself washed. Course
I was dropping onto the basin, couldn’t breathe, gasping for breath. I finally settled
down and I just swilled my face basically and she came in, have you finished yet?
I said I want to go to the toilet. So she put me on to the toilet, but I couldn’t do
anything because I couldn’t breathe properly because of pain. She come back down
and frog marched me back to the bed. Sat me in the chair, put the oxygen back on
and that were it.”
Some participants also expressed that they had not expected the severity of pain that they expe-
rienced. For example, PID10 (severe - THORACOTOMY, BI-LOBECTOMY, 7MPS) explained:
PID10: “Looking back, I didn’t realise how big an impact the operation would have and
how harsh the operation - it’s really bad. I’ve had caesareans, I’ve had a hysterec-
tomy, I’ve had little minor surgeries and I thought I’d walk it, I thought I’d be OK.
Oh my God, honestly, I felt as though I’d been in a car crash. It was horrid. Horrid.
It really is a nasty operation, I didn’t realise it . . . ”
PID21 (severe - THORACOTOMY, LOBECTOMY, 3MPS) disclosed that she had contemplated suicide,
and that if she had known how much she was going to suffer she would have chosen to go the
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palliative care route:
PID21: “if I’d have known what was involved and how I was going to suffer, I wouldn’t
have bothered. . . it’s been so difficult, the pain has been terrible . . . I’d have either
gone into [hospice 1] and just gone under their sort of niceness, or, to be perfectly
frank, if I hadn’t got my cat, it would’ve been an exhaust on the car job.”
Unexpected, enduring high levels of pain also led some participants to worry that ‘something
had gone wrong’. For example, PID28 (severe - THORACOTOMY, LOBECTOMY, 3MPS) described
being “shocked” by what had happened as a result of the surgery, and added:
PID28: “You don’t know, whether it’s normal to be sort of coughing and the pain but then,
I suppose they don’t know either really do they? I think it’s just the fear of the
unknown. I’d sort of get a pain or it would be something that I hadn’t had before
and you think oh gosh, is everything okay?”
PID21 (severe - THORACOTOMY, LOBECTOMY, 3MPS) was also worried about the significance of her
pain experiences. She described experiencing three types of pain, and additionally described a
‘moving pain’ similar to those described in section 3.4.2.2:
PID21: “But, sometimes it actually feels like something’s moving round in there . . . and
I think, God’s sake, what’s going on in here! You know what I mean . . . and it’s
frightening, it’s worrying. I mean the pain moves around. And I started to think,
well why? . . . you imagine all sorts of stuff, ’cause I was starting to think, there’s
something gone wrong here.”
In summary, only patients who had experienced high levels of pain severity after thoracotomy
reported feeling distressed by their experience. No patients who had undergone VATS reported
high levels of pain and they did not report feeling distressed by the pain that they experienced.
Often high levels of pain severity that continued for a protracted length of time (severely af-
fected) were unexpected and led participants to worry that something had gone wrong. Of those
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who had been severely affected, both those who had received standard care and those who had
participated in the rehabilitation programme pilot reported being worried about the significance
of their pain experience.
3.4.3 Main topic 1, theme 3: other health challenges
Although breathlessness and pain were the most commonly reported health challenges, some
participants reported additional post-surgical health challenges including: reduced appetite,
weight loss, altered sleep and general fatigue.
Appetite and weight loss Thirteen participants reported loss of appetite and some had also
lost weight. For all participants, appetite had improved over time but many still felt that they
didn’t have their full appetite back at the time of interview. Although participants were often un-
certain about the cause of their loss of appetite, there were a range of factors that were reported
as possible contributors. Both PID29 (BT moderate, PT moderate7 -THORACOTOMY, LOBECTOMY AND
WEDGE RESECTION, 3MPS) and PID31 (BT absent, PT mild - VATS, LOBECTOMY, 4MPS) described loss
of appetite and nausea concurrent to chemotherapy, although neither reported significant weight
loss. PID29 added that she had been making an effort to eat in order to “keep (her) weight up”.
PID10 (BT moderate, PT severe -THORACOTOMY, BILOBECTOMY, 7MPS) reported that she did not have
much of an appetite until her pain medication was changed, after which she started to put on
weight. PID17 (BT moderate, PT moderate -THORACOTOMY, LOBECTOMY, 5MPS) noticed that she was
“never ready for any meal” and that she had lost her sense of taste. She was not sure whether
she was experiencing this as a side effect of the anaesthetic or chemotherapy:
PID17: “It’s only probably about the last six weeks that I began to feel that I’ve gone back
onto taking some foods that I just couldn’t stand the sight of . . . Nothing tasted . . .
But my appetite has got much better . . . it has improved, but I can’t say, still say,
that I’m hungry or ready for a meal. I’m not, (but) it’s much better than it was.”
7BT = breathlessness typology, PT = pain typology
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PID20 (BT severe, PT absent -THORACOTOMY, PNEUMONECTOMY, 3MPS) reported loss of appetite
after being discharge from hospital although he was not sure what was causing it. However,
this participant had been severely affected by breathlessness and was largely housebound as a
result, he also demonstrated low mood. He was not undergoing adjuvant therapy and neither
had he lost a significant amount of weight. He explained:
PID20: “I’ve gone off my food . . . Just don’t feel like eating, and when I do, it’s only certain
things I like to eat like, [person 1] put some dinner out yesterday. I ate the mash
potatoes, struggled with the vegetables. I had one piece of the chop. And that’s all
I could eat. I couldn’t eat anymore . . . I used to have a fairly good appetite at one
point but, when I look at things, for some reason, (I) think I don’t want that. It’s
strange.”
PID14 (BT moderate, PT moderate -THORACOTOMY, BILOBECTOMY, 5MPS), PID16 (BT moderate, PT
moderate -THORACOTOMY, BILOBECTOMY, 5MPS) and PID21 (BT moderate, PT severe - THORACOTOMY,
LOBECTOMY, 3MPS) all reported losing an amount of weight that they were concerned about,
and they were actively trying to gain weight. PID14 reported having his full appetite back at
interview, however PID16 and 21 were still not back to normal in terms of appetite. Although
PID14 did not offer a possible cause, PID16 cited the effect of chemotherapy on her sense of
taste. PID21 suggested that it was due to the combined stress of her cancer treatment and also a
difficult relationship. She explained:
PID21: “The eating has been a problem . . . people may be at risk from malnutrition, I don’t
think I’m that far down the road but like, I’ve got no appetite . . . I buy myself all
nice things . . . but I’ve not got a lot of appetite . . . I’ve always been tiny, but it’s got
ridiculous . . . nothing fits, and I’m hard pressed to find something to get dressed in.
And, I think, well, shall I buy a pair of size six? But then I was online looking when
you came and it’s difficult to find.”
In summary, about a third of participants reported loss of appetite and for some this was still
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present at the time of interview. Loss of appetite was more often reported by those who had
undergone thoracotomy, but participants specifically stated a range of other reasons for loss of
appetite including chemotherapy, pain medication, stress and change in routine. Weight loss
only occurred in a few participants, and these participants reported being concerned about it
and were actively trying to regain weight.
Altered sleep Eleven participants reported disturbances in their sleep. Some were able to
sleep at night but found themselves needing more sleep than usual, and/or were also falling
asleep during the day. HTO1 (BT mild, PT mild - VATS, LOBECTOMY, 3MPS) reported being “shat-
tered” on the first day he was discharged from hospital and sleeping more than he normally
would on his first night at home. He felt that his tiredness was due to lack of sleep in hospital:
HTO1: “I arrived home about six o’clock in the evening, and I desperately wanted to watch
the football highlights at 10.30pm (but) I was in bed at 9.30pm . . . and I woke up
the following morning at about eight o’clock, I couldn’t believe the time . . . ”
Four participants (PID3 (BT severe, PT severe - THORACOTOMY, WEDGE RESECTION, 6MPS), PID10
(BT moderate, PT severe - THORACOTOMY, BILOBECTOMY, 7MPS), PID19 (BT absent, PT severe -THORACOTOMY,
LOBECTOMY, 6MPS) and PID21 (BT moderate, PT severe - THORACOTOMY, LOBECTOMY, 3MPS)) who
had undergone thoracotomy also reported needing more sleep than normal, but in contrast to
HTO1 it lasted for a much longer length of time. Two participants (PID3 and PID19) both de-
scribed sleeping because of tiredness, or running out of energy. PID3 explained that after his
surgery he started sleeping heavily, “for hours and hours” because “there’s just nothing left.”
His wife added:
PID3: “[Wife: You still do that now. He can have his first sleep until 11 o’clock. Then he’ll
have his lunch then he’ll sleep again and then he’ll sleep again during the evening
and it’s like he just switches off].”
PID19 reported not sleeping during the day but getting very tired towards the evening and going
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to bed earlier than had been normal for her before surgery.
PID21 reported needing up to 16 hours of sleep a day after she was discharged from hospital,
but referenced the fact that she was on “heavy drugs” (including morphine). PID10 had been
able to return to work, but described how she often came home feeling exhausted and would
fall sleep. She explained that she thought the tiredness was due to shortness of breath:
PID10: “I’d work till 2, come home and go to sleep. Literally come in the door, go up the
stairs, sit on the bed and fall asleep . . . even now I only work a Wednesday and
a Friday, I come home from work on a Friday I literally go upstairs, have a quick
shower get my pyjamas on and then I don’t move because . . . I’m just so tired, I get
physically exhausted quite easily. Like a nanny . . . I think probably the tiredness
comes from the shortness of breath the two sort of go together I think.”
One participant who had undergone VATS and also some participants who had undergone thora-
cotomy reported not being able to sleep properly during the night. Again, this situation resolved
within days for the participant who had undergone VATS, but was a protracted problem for those
who had undergone thoracotomy. PID29 (BT moderate, PT moderate - THORACOTOMY, LOBECTOMY
AND WEDGE RESECTION, 3MPS), PID30 (BT moderate, PT severe - THORACOTOMY, BI-WEDGE RESEC-
TION, 4MPS) and PID31 (BT absent, PT mild - VATS, LOBECTOMY, 4MPS) all reported that the cause of
their disturbed sleep was pain when moving position. Each also described that they had needed
to change from their normal sleeping positions in order to avoid triggering pain, which had
initially disturbed their ability to sleep. PID20 described how he had not had a “good night’s
sleep” for a long time but due to breathlessness rather than pain:
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PID20: “And I’m struggling for me breath at night, most nights, it’s been ages since I’ve
had a good night’s sleep. Ages. What’s stopping you from sleeping? Breathing . . .
I’ve got to get comfortable . . . I sit up most of the time . . . because I found . . . if I
lay . . . on my sides . . . I was really struggling to get me breath. So I found it best
to sit up, pack my pillows behind me . . . even then I have trouble . . . last night . . .
about five o’clock, I moved that side, and lay on some pillows. I just found . . . a
nice position, where I found me breathing a lot easier. And I dosed off for a couple
of hours. That’s very rare that is.”
PID14 (BT moderate, PT moderate - THORACOTOMY, BI-WEDGE RESECTION, 5MPS) found himself
waking up multiple times a night for a few weeks after discharge. However, he couldn’t under-
stand why, and reported not being in any pain. The situation resolved after he was prescribed a
course of sleeping pills by his GP. PID4 (BT, moderate PT, severe - THORACOTOMY, WEDGE RESEC-
TION, 12MPS) reported finding it difficult to sleep at night, and that instead she was sleeping in the
day. This had been a difficulty since the treatment and had not resolved after 12 months. PID21
(BT moderate, PT severe - THORACOTOMY, LOBECTOMY, 3MPS) also reported sleeping more than nor-
mal during the day when she was first discharged from hospital, and that then she started to find
it difficult to sleep at night. Both PID4 and 21 felt that their sleep disturbances were rooted in
anxiety, with PID21 adding that she often experienced nightmares.
In summary, some participants reported needing more sleep than normal, whereas others found
it difficult to sleep during the night. Alterations in sleep were reported to arise due to a range of
reasons, including pain, breathlessness and anxiety. This difficulty resolved quickly for those
who had undergone VATS but was a protracted problem for those who had undergone thoraco-
tomy.
General fatigue Five participants described a general feeling of fatigue, and in particular re-
ported that activities left them feeling more tired than usual, or that they got tired more quickly.
These participants did not report that their sleep was also affected, although they were not
probed directly about this. For example, PID9 (BT absent, PT absent - VATS, WEDGE RESCTION,
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9MPS) reported that she was not greatly affected by surgery and was able to return to her em-
ployment as a care worker, although she had changed her working hours. She later explained
this was because of tiredness. PID16 (BT moderate, PT moderate - THOROCOTMY, LOBECTOMY, 5MPS)
also described how she had returned to work but five months after surgery was still finding that
she returned home feeling “really, really tired’’:
PID16: “I’m still getting very tired . . . after the work, I come home and I’m really really
tired . . . it’s just one of these things you’ve just got to [pause 1 sec], I mean they’re
very supportive at work. I have thought about reducing my hours if I can’t cope and
I’m sure they’re fine with that and I asked if I can say maybe work one day a week
from home so, I am trying to think of things to sort of help me get back to normal.
But I know it’s going to take time.”
PID17 (BT moderate, PT moderate - THOROCOTMY, LOBECTOMY, 5MPS) described experiencing “lethargy”
as a side effect of chemotherapy, and that sometimes if she had done too much during the day
she “suddenly slumps’’ and has to rest:
PID17: “But it’s something about . . . stamina, I hadn’t got the stamina I was used to hav-
ing . . . the main side effect (of chemotherapy) . . . has been the breathlessness and
terrible tiredness on days six seven and eight . . . then I might have an occasional
day, when perhaps I’ve done too much and I suddenly have to, I suddenly slump.
And I have to sit down.”
PID1 (BT moderate, PT moderate - THOROCOTMY, WEDGE RESECTION, 11MPS) and PID28 (BT moder-
ate, PT severe - THOROCOTMY, LOBECTOMY AND WEDGE RESECTION, 5MPS) described feeling tired
although they did not know why. PID28 had experienced tiredness since surgery and reported
that although she was recovered in other ways at the time of interview she still felt more tired
than usual:
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PID28: “But I do find now that I want to get on and do things but I get so tired . . . I don’t
know why . . . just sort of weary . . . making the effort to do things . . . I still get tired,
at the end of the day I think, you know, glad that’s over.”
In summary, fatigue was reported by both one participant who had undergone VATS and by
four participants who had undergone thoracotomy. It appeared that regardless of surgery type,
fatigue was an ongoing challenge that remained in the background at the time of interview.
Unlike other physical challenges, descriptions suggested that this ‘background level’ of fatigue
did not improved over time and also for many the phenomenon was not linked with a particular
trigger.
3.4.4 Summary of participants health experiences during the first 12
months after surgery
Although a typology of breathlessness and pain experiences emerged from the reported experi-
ences of participants in this study, no unifying typology was evident. A summary of the health
experiences of individual participants during the first year after surgery are found in tables 3.12
and 3.13. The extent to which these findings confirm and extend existing, commonly used
measures of breathlessness and pain will be addressed in the discussion.
3.5 Main topic 2: smoking
Most participants (26/29) had a history of smoking. Eleven patients were current smokers at
diagnosis, 15 participants had quit smoking between two months and 40+ years previous to
diagnosis and three participants were never smokers. All 11 participants smoking at diagnosis
reported abstinence throughout hospitalisation. Of those 11, three remained abstinent until in-
terview, four attempted to remain abstinent but had relapsed, and four chose to resume smoking
on discharge and were still smoking at interview. Of the two participants that had quit in the
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year leading up to their diagnosis (PID4, two months and PID6, 8 months), only PID6 remained
abstinent after discharge.
In the following sections, the attitudes of participants towards smoking, smoking cessation and
NHS services for smoking cessation support is considered in the light of smoking behaviour
groups (see table 3.14). Never smokers were not included in the analysis as they provided no
relevant data. Participants were assigned to groups as follows:
Table 3.14: Smoking behaviour groups
Smoking behaviour group Participants
Ex-smoker at diagnosis HTO1, HTO2, HTO3, PID1 PID41, PID6, PID10, PID11,
PID12, PID14, PID19, PID24, PID25, PID29, PID31
Smoker at diagnosis – con-
tinuous abstinence after dis-
charge
PID15, PID20, PID30
Smoker at diagnosis – quit
and relapsed after discharge
PID3, PID41, PID13, PID16, PID23
Smoker at diagnosis – con-
tinuous smoking after dis-
charge
PID5, PID9, PID21, PID26
3.5.1 Ex-smoker at diagnosis
3.5.1.1 Main topic 2, theme 1: attitudes towards smoking and smoking cessation
Ex-smokers generally reported that they had no desire to smoke. Those who had quit smoking
more than 1 year before surgery felt that smoking cessation support was not relevant to them-
selves. They did not express concern about being asked about their smoking during their cancer
care, and were able to answer the question with ease. No ex-smoker of eight months or more
reported benefits that they perceived to be associated with smoking and some expressed their
dislike of smoking, explaining that they were thankful that they no longer smoked and some
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added that they wish they had never started in the first place. Regardless of the stress experi-
enced due to their diagnosis and treatment, ex-smokers of 8 months or more found that they
were not tempted to start smoking again at diagnosis. For example, PID1 who had quit 20+
years before diagnosis explained that smoking “didn’t bother (him) whatsoever”. PID6 (THO-
RACOTMY, PNEUMONECTOMY, 11MPS) quit smoking eight months before she was diagnosed, and
she reported that “it never occurred to (her) to smoke again”. She explained that the first two
months of quitting had been difficult, but now she “couldn’t stand the smell of (smoke)”. PID4
quit two months before diagnosis, but found it difficult to not smoke after she was discharged
from hospital and relapsed to smoking 40 cigarettes per day three months after discharge. When
discussing her views towards smoking, unlike other ex smokers, she emphasised the benefits of
smoking, such as her belief that it provided stress relief (see section 3.5.2.1).
There was some evidence that ex-smokers felt stigma attached to the diagnosis of lung cancer,
which was deemed to be unfair. PID10 (THORACOTMY, BI-LOBECTOMY, 7MPS) had a history of
smoking, but had not smoked for many years. She was particularly worried at the beginning of
her cancer journey that people would assume she had ‘smoked herself a tumour’. She was the
youngest participant (diagnosed at age 39) and believed that her diagnosis was not related to
smoking:
PID10: “That’s a big thing as well . . . I felt a stigma, and it’s a dirty cancer . . . I felt, it
feels terrible to say that word but it did feel like a dirty cancer from smoking, and
it’s not. That’s how I perceived that people saw me at the beginning.”
Similar to participants who were smoking at diagnosis (see section 3.5.2.1), PID6 (THORA-
COTMY, PNEUMONECTOMY, 11MPS), who had stopped smoking eight months prior to diagnosis,
explained that she felt ashamed when asked by doctors if she was smoking, although she later
pointed out that often doctors and nurses are seen smoking outside of hospitals and she felt that
this did not set a good example.
158
CHAPTER 3. QUALITATIVE INTERVIEW RESULTS
PID6: “I felt ashamed. I’ve done this to myself you know. It’s my fault I’ve got it. But it
was my own fault, wasn’t it . . . I don’t think anyone realises how addictive it is and
I feel it should be banned, cause it’s a drug, you know . . . I couldn’t give it up so . . .
I did in the end, but too late.”
Despite finding it uncomfortable to answer questions about her smoking behaviours, PID6 ex-
plained that she thought that it was the rightful place of doctors to ask those questions, and that
it did not offend her. No other ex-smokers described feeling guilty about their past smoking or
expressed feeling a weight of responsibility for their diagnosis. However, some did wonder if
smoking had contributed to their diagnosis.
3.5.2 Current smoker at diagnosis
3.5.2.1 Main topic 2, theme 1: attitudes towards smoking and smoking cessation
The attitudes of current smokers towards smoking and smoking cessation fell into three main
categories: a resolute desire to quit, internal conflict with regards to desire to quit and resolute
desire not to quit.
Resolute desire to be quit The majority of participants who were smoking at diagnosis stated
that they would prefer to be a non-smoker. For some participants, this desire was expressed res-
olutely, with no evidence of an internal conflict of attitude. For example, two of the three partic-
ipants who were continually abstinent after diagnosis explained that they had ‘just decided’ that
they would no longer smoke, and that they would never smoke again. PID30 (THORACOTMY,
BI-WEDGE RESECTION, 4MPS) explained that from the moment she was first told that she had
cancer, she stopped smoking and was able to “just throw away her cigarettes”. She reported
that she could not describe how she felt, but that she “felt like a different person” and wished
that she had stopped like that years before. PID20 (THORACOTMY, PNEUMONECTOMY, 3MPS) was
continually abstinent after discharge and explained that he had made this decision due to his
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health:
PID20: “When I had this operation, I thought, smoking isn’t going to do me any good at
all, I’ve only got one lung, if something happens to that I’m going be in trouble, so I
just said I wouldn’t smoke anymore. And I won’t . . . I shan’t smoke again . . . I wish
I could have taken that (decision) thirty years ago but there you are, that’s hindsight
isn’t it.”
Internal conflict with regards to desire to quit In addition to expressing concerns regarding
their smoking behaviour and the desire to be a non-smoker, some participants also expressed
conflicting attitudes. There were a variety of conflicts described by participants including: lack
of will power/ability to overcome addiction, concerns about impact on physical health, reflect-
ing on smoking with fondness and beliefs that smoking helps maintain mood, deals with acute
anxiety and relieves boredom.
Some who had relapsed back to smoking after a period of abstinence, or who had returned to
smoking immediately after discharge cited no benefits for continuing to smoke, and explained
that the only thing standing in the way of quitting was a lack of will power to overcome the
addiction. For example, PID21 (THORACOTMY, LOBECTOMY, 3MPS) explained that, after returning
home, she immediately resumed smoking although she felt that this was “stupid”:
PID21: “I knew I’d got a pack somewhere. And I sat here for quite a while. And I thought,
I wonder if it’ll hurt if I, I wonder if it’ll actually I mean physically hurt. I thought,
I’ve got to have a cigarette. And I did, and it didn’t hurt, so you know, stupid. Don’t
make any sense whatsoever.”
She also reported feeling guilty about her smoking, explaining that the care that she had received
from the NHS must have cost “thousands upon thousands” of pounds and that it was necessary
because of her smoking behaviour. She added:
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PID21: “Not only that but I mean, obviously I’d probably be breathing a lot better if I didn’t
continue smoking. Um, [pause 2 sec] I just feel bad about it, but I can’t do anything
about it . . . . I’ve got the best intentions in the world, I could open a cupboard
there, and show you every stop smoking product known to mankind. But none of
them work . . . (cigarettes are) the thing I reach for.”
PID3 (THORACOTMY, WEDGE RESECTION, 10MPS) relapsed to smoking a short while after dis-
charge. He explained that he would like to be able to quit smoking, but he felt that he did not
have enough will power and that the only way he would be able to quit now was by undergoing
hypnotherapy. However, he also defended his smoking explaining that smoking helped him to
cough and clear his lungs of mucus. He felt that he had reduced the risk of his smoking by
cutting down. When probed to explain what he meant by the term ‘cutting down’ he explained
that he no longer inhaled the smoke into his lungs:
PID3: “I’ve got no will power now . . . I don’t want to give it up so I’ll carry on doing what
I’m doing, take the smoke into my mouth and blow it out again rather than take it
all the way down and I’ll carry on like that. And eventually one day I will be able
to.”
Some who expressed a desire to be a non-smoker also reflected on smoking with fondness. For
example, PID15 (THORACOTMY, LOBECTOMY, 5MPS) had quit since being admitted to hospital
for his surgery and his GP had prescribed him patches to help maintain abstinence. He reported
having two cigarettes since being discharged, although his wife ‘told him off’ and they had made
him vomit. Although he was determined to stay quit, he described smoking as “an old friend”.
PID23 (THORACOTMY, WEDGE RESECTION, 3MPS) explained that he was an addicted smoker, but
was “not proud of the fact”, stating that he was “guilty as charged’’ and that smoking was his
“biggest enemy”. He added:
PID23: “I hate myself for smoking, really do. There’s not a day goes by that I don’t think
I’m going to stop it today. I’m going to smoke that pack, then that’s it . . . but there
you go. I’m just a bad example.”
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Despite feeling this way he explained that a beer and a cigarette outside in the sunshine was “like
seventh heaven” and that three weeks after discharge he had returned to smoking 40 cigarettes
per day. Similarly, PID5 (THORACOTMY, WEDGE RESECTION, 6MPS) consulted with his GP prior
to his surgery and was prescribed patches, but decided not to use them. He continued to smoke
after he was discharged from hospital, although described it as “stupidity”, adding “but there
are all kinds in this world young lady!”. He started smoking whilst still a teenager in the air
force and he explained:
PID5: “We all did . . . like a load of idiots I suppose . . . Have you been a smoker for the
rest of you life? Yeah. No one to complain, only my stupid self. Like I say I’ve had
my fun, keep it quiet, I’ve had my kicks . . . I’ll kick it tomorrow [laughs].”
PID4 (THORACOTMY, WEDGE RESECTION, 12MPS) described how she had relapsed to smoking 40
cigarettes per day two months after discharge. She regretted having relapsed and explained that
“it played on (her) mind and (she) felt guilty about it . . . terrible about it” adding that she
hadn’t been enjoying smoking. Two weeks before the interview, she had started a new quit
attempt and felt confident that this time she would be successful. However, she also defended
her smoking with strong feeling, arguing that it had kept her sane:
PID4: “But . . . you’ve got to put yourself in my position . . . it’s like your own little prison,
your own little world . . . And when you’ve got nothing else and you’ve got no one to
talk to . . . I always called my cigarette my comfort hat . . . Anytime you feel wound
up or anything, have a cigarette. And that’s how I felt about smoking . . . and I know
it’s no good for your lungs . . . but people need to understand it is a calmer . . . it
keeps you together sometimes . . . I know it’s a drug . . . but at the end of the day it
keeps you sane.”
PID13 (THORACOTMY, BI-WEDGE RESECTION, 5MPS) had found it easy to not smoke whilst in
hospital, and had continued to be abstinent for two or three weeks after discharge but then
relapsed. She explained that she “tried not to” smoke, and knew that she should not, but she
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did still smoke. However, she also defended her smoking by explaining that she was concerned
that quitting may be harmful to her health, and that smoking made her happy:
PID13: “it’s frightening . . . because I know people that have smoked for a long time and
they pack up smoking and their body can’t cope. I know people have strokes and
everything. So you’re worried about what will happen to your body? And . . . the
weight, because the steroids have piled the weight on me . . . the weight’s no good
for my arthritis. It’s all a jumble of things really . . . and I’m sixty six, Amanda! I
don’t expect to live much longer. And when you see this world, I don’t know whether
I want to. [Pause 4 sec], I’m alright . . . . [Pause 4 sec].I just want to be happy and
if a cigarette makes me happy, why shouldn’t I have one. . . . I know I’m naughty
and I shouldn’t do it and . . . [pause 3 sec] but I’m ok.”
Resolute desire not to quit Finally, unlike other participants, PID9 (VATS, WEDGE RESECTION,
9MPS) defended her decision to smoke and did not raise any concerns associated with smoking
or express any remorse. After her diagnosis, she reported having “made herself think about
(smoking)” and that she had cut down the number that she smoked at the time of surgery, with
the aid of patches. Ultimately, however, she reported that she could not stop smoking and neither
did she want to. She worked (and had returned to work after surgery) as a care worker, providing
respite care. She expressed concern at the possibility of becoming like her clients, dependent
and unable to do things for themselves. She expressed a preference for just “dropping dead”
as her husband had done years before, rather than being dependent. Her family had expressed
their wishes for her to quit smoking but she explained:
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PID9: “I said “[daughter], I’m sorry, being on my own”, (it’s been) 11 years since my
husband died, “if I haven’t got my cigarettes I might as well just pack up.” Pack
up? Pack up life . . . I’ve always got something I’m doing, and if they were going
to make me sit here and do nothing then I didn’t see any reason for me to live. And
those were the doubts . . . I took the chance . . . Yes I was lucky, yes it was caught in
time, but I don’t want to live another 20 years. At least I know I’m still driving and
I’m still able to work.”
In summary, all but one of the smokers at diagnosis reported that they wished that they were
not smoking, or were glad that they had managed to quit. There was evidence that many who
continued to smoke felt guilty about their smoking. For those who had managed to quit, they
were often regretful that they had not managed to quit earlier. Some participants were resolute
in a desire to not smoke and these were more likely to be abstinent. However, the majority also
expressed a range of conflicting desires and beliefs that supported continued smoking (see table
3.15).
3.5.2.2 Main topic 2, theme 2: reasons for relapse to smoking after discharge
Most smokers at diagnosis found it easy to be abstinent whilst an inpatient, and stated that they
had not thought about smoking or that they had felt too ill to smoke whilst in hospital and it
was when they got home that the cravings had returned. An exception to this was PID21, a
smoker of 40 cigarettes per day. Although using nicotine replacement patches, she had found it
difficult to be abstinent in hospital, and had found herself reaching out for a cigarette packet on
the bedside table out of habit.
Four participants (PID3, PID13, PID16, PID23) who had been abstinent since diagnosis or
admission for surgery, and one participant (PID4) who had been abstinent for two months prior
to diagnosis, relapsed to smoking after trying to remain abstinent when discharged home. For
each of these participants, relapse occurred within the first three months after discharge. Three
described just smoking one cigarette, or a reduced number, but then relapsing back to smoking
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regularly as they had done before surgery. Four out of five explained that they had returned to
smoking to help them cope psychologically. For instance, PID4 and PID13 lived on their own
and were both too unwell to live active lives. Both explained that smoking helped to relieve the
boredom of sitting at home alone. PID4 (THORACOTMY, WEDGE RESECTION, 12MPS), in particular,
had received many visits from friends and family after she was discharged home, but explained
how after a while the visits became less frequent and she was left on her own:
PID4: “You get the fuss when you first come out, everybody’s knocking the door, people
come to see you, you have visitors every night, so many every day and then it all
wears off and you’re left suddenly on your own . . . two, three days sometimes you
won’t see anybody and I think that’s why. I started off with 10 and I ended up now
since last year going up to 40. . . don’t forget I wasn’t able to do anything, much
cleaning or anything because I was too weak . . . I was too tired so I was just lying
about most times. You know, you can’t watch the telly 24/7 . . . so that was the reason
why I think I started to smoke again, boredom. Just boredom.”
PID3 (THORACOTMY, WEDGE RESECTION, 10MPS) explained how stress related to ongoing health
care needs “built up’’ over time and he found himself wanting to smoke:
PID3: “Something made me start worrying I think . . . it just started building up, having to
ring for ambulances to get to the hospital for blood and this that and the other. And
it more or less got on top of me an all. I’ve got to have a cigarette, so I did. I had
one and then of course the craving came back 3 o’clock in the morning, I’ve got to
have a fag. I need a fag. But you don’t give in. Same first thing in the morning. Got
to have a fag. But the craving’s there all the time . . . ”
After first of all resisting the urges to smoke, PID3 relapsed to smoking 20 cigarettes per day.
PID16 (THORACOTMY, LOBECTOMY, 5MPS) explained how family related stress, and in particular
the death of her father, had made it difficult for her to cope and although she felt she had done
well in maintaining abstinence during her surgery and chemotherapy, she had relapsed back
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to smoking “the odd cigarette” a day by the time of interview. Finally, PID23 (THORACOTMY,
WEDGE RESECTION, 3MPS), unlike the other participants, stated that stress was not the reason that
he returned to smoking, but he became vulnerable to relapse when he started feeling well again:
PID23: “When I did stop smoking I felt marvellous, because I did stop for about three
weeks, not long, but I felt so good. “Well one won’t hurt” because I felt so well . . .
it’s when I feel well, that’s my danger time. I mean it’s not when I’m stressed . . .
It’s when I feel good I think.”
In summary, despite finding it easy to remain abstinent whilst in hospital, and a resolve to remain
abstinent after discharge, many smokers who quit subsequently relapsed. The most vulnerable
time for relapse appeared to be within the first three months after discharge. There was evidence
that the challenges of being alone and psychological factors played a major role in the reason
for relapse. In total, four categories of reasons for relapse and benefits for continued smoking
cited by participants were noted that supported continued smoking behaviour.
Table 3.15: Participant held beliefs and challenges that support continued smoking behaviour
Category Explanation
Lack of will
power
Unable to overcome the drive to smoke.
Pleasurable Described as “an old friend”, “like seventh heaven”, “if I can’t smoke there
is no pleasure in life.”
Maintenance
of mood
Encourages feelings of happiness, helps to cope with acute anxiety, helps
overcome boredom/loneliness.
Health
concerns
Fear of health consequence of quitting, including stroke, weight gain.
Smoking helps to clear airways of mucus.
3.5.2.3 Main topic 2, theme 3: views about NHS intervention for smoking cessation
Many participants stated that throughout their cancer care they had not been asked their smoking
status. However, without exception, all participants felt that it was the responsibility of the
clinical staff involved in their cancer care to discuss smoking with them. Despite feeling this
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way, for those who were asked about smoking, some explained that it had made them feel
uncomfortable. One participant (PID4 - relapsed) reported not telling the truth when asked by her
GP if she was smoking in a consultation after she was discharged from hospital. Her records
showed that she was a non-smoker and she admitted that it had taken her about 12 months to
“confess” to having relapsed. She explained:
PID4: “It’s hard because (my GP has) been very good with me. You feel like you’re wasting
their time, you feel guilty but she was great with me and she . . . asked me what I
wanted to go on.”
Despite the possibility of feeling uncomfortable, participants reported that being asked about
smoking was not offensive to them. For example PID5 (continued) stated:
PID5: “Whether it was size, whether it was brand, whether it is the count, it wouldn’t
offend me.”
PID9 (continued) and PID21 (continued) both expressed the view that although it was acceptable
for a doctor to ask about smoking, the way in which it was approached was important. PID21
stated that she did not mind being asked about her smoking but she continued to explain that her
ex-partner had nagged her and she had found that irritating. She emphasised the importance of
a health professional showing understanding of how difficult it is to quit. A number of clinical
staff had asked PID9 about her smoking, and the majority had been sympathetic and given her
a choice which she felt was the right approach. However, she was told by one member of staff
that if she did not stop smoking then the surgeon would not operate on her. She felt that this
was unjust given that she was a law abiding citizen who had paid her taxes, and it made her feel
angry. She later explained that she did believe that it was the place of the doctor to ask their
patients about smoking, but felt that they shouldn’t “hold it over (your) head.” She added
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PID9: “I think that they should know because, yes they are going to take the risk of the
anaesthetic and the operation and I don’t hide it . . . I know that I shouldn’t do it
but I can’t give it up but why should they hold it over my head? And I think it’s so
unfair and they turn around to me and say you’re fit and healthy . . . but because you
smoke we’re not going to operate on you. Hello.”
Five participants that were current smokers at diagnosis (PID3(relapsed), PID4 (relapsed), PID5
(continued) , PID21 (continued), PID26 (continued) ) described being offered stop smoking support.
Three (PID4, PID5, PID21) were offered help by their GP in a consultation after discharge.
PID26 was offered referral to the local stop smoking service as part of his participating in the
ROC programme, although he declined the offer. PID3 was admitted to hospital one week be-
fore surgery to undergo respiratory conditioning in preparation for surgery and during that time
he was prescribed patches to help him maintain abstinence. However, no follow up smoking
cessation care was arranged after discharge. The remaining participants (6/11) that were smok-
ers at diagnosis were not offered help either during their cancer treatment or by their GP. Most
participants specifically indicated that it would not offend them to be offered the help, even if
they thought that it would not work for them or that they did not need the extra support. For
example, PID5 (continued) expressed the feeling that maybe it was “too late in the day” for him
to try and quit but stated he would not mind being asked if he wanted help. PID26 (continued)
explained that although he thought treatment would not be helpful to him, he understood that it
might be useful to other people:
PID26: “I don’t mind being offered that sort of help because it might be the right thing
for the next person and nobody knows until the help is offered, so I could quite
understand why I was offered the help but it just didn’t work.”
Others indicated that not only would they not be offended, they felt it was important and neces-
sary. PID4 explained:
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PID4: “The way I look at it is that you do need help, you do need someone to stop you from
doing it really but I mean it’s easier said than done . . . It was about 3 months after
(surgery) I started to smoke (again) . . . It would have been nice to have been able
to contact someone you know. They may have been able to talk me through or come
out and give you patches at the time cause, don’t forget I couldn’t get to the doctors
because I was too ill, I couldn’t do anything really for myself them early days. So
it would have been nice for them to say well, we’ll send . . . the district nurse round
with some patches . . . but no, you just had to do it on your own didn’t you.”
As with being asked smoking status, participants commonly underlined the importance of an
understanding approach by health practitioners offering smoking cessation help. In addition,
there was evidence that feelings of guilt and shame could act as a barrier to participants telling
their doctor that they had relapsed after a quit attempt. For example, PID23 (relapsed) explained
that he felt uncomfortable returning to his GP to ask for help for additional support after a
relapse:
PID23: “And I didn’t have the nerve to ask her again because I felt so, like a failure. So I
wouldn’t ask her again, because . . . I am conscientious . . . I really do not want to
waste her time. But I would like to stop. Yes, I would like to stop smoking.”
All participants felt that smoking should be addressed as soon as possible within the cancer care
pathway. For example, PID3 felt that patients should be given help a month before surgery to
give enough time for cutting down. PID4 felt that offering of smoking cessation support should
be considered as “part and parcel” in the diagnostic consultation. She further highlighted the
importance of intervention at the bedside. She explained:
PID4: “I reckon it should be done there at the bedside. Not wait for the office after you’ve
been discharged. I think it should start being drummed into the patients there and
then who are smokers. . . if you’re smoking . . . we can help you with it and things
like that. I think straight, at the bed, you know as soon as they are well enough to
take it . . . on board . . . You know the seriousness of it and everything else.”
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Other participants explained that it was important for support to continue after discharge:
PID16: “Obviously you’re not smoking in hospital and from the point of that, which you’ve
done so well, it should continue, so straight away after you’ve come out of hospital.
I mean if you’ve managed to do it for that long, that’s probably what you need
[pause 1 sec] . . . to inspire you to carry on. So straight away.”
PID23: “You’re on a very tender hook when you stop smoking. And you can go either way
at any time. But I wasn’t craving for cigarettes, in the hospital, (it was) when I came
out.”
In summary, regardless of smoking status (ex-smoker or current smoker at diagnosis) partic-
ipants were open to discussing their smoking status and being offered help to quit smoking
where appropriate. Universally, participants accepted that it was the place of health profes-
sionals to discuss smoking with them, although some acknowledged the importance of health
professionals adopting an understanding and approachable attitude. There was some evidence
that participants felt ‘like a failure’ if they had returned to smoking and that this could act as
a barrier to them reporting their true smoking status or pro-actively seeking help. Participants
highlighted the importance of smoking cessation support as soon as possible, and that continued
support after discharge was vital.
3.6 Main topic 3: attitudes towards recovery, supportive
care and rehabilitation programme design from the
perspective of participants receiving standard care
The previous sections have explored in detail the nature of specific health challenges that partic-
ipants faced during the first year after surgery, and the attitudes of participants with a smoking
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history towards smoking, smoking cessation and NHS stop smoking support. This section ex-
plores the attitudes of participants who had received standard care (n= 18) towards their recov-
ery after surgery, focusing on the way in which participants evaluated their recovery in general
rather than the specific challenges that they faced. In addition, attitudes of participants towards
the level of supportive care that they had received after surgery and their opinions about the
optimum content/format of a rehabilitation programme are presented. There was a clear divide
in attitudes between participants who had undergone VATS compared to those who had un-
dergone thoracotomy. Therefore, the findings are considered separately by primary procedure
sub-group.
3.6.1 Main topic 3, theme 1: satisfaction with recovery
3.6.1.1 VATS
All participants who had undergone VATS described being highly satisfied with the surgical
procedure, and also with their recovery. Often participants indicated that they were surprised
at how little an impact the surgery had made and the speed at which they had recovered. For
instance, HTO1 (BT=mild, PT=mild) explained how all the way through his cancer journey “health
wise (he) felt fine”. He explained:
HTO1: “Nothing’s changed really . . . I feel absolutely fine. (I feel) so, so lucky, I really do
. . . I tell everybody I feel so lucky, I do honestly.”
HTO2 (BT=mild, PT=moderate) added:
HTO2: “I’m thankful that they have done it. Honest to God, I feel really healthy.”
When asked how she felt physically after being discharged from hospital, PID9 (BT=none, PT=none)
responded:
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PID9: “How was I? Oh I just got back to work and drove my car and everything. . . ”
Some participants acknowledged that they had felt nervous about undergoing surgery but, after
describing how little it had impacted their health and functioning, stated that it was nothing to be
worried about. HTO2 (BT=mild, PT=moderate) added that she “would never be afraid of it again”.
Most participants explained how family and friends ‘could not believe’ how quickly they had
recovered. In addition some participants described how their GP or other health professionals
involved in their cancer care remarked on how quickly they had recovered. All participants who
had undergone VATS described being fully recovered within 3 months of surgery, and HTO2
(BT=mild, PT=moderate) and HTO3 (BT=mild, PT=mild) described feeling better than before they
had undergone surgery. Despite being almost back to normal, at interview HTO2 continued
to experience occasional shooting pains and PID9 experienced tiredness (see section 3.4.2 and
3.4.3). However, neither of these participants reported feeling distressed by these experiences
and they were satisfied with their recovery.
3.6.1.2 Thoracotomy
Like those who had undergone VATS, a minority of participants who had undergone thoraco-
tomy indicated that the surgery had not affected them greatly. For instance, when asked how
he was feeling after his surgery, PID5 (BT=mild, PT=absent) denied experiencing any effects from
the surgery:
PID5: “(I was) alright. Memory good, hearing good, eyesight good. Didn’t affect any
other parts of my body like, as I know of.”
He repeated many times through the interview that the health professionals involved in his care
were “nice people” and that they had “done a good job”. Although it was explained to him
that it would be normal to feel some effects from surgery, and that this would not be taken as
a bad reflection on those involved in his care, he maintained that the surgery had not affected
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him. On probing, he did admitted that sometimes he felt breathless. However, he also stated
that he could “still run like a rabbit”.
PID12 (BT=moderate, PT=moderate) had not lived an active life before surgery due to a co-morbid
heart condition, and described feeling philosophical that for the past few years he had “not
(been) able to do the things (he) used to do” and he was satisfied with his recovery. Despite
reporting some pain and breathlessness over the first 4-5 months after discharge, his main con-
cern was the effect of his diagnosis on the price of holiday insurance. He reported that on a visit
to his GP three weeks after his surgery, his doctor remarked “well I never would have thought
you’d just had a serious operation”. Five months after surgery, PID12 added:
PID12: “I could feel myself getting better all the while . . . my breathing and everything,
it’s just stabilised now like . . . everything seems alright, I’m not worried about
anything, I weren’t worried about anything before, it’s just one of them things.”
In contrast, all other participants who had undergone thoracotomy and received standard care
(PID1, PID3, PID4, PID6, PID10, PID11, PID13, PID14, PID16, PID20, PID21) described
a difficult and protracted recovery period, and were not back to normal by the time of in-
terview . Many of these participants had described feeling emotional distress regarding the
health challenges that they had experienced (see section 3.4). Some specifically stated that they
were dissatisfied with the level and speed of their recovery. For example, PID14 (BT=moderate,
PT=moderate) had been left with moderate breathlessness, low level of pain, had experienced
loss of appetite, significant weight loss and also disturbed sleep after surgery. He was the eldest
participant, at 82 years of age, and he reported having decided not to leave the house for the
foreseeable future after a negative experience. He explained:
PID14: “I’d much rather go back to what it was like before the operation, but . . . [doctor
1] did apologise to me when I went. He said “I’m very, very sorry I’ve got you in
this state, as you’re in now” he says “but I had to make a decision and” he says “I
think I’ve took the right decision.” . . . [pause 1 sec] it isn’t his fault . . . but as I say,
I’d much rather go back to what I was before.”
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PID10 (BT=moderate, PT=severe) was the youngest participant, at 39 years of age. Although she
had returned to work, seven months after surgery she reported that she was not back to normal
and that she had struggled both mentally and physically during her recovery. She explained:
PID10: “I just wanted to get back to normal and I’m always struggling to try and get back
to normal and then you push yourself too far and I feel myself flying backwards . . .
I feel a little bit angry that I can’t get back to normal. I realise that I’m probably
not going to be the same again, I’m not going to be able to do as much as I wanted
to . . . I felt really disabled . . . and I rushed to get back to work to avoid that. I went
back . . . too quickly and so I’ve been steadily using up annual leave ever since.”
For some participants, health challenges resulting from surgery were compounded by side ef-
fects of chemotherapy and/or radiotherapy. For example, PID4 had undergone surgery and
adjuvant radiotherapy. She described experiencing breathlessness, aching bones, sleep distur-
bance and weight loss that were still present 12 months after her surgery. She explained that
after evaluating what had happened to her, she had told her son “I don’t think I can go through
it again”, referring to the possibility of the cancer recurring. She added:
PID4: “Oh yeah it certainly knocked the socks off me, I mean I’m not the same person I
was over 12 months ago you know what I mean. No way.”
3.6.2 Main topic 3, theme 2: attitudes towards supportive care received
3.6.2.1 VATS
All participants that had undergone VATS and received standard care were highly satisfied with
the level of care and felt that they did not need additional support after discharge to aid their
recovery. For instance, HTO2 (BT=mild, PT=moderate) explained that she had been able to do
exercises by herself and felt fitter than she had for many years. PID31 (BT=absent, PT=mild)
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reported that he felt “as if (he) could pick up the phone and talk to a face (he) knew”. However,
he had never needed to do that during his recovery. In addition, participants who had undergone
VATS felt they had been fully informed about the nature of their surgery. They expressed
no concerns regarding a mismatch between information or explanations they received prior to
surgery to their actual experience of surgery and recovery. Interestingly, although they had
been informed, two participants explained that they had not really understood what was going
to happen during the procedure. However, they were not concerned about this. In particular,
HTO1 explained that although the consultant had “tried his best” to explain what was going to
happen, he had not been able to process the information. He explained:
HTO1: “I think your mind is in such turmoil, you don’t take it in . . . nothing registers. He
was excellent really, smashing guy, and he explained in detail what was going to
happen, but it never registered.”
3.6.2.2 Thoracotomy
When asked if they felt that they had needed more support after discharge, some participants
(PID1, PID5, PID12, PID14) who had undergone thoracotomy took a similar view, reporting
that they were able to manage their own recovery. They expressed the opinion that the infor-
mation about breathing exercises that they were given on discharge by physiotherapists, and
follow up phone call(s) from a lung CNS were sufficient for their needs. Interestingly, although
two of the participants expressing this view had described a relatively easy recovery (PID5 and
PID12), two participants (PID1, PID14) described difficulty during recovery, but maintained
that they preferred to manage things on their own. PID1 (BT=moderate, PT=moderate) explained:
PID1: “I would rather do it on my own . . . I don’t need anyone to motivate me. I can do it
myself.”
PID14 (BT=moderate, PT=moderate) praised the hospital team that had cared for him and explained
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that they had been “very helpful”. He added:
PID14: “We do have (neighbour) comes, to check if we want anything, which we don’t. We
don’t want anything really.”
However, the majority of participants that had undergone thoracotomy and received standard
care expressed the view that additional support after being discharged from hospital was needed.
Some described feeling abandoned on discharge, that they were left to recover from major
surgery without the knowledge and support that they had needed. Some indicated this by stating
that they felt they had been discharged too soon. When probed as to why they felt this, they all
described feeling too ill to cope when leaving hospital. PID3 explained:
PID3: “Anyway they decided to send me home and they didn’t give me a thing. Because
they were talking about oxygen and this thing and the other and they sent me out
with a few tablets. And I think they sent me home far too early. What made you feel
like that? Well the way I was. I was still struggling to walk. I couldn’t really climb
a flight of stairs . . . I felt so vulnerable . . . I couldn’t cope.”
Although PID3 and his wife reported that contact with the lung CNS had been very valuable,
they felt that contact was removed too soon. His wife stated that she “felt like (her) right hand
had been cut off when (she) lost her’’ support, and at one point she reported that she got to the
stage where she did not feel she could cope supporting her husband on her own.
PID6 expressed her surprise at being sent home seven days after surgery as she thought she
“should have been in longer’’. She was worried that she would be too ill to manage at home,
and she did in fact find it difficult to cope. She explained that for the first few days she had not
been able to climb the stairs to get to the bathroom in order to have a shower. She further added:
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PID6: “I thought perhaps I would have a nurse come in when I come out for a while but no
there’s nothing afterwards . . . I mean I had a phone number that I could have rung
the ward if I’d needed it, obviously I could have rung my doctor but I just thought
perhaps a nurse would have come and checked me over or something, you know,
after having major surgery. That’s the only thing.”
PID20 reported that although he had wanted to come home from hospital, he didn’t feel ready
when he was discharged and he also felt that he had been “sent (home) a little bit too early’’
and that he “didn’t have enough backing”. He further explained:
PID20: “I . . . never had no contact with anyone from the . . . hospital since I came out, I
got macmillan nurses round me when I was there and once I’d left the hospital, I
never had another contact at all. As regards assistance or helping . . . I still think
. . . there should be more aftercare, or assistance . . . (the) way they just threw me
out and then nothing, no anyone . . . after that.”
When probed about the specific type of assistance, PID20 explained that he needed both help
to improve his breathing but also equipment such as cushions and padding to prevent bed sores
and a wheelchair. Due to severe breathlessness he was largely housebound and immobile at
the time of interview, but he reported that “nobody wanted to know” and that he would have to
fund or organise these things himself. He had consulted with his GP who was sympathetic to
his situation, but was not proactive in organising care. He explained:
PID20: “I’ve seen my doctor, she seems to think I should have, pulmonary therapy is it? . . .
and the next appointment I’ve got with the surgeon, which is probably in a couple of
months time, she asked me to mention it to him if I could get any assistance in that
way . . . what you want is a normal breath . . . that’s what I was looking for . . . so I
was wondering whether there’s anybody that’s capable of giving advice on that.”
PID10 (BT=moderate, PT=severe), who had struggled with both breathlessness, pain and fatigue
until the time of her interview, acknowledged that breathing exercises given by physiotherapists
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and contact with the lung specialist nurse had both been helpful but explained that it had not
provided enough support. She also remarked on how there had been no contact with anybody
once the follow up phone calls had stopped, until she went back to clinic. She stated:
PID10: “I’d gone home . . . the lung specialist nurse (called), but that was it. That was all
the after care and I just think that for something so big that it would be good to have
a little more. I’m not saying you should have, it’s the NHS, it’s limited you know,
it’s not your right to have everything laid at your feet but it would be nice . . . I think
everybody has the right to know as well . . . I just think it would be good if people
were able to prepare themselves.”
Finally, PID16 (BT=moderate, PT=moderate) stated that she “thought there was a real blip in the
follow-up from surgery”, and that she “felt as if (she) had the surgery and then there was nothing
. . . no after care”. She explained:
PID16: “I felt a bit on my own for a while. Then I decided to go to my GP because I was
still in a lot of pain and (then) it was down to the GP to follow-up my care.”
However, although she had accessed support from her GP to help with pain, she still felt that
more support was needed, particularly emotional support. She added:
PID16: “I think that cancer, I think there needs to be a follow-up service because the cancer
just doesn’t stop . . . does it? . . . it’s not like . . . having your tonsils out and that’s
it, that’s the end of it. In cancer, it’s very emotional and there is a lot that falls out
of it . . . I think once you’ve had it, it’s there for life. And it becomes part of your
life.”
PID1, PID10, PID11, PID16, PID20 and PID21 all emphasised during interview that they did
not feel fully informed or prepared for the impact that surgery would have on them, or the length
of time it would take to recover. For example, PID1 (BT= moderate, PT=severe) had experienced
enduring breathlessness after surgery. He reported that health professionals involved in his care
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had said “as time goes on and the more exercise you do, your lungs will get stronger” and “you
will get over it”. Although he did report that his breathlessness improved, eleven months after
surgery he protested that it was not true that he had ‘got over it’. He explained:
PID1: “He [a health professional] said . . . “it will take time obviously . . . but you will get
over it”. I can’t, I can’t, because I was in the industrial cleaning, that was my job,
and there’s no way I can do industrial cleaning (now).”
PID10 (BT=moderate, PT=severe) explained that she had underestimated the impact that the surgery
would have and that it was a “nasty operation”. She felt that she had underestimated the
impact because she had not received accurate information from those involved in her care. She
explained:
PID10: “Instead of using the word pain, I think they used the word discomfort too much.
To me discomfort is period pain . . . or a migraine . . . this isn’t discomfort, it was
horrendous, honestly, it was awful pain and . . . I do think there is more that can be
done to prepare people for it . . . I never knew how bad it was. I just thought they
would get through that hole, I didn’t realise how . . . obviously, you know it’s going
to be invasive but I didn’t realise how much, it was quite barbaric . . . I thought I
would be back to normal in about 3 months. And I wasn’t . . . ”
In addition, PID10 explained that she had imagined waking up after the surgery lying in bed
with small nasal tubes inserted. However, instead she described feeling “intimidated (by) the
amount of equipment (she’d) got going on around (her)”. She explained:
PID10: “I had . . . a thermal blanket underneath, these boots on my feet to keep my feet
warm and probes on my feet, drains coming off . . . bigger than I imagined. It
wasn’t (how I imagined). It was a lot different to that.”
In summary, there was a stark difference between the attitudes of participants who had under-
gone a VATS procedure and the majority of those who had undergone thoracotomy. Although,
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similar to all those who had undergone VATS, a few participants who had undergone thoraco-
tomy did not see a need for additional follow up care, or felt that they would prefer to manage
their recovery alone, most reported that the level of standard care was not sufficient for their
needs. Many reported feeling under prepared for what to expect or how to manage their recov-
ery. Many used language that suggested that they felt abandoned after discharge, and that they
felt vulnerable. In particular, participants highlighted that they had struggled with day to day
living immediately after discharge and would have found a home visit from a nurse helpful.
There was also an indication that, for those most severely affected, participants would have also
benefited from an occupational health assessment and access to mobility aids. Participants also
indicated that they felt they needed help to manage specific symptoms, such as breathlessness
and pain. Although some felt strongly that more help should be available, many participants
also added the caveat that the health professionals involved in their care had ‘done a good job’
and expressed the attitude that they did not feel they could demand entitlement to care. Al-
though some participants indicated that they were aware that they could approach their GP, or
phone the hospital, there was evidence of reticence to do this. Those who did approach their
GP indicated that their needs were still not completely met.
3.6.3 Main topic 3, theme 3: preferences for the content and format of a
tailored rehabilitation programme
In general, although participants clearly articulated health difficulties that they had faced during
their recovery and many participants felt that they had needed more information and additional
care, most found it somewhat difficult to formulate and express preferences for the design of a
tailored rehabilitation programme. For instance, a few participants did not answer the question
when asked to specify their service preferences in order for their needs to be addressed. Instead,
they responded tangentially, continued to explain the difficulties that they had faced or said that
they did not know. When given examples of what a rehabilitation programme may contain
and asked if they thought that would be beneficial they responded by saying ‘probably yes’,
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‘maybe’, ‘makes sense’ or ‘I’m sure that would help’. Therefore, it was not clear if they were
agreeing because they believed it would be helpful or whether their answers were influenced by
social acceptability bias. PID11 (BT=moderate, PT=mild) was forthright in answering that it was
not his place to comment on somebody else’s job, and that “they are the experts”. He further
added that if somebody had told him how to do his job, he would have told them to [go away].
He said that he would not know what would help until he tried it. Despite it being made clear
that any thoughts shared on how services could improve would not be regarded as a criticism,
when asked how things could be improved participants often stated that the team in charge of
their care had done their best.
However, some participants (only those who had undergone thoracotomy) did discuss specific
content preferences for a tailored rehabilitation programme. Some expressed preference for
structured and supervised exercise. For example, PID4 (BTmoderate, PT=severe) explained:
PID4: “Do you think you would have found it helpful to have someone help you to get
back onto your feet again? Well it would have been nice, you know, even if you
went to a day centre for a day and did a bit of exercise... even to be able to go use
their machines, one day a week even... things like (exercise bikes) or for them to
give us gentle exercises.”
PID10 (BT=moderate, PT=severe) also felt that supervised exercise would have been helpful to
her. Although she attended the gym and had a personal trainer before she was diagnosed with
lung cancer, she felt that she now needed specialist support from a health professional who
understood the consequences of thoracic surgery:
PID10: “Some kind of rehabilitation, to be in a controlled place, to have somebody who
knows what they are doing to say, “you can do this”, “push this”, “do that” . . .
“this is what you are able to do” and perhaps some real physio . . . I don’t know
what I’m capable of and I don’t know what muscles are what and how I . . . need to
work on them to get some strength back and mobility in my sides.”
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PID20 (BT=severe, PT=none) felt that it would have been useful to have additional support to
improve his breathing:
PID20: “Well, somebody probably got some idea, of how I could best . . . breathe, to get . . .
the air where it should be going.”
Some participants felt that emotional support had been lacking in their care and would have
been a helpful addition. PID10 (BT=moderate, PT=severe) explained:
PID10: “I’ve got a good group of girls but you don’t want to share . . . {it’s} too deep I think
to share with other people and {it’s} too frightening and I think... if you could talk
to someone who was not emotionally involved or you could have someone to just
listen to you that would be good.”
and PID16 (BT=moderate, PT=moderate) added:
PID16: “I think there should be some follow up care . . . somewhere to go to talk if you got
problems or just somebody to say you’re doing fine. Because you don’t know, do
you? . . . you’re just left on your own.”
Some participants expressed a preference for more accurate information regarding how they
would be affected by surgery and a realistic picture of the length of recovery. PID4 felt that
she had asked questions but she stated that she would “have liked more answers”. PID10
(BT=moderate, PT=severe) added:
PID10: “I think for me. . . it’s the not being as prepared as I could have been perhaps for
how big it was and have realistic expectations for getting back to normal and the
time it took to get better . . . I suppose it would be nice to sort of be a bit more
prepared and know how to deal with it.”
Although many participants had also been in pain, and some had experienced appetite and
weight loss, none suggested incorporating pain or dietetic review/management into a rehabili-
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tation programme.
All participants who expressed an opinion felt that the start of a rehabilitation programme would
need to be delayed after surgery as they would not feel well enough to participate straight away,
or to give time for the wound to heal. The length of delay stated by participants was normally be-
tween 1-2 months. However, one participant (PID4 - BT=moderate, PT=severe) said that she would
not have felt well enough to participate in a rehabilitation programme for the first year after
her surgery. In addition to not feeling well enough, PID10 (BT=moderate, PT=severe) explained
that immediately after surgery it would be difficult to focus on a rehabilitation programme. She
added:
PID10: “I don’t think it would sink in. Everything is still for me . . . full of “oh my god, it’s
done, it’s done, I’m over”, do my breathing exercises, take my pain killers that was
it and I think that was probably for the first month and I think probably from then.
It’s to get over the shock of the operation, is a big one.”
However, when talking specifically about the timing of support for smoking cessation, all who
smoked at diagnosis stated this help should be given straight away, with one participant advocat-
ing it to be ‘part and parcel’ of the diagnostic consultation, and others emphasising the benefits
of having support to reduce or quit before surgery and of continued support after discharge (see
section 3.5.2.1 ).
When asked whether they would prefer a rehabilitation programme to take place at either the
hospital or locally, participants opted for the hospital. However, the reason for this was that
they felt it was important to have access to health professionals who knew about their care so
far. For instance, PID11 (BT=moderate, PT=mild) explained:
PID11: “I think the hospital would be better (to host rehab programme) because they know
a lot more. Your dates, all your records and everything.”
PID20 (BT=severe, PT=none) also expressed a preference for having continued access to help from
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health professionals that had been involved in his care. When asked how additional help could
best be given he explained:
PID20: “Well . . . just somebody to keep in touch with you. Somebody from [hospital 1]
basically . . . involved in the operation. Knows the score, what’s going to happen,
to just keep in touch and ask you how’s it going and if you want . . . well anything
in general really to try and help you out, that’s all.”
Finally, there was a mixture of responses to preferences for group rehabilitation or individ-
ual contact. Some participants did not express greater preference for one format over the
other. Where participants did express a preference, most favoured individual contact stating
that groups ‘were not their thing’ or that they would not feel comfortable in a group setting.
This was particularly true for smoking cessation support. However, one participant (PID10 -
BT=moderate, PT=severe) did express preference for rehabilitation to be delivered in a group set-
ting, as she would value the opportunity to learn and draw comfort from people in a similar
situation. She stated that it would help her feel less abnormal. PID10 was the youngest in-
terviewee at 39 years of age, significantly younger than the average age at which patients are
diagnosed with lung cancer. Despite the probability of a large age gap, she still felt that group
sessions would be preferable. She explained:
PID10: “I probably would feel a little bit different . . . but even listening to someone else, it
doesn’t matter if they are 15 years older than me or whatever. If they were saying I
had this, did you have that? And knowing that someone else gets the same no matter
how old you are (is helpful).”
In summary, most participants were unable to offer specific preferences for the content and
format of a tailored rehabilitation programme. However, some participants did express specific
preferences and these are summarised in table 3.16.
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Table 3.16: Preferences regarding content and format of a future rehabilitation intervention from
participants who had received standard care
Content (1) Exercises to improve lung and general strength
(2) Emotional/psychological support
(3) Information regarding surgery and recovery
(4) Smoking cessation support
(5) Support on discharge from community nurse
(6) Occupational health assessment and access to mobility aids
Delivered by Health professionals who know about previous care and are able to an-
swer questions specific to the impact of lung surgery
Timing Start 1-2 months after surgery
Group or
individual
Both equally acceptable
3.7 Main topic 4: attitudes towards recovery, supportive
care and rehabilitation programme design from the
perspective of participants enrolled in the ROC
programme
Eleven of the 29 participants interviewed had taken part in a rehabilitation programme that was
being piloted at Birmingham Heartlands Hospital (BHH) and Worcester Royal Infirmary (WRI).
For full details of the ROC programme content see section 2.3.4.1. This programme contained
many elements that participants who had received standard care identified as being important
to met their needs (see table 3.16), and provides the opportunity to explore participants’ assess-
ment of and attitudes towards receiving such an intervention.
Participants attended an average of two pre- and four post-surgery sessions and, on average,
returned for their post-surgery sessions four weeks after discharge. One participant had under-
gone VATS (and also had been diagnosed with COPD four years previously) and the remaining
participants had undergone thoracotomy. No participants had been referred for smoking ces-
sation or dietary support, although one participant was offered a referral to the stop smoking
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service and declined.
3.7.1 Main topic 4, theme 1 and 2: satisfaction with recovery and
attitudes towards supportive care received
All participants enrolled in the ROC programme spoke about the programme with enthusiasm
and felt that it had been worthwhile. They stated that it was a “very good programme”, “the
exercises were great”, “the physiotherapy was great”, “it certainly had the effect of helping”
or “it really helped”. For example, PID29 (BT=moderate, PT=moderate) added:
PID29: “The rehabilitation programme is one of the best things going, to be honest, as long
as there is money around for those sort of things, I think then that’s fantastic.”
In addition, when asked to describe the worst aspects of the ROC programme sessions, PID26
(BT=mild, PT=moderate) responded:
PID26: “I can’t really say there was a worst thing about them, because as I say, I quite
enjoyed them”
Although the exercise sessions were run in a group, participants followed a set exercise pro-
gramme on an individual basis and were also given one-to-one support when requested within
the session. Commonly, participants commented on how they were ‘able to go at their own
pace’, and that they highly valued this approach as it made the programme enjoyable. Some
participants remarked that it was ‘unlike school’, and that they felt that they were treated like
adults. PID15 (BT=moderate, PT=none) explained:
PID15: “As regards to the exercise and what have you, they don’t pressure you to do it.
They ask you to do it. And if you don’t want to do it, you don’t do it.”
HTO3 (BT=mild, PT=mild) explained that she had found an exercise particularly painful around
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the surgical scar, and had talked to the physiotherapist to find out how she should proceed. She
reported that the physiotherapist demonstrated a different exercise which might be less painful
but advised her to “take it easy and if it still hurts, don’t do it”. HTO3 explained that she found
this very comforting and added “so yes they don’t push you to do things that are painful”.
In contrast to participants that had received standard care, participants also spoke positively
about their recovery, and were generally satisfied with the progress they were experiencing.
They mainly attributed this to participation in the programme, and in particular described phys-
ical, motivational, informational and emotional benefits to participation. Participants most read-
ily attributed these benefits to the exercise classes, rather than the group educational sessions or
extra contact from a lung CNS/physiotherapists. However, there was evidence that both the ex-
ercise and educational/support elements of the rehabilitation sessions had been beneficial from
the point of view of participants.
Physical Most participants reported that they believed the exercise programme had made them
feel generally fitter and had strengthened their lungs. HTO3 (BT=mild, PT=mild), a COPD sufferer,
added that she had noticed that she was becoming less breathless when engaging in activities:
HTO3: “. . . My breathing is probably better than it has been for a long time so that defi-
nitely helps and I would recommend that to anyone . . . I can get up the stairs a lot
better now. Before the operation I would be puffing and panting when I got to the
top of the stairs. Now I can go up and down with no problems. I can walk a better
distance on a flat not too good on hills still but I can walk on the flat ok. It’s just
general breathing is much better. Since the operation? Yes and since the physio as
well.”
As well as improving health and levels of breathlessness, some participants reported that they
used the techniques that they had learned during the educational sessions to deal with acute
episodes of breathlessness whilst at home, and also to help with chest clearance. For example,
PID25 (BT=moderate, PT=moderate) explained:
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PID25: “Since I’ve (participated in the ROC programme), I can breathe better, and phlegm,
I can get that out easier.”
Motivational Participants commonly expressed the view that attending the programme had
increased their motivation to work on their recovery, with participants often continuing to exer-
cise at home. PID25 (BT=moderate, PT=moderate) explained that he had found the sessions moti-
vational and that “they made you want to get back on your feet”. PID17 (BT=moderate, PT=mild)
described how the ROC programme had “encouraged (her) to get as fit as (she) could” before
her surgery. She had also decided to follow a walking regime at home after discharge, in ad-
dition to attending the rehabilitation exercise classes. She explained that during her walking
regime she would deliberately get breathless as she had been instructed to do in the classes.
PID29 (BT=moderate, PT=moderate) explained that she would not have found the motivation to
exercise during her recovery at home on her own. She admitted that:
PID29: “If I’d have been sat down, . . . doing nothing . . . I think I would have given up,
I would not have wanted to do anything, I would have found breathing even more
difficult because I’m not getting up, and getting my lungs to even try and work to
their full capacity.”
She felt that the classes gave her “the incentive, it makes you do that one more little stand and
sit or whatever it is that we are doing at the time”.
Informational The majority of participants reported that they were happy with the informa-
tion that they received with regards to the surgical procedure and its impact. For example,
PID30 (BT=moderate, PT=severe) stated that one of the benefits of the ROC programme was that
“they could tell you what was going to happen”. PID17 (BT=moderate, PT=mild) explained that
the one hour one-to-one session with the physiotherapist before she had started the exercise
sessions had “allayed (her) fears”, and that it had refreshed her memory of the anatomy of the
lungs and put her surgery in context. She also reported that the physiotherapy sessions were an
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ideal opportunity to ask questions, and she also found that comments made by the physiothera-
pists during the exercise sessions had helped her:
PID17: “One physiotherapist said, “your lungs are big enough to fill this room. So the fact
that . . . you’re going to have a bit missing, it’s neither here or there really. But your
body’s just got to mend from it.” So, you know, there were lots of kind of, if you like,
offhand comments that really help . . . when you do a job like that, you’re so used to
it, sometimes you don’t realise, that a throw away remark really helps somebody.”
There was evidence that participants believed that they would not have been able to have fa-
cilitated their own recovery as well if they had not participated in the ROC programme. This
was partly due to an increase in motivation, but also because of what they had learned during
the programme. PID29 (BT=moderate, PT=moderate) found that as a result of what she had learned
during the classes, she was building gentle exercises into her day:
PID29: “At home here, I can sit here and watch TV and go like that [demonstrates shoul-
der rolls] and I’m exercising my shoulder blades, and I’m stretching my lungs. I
wouldn’t have thought of things like that, had I not gone to this, and been told about
it. And just by standing up in the kitchen, washing up, marching on the spot, gets the
blood pumping, keeps the legs going, that stops blood clots if you are sitting down
quite a bit. It’s all these things that I would never ever have taken into considera-
tion.”
PID30 (BT=moderate, PT=severe) also explained:
PID30: “You can carry on, on your own (at home).” Do you think that would have been
something that you would have done. . . “Oh no, I wouldn’t have even known what
to do. No they teach you, if you listen, you learn.”
Although the majority of participants reported that they were satisfied with the level of infor-
mation that they had received, one participant (PID28 - BT=moderate, PT=severe) indicated that she
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was not satisfied. She reported that although she had been given an explanation of the surgical
procedure and what to expect during recovery, she had not fully understood it. She reported
feeling as though she was “in the dark” and that she had not “quite realised what (she) would
feel like afterwards”. She further explained:
PID28: “(it’s) just the uncertainty and the not knowing, they give you this leaflet of what
you can do over the four weeks and eight weeks and everything but, I mean I don’t
know what my GP must have thought but I think I’ve been to see her three times,
because you panic. Because you don’t know. Um, and you know, I go off and see
her. You don’t know? Whether it’s normal to be sort of coughing and the pain and,
but then I suppose they don’t know either really do they? But you know, I mean she
was always very nice, you know, “don’t worry you can always come and see me”.
But, I think it’s just the fear of the unknown. Um, you know, if you sort of wake up
in the middle of the night and you can’t breathe, you panic. You know, if they’d said
before that this might happen, I think that may have helped, I don’t know.”
Emotional Generally, participants reported that participating in the ROC programme had
been a positive experience and had helped them to remain optimistic throughout their recov-
ery. In addition, participants felt that the physical exercise had increased their confidence and
information had addressed their fears. In particular, participants generally found it supportive
to be part of a group with other patients who were ‘in the same boat’, especially as some were
further on in the treatment pathway and could therefore provide insight on what they were about
to go through. For instance, PID29 (BT=moderate, PT=moderate) explained:
PID29: “It is absolutely fantastic that you can go to something, where there are other people
exactly the same as you, we’ve all got breathing difficulties of different varying
degrees.”
Some participants reported that they had received encouragement not only from the health pro-
fessionals, but from other members of the group. PID17 (BT=moderate, PT=mild) explained:
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PID17: “It was actually being part of a group . . . and meeting other people . . . hearing,
and noticing how people supported each other . . . that was really good.”
In addition, some participants reported that they found it somewhat comforting to compare
themselves with others in the group. For instance, PID30 (BT=moderate, PT=severe) explained:
PID30: “That lady’s a lot older than you, there’s one there 86, and look, “They’ve come
through this”. And its such a help. And this was before your op, so that was really
nice. “Oh you’ll be alright, look at me, I’ve had it.” It’s a good thing that is. You
were able to talk to other patients, oh yes . . . we all spoke to each other, it was really
nice, really nice.”
3.7.2 Main topic 4, theme 3: suggested changes to the design of the ROC
programme
Similar to participants that had received standard care, participants found it difficult to make
specific suggestions for changes necessary to improve tailoring of the ROC programme to their
needs. However, four negative aspects associated with participation in the programme were
reported. The first two were the additional cost of parking at the hospital and demand on time,
which was a concern expressed by one participant (PID15 - BT=moderate, PT=none). However,
although there had been an additional cost, he felt that overall it was worth it. He explained:
PID15: “Park the car and your time . . . it’s a bit much but apart from that if I can get up, I
don’t care. I can do anything they’ve asked me to, simple as that. If I think it helps
me, I’ll do it.”
The third concern was expressed by two participants and related to the pre-surgery sessions.
Both participants had felt well and not at all breathless before surgery, and so found it difficult
to understand why it was necessary to attend the exercise classes in the run up to surgery. PID26
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(BT=mild, PT=moderate) explained that he had “felt a bit of a fraud” and had felt “embarrassed”
that he was able to walk at a fast pace during the six minute walk test, he was concerned that it
gave the impression that he was “showing off”. PID28 (BT=moderate, PT=severe) explained that
the pre-surgery exercise sessions had felt pointless, as at the time she had not fully realised how
she would be affected by surgery. Related to this, PID28 went on to highlight the forth concern.
She reported that sharing rehabilitation sessions with other participants with severe COPD had
been disconcerting. She explained
PID28: “The first time I went, I thought, you see these old peoples’ homes on the television
and these people sitting in chairs doing things, and I thought oh my goodness, is this
what I’ve come to . . . I’m sure a lot of people there are far worse than me, they have
oxygen cylinders and things. . . . I found that very difficult . . . because I thought oh
gosh is that what I’m going to be like?”
The ROC programme design features that participants valued and also expressed preferences
for change are summarised in the table below.
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Table 3.17: Participants preferences regarding the content and format of the ROC programme, including
suggestions for change
Content (1) Exercises to improve lung and general strength, deal with acute
breathlessness, and aid chest clearance - Participants value following
the programme on an individual basis giving them the flexibility to tai-
lor the exercises to their ability and go at their own pace. They also val-
ued being treated like an adult rather than feeling like they were back at
school.
(2) Information - Participants value having a greater understanding of
the nature of the surgical procedure, what to expect/ how to deal with
health challenges during recovery and to understand the boundary be-
tween ‘normal’ and indication of something wrong.
Delivered by Health professionals who are able to answer questions specific to the
impact of lung surgery.
Timing Restart 1–2 months after surgery was acceptable to participants.
Group or
individual
Support from group members who are in a similar position is valued by
participants.
Potential
challenges
Suggestions
for change
Some participants may find it difficult to travel to rehabilitation sessions
due to ill health or lack of funds for travel/parking.
Some participants may find it unsettling to be placed in a group with
other patients who are seriously ill.
Some participants may not understand why they are exercising before
the surgery and need further explanation.
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FOUR
QUALITATIVE INTERVIEW: DISCUSSION AND
CONCLUSIONS
This chapter is split into three main sections. In the first section (section 4.1) the findings
regarding the four study aims/main topics are crystallised, integrated and interpreted in light
of findings from previously reported studies. This section ends with the design features of
a tailored rehabilitation programme that were identified as important, based on participants’
expressed needs and preferences. The second section (section 4.2) considers the strengths and
weakness of the study, and reflections on my experience of conducting the study. Finally, the
third section (section 4.3) summarises the conclusions to be taken from the findings of the study
and identifies priorities for further research
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4.1 Discussion of findings
4.1.1 Participants’ health experiences during the first year after surgery
and effect on function (interview aim/main topic 1)
This study found that many participants experienced ongoing health challenges during the first
12 months after surgery, particularly after thoracotomy. Although some participants were not
greatly affected by surgery, for many recovery was difficult and protracted, and they were not
back to normal at the time of interview. The most commonly reported health challenges were
breathlessness and pain, which were normally discussed without any prompting from the inter-
viewer. Although participants also described other health challenges, breathlessness and pain
were the first to be described, and usually dominated the interview. Given the priority that par-
ticipants gave breathlessness and pain in terms of order and time devoted at interview, findings
from this study add to the literature by indicating that these health challenges are of importance
to participants in terms of improving recovery experience. Indeed, some participants explicitly
stated that breathlessness or pain had been of the greatest concern to them during recovery (see
section 3.6).
Breathlessness The descriptions of experience of breathlessness were complex and rich in
detail. Some QOL instruments include measures of breathlessness, but involve rating general
levels of breathlessness on a scale. The exploration of experience complexity in this study adds
further detail to the evidence available from these previously published studies. Experiences of
breathlessness were found to vary in seven dimensions (see table 3.6). Variations in experiences
within the dimensions of ‘level of severity’, ‘effect on function’, ‘duration’ and ‘trajectory’ were
able to be grouped together to form a typology of experience which categorised participants as
being either not affected or being mildly, moderately or severely affected by breathlessness (see
table 3.7). Some participants in this study reported either not being affected by breathlessness,
or being midly affected. Participants were classified as mildly affected if breathlessness limited
195
CHAPTER 4. QUALITATIVE INTERVIEW: DISCUSSION AND CONCLUSIONS
only strenuous activities such as sport or DIY, or else mild breathlessness was experienced
when engaging in moderate activities such as walking, carrying shopping or climbing stairs, for
example. Although these participants felt that their functioning was somewhat limited in the
immediate days/weeks after surgery, they were back to normal by 3 months post-surgery and
they described coping well with the course of their recovery. They were not distressed by their
experiences of breathlessness as they felt that it was to be expected, and on the contrary often
expressed a positive emotional response including relief that they had not been greatly affected
and that they felt ‘lucky’.
Most participants in this study were classified as being either moderately or severely affected
by breathlessness. Those who were moderately affect experienced medium or high levels of
breathlessness when engaging in moderately strenuous activities that had not disappeared by
three months and for some was still ongoing up to 12 months after surgery. As moderate activity
was a normal part of day to day life for most of these participants, they often felt that their
life had been significantly disrupted and were sometimes not satisfied with the level of their
recovery. Some participants who had received standard care expressed concern that they had
not realised that they would be affected after surgery to such an extent and their experience
caused them emotional distress. Largely, participants did not receive any support from primary
or secondary care health practitioners for breathlessness and participants reported setting up
their own ‘programmes’ to aid recovery, particularly daily walking routines. Participants who
were enrolled on the ROC programme generally felt more prepared for their experience of
breathlessness after surgery and felt that exercising helped their breathing. A small number
of participants had access to prescribed steroid and bronchodilator inhalers due to co-morbid
diagnoses of COPD or asthma. All participants that used this type of pharmacotherapy reported
that it was helpful in managing their breathlessness after surgery. For participants that were
severely affected by breathlessness, activities of daily living such as washing, dressing, sleeping
and moving from one room of the house to another proved difficult. Two participants fell
into this category. These participants were interviewed at three months and 10 months after
surgery. Both were largely housebound and felt distressed by their experience. In addition, they
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described feeling alone and unsupported because help was difficult to secure and was achieved
through their own efforts only.
Although this study was able to elicit rich detail regarding participants’ experiences sampling
was purposeful and therefore the distribution of breathlessness severity may not be represen-
tative of surgical lung cancer patients on the whole. Quantitative QOL studies with patients
that represent different clinical or demographic sub-groups have given mixed reports regard-
ing the length of time that breathlessness remains elevated above baseline levels. However,
these studies confirm that most experience breathlessness for at least one month, but for many
it continues for more than 3 months and some groups of patients (particularly those who un-
dergo pneumonectomy) may experience breathlessness for 12 months or more after surgery (see
section 1.5.1). This general pattern is consistent with the distribution found in this study, and
confirms that breathlessness remains a problem for many for at least 3 months after surgery.
It is possible that some of the breathlessness described by participants could be explained by
pre-existing cardiorespiratory diseases, most notably COPD and CHD. However, those with
pre-existing disease were not more likely to report being more affected by breathlessness. One
of the participants who described being severely affected by breathlessness was a life time
smoker who relapsed back to smoking after surgery. He had also been diagnosed with COPD
previous to developing lung cancer and was receiving oxygen therapy. It is possible that this
had predisposed him to be more severely affected. However, he reported noticing a marked
increase in breathlessness after surgery, suggesting that his experience could not be completely
explained by co-morbid COPD. This finding was also noted for other participants who did, and
those that did not, have pre-existing lung conditions. Almost without exception, all participants
who experienced breathlessness noted that this symptom notably increased, or first emerged
immediately after surgery. This finding supports the position that over and above pre-existing
cardiopulmonary disease and functioning, most patients experience breathlessness after surgery
and further investigation is necessary to identify causes and appropriate treatment and care.
Breathlessness is a symptom, and therefore represents participants’ subjective experience of
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being “unable to breath easily.”[39] Breathlessness has been noted as a common problem in
advanced cancer,[108, 224] both for patients with primary or metastatic involvement of the
lungs and also those with disease that does not involve the lungs.[105] Increasingly, the causal
roots are being recognised as a complex interplay between physical, psychological, emotional
and functional factors.[108] Palliative care medicine utilises a range of techniques to alleviate
breathlessness, as well as both pharmacological and non-pharmacological treatments. These
include radiotherapy to reduce tumour volume or drainage of pleural effusions and use of bron-
chodilators, inhaled steroid, oral opioids, anxiolytics such as benzodiazepines or oxygen ther-
apy. Non-pharmacological treatment includes controlled breathing exercising, anxiety manage-
ment and patient counselling.[105, 189, 225–227]. In the context of advance disease, anxiety
and emotional factors may have an important role in the exacerbation of breathlessness, but it
is unknown if this applies to surgical patients. Although it is not captured in the academic lit-
erature, anecdotally there is evidence that health care practitioners have often attributed breath-
lessness after surgery to a ‘loss in confidence’ or being ‘anxiety driven’.
A striking feature of the descriptions of breathlessness was that many participants in this study
had not anticipated the degree to which they would be affected. It was quite common for
participants to say that they became breathless when rushing around, forgetting that they had
undergone a serious operation (although this was confined to those who were mildly and mod-
erately affected). In addition, many participants were motivated to strengthen their lungs and
increase their exercise tolerance by exercising daily, and reported experiencing breathlessness
in this context. This is important for two reasons. Firstly, the lack of awareness indicates an in-
formational gap which needs to be addressed in a rehabilitation programme, in order to prepare
patients for what to expect after surgery and to support them if they do experience breathless-
ness. A general feeling amongst participants was that they were more able to deal with health
challenges if they had been told to expect them and had been reassured that it was a normal
experience, although they also suggested it was difficult to assimilate information in the di-
agnostic consultation. Secondly, the unexpected nature of breathlessness and the experience
of breathlessness in the face of attempts to exercise is an interesting finding to consider when
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speculating on the potential cause of breathlessness. During interview some participants did
specifically refer to anxiety and loss of confidence and it may be that psychological and emo-
tional factors have some role to play. However, that the majority of participants actively exerted
themselves and still experienced breathlessness, and did not expect the experiences they had,
indicates that for this group of patients breathlessness seems mainly rooted in physical causes.
Additional findings that support this hypothesis are the descriptions that participants gave of the
physical experience of breathlessness. Often participants explained that they felt a tightening of
the airway, that they had increased difficulty in breathing when lying down in bed at night, in
extremes of temperature and in smoking environments. These are descriptions that are indica-
tive of inflammatory lung conditions such as asthma and COPD.[228] However, although some
participants were diagnosed with an inflammatory lung condition this did not adequately ac-
count for the experience of breathlessness. The cytokine network is recognized to play a pivotal
role in inducing the acute phase inflammatory response to surgical trauma,[229–231] and raised
inflammatory cytokines have been found to circulate in the blood after lung resection.[231,
232] VATS procedures have been associated with a reduced level in these inflammatory mark-
ers.[231, 233] It is thought that this may account, in part, for lower pain levels experienced
compared to thoracotomy.[231] However, the presence, cause and role of pulmonary inflamma-
tion during the first year after surgery in post-surgical breathlessness has not been investigated.
Some participants in this study had been prescribed corticosteroid inhalers and bronchodilators,
and felt that this helped them manage their breathlessness. Some also felt that participating
in a COPD-rehabilitation programme improved and helped them manage breathlessness. It is
possible that surgical lung cancer patients may benefit from a respiratory assessment and ac-
cess to treatments that are widely available for other respiratory conditions, although the design
of this study was not able to assess this. The benefit of pulmonary rehabilitation and inhaled
anti-inflammatory pharmacotherapy needs to undergo definitive testing in this patient group.
Another indicator that breathlessness may be rooted in physical causes was participants’ de-
scriptions of not being able to expand the lungs fully in order to breathe to a satisfactory depth.
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This may in part be down to technique or possibly psychological barriers. However, descrip-
tions did not convey that. For instance, PID10 reported: “I can’t take a deep breath, it kind
of just stops dead and that’s it . . . when I really need to take a deep breath in, I can’t do it,
it just doesn’t happen”. This participant had undergone bilobectomy, indicating that physical
reduction in lung volume may be the reason.
No known clinical instrument has been specifically designed to measure breathlessness experi-
enced by surgical lung cancer patients. Commonly, history taking for patients with respiratory
symptoms includes use of the Borg scale and the MRC breathlessness scale. Categories of
breathlessness experiences that have been described in this study mapped on to these two scales
of breathlessness. These scales take into account the severity of breathlessness (e.g. slight,
moderate, severe, maximal breathlessness) and the effect on function respectively. The Borg
scale was found to sufficiently describe the levels of breathlessness experienced by participants
in this study. However, the MRC breathlessness scale described breathlessness in terms of
strenuous exercise, walking and undressing only and therefore was not sensitive to the range of
activities that may be limited by breathlessness.
From accounts of participants in this study, combined with findings from other studies, as-
sessment and management of breathlessness emerges as a priority for a tailored rehabilitation
intervention to target. Further work is needed to understand the root causes of breathlessness
and to assess the effectiveness of pharmacological and non-pharmacological treatments in man-
aging breathlessness. In addition, the suitability of common measures of breathlessness needs
to be assessed from the patients’ perspective, and measures developed that indicate the need for
intervention and can capture improvements in the experience of this symptom.
Pain As with breathlessness, participants’ descriptions of pain experiences were complex and
rich in detail. Participants received varying regimens of analgesia whilst in hospital and to cover
the first weeks at home, although participants were not able to reliably recount the specifics of
these regimens. It has been reported that despite the availability of a range of analgesia and
routes of administration, acute and chronic post-thoracotomy pain remains a frequent clinical
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presentation.[118] This was found to be true for the participants in the present study.
A typology was constructed that classified participants as being either not affected, or being
mildly, moderately or severely affected by pain. Participants were classified as mildly affected
if they had experienced low levels of pain (e.g. a little, discomfort, sore) that had largely re-
solved within 2 months after surgery, or had lasted for no more than 2 months in the case of
participants who were pain free in hospital but developed some pain after discharge, once anal-
gesic prescriptions had been used and the effect had ‘worn off’. Participants were classified as
being moderately affected by pain if they reported either low or medium levels of pain sever-
ity (e.g. a little, discomfort, sore, a lot of pain, quite painful) that continued for more than 2
months but had disappeared within 6 months, or else they experienced high levels of pain (e.g.
agony, tremendous, terrible) that had resolved within 2 months. High levels of pain lasting
less than two months was included in this category as participants experiencing pain of this
description were generally distressed by the experience and pain significantly impacted activity
levels, therefore moderately affected was chosen as a more adequate description than mildly af-
fected. Participants that experienced high levels of pain severity that continued for longer than
6 months, either at the same level of severity or at lower levels, were classified as being severely
affected by pain.
Similar to breathlessness, pain is a subjective experience and its aetiology is complex (see sec-
tion 1.5.2.2).[234] It is a commonly held clinical belief that pain after thoracotomy is tran-
sient.[111, 112, 118] It is recognised that some can experience post-thoracotomy pain syndrome
(PTPS), which is defined as persistent pain that continues for longer than two months after tho-
racotomy (see section 1.5.2.2). Two months was used to define the transition from mildly to
moderately affected in the typology of pain experiences presented in this thesis, in order to
map on to this definition. There was a clear divide in the extent to which participants in this
study were affected by pain based on primary surgical procedure. Those who had undergone
VATS procedure reported either not being affected or being mildly affect by pain, whereas most
were moderately or severely affected after thoracotomy (i.e. the majority fulfilled the criteria
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for PTPS). This is consistent with other work that has indicated that compared to thoracotomy,
VATS is associated with less reported post-surgical pain.[232, 235] As with breathlessness, the
distribution of the participants within levels of the typology may not be representative of the
underlying population. However, other studies have also found that many continue to experi-
ence pain for more than 2 months after thoracotomy (see section 1.5.1). If most patients do
experience pain for at least two months after surgery, this calls into question the clinical belief
that development of PTPS is the ‘exception’ and highlights the need to improve identification
of patients with PTPS and to investigate effectiveness of treatments. .
The current description of type of pain experienced by those with PTPS did not adequately
describe the pain experiences reported by participants in this study. PTPS has been described as
an aching, burning dysaesthesia and/or having a pleuritic component which is largely confined
to the thoracotomy incision.[111] Participants in this study described aching, sharp pains and
impairment in sensitivity (dysaesthesia). However, no participant described a burning sensation.
Words used by participants to describe pain were largely captured by the categories of spatial,
pressure and punishing pains of the McGill Pain Questionnaire. However, participants also
described movement of a clamping/cramping pain along the thoracotomy scar which is not
described by the MPQ. In addition, a common observation from participants in this study was
that the site of the chest drain had been particularly painful, with some going as far as to say that
this site had caused the most pain. Many also experience ipsilateral shoulder pain, which may be
partly caused by the extended period of time for which the arm is extended and held in a brace
in order to allow access the thoracic cage.[236] Largely, therefore, although the description of
pain experienced by those with PTPS fitted some of the participants’ descriptions of pain, much
was not described by this definition.
There were two other points of interest regarding participants’ accounts of pain. The first is the
effect of pain on activity levels and functioning. It has been acknowledged that there is limited
evidence available that describes the impact of post-thoracotomy pain on patients’ activity.[111]
As in the hospital setting, adequate long term pain control is desirable to enable participants to
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rehabilitate and resume their normal levels of activity as soon as possible, in order to reduce
the risk of developing complications (see section 1.5.2.2). Participants in this study described
the impact of pain on activity and function, and there was a noticeable qualitative distinction
between the accounts of the effects of breathlessness and pain on this dimension. Whereas
breathlessness was most often experienced as a result of and during physical activity, and limited
the extent to which participants could continue with or the speed at which they completed the
activity, pain was most often reported in association with breathing, coughing, or when pressure
was applied to the wound whilst lying in bed or sitting in a chair, for example. When the pain
provoked was either at a low or medium level, participants did not report that it limited their
degree of activity, and they continued as normal despite the pain. There was some evidence of
slight sleep disturbance due to low or moderate pain experienced when changing position, but
overall participants spoke pragmatically about this stating that it was to be expected. However,
high levels of pain severity often caused a general reduction in participants’ activity level leaving
them vulnerable to the adverse consequences of immobility, and decreasing their confidence to
go outside.
Secondly, the two main dimensions of pain experience that seemed to differentiate emotional
response were level of severity and duration. There appeared to be a ‘two tier’ emotional re-
sponse; the first being acute distress and the second being anxiety regarding the cause of pain.
As would be expected, even when experienced for a short amount of time, those who experi-
enced high levels of pain found this acutely distressing. However, when severe pain lasted for
longer than two months or lower levels of pain lasted longer than six months, some participants
reported that they began to worry about what was causing the pain and whether ‘something had
gone wrong’. This anxiety was augmented by the fact that often participants had not expected
to experience pain to the level or for the length of time that they did. Some participants reported
that they had not been given an accurate picture of what to expect after surgery regarding pain.
This added to the shock, and one participant even disclosed that she had contemplated suicide.
Those who had managed to speak to a health professional involved in their care after starting
to feel anxious found it reassuring, and wished that they had been able to have the conversation
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sooner.
The findings from this study, combined with past studies, indicate that many patients experience
persistent pain for more than two months after surgery. This indicates that assessment and
management of pain is also a priority target for a tailored rehabilitation intervention. Evidence
from this study indicates that the current definition and description of PTPS may not be accurate
or useful, and that further work is needed to define this clinical problem and also to improve
identification, communication and management of the issue.
Other health challenges In addition to breathlessness and/or pain, some participants also re-
ported experiencing sleep disturbance, fatigue, loss of appetite and/or weight loss, to varying
degrees. For the majority, these topics did not dominate the interview but some participants
were concerned, particularly if the experiences severely affected day to day functioning and/or
were enduring. In addition, some participants reported experiencing anxiety related to their
experiences. There was some evidence that these experiences may have been secondary to ad-
juvant treatments, to analgesia, or to experiences of breathlessness and/or pain. For instance, it
was not uncommon for participants to note that pain and breathlessness experienced when lying
down at night disrupted their sleep. Also, the extra exertion involved in daily activity and the
struggle for adequate breath left some participants feeling fatigued. Often participants felt that
they lost their appetite, or that their sense of taste was impaired, whilst undergoing radiotherapy
or chemotherapy regimens, or taking high dose analgesia. Anxiety and psychological distress
associated with cancer diagnosis, treatment and health challenges during recovery from surgery
were laced through some participants’ accounts, and again it was not uncommon for participants
to feel that they had lost weight because of anxiety or to report that their sleep was disrupted. In
short, from a combination of the physical and psychological affects of diagnosis and treatment,
participants generally experienced a complex of one or more of these health challenges after
surgery. However, priority in participants accounts was given to breathlessness and pain.
As with breathlessness and pain, little research has focused on investigating causes of or po-
tential treatments for these additional health challenges for surgical lung cancer patients.[186]
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However, there is some evidence to suggest that exercise may improve symptoms of fatigue, as
it has been demonstrated to improve exercise tolerance and fatigue both in health populations
and those with long term conditions.[187] Fatigue is a symptom that affects 70-100% of cancer
patients. A recent Cochrane review summarised the findings from 56 studies that investigated
the effect of exercise on fatigue in cancer patients. This review found that engaging in aerobic
exercise either during or after adjuvant treatment led to a significant reduction in fatigue score
rating at the end of treatment.[187] However, most studies in this review were conducted on
patients with breast cancer whose average age at diagnosis is younger, and treatment differs.
No research investigating the effect of exercise on fatigue has focused on surgical lung cancer
patients, and further studies are needed to assess the benefits of exercise in this group not only
on respiratory function and breathlessness but also on measures of fatigue.
Differences between sub-groups There are various participant or treatment characteristics
that could have influenced the extent to which participants were affected by health challenges.
The nature of the primary incision (VATS or thoracotomy) and the extent of lung resection
(wedge resection, lobectomy, pneumonectomy) have previously been shown to be associated
with worse QOL scores (see section 1.5.1). In addition, a study investigating QOL in lung
cancer patients found that persistent smoking behaviour after diagnosis was also associated
with poorer QOL compared with those who did not smoke.[135] It was also considered likely
that participants with a pre-existing cardiorespiratory disease may experience higher levels of
breathlessness.
When comparing the qualitative descriptions of health during the first 12 months after surgery
between participants of difference sub-groups in this study, the only factor that clearly differ-
entiated reports was the nature of the primary incision. Participants who had undergone VATS
were more likely to report either not being affected or being only mildly affected by health
challenges. These findings add to a growing body of literature indicating advantages of VATS
compared to thoracotomy (see section 1.4.1.1). Some have expressed concern that this proce-
dure is not more widely available to patients.[232, 233, 237] Despite the potential for improved
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outcomes from this minimally invasive procedure it is not specifically recommended for use in
current BTS guidelines.[47] Barriers to nationwide use of this technique include some concerns
that VATS may result in inferior disease progression and survival outcomes[238], although
systematic reviews showing comparable prognostic outcomes for VATS and thoracotomy ex-
ist.[218, 239] The findings of the present study, in addition to previous studies, indicate that
VATS may have an important role in improving the treatment and recovery experience of el-
igible lung cancer patients, and underline the urgent importance of further research that will
lead to definitive answers regarding its potential as a less invasive, oncologically comparable
alternative treatment.
During the lifetime of this PhD, a review of QOL studies in surgical lung cancer patients has
been published.[240] In addition to the studies that were reviewed in the introduction (see sec-
tion 1.5.1), a further five studies were identified that had been published since 2009.[241–245]
Considering findings from all identified studies (pre- and post-2009), this review concluded that
lobectomy was associated with a deterioration in QOL with partial recovery over time. How-
ever, pneumonectomy was associated with a greater deterioration which did not improve, or
in some cases deteriorated further over time. This is consistent with the experience that was
described by one participant who had undergone a left pneumonectomy via thoracotomy in
this study (PID20). This participant was severely affected by breathlessness, and was the only
participant to report deterioration over time. However, one other participant who underwent
pneumonectomy, and others who underwent bi-lobectomy via thoracotomy described being
mildly and moderately effected by health challenges, as did those who underwent lobectomy
and wedge resection in this qualitative study. Although not identified in this study it is possible
that there are important qualitative differences between other sub-groups, particularly between
patients who undergo pneumonectomy compared to lesser resections.
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4.1.2 Participants’ attitudes towards smoking, smoking cessation and
NHS stop smoking support (interview aim/main topic 2)
Around half of the participants in this study were smokers at the time of diagnosis and although
some were able to quit, others continued to smoke immediately after discharge or relapsed
within the first three months after discharge. Although participants were purposefully sampled
(however, not on the basis of smoking behaviour), this findings supports previously published
studies that indicate a notable proportion of lung cancer patients continue to smoke after diag-
nosis (see section 1.6.1). Most participants stated that they would rather smoking was not a part
of their life and that they would like to quit, but also expressed conflicting beliefs/attitudes that
were supportive of continued smoking behaviour. Reasons for relapse or continued smoking
after discharge are likely to have involved a number of factors, but predominantly participants
cited reasons of enjoyment, lack of will power, psychological coping and living alone. These
findings have important implications for smoking cessation support as they indicate that surgical
lung cancer patients are no different to the general public in terms of desire to quit and reasons
for smoking.[246, 247] Regardless of participants’ attitudes towards smoking and smoking be-
haviour after diagnosis, all participants felt that it was the place of health professionals to ask
about smoking behaviour and to offer smoking cessation support.
Given that notable numbers continue to smoke and openness to intervention, these findings indi-
cate that smoking cessation support is of relevance to many in this patient group and needs to be
addressed. No study has quantified the proportion of surgical lung cancer patient smokers that
are offered support either within primary or secondary care in the UK, but a survey conducted
with clinician members of the International Association for the Study of Lung Cancer (IASLC)
showed that low numbers of clinicians offered smoking cessation support as a standard aspect
of their practice.[248] Most participants in the present study reported that they were not offered
support to quit smoking, despite recommendations by NICE that smoking cessation support
should be offered to lung cancer patients.[46] It is likely that in practice there is a gap for most
surgical lung cancer patients between the need for support and the level of smoking cessation
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support provided within cancer services.
Patient, physician and service barriers to accessing smoking cessation treatment There
are a few possible factors that may be acting as barriers to patients accessing smoking cessa-
tion support within cancer services. This study found that some participants reported feeling
stigma and guilt associated with smoking. This is consistent with a previous qualitative study
that reported lung cancer patients often feel stigmatised, whether smokers or not, due to the link
between smoking and lung cancer and that some who continue to smoke after diagnosis expe-
rience guilt and shame due to their continued smoking.[249] Some participants in this study
explicitly stated that feelings of guilt and shame had prevented them from being truthful about
their smoking status and from seeking support. Stigma, guilt and shame experienced by pa-
tients whose behaviour is linked to ill health has also been reported in other clinical contexts,
and these feelings can prevent help seeking behaviour.[250–253] These findings underline the
importance of sensitive, proactive management of smoking by health professionals. As identi-
fied by participants in this study, a non-judgemental approach is key, allowing patients to feel
they can be honest about their smoking behaviour and to return for further support after re-
lapse.[254] Further it suggests that biochemical validation of smoking status may be important
in this patient group. Biochemical validation has been shown to be a more reliable method
of assessing smoking status than self report.[255] Monitoring of CO levels in exhaled air are
used as standard within specialist smoking cessation clinics and anecdotally it is known to be
acceptable to patients.
It has previously been reported that clinicians also hold concerns that may be acting as barriers.
In general, clinicians report a lack of time, training and resources to engage in smoking cessa-
tion activities with patients.[254, 256, 257] Relapse rates after attempts to quit are high,[258]
and this may be de-motivating to both a patient and clinician.[254] These concerns may be com-
pounded in this particular context by nihilism born out of an historically poor outlook for lung
cancer patients as a whole, and smoking cessation is not seen as a priority by health profession-
als.[1, 259–261] Whilst it is possible that smoking cessation is not associated with improved
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outcomes in patients with advanced disease, there is mounting evidence that smoking cessation
after a diagnosis of early stage lung cancer is associated with short and long term health benefits
in addition to improvements in quality of life (see section 1.6, also the strength of evidence for
the association between smoking cessation and prognosis in early stage lung cancer patients is
investigated in chapter 6 of this thesis), indicating that smoking cessation may be worthwhile in
this patient group.
A cancer diagnosis has often been referred to in the literature as a ‘teachable moment’, where
patients may be more receptive to intervention, and indeed there have been calls to capitalise on
this time and make smoking cessation support an integral part of cancer treatment.[254, 262–
264] The legal ban of smoking in enclosed spaces in July 2007 [265] means that patients are
no longer able to smoke whilst in hospital, providing an external imperative to be temporarily
abstinent. This has the potential to provide added impetus to initiate and support a quit attempt,
although no study has been conducted to assess the impact of UK smoke-free legislation on
smoking attitudes and behaviour amongst hospitalised patients. Given the notable proportion
of continuing smokers, the potential benefits of quitting to health, the proximity of patients
to health services whilst receiving treatment for cancer and the willingness of surgical lung
cancer patients to be offered support, there is a strong rationale for the incorporation of smoking
cessation support into standard care for this group. Despite this, today in the UK, smoking
cessation is not explicitly recommended in the BTS guidelines for the radical management of
lung cancer patients [47], and general practitioners are not incentivised by the Quality and
Outcomes Framework (QOF) to arrange smoking cessation support for cancer patients. The
latest version of NICE guidance for the diagnosis and treatment of lung cancer recommends
that patients should receive support to stop smoking, but smoking cessation care is still not
embedded within standard cancer care pathways.
Anecdotally it is known that secondary care health professionals do not perceive smoking ces-
sation support or referral to be part of their responsibility,[254, 266] and smoking cessation is
poorly integrated into secondary care services generally. NICE are currently drawing up guid-
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ance for smoking cessation in secondary care, which is due to be published in October 2013.
This will be the first version of guidance on this topic and promises to increase impetus for
embedding smoking cessation into secondary care pathways for all patients, and also to im-
prove communication between secondary care, primary care and specialist smoking cessation
services. In terms of lung cancer patients specifically, added to improved service infrastructure
for identifying and supporting smokers to stop, awareness needs to be raised amongst health
professionals that patients are open to discussing their smoking behaviour and would like help
to quit. Health professionals need to have access to training which would increase their knowl-
edge of how to tackle this issue, and reassure them that sensitive management of the issue would
not affect the patient-health professional relationship.
Timing, content and level of intensity of smoking cessation services for surgical lung can-
cer patients: participants’ preferences and evidence Smokers in this study indicated that
they would prefer support for smoking cessation to be initiated as soon as possible during their
cancer care, with some specifically stating that support to quit before surgery would be best.
No strong preferences were expressed by participants for type of pharmacological support. No
known previous studies have tested the effectiveness of smoking cessation interventions with
surgical lung cancer patients, but there is no reason to believe that effectiveness of treatments
are likely to differ for this population compared to the general population. Many participants
had tried several available pharmacological products without success in the past. Some indi-
cated that they would be open to trying these treatments again. Indeed, some had attempted to
quit again using NRT patches or varenicline as offered by (usually) their GP. An interesting ob-
servation from participants’ accounts was that although some found it difficult, many reported
that it was easy to be abstinent whilst an inpatient as they felt too ill to smoke or because they
‘just did not think about it’. Many left hospital with good intentions to continue their absti-
nence, although often with minimal or no support, but found that within the first three months
of discharge they had relapsed. Although no strong preferences regarding type of pharmacolog-
ical were expressed, many had a strong preference for extended support during the immediate
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post-surgical period, because of particular vulnerability to relapse during this time.
There are several reasons to suggest that quitting before surgery and extended follow up would
be beneficial, in addition to being preferred by patients. As was discussed at length in the
introduction, there is evidence that quitting smoking immediately before surgery does not in-
crease risk of post-surgical complications (see section 1.6.2), and quitting smoking more than
four weeks before surgery and continual abstinence after treatment may lead to reductions in
risk.[66, 169] In addition, two systematic reviews provide evidence that extended follow up
significantly increase long term quit rates. A Cochrane review that assessed the effectiveness
of smoking cessation interventions in hospitalised patients found that of five levels of interven-
tion intensity, the only level that resulted in a significantly increased long term quit rate (6+
months) started at the bedside and continued for at least one month after discharge (RR 1.37
(95% CI 1.27 to 1.48; 25 trials).[267] This level of support was also significantly improved with
supplementation of NRT. (RR 1.54 (95% CI 1.34 to 1.79); six trials)
A second Cochrane review [170] reporting evidence from 5 trials (n = 535) on the effect of
a pre-surgical smoking cessation intervention on smoking cessation reported similar findings.
None of these trials were included in the first Cochrane review because the intervention was
initiated before hospitalisation. Although both brief intervention (1 face-to-face or by post con-
tact as part of routine pre-surgical assessment) and intensive intervention (weekly counselling
for between 4 and 8 weeks) significantly increased the number who had quit at time of surgery
(Intensive RR 10.76 (95% CI 4.55, 25.46) and brief RR 1.41 (95%CI 1.22, 1.63)), intensive
intervention only led to significantly increased quit rates at 12 months (RR 2.96 (95% CI 1.57,
5.55). Interestingly, this review also reported data on risk of any complication or wound com-
plications and for both analyses, only the intensive intervention led to significant reductions in
risk (Any complication RR 0.42 (95% CI 0.27, 0.65), wound healing complication RR 0.31
(95% CI 0.16, 0.62)). These interventions initiated quit attempts within 8 weeks of surgery.
In summary, combining the findings from this study and evidence from previously published
studies, it appears that a notable proportion of lung cancer patients continue to smoke after
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diagnosis and are open to support to quit. Research evidence has shown that initiation of sup-
port before surgery and continuation for at least 1 month after surgery is the most effective,
and this was also the preference for care expressed by participants in this study. A proactive
non-judgemental approach by health professionals may be important to help patients overcome
feelings of guilt and shame associated with their smoking behaviour. The rationale for priori-
tising smoking cessation support for surgical lung cancer patients is strong. However, further
work is required to embed smoking cessation support into standard care. Previous and pending
NICE guidance needs to catalyse the development of improved infrastructure for identifying
and referring patients for smoking cessation support. In addition, training of health profession-
als is needed to equip them with the knowledge and understanding necessary to implement the
guidance.
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4.1.3 Participants’ attitudes towards recovery and supportive care
received (interview aims/main topics 3 and 4)
VATS A finding that has emerged throughout this chapter is the stark difference in experience
between those who had undergone VATS compared with most who had undergone thoracotomy.
In line with this, when evaluating their general experience of recovery, all participants who had
undergone VATS were highly satisfied with their recovery, and felt that standard care had met
their needs. This lends further weight to the argument that, wherever clinically possible, VATS
should be surgicial procedure of choice, from the point of view of the patient reported outcomes.
However, as described in section , there remains uncertainty as to whether oncological outcomes
(e.g. recurrence, mortality) are equivalent or superior for patients undergoing VATS compared
to thoracotomy. .
The NSCI have defined a new model of follow up which stratifies patients to one of three levels
of care based on needs (see section 1.7.2). The first level of care is ‘self-management’. Within
this pathway, patients who do not have complex on going needs will be given the support and
information necessary to manage their own recovery, with the caveat that they may receive
more intensive follow up if the need arises. The second level of care involves ‘shared care’
and is appropriate for patients who have ongoing needs that they would not be able to manage
alone and need contact either with primary care or nurse/clinician led secondary care. The third
level is termed ‘complex care’, which will be led by consultants. It is thought that this will be
necessary for a minority of patients who have complex ongoing needs. Findings of this study, in
combination with previous studies, indicate that patients who have undergone VATS are likely
to have less complex needs than patients who have undergone thoracotomy. Participants who
had undergone VATS in this study were able to self-manage health challenges that had arisen,
and it is likely that this level of care will be sufficient for many of these patients. However, the
possibility that patients do need shared or complex care during their recovery cannot be ruled
out based in the findings of these studies alone.
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Thoracotomy In contrast to participants who had undergone VATS, most participants who
had undergone thoracotomy and received standard care were not satisfied with the course of
their recovery. They reported feeling that they had not been given a correct picture of what
occurred during surgery and what to expect during recovery, and felt that standard care had
not been sufficient to meet their ongoing care needs. Some expressed that they had felt aban-
doned by the health care system. Many participants who had received standard care felt that
they needed additional supportive care services, and felt that a rehabilitation programme would
help with recovery. The potential benefit of a rehabilitation programme in terms of participant
experience of recovery was confirmed by the experiences of those who had enrolled in the ROC
programme. In general, these patients spoke positively about their recovery, and the rehabilita-
tion programme content and format was praised by participants. Indeed, these participants did
feel that they had benefited from participating in the programme in a variety of different ways
that had aided their recovery.
A detailed understanding of differences in the satisfaction with recovery between participants
who received standard care and those enrolled in the ROC programme, and satisfaction with the
level of care, would be best gained by analysing how participants chose to communicate about
these issues during the interview (i.e. choice of words, tone of voice, hesitancy or confidence
for example) given that participants could not compare these conditions themselves. Analy-
sis of this type falls into the methodological approach of discourse analysis, and is outside the
scope of the analysis performed in this thesis. However, in general, compared with partici-
pants who had received standard care, those who participated in the ROC programme were less
concerned about the health challenges they had faced during recovery, particularly breathless-
ness, and used language which suggested that they felt more in control of their recovery. For
example, a characteristic that emerged from the accounts of all participants in this study was
of high levels of motivation to aid their own recovery, particularly to improve their physical
fitness and breathing. Most participants recounted some form of ‘rehabilitation programme’
that they had constructed for themselves to improve their fitness and to measure the improve-
ment. Many spoke of building regular exercise into their day (normally walking), and noted how
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their breathlessness improved. However, those who had enrolled in the ROC programme spoke
about their own personal programmes with enthusiasm and found direction/support from the
ROC programme invaluable in helping them to continue improving their fitness on their own.
In contrast, those who had received standard care, and in particular those who had undergone
thoracotomy and had been moderately/severely affected by health challenges, spoke about their
routines with an air of anxiety and struggle for survival. Taken together, the findings indicate
that shared or complex care may be most suitable for many patients after thoracotomy, based
on patient reported experience and views.
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4.1.4 Content and format of a tailored rehabilitation programme
(interview aim/main topics 1, 2, 3 and 4)
The detailed exploration of health and health behaviour (i.e. smoking) presented in the first
and second main topics of analysis (see section 3.4 and 3.5), combined with attitudes towards
recovery and supportive care preferences expressed by participants as reported in the second,
third and fourth main topics of analysis (see section 3.5, 3.6 and 3.7) create a detailed picture of
participants’ additional supportive care needs. The purpose of this section is to integrate these
findings and considerations, and suggest important components of a rehabilitation programme
tailored to the needs of surgical lung cancer patients. The findings of this study, along with other
considerations of this thesis, will then be discussed in the context of the lung cancer stratified
pathways as defined by the NCSI, in association with NHS Improvement, and mapped onto the
pathway in the final discussion (see chapter 7). It should be noted that most of the detail has
been provided by participants who had undergone thoracotomy, as it was this group that were
experiencing ongoing needs that were unmet by current services.
Participants in standard care found it difficult to describe specific preferences for the content and
format of a rehabilitation programme. However, five did express preferences and interestingly
they involved many features that are currently delivered as part of a pulmonary rehabilitation
programme for COPD (e.g. structured and supervised exercise, enhanced information giving
and disease education), and hence also the ROC programme.[3] Three of these patients had
undergone surgical treatment before the ROC programme had begun (PID4, PID10, PID11),
and therefore did not know about it, and the principles or possibilities of pulmonary rehabilita-
tion were not introduced during the interview by myself. The remaining two patients (PID16,
PID20) received standard care whilst the ROC programme was running, as they were referred
for surgery from a non-participating hospital. It is possible that these patients had heard about
the programme, and it was for this reason that they made suggestions that involved similar el-
ements. However, neither of these patients explicitly referred to a programme that had been
available to some, but not to them.
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Based on the point of view of participants who had received standard care, pulmonary rehabil-
itation represents a promising template to build an intervention that is tailored to the needs of
surgical lung cancer patients. The potential of pulmonary rehabilitation to improve outcomes
has also been recognised by NICE who recommended further research to evaluate the benefits
of pulmonary rehabilitation for surgical lung cancer patients.[46] Previous studies have piloted
this approach with promising results,[191–193] although participants’ views on this type of
programme and suggestions for change have not been explored (see section 1.8.3). The ROC
programme pilot running at the time of this study provided an ideal opportunity to explore if
patients who had received a programme based on pulmonary rehabilitation found this to be
helpful, as those who had received standard care suggested that it would be, and to assess from
the participants point of view if any changes were needed to improve the fit of the programme
to their specific needs.
As was described in section 3.7, the ROC programme was well received. Those who partici-
pated in the ROC programme articulated aspects of the programme that they particularly valued,
but again did not have ideas for changes necessary to improve the programme. In particular,
participants were happy with the group format, with the opportunity to exercise at their own
pace and also receive one-to-one support if necessary. Participants were happy to return around
4 weeks after surgery and felt that taking part in the programme improved their health and
motivation to exercise. In addition, participants felt that the ROC programme gave sufficient
opportunity for dissemination of information that was useful to them. This confirms the poten-
tial of using pulmonary rehabilitation as a starting point, or a template from which to build a
tailored intervention.
Although not raised by participants as specific ideas for change, some challenges identified by
participants in the first main topic of analysis were not covered by the programme indicating
areas which require improved tailoring. First, both participants who had received standard
care and those enrolled on the ROC programme expressed the view that there was a lack of
information regarding the cause of pain and the expected length of time that pain experiences
217
CHAPTER 4. QUALITATIVE INTERVIEW: DISCUSSION AND CONCLUSIONS
would continue. They indicated difficultly in managing pain, including getting help. In addition,
participants indicated that they did not know how to differentiate ‘normal’ from ‘cause from
concern’, and that they were anxious regarding the significance of pain that they experienced.
As part of the enhanced information given in the ROC programme, participants were told that
they might experience pain and to go to a GP if it persists for longer than a few weeks or
becomes unbearable. However, this did not seem to filter through to the patients. This indicated
that this aspect of the programme needs to be augmented.
Second, the possibility that participants may benefit from a respiratory assessment and pre-
scription of appropriate pharmacotherapy was highlighted by this study. Little research has
been carried out regarding post-surgical breathlessness, and the cause is largely unknown (see
section 1.5.2.1). Although most participants experienced respiratory symptoms after surgery,
and this has also been reported in other studies of lung cancer patients (see section 1.5.2.1),
current UK guidelines do not advocate referring symptomatic patients to respiratory care for an
assessment and treatment. Thus these patients ‘fall through the cracks’ and are not gaining ac-
cess to already well developed pathways of care for patients with other respiratory diseases. A
few participants in this study reported that they had been prescribed bronchodilator and steroid
inhalers to help manage their breathless by their GP and that they felt that this pharmacological
intervention had relieved their symptoms. This indicates that for some patients breathlessness
may be reversible. Further investigation of the causes of breathlessness and potential benefits
of pharmacological treatments such as corticosteroid and bronchodilator therapy is warranted.
It is possible that respiratory assessment and care in addition to the benefits of participating in
pulmonary rehabilitation may further improve patient experience and health.
Third, there was evidence that some participants may be in need of an occupational health
assessment at home. This is especially important if patients are living on their own with no
carers to help. The worst affected of participants felt vulnerable when they were discharged
and were severely compromised in their ability to carry out essential day to day functioning.
In addition, some participants indicated that they would have benefited from having access to
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mobility aids, and also practical help to prevent bed sores.
In summary, consistent with previous studies, this study has found that surgical lung cancer pa-
tients have ongoing healthcare needs after discharge that are not currently met by standard care.
This is particularly the case after thoracotomy. Pharmacological and non-pharmacological treat-
ments that are routinely made available to patients with other conditions for respiratory and pain
management may prove to be effective in improving surgical lung cancer patients’ quality of
life after surgery, although this remains to be formally tested. Rehabilitation programmes based
on pulmonary rehabilitation have shown promise as a useful and relevant template on which to
build specifically tailored support. Table 4.2 summarises the design features of a tailored reha-
bilitation programme that were identified as important, based on participants’ expressed needs
and preferences, building on the structure of the ROC programme.
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Table 4.1: Final content and format priorities and considerations for a rehabilitation programme for
surgical lung cancer patients
Identified needs
to be
addressed
Health challenges - Breathlessness, pain, appetite and sleep disturbance, weight loss and fatigue
Support - Informational, emotional, mobility, dietary and smoking cessation
Proposed
content
(1) Spirometric and other respiratory function assessment to ascertain the underlying cause of
breathlessness
(2) Management of breathlessness with appropriate pharmacotherapy
(3) Exercises to improve lung and general strength, deal with acute breathlessness, and aid chest
clearance - participants valued following an individual programme that they can tailor to their
ability and are able to take at their own pace.
(4) Pain assessment - referral to pain management clinic for those who continue to be affected by
pain
(5) Dietary assessment - participants who had lost more than 10% of their body weight should be
referred to a Macmillan dietician
(6) Smoking assessment - participants were not offended by being asked their smoking status or an
offer of support. Support needs to be proactively offered by NHS rather than relying on patients to
contact their general practitioner
(7) Mobility assessment - some participants felt vulnerable after discharge home and felt that they
needed mobility aids such as wheelchair, walking frames and also preventative care for pressure
sores
(8) Enhance information regarding the nature of the surgical procedure, what to expect/ how to deal
with health challenges during recovery and to understand the boundary between ’normal’ and
indication of something wrong
Delivered by Health professionals who know about previous care and are able to answer questions specific to the
impact of lung surgery
Timing Smoking cessation support - as soon as possible after diagnosis
Exercise and information - restart 1-2 months after surgery
Group or
individual
Support from group members who are in a similar position is valued by participants
Potential
challenges
Some participants may find it difficult to travel to rehabilitation sessions due to ill health or lack of
funds for travel/parking
Some participants may find it unsettling to be placed in a group with other patients who are
seriously ill
Some participants may not understand why they are exercising before the surgery and need further
explanation
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4.2 Strengths and weaknesses of the study and reflections on
the process
This is the first known qualitative study to have been undertaken with post-surgical lung cancer
patients that has aimed to describe the health and explore supportive care preferences. Inves-
tigation of these issues is timely as national developments are under way to improve current
services for cancer survivors who, until recently, have received care that does not fully address
their needs.[177] The following sections discuss the strengths and weaknesses of the study,
including personal reflections on conducting specific aspects of the study and scrutiny of the
risk of investigator bias. Many have argued that quality standards of quantitative methods, for
example internal validity, external validity, reliability and objectivity, are not appropriate for
qualitative inquiry.[199, 268, 269] Guba and Lincoln [270] offered alternative quality criteria
to these, of credibility (the results accurately represent the experiences of participants, and are
sufficiently supported with evidence from the underlying data), transferability (sampling that
represents diversity of participant characteristics, with sufficient information given for others to
determine if the results are transferable to other settings), dependability (the researcher gives a
detailed account of the methods so that the study could be repeated, and these methods include
efforts to ensure internal validity ) and confirmability (the role of investigator bias is fully dis-
closed), respectively. The strengths and weaknesses of this study will be considered in light of
these criteria.
General reflections: use of qualitative inquiry and role of personal bias within data collec-
tion and analysis Before this study, I had been involved in one other qualitative project seven
years ago. My role in this project was small and, therefore, constitutes minimal experience with
qualitative inquiry. As such, whilst conducting this project I had a steep learning curve. Most
of my previous training has been in quantitative methods within epidemiology, although before
embarking on this project I completed a total of three days training with the National Centre
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for Social Research on in-depth interviewing and data analysis using Framework Approach. It
became clear to me, particularly as I started both the interview and the analysis process, that
although I understood that the emphasis of qualitative research is different to quantitative re-
search, I still found myself trying to fulfil the quantitative mindset regarding research quality
and felt uncomfortable departing from it. Some particular examples of this are given in subse-
quent sections.
Reflecting on the possibility of the influence of personal bias on the construction of the coding
framework and presentation of the data, I feel that there is low risk. Before this study, I have
not had experience with this group of patients, either in a research, clinical or personal capacity.
I had read and summarised findings of QOL studies, but until I conducted the interviews with
patients I had not realised the extent to which many experience difficulties during recovery or
are affected in their day-to-day functioning. In addition, although QOL studies had identified
that some groups of patients continue to experience breathlessness and pain, I did not anticipate
how these challenges would dominate their recovery experience. In this way, although I had
some indication as to the challenges that participants may experience, I was largely able to
build a picture of patients recovery from their descriptions rather than fitting them to a strong
vision of what I expected, aiding impartiality and an unbiased interpretation of the data. This
impartial view of the data is a strength of this study.
Sampling This qualitative study was carried out on a large group of purposefully sampled
patients to represent a broad range of demographic and clinical characteristics. Purposeful sam-
pling is commonly used within the discipline of qualitative research.[200] Rather than recruit-
ing a large random sample of participants that will allow for assessment of statistical differences
between groups, the goal of sampling is to reflect diversity.[219, 271] For this study in particu-
lar, high diversity within the sample was achieved allowing the exploration of experiences and
attitudes demonstrated within and between different sub-groups of post-surgical lung cancer pa-
tients, with wide representation from groups based on primary incision procedure (thoracotomy
or VATS), extent of lung resection (wedge resection, lobectomy, pneumonectomy), demograph-
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ics (age, gender) and the level of care that they received (standard care or ROC programme
participant) during their first year after surgery. Although smoking behaviour was not a crite-
ria for sampling, the sample represented a broad range of behaviours including non-smokers,
ex-smokers and those who were smoking at diagnosis that either quit, attempted to quit and
relapsed or continued to smoke. The diversity of the final sample of participants represents a
main strength of this study.
Although the sample was represented by patients belonging to each of these sub-groups above,
the sample included participants of white British ethnicity only. Participants were recruited in
batches, and the diversity of the sample in terms of sub-group representation was assessed on an
ongoing basis, with this process informing the characteristics of patients that were invited to be
interviewed in future recruitment batches. Participants’ clinical and demographic characteristics
were recorded confidentially in a spreadsheet. I realised late in the process that no patients
from ethnic minorities had been recruited, possibly because I had prioritised ensuring sufficient
sampling of clinical sub-groups over this demographic sub-group. To rectify this, I attempted
to interview some patients who belonged to this demographic group. However, I was unable to
find a patient fulfilling this criterion that was available and willing to be interviewed within the
time frame that remained for conducting interviews.
To avoid this in the future, rather than listing details of recruited patients on a spreadsheet, mixed
with other administrative details, I will ensure that a separate spreadsheet is constructed for a
tally to be made of participants who have been recruited that represent the sub-groups of interest
to the project. This will more readily identify patient sub-groups that are under represented by
the sample. Despite this omission, there is no reason to believe that the health challenges faced
by participants after surgery would greatly differ based on ethnic background, if these chal-
lenges are largely biologically determined. However, the attitudes towards recovery, smoking
cessation and additional supportive care needs may not be generalisable to those from different
ethnic or cultural backgrounds. To fully explore the impact of health challenges on recovery,
the attitudes towards recovery and needs of patients from different cultural background, future
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studies need to include these groups to understand how they differ and how supportive care can
be further tailored to the needs of these populations.
Whilst considering the transferability (i.e. representativeness[270]) of the findings, i t should
also be noted that participants in this study were recruited from one hospital only. Although
this hospital is a tertiary referral centre for thoracic surgery, and therefore the catchment area
for patients is large, there may be regional variations in the amount of supportive care offered to
patients. However, at the time of interview, this hospital was the only known place in the country
to be piloting a programme aimed at rehabilitation. In addition, according to the 2011 National
Lung Cancer Audit report [48], 91.7% of patients within this hospital trust were seen by a
Clinical Nurse Specialist which was above the national average of 75%. It is likely, therefore
that participants in this study received the same or better supportive care than others in the
country.
An additional consideration regarding transferability of the findings is of the potential for sam-
pling bias. Given the qualitative methododology used, random sampling is not necessary.[219]
The purposeful nature of sampling involves non-random selection of patients in order to rep-
resent diversity. However, these sampling decisions, as outline above, should be based on pre-
determined patient characteristics. Bias would occur if inclusion of participants in the final
sampling was based either on recruiter knowledge of patient experiences/views or if partici-
pants are more or less likely to participate based on their knowledge of the project.[200]
It is possible that bias may have been introduced by the research nurse/physiotherapist who ini-
tially contacted patients. Patients that fulfilled the inclusion criteria for the study were sampled
from a list of all patients who had received surgery for lung cancer at Heartlands Hospital during
the course of recruitment. Although I informed the research nurse/physiotherapist of the inclu-
sion criteria, and of the characteristics to be purposefully sampled, due to ethical constraints I
was not involved in the decision process regarding which patients would be contacted.
The research nurse/physiotherapist were not involved in the care of patients who received stan-
dard care; however, they were involved in the day-to-day running of the ROC programme (i.e.
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recruitment and collection of research measures). This meant that they had prior knowledge
of the patients who were enrolled on this programme. It is possible that participants who had
been particularly difficult or expressed issues with the programme may have not been given
the opportunity to participate, or vice versa. Data regarding eligible patients who were not
contacted by the research nurse/physiotherapist was not available to myself due to ethical con-
straints. Therefore, it is not possible to tell if the selection of these patients was biased. This is a
potential limitation of the findings that the ROC programme was well received by participants,
and there may have been additional issues with the programme to those that were identified.
To avoid this in future qualitative studies that I run, I will include explicit instructions to guard
against this type of bias.
There is also potential for bias to have been introduced through non-participation. By choosing
to recruit patients throughout 3-12 months after surgery rather than all at 12 months, the risk
of non-participation due to death (i.e. survival bias) was reduced. However, there may have
been patients who died within the first three months after surgery who were not interviewed.
Survival to one year after surgery is high at 80%,[216–218] and is likely to be higher to 3
months. Therefore, the potential for survival bias to have affected the findings is regarded as
minimal. In addition, given this thesis focuses on the experiences and care needs of survivors
(rather than patients eligible for palliative treatment), the experiences of those who die within 3
months are not as relevant.
Although influence of survival bias was deemed to be low, there is a possibility of selection
bias due to non-participation for other reasons. Ten of the patients who were identified as
eligible did not participate. Various reasons for non-participation were given, including not
interested, not the right time or they didn’t answer their phone. It is possible that for some the
underlying reason was that they felt too unwell to be interviewed. If the sample was biased
in this way, the findings would have underestimated the extent to which patients are affected
after surgery. Another underlying reason for non-participation may have been that patients
were not comfortable to talk about the proposed interview topics. In general, this is particularly
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problematic for discussion of sensitive issues. Of all the topics discussion at interview, patients’
smoking behaviour and attitudes were thought to be the most sensitive. During the initial phone
contact by the research nurse/physiotherapist, patients were given a broad description of what
the interview was about and smoking was not specifically identified. When I called patients
who were willing to participate, I gave a more detailed description of the aims of the interview,
which included smoking. Many of the patients would begin to start telling me about their
smoking during this conversation, and were not apparently uncomfortable talking about it. This
was also my experience during interviews. Although some patients may not have participated
because they felt uncomfortable about their smoking, the experience of consent and talking to
patients makes me concluded that the findings regarding smoking are likely to be transferable
(i.e. representative).
The interview Using a semi-structured one-to-one interview format, I was able to obtain rich
descriptions of participants’ experiences and attitudes, and the meaning and impact attributed to
experiences by individual participants. As noted by Barbour [208], semi-structured interview-
ing“allows for the ordering of questions to be employed flexibly to take account of the priority
accorded each topic by the interviewee.” A strength of using this approach is that participants
are able to indicate which topics were of the most importance to them, meaning that issues
raised by the participants in this study were those that were ‘at the forefront of their minds’
and, therefore, of priority. Encouraging participants to ‘tell their story’ as they had experienced
it, allowed participants to initiate the discussion of topics of importance to them and gave par-
ticipants the freedom to define issues and express their views in relation to their care needs in
their own way. It is possible that there were topics that may have also been priority but were
not initially raised because participants found them difficult to discuss. To take account of this,
after having built rapport with participants, I asked if there had been ‘anything else’ that they
had struggled with. A few participants proceeded to disclose difficulties that they had not men-
tioned at first, but generally, given the opportunity, participants did not feel that there were any
topics that were left unraised.
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A challenging aspect in the design of this study was the ability to accurately capture partici-
pants’ health experiences, which evolved during recovery, through the first year after surgery.
It would have been preferable to conduct serial interviews with participants throughout the first
12 months to see how their experience evolved. However, due to time and budget restraints,
participants were interviewed once only. Instead of interviewing all participants at 12 months
and asking them to describe how there health experiences had evolved since surgery, partici-
pants were interviewed at different time points between 3-12 months after their surgery. As has
already been described, the strengths of this chosen method were considered to be minimisation
of the potential for recall and survival bias. Although, in general, participants health improved,
a weakness of recruiting people at different time points is that it is not possible to be sure of
the full trajectory of all patients. As all participants were interviewed at least 3 months after
surgery, a full account was given by all participants of this period; however, in effect, cross sec-
tions of experiences were elicited throughout the time period between 3 and 12 months through
different sub sets of participants. However, if sampling was relatively unbiased at each time
point and, considering the low death rate, then it is likely that the findings will be representative
of the range of experiences that patients may report throughout this period.
Although it was useful to interview patients contemporanously about experience during 3-12
months after surgery, an additional limitation of the study design was that there would be vary-
ing degrees of recall bias between participants’ accounts of how experience evolved. For ex-
ample, those who were interviewed at 3 months would likely recall their experiences during
these first 3 months after surgery more precisely than participants who were interviewed at 12
months. Collecting data on the evolution of experiences also posed challenges, as often partici-
pants would skip between past and present, particularly if they were still experiencing the health
challenge. This lead to some confusion, particularly in the earlier interviews, regarding the time
point that the participant had experienced the health challenge that they were describing. As I
proceeded to complete more interviews, I became more adept at explaining to participants that I
was wanting to understand how their experience had evolved over time and at keeping them on
track with that pursuit. In earlier interviews I found myself asking leading questions to clarify
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timing in participants’ accounts, such as “so the breathlessness started straight after surgery,
did it?” for example. However, I learned to turn this type of prompt into a non-leading open
question of clarification such as “so when did you first notice that you were breathless?”
Although I was able to gain in-depth understanding regarding the recovery experiences of pa-
tients over the full course of the first year within one interview, as previously mentioned, an
alternative approach to the method taken in this study would be to conduct serial interviews
with each participant at different time points. This would give greater precision as to how the
experience evolves over time, and direct comparisons between all interviewees at each time
point could be made to understand different experiences. This approach has previously been
advocated for gaining an understanding of dynamic health experiences.[272] In addition, serial
interviews can enable the development of a relationship between the participant and researcher
which may facilitate the discussion of personal and sensitive issues. Conducting multiple in-
terviews with the number of participants recruited in this study was outside the scope and con-
straints on time of this study. However, in order to gain a clearer view of the evolution of
participants’ health experiences and care needs over time, this method may be more appropriate
for future research of a similar nature.
In addition to capturing evolution of experiences over time, exploring participants’ attitudes
towards post-surgical supportive care and discussion of their ideas for the content and format
of a rehabilitation programme posed some challenges. This was particularly the case for those
who had received standard care. There were a few possible reasons why this was difficult. First,
although it was explained to participants at the beginning of the interview, and sometimes re-
iterated during interview, that highlighting unmet needs would not be taken as a bad reflection
on the hospital staff, there was sometimes a feeling that participants did not speak candidly
about their attitudes towards gaps in the present service and future supportive care. When being
asked to evaluate their experience of care, some participants did not move beyond explaining
that the health professionals involved in their care had done their best. It is possible that this
participant group found the interview particularly difficult because their generation are not as
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familiar with the concept of patient involvement in service development as maybe people from
younger generations. Participants’ use of language often represented themselves as grateful
users of a service which was administered by experts, and they may have felt uncomfortable
offering constructive criticism.
Second, even if participants felt comfortable highlighting areas of unmet need, often they were
not able to specifically imagine or articulate what kind of service they felt they needed in the
absence of that service. It was possible that a single one-to-one interview was not the best
method of facilitating this kind of discussion with participants, particularly when the interviews
had also focused on a number of other topics. It is possible that participants would be in a
position to fully reflect on their attitudes towards services if this was the single subject of an
interview, and also if they were presented with a range of options to stimulate discussion and
help understanding of what might be possible. For those who had participated in the ROC
programme, discussion regarding their attitudes towards care and the design of a rehabilitation
programme were easier, although again participants did not provide an in-depth critique of the
programme and did not offer specific ideas for improvement, although they had indicated needs
that remained unmet in earlier discussion within the interview. In future work, this may be
overcome by conducting more that one interview thus giving the time to focus on this aspect
of discussion in more depth, and by providing options for design change with visual prompts
within the interview to stimulate discussion.
Reflecting on my experience of conducting the interview, I found the process a little unnerv-
ing, particularly for the initial interviews. In summary, this came down to two reasons. First,
as noted by Barbour [208], qualitative interviewing is somewhat a rarefied version of normal
human interaction. Although I knew this in theory before conducting the interviews, I found
this uncomfortable at the beginning and had to adjust to the mindset of an impartial researcher.
After some of the earliest interviews, I realised that I had fallen into the trap of trying to help
the interviewee feel that I was ‘on their side’. I was conscious of raising participants’ aware-
ness of their situation, asking them what help they felt they needed and then not being able
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to address these concerns. In the initial interviews, I often finished participants’ sentences in
what I quickly recognised was an unnecessary attempt to show that I had understood and ‘back
them up’. I realised that this may also have the undesirable effect of leading participants, and
participants may not have felt able to challenge my interruptions if I had not fully understood
what had been explained. After I realised that I was doing this, I made a conscious effort to
stop this practice and allow the participant to explain their thoughts without interference. As
I became more experienced at interviewing, I was more able to distance myself emotionally
and empathetically from interviewees, and act as a non-leading prompt, guiding participants to
discuss issues of relevance to the interview aims.
Second, I found interviewing challenging initially because I was concerned about a lack of
rigour. This is an example of an uncomfortable departure from quantitative approaches. This is
a common experience according to Barbour[208], who also goes on to explain that “There is a
bit of an art to asking questions that departs very markedly from the approach favoured in fixed-
choice formats”. Whilst interviewing participants, I was also conscious of the recommendation
given during my training, and by a number of experts in this area, to anticipate the analysis while
generating data, and to ensure that you have sufficiently probed an area during interview.[199,
200, 208] Combining these two elements, I found I had to adjust to participants describing
phenomena in different ways, in different orders and from different perspectives, and that, as
is necessary with semi-structured interviews, I was using questions that were often phrased
differently, depending on how the interview evolved. In earlier interviews, I found myself
trying to re-cover ground that had already been covered in order to ensure that when I got to the
analysis I would not have missed out probing on important areas and in an attempt to ensure that
participants’ accounts were directly comparable. As mentioned before, often participants did
not give strictly chronological accounts, and I also found myself interrupting the flow of their
accounts trying to bring participants back to points in the story where they had jumped. This
often had the effect of participants restarting the story at that point but then veering off on other
tangents before providing the clarification I had sought. It took a few interviews to strike the
balance between understanding where clarification of points and chronology were important,
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and where clarification was not needed and would just lengthen the period of time spent on
issues that were not important. In addition, as I gained more experience, I found myself being
able to be more direct with participants regarding what was of interest and what was a tangent
(such as their views on the food and nursing care that they received whilst an inpatient).
The analysis A strength of the analytical method used for this study (framework approach) is
that it allows themes to be ordered under pre-existing headings. This allowed me to analyse the
data from the perspective of the pre-defined interview aims, whilst remaining grounded in the
data and also exploring unanticipated themes emerging within each aim. As outlined by Richie
and Lewis [200], analysis of the data was an iterative process, and a coding tree was constructed
and modified as the process of interviewing and analysis continued. At the time that I began
this, a new version of NVivo (version 9.2) was released that merged the functionality of this
widely used and well developed package for qualitative analysis with functions that had been
available previously using FrameWork software. Using NVivo 9.2 allowed me to be able to
code data and build framework matrices within the same package. This helped me to keep
track of the data through the analysis trail, from interview transcript, through to coding and
summarising the data, ensuring the analysis remained grounded or in other words that fidelity
to the underlying data was maintained in the summaries making the analysis credible.[199]
Iterative analysis also allowed me to assess whether ‘saturation of themes’ had been reached
within participant sub-groups and for the different study aims. The material covered in the
interviews was complex, and although I was confident saturation of themes had occurred for the
majority of themes, some sub-themes within participant sub-groups may not have been explored
to exhaustion. For example, although there were only six participants that had undergone a
VATS procedure, I am confident that saturation of themes was reached in terms of the first and
third aim of the project, as interviews with both participants who had undergone thoracotomy
and those who had undergone VATS were not generating any new themes for these aims. It
is likely that a smaller number of participants who had undergone VATS were needed because
this surgical procedure did not impact participants to the same degree as thoracotomy, and their
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experiences were less complex. However, within the group of participants that had undergone
VATS, there was only one who had participated in the rehabilitation intervention pilot and one
who was a smoker. It is therefore likely that saturation of themes within the VATS surgical sub-
group was not reached for interview aims two and four. It is possible that participants’ attitudes
to smoking may differ in those who have undergone thoracotomy compared with those who had
undergone VATS, due to the higher impact of the former on health and functioning. Those who
had undergone VATS did not report needing extra supportive care and are likely to represent
those who would benefit least from a rehabilitation programme. However, this could not be
ruled out given the small number of patients interviewed.
Dependability (i.e internal validity [270]) of the analysis is subject to rigorous identification
of themes and coding of interviews, and elimination of investigator bias or error.[270] Investi-
gator bias or error may manifest as an incorrect definition of emerging themes/sub-themes, as
assigning data to themes/sub-themes to which they did not belong or by missing relevant data
for coding altogether. The potential for these biases/errors in identification of themes and in
coding of data were minimised using two methods. First, my supervisor independently coded
five interviews throughout the series of interviews (PID1, PID4, PID9, PID12, PID17) in order
to compare our indexing decisions on the evolving coding structure. My supervisor coded data
blind to my coding assignments, using the coding structure that I had created (inter-rater relia-
bility[205]). It was deemed appropriate for my supervisor to use the created coding structure as
it was largely defined by the interview aims, although the appropriateness of emerging themes
and sub-themes were also double checked. Our decisions regarding assignment of data to main
themes were largely the same. However, coding decisions regarding sub-themes were not an
exact replica. Differences were mainly of three main types: 1) assigning a different amount
of contextual data around a quote, 2) failure to code data under all of the themes which it was
relevant to, 3) differences in the language used to define emerging themes, each of which were
resolved through discussion.
Checking inter-rater reliability whilst the coding structure evolved minimised the potential for
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investigator bias to affect the coding structure (and therefore identification of emerging themes).
However, it was possible that data within unchecked interviews had been missed, especially
when they were relevant to more than one theme. To overcome this, a second method was
used to minimise investigator bias/error. Specifically, this involved running queries in NVivo to
retrieve portions of the interview script that referred to key words that identified main topics and
themes (see appendix A.17). Queries were carried out to identify data relevant to the themes of
breathlessness, pain, fatigue and sleep, appetite and weight loss and smoking. However, due to
a lack of common key words that could identify data relevant to the themes of attitudes towards
recovery, supportive care received or preferences for a rehabilitation programme, queries were
not for these themes. Running queries minimised the potential for missing relevant data for
coding. All conscious effort was made to objectively assess the relevance of data to themes
and sub-themes, which was done in the context of understanding derived from a non-clinical
background. Overall, it was considered that the potential of the findings of the study to be
affected by investigator bias were reduced to a minimum.
4.3 Conclusion
This study has investigated the health and supportive care needs of surgical lung cancer pa-
tients during the first year after surgery. Participants were found to experience a number of
ongoing health challenges to varying extents, which often limited function. For many, health
challenges had been a source of emotional distress. Health and functioning was compromised
to the greatest extent after thoracotomy. Although there were some participants who were sat-
isfied with the level of support they received in standard care, there were many whose needs
were not met and they were unsatisfied with standard care. It is possible that treatments and
services that are widely available to other patients may be beneficial to surgical lung cancer
patients. In particular, breathlessness and pain emerged as dominant challenges during recov-
ery, and pulmonary rehabilitation was found to be a promising template on which to build a
tailored rehabilitation intervention. Participants who had access to inhaled corticosteroids and
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bronchodilators reported that this helped them manage breathlessness, and in addition access to
specialist pain management was highly valued. There is a strong rationale for the integration
of smoking cessation support into standard care, and participants in this study felt that it was
the place of health professionals involved in their care to ask them about their smoking and
were open to offers of support. On the foundation of the ROC programme design, which was
based on COPD rehabilitation, design components identified as important for a tailored reha-
bilitation programme based on the expressed needs and preferences of participants have been
suggested (see table 4.2). Future work is needed to assess the acceptability of the proposals to
clinicians and patients, before a final design of the programme can be taken forward and tested
for effectiveness.
4.3.1 Identified research priorities
The following is a list of research questions that have been identified based on the findings of
this study:
1. What is the best method to measure breathlessness after surgery and to what extent can
breathlessness after surgery be attributed to physiological and psychological factors?
2. What are the most suitable and effective pharmacological and non-pharmacological treat-
ments for post-surgical breathlessness?
3. What are the most suitable and effective identification tools and treatment protocols for lung
cancer patients experiencing enduring post-surgical pain?
4. Assess the acceptability of the proposed components for a tailored rehabilitation programme
to health professionals and patients and design a final programme for testing.
4. What is the effectiveness of a tailored rehabilitation programme based on pulmonary reha-
bilitation in improving symptoms that have been identified as important by participants in this
study (breathlessness and pain, and secondarily appetite, sleep disturbance and fatigue), QOL
measures, respiratory function, respiratory complication rates and survival.
239
CHAPTER
FIVE
INVESTIGATION OF THE ASSOCIATION BETWEEN
SMOKING HISTORY AND LUNG CANCER PROGNOSIS:
SYSTEMATIC REVIEW WITH META-ANALYSIS AND
META-REGRESSION
5.1 Review questions
1. Main question: What is the association between smoking history (in terms of presence of
a smoking history, recency of smoking history or intensity of smoking history) and the
risk of all cause mortality, cancer specific mortality, development of a second primary
tumour or tumour recurrence in lung cancer patients?
2. If an increased risk is found, can this be explained by reduced eligibility for curative
surgical treatment?
3. If risk is not totally explained by eligibility for curative surgical treatment, is increased
risk in surgical patients explained by histology, stage at diagnosis or presence of co-
morbidity?
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5.2 Introduction
The causal role of smoking in the development of lung cancer has previously been discussed
in detail (see section 1.3.2). In brief, smokers aged 55 years and over have around a 26 fold
age-adjusted increased risk of dying of lung cancer compared to those who never smoke.[23]
Around 40% of patients are current smokers at the time of diagnosis, and most patients have
a history of smoking.[144] Past literature has focused on the role of smoking in developing
lung cancer.[23, 31] However, the influence of smoking history on prognosis has received less
attention. Although various studies have been published in this area, this evidence has not been
systematically reviewed and there is no consensus on the prognostic significance of smoking
history in lung cancer.
Understanding the prognostic significance of smoking history is important for a number of rea-
sons. First, it has been recognised that the current system of follow up care for cancer patients is
not sustainable as the number of patients requiring follow up in the future is predicted to rise (see
section 1.7.2).[177] Currently, all cancer patients receive regular specialist follow up appoint-
ments with the primary aim of checking for tumour recurrence.[47] In the future, surveillance
is likely to be prioritised based on risk and therefore understanding the prognostic significance
of smoking history may be important for risk stratification.[182] Second, improvements in pre-
diction of prognosis may aid patient counselling, and help in clinical decision making. For
example, improved prognostic information is of potential importance for patients of borderline
fitness for surgery and may help the clinician or patient to decide on a most appropriate course
of action.[273] Third, investigation of the prognostic significance of smoking history using both
all cause mortality and cancer progression related outcomes may shed further light on the the
mechanism by which smoking history may affect prognosis, and the role of co-morbidity in the
prognosis of lung cancer patients.[274] Fourth, smoking history is not generally used as a strat-
ification factor in clinical trials. However, if smoking history independently predicts prognosis,
this should be taken into account in future trials.[273]
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Smoking history Prognosis
Eligibility for surgery
Histology 
Stage at presentation
Figure 5.1: Hypothesis 1: smoking history is associated with an increased risk of death as it decreases
eligibility for surgery. If this is true, smoking history would not be associated with risk when
sub-grouping studies based on treatment.
There are a number of different pathways through which smoking history could influence the
prognosis of patients with lung cancer. In addition to investigating the association between
smoking history and prognois, these pathways have also been investigated and for clarity are
outlined in figure 5.1 and 5.2. It is possible that having a history of smoking reduces eligi-
bility for curative surgical treatment (hypothesis 1 - see figure 5.1).1 The decision to proceed
with surgical treatment is largely dependent on disease stage at presentation and also patient
fitness,[47] and receipt of surgery greatly improves prognosis.[57] Smoking is more strongly
associated with factors that reduce eligibility for surgery i.e. the development of more aggres-
sive tumour histologies, later presentation and compromised cardiorespiratory function due to
smoking related diseases. [31, 39, 275] If smoking history influenced prognosis by reducing
the chance of being selected for surgery, it would be expected that in a stratified analysis based
on receipt of surgical treatment no association would be found in each stratum. In this case,
smoking history would not be a prognostic factor for patients treated with surgery.
However, it is also possible that smoking history does hold prognostic significance for surgical
patients. I have hypothesised that in surgically treated patients, smoking history may be asso-
ciated with a worse prognosis due to reasons related to cancer (hypothesis 2-3, see figure 5.2)
1This is because surgery is a curative treatment, which significantly improves prognosis. Although either
surgery or radiotherapy can be administered with curative intent,[47] the mainstay of curative treatment is surgery.
Studies in this review did not include any patients that had been treated with radical radiotherapy. Therefore,
only mediation by surgical treatment for curative intent was investigated. Exploration of the relationship between
smoking history and prognosis was subsequently confined to curatively treated surgical patients only (hypothesis
2-4), as this patient group is the focus of this thesis.
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or that are unrelated to cancer (hypothesis 4, see figure 5.2). Tumour histology and stage of at
diagnosis[41, 276] have both been shown to be independent prognostic markers in surgical pa-
tients. This means that these cancer-related factors can increase risk of death in additional ways
than indicating treatment, although the mechanisms by which this may happen are a matter of
ongoing research and not fully understood. It may be that even though surgery was apparently
successful, patients with a smoking history are still at a greater risk of dying because they are
more likely to have been diagnosed in a later stage (i.e Stage IIIa instead of Stage Ia for example,
both are eligible for surgery) or with a more aggressive tumour (i.e. squamous cell carcinoma
rather than adenocarcinoma). Alternatively, co-morbid disease has also been shown to be an
independent prognostic factor for surgical patients.[60, 277] As patients with a smoking history
are more likely to have co-morbid disease, this factor which is unrelated to cancer may explain
an increased risk of death associated with smoking history in this group.
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Smoking history Prognosis
Histology
(a) Hypothesis 2
Smoking history Prognosis
Stage at presentation
(b) Hypothesis 3
Smoking history Prognosis
co-mobitity
(c) Hypothesis 4
Figure 5.2: Hypothesis 2–4: These are tested in surgical patients only. Smoking history may cause
increased risk due to a more aggressive tumour histology (hypothesis 2) or later stage at diagnosis
(hypothesis 3) which leads to a greater chance of the cancer recurring. If this is true, risk of both all
cause and cancer-related mortality would be raised. Alternatively, patients with a smoking history may
have an elevated risk of dying due to other co-morbid diseases (hypothesis 4). If this is true, risk of
all-cause mortality would be raised only.
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The relationship between smoking history and prognosis, and these hypothetical pathways
through which a relationship might operate were investigated by systematically reviewing ob-
servational longitudinal studies. In addition to comparing patients with smoking history (ever
smokers) with those without a smoking history (never smokers), the importance of recency (cur-
rent, former, never smokers) or heaviness of smoking history (pack years) was also investigated.
5.2.1 Theoretical and methodological considerations
It has previously been acknowledged that systematic reviews of observational prognostic studies
pose a number of challenges.[273] The following section outlines these challenges and also
describes the rationale for the methodological approaches that have been taken.
Study design and confounding Randomised clinical trials are the most robust study design
to determine the size of an association between two variables from primary data, normally
healthcare treatment and treatment outcome. This is because randomisation ensures equal dis-
tribution of potential confounding factors between randomisation groups. Assuming results are
not influenced by post-randomisation bias, a statistically significant difference between groups
is considered evidence of treatment being causally related to the outcome.[278] It is not possi-
ble to randomise people to a level of smoking history, making randomised controlled trials an
unsuitable study design to investigate the questions posed by this review.[279] Therefore, data
from longitudinal observational (cohort) studies have been used.
Cohort studies are the second most robust study design in the hierarchy of evidence,[280] and
are the only suitable observational study design to consider prognostic outcomes using time to
event data, as this type of data necessitates a follow up period. For meta-analysis of observa-
tional data, combination of individual patient data is most favourable.[273] This is because in
studies that employ an observational design, it is possible that confounding variables are not
balanced between exposure groups, obscuring the true effect. Although groups may not be
balanced at the start, the use of individual level patient data enables modeling of the data in a
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uniform way and confounding factors can be adjusted for and moderation/mediation explored
in the same way as if all data had originated from the same study.[273]
In the absence of individual patient data, association between two variables can also be explored
using study level estimates as has been done in this review. However, this method does pose
some challenges with regards to control of confounding.[281] 2 Prognostic studies may present
study level estimates that are adjusted and/or unadjusted for confounders As exposure groups
are not randomised, the unadjusted model may be subject to uncontrolled confounding. Base-
line characteristics may be presented for the study group as a whole, or by the exposure of
main interest for that particular study. However, if baseline characteristics are not presented
by the exposure of interest to the review, it is not possible to assess if potential confounders
are unbalanced. Although ‘best fit’ adjusted models may be chosen for use within systematic
reviews of prognostic studies to over come this difficulty, often studies use different adjusted
models which can create difficulties for interpretation if pooled.[273]
2Confounding factors are associated with the exposure and also the outcome, but do not lie on the causal
pathway between the exposure and outcome (see figure 5.3)
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Exposure Outcome
Confounder
Exposure Outcome
Mediator
Exposure Outcome
Eﬀect Modiﬁer
Figure 5.3: Diagramatic reprentations of confounding, mediation and effect modification
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For this review, it was decided that unadjusted estimates would be used as a basis for the analy-
sis. This decision was taken due to the difficulty in interpreting a combined estimate of models
adjusted for different factors. Interpretation was considered to be particularly challenging for
this review, as from scoping searches it was clear that many studies presented models adjusted
for both potential confounders and also modifiers and/or mediators 3 e.g. tumour histology,
stage, treatment and co-morbidity. When mediators are controlled for in a regression analysis,
the association between the exposure and outcome partially or completely disappears, depend-
ing on whether the association is partially or completely mediated through the third variable of
interest.[282] Therefore, it would not be possible to assess the effect of smoking history itself
on prognosis using an estimate adjusted for mediators. Using an estimate controlled for a mod-
ifier would give an average estimate of the association between smoking history and prognosis
across different strata, and the size of association would be better explored within individual
strata of the modifier.[281]
For these reasons, it was considered that unadjusted estimates should be used. In order to assess
the potential for uncontrolled confounding that would arise due to using unadjusted estimates,
baseline characteristics by smoking history exposure group were extracted where presented.
Both age and gender predict smoking behaviour,[283] and these factors have also been shown
to be independent prognostic factors in lung cancer.[284–287] These factors were considered
to be the main possible confounders. A full consideration of the potential for uncontrolled
confounding to influence the results is given in the discussion section of this chapter.
Due to many of the difficulties outlined above, some have argued against meta-analysis of ob-
servational studies using study level estimates.[288, 289] However, others have argued that the
inherent difficulties do not preclude meta-analysis, but that the emphasis should be on explo-
ration of heterogeneity rather than quantifying the magnitude of the true effect.[273, 290] This
latter approach has been taken for this review.
3A modifying factor is a third variable that, when present, alters the size of the association between exposure
and outcome. In contrast, a mediating factor is a third variable that lies on the causal pathway between the exposure
and outcome (see figure 5.3).
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Heterogeneity and investigating effect modification Statistical heterogeneity indicates that
studies in a meta-analysis are estimating different underlying values of effect size. There are two
main sources of heterogeneity, clinical characteristics of study participants and methodological
difference between studies.[291] Methodological heterogeneity is present when study design or
outcome measures lead to measurement of different quantities. For example, in this review, it
is possible that differences in the way that smoking exposure is measured (e.g. retrospectively
from case notes or prospectively with biochemical validation) may lead to differences in effect
size. In this case, the underlying ‘true’ effect size may be the same, but studies are not mea-
suring exactly the same aspect of the effect. Clinical heterogeneity is present when the ‘true’
underlying effect size differs between clinical populations. The factor that defines the clinical
population is said to be an effect modifier (see figure 5.3).[282, 291] For example, I have hy-
pothesised that risk of death associated with smoking history may be modified by receipt of
curative treatment.
Modification was investigated using sub-group analysis, and study sub-groups were formed
based on participant characteristics within each study. If the size, or direction, of the association
was found to be different between two sub-groups this was interpreted as modification by the
factor that defined the sub-group.[281] In addition, the effect of sub-grouping on heterogeneity
was noted using I2 statistic which gives the percentage of variability due to heterogeneity of the
underlying effect sizes rather than chance. Heterogeneity of above 50% is considered to be high,
and indicates that there is more than one underlying ‘true’ effect.[291] If a particular clinical
characteristic (e.g. receipt of surgical treatment) was acting as a modifier, then sub-grouped
analyses based on the presence or absence of the characteristic should reduce the heterogeneity
observed compared with when all studies are combined. However, it is widely recognised that
the power of this measure to detect heterogeneity is low, and it is possible that heterogeneity
exists even if not detected.[292]
It should be noted that in addition to the possibility of unbalanced confounding within stud-
ies, characteristics of patients between studies may also differ in important ways other than the
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sub-grouping factor as patients are not randomised to the study that they participate in.[292]
Therefore, sub-analyses must be considered exploratory, and the focus of the analysis be on
observing changes in the magnitude or direction of the association and in the amount of hetero-
geneity after sub-grouping, rather than estimating the magnitude and direction per se.
Meta-analytic combination of study estimates can be done using fixed effects or random effects
models.[293] A fixed effect model assumes that all combined studies are estimating a common
effect size, and that any variability between the studies is due to chance. In other words, if each
study had an infinitely large sample size, a fixed effects model assumes that they would all find
the same effect size. Based on this assumption, the 95%CI are calculated using a measure of
within study variation only (the standard error), as it is not necessary to take into account non-
random variation between studies. In this review, pooling of study estimates was done using
a random effects meta-analysis model rather than fixed effects for all meta-analyses. Random
effects models assume that studies are estimating different underlying effect sizes (i.e. there
is heterogeneity between study estimates and infinitely large studies would find different effect
sizes).[294] Based on this assumption, calculation of the 95% CI for a random effects meta-
regression includes both a measure of the variability within studies (represented by study SE)
and between studies (represented by tau).[291] Random effects modeling was chosen because
it was considered that there were many potential sources of both clinical and methodological
heterogeneity within individual meta-analyses conducted for this review.
The interpretation of combined summary estimates generated by a random effects meta-analysis
model differs from the interpretation of a fixed effects model. This is because of differences in
the underlying assumptions of each model, and the way in which 95% CI are calculated. For
a fixed effects model, the summary estimate gives the ‘best’ estimate of the single underlying
effect size, and the confidence intervals depict the range in which the single effect size may fall
with 95% confidence. In contrast, as a random effects model assumes that studies are measuring
different underlying effect sizes, the summary estimate represents the mean of these different
effect sizes and the confidence intervals depict the range in which the mean effect size may fall.
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Thus, the 95% CI intervals do not include the full range of values that an individual underlying
effect size may take.[294]
In order to estimate the full range of values an individual effect size may take, it is neces-
sary to calculate a ‘prediction interval’.[294] A prediction interval is calculated by adding the
within study variance (se-squared) to the between study variance (tau-squared). This is then
squared rooted, and multiplied by the 100(1- alpha/2) percentile of the t-distribution with the
number of studies in meta-analysis (k) minus two degrees of freedom. Given k-2 degrees of
freedom, at least 3 studies have to be included in a meta-analysis in order for the calculation to
be made.[294] It was decided that the 95%CI would be reported in the text, as the focus of this
review is to understand if clinical or methodological factors change the size or magnitude of the
summary effect size. However, prediction intervals are also presented on forest plots in order to
indicate the full range of possible underlying values.
In an exploratory analysis, the difference between sub-group estimates were tested using a ran-
dom effects meta-regression. As with simple regression, meta-regression tests if independent
variable(s) predict the outcome of interest, which in this case is prognosis. However, instead
of using individual level data, meta-regression uses study level data. Studies are sub grouped
based on a their characteristics (e.g. participant characteristics, methodological characteristic)
and this sub-grouping is entered as an explanatory variable into the meta-regression model in
order to assess if the outcome is predicted by these study features.[291] If the co-efficient for
the sub-group term entered into the meta-regression model is significant, this indicates that the
mean of the underlying true effects is different between sub-groups. In general, the more
studies included in a meta-regression, the more reliable the findings, including the estimate of
between study variance (tau-squared). Meta-regression is not suitable when there are fewer
than 10 studies in a meta-analysis,[291] and if this was the case, sub-group differences were not
tested.
Mediation Baron and Kenny proposed four steps necessary for establishing that a factor me-
diates the relationship between an exposure (in this case smoking history) and outcome (in
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this case prognosis).[295] First, a relationship between exposure and outcome must be demon-
strated. Second, the exposure must be associated with the mediating factor. Thirdly, the medi-
ating factor must affect the outcome variable. Fourth, in order to demonstrate complete medi-
ation by the mediating factor, controlling for the factor must abolish the relationship between
the exposure and the outcome. Based on this framework, this review has attempted to explore
mediation by receipt of surgical treatment, and in surgical patients only by stage at diagnosis,
tumour histology and presence of a co-morbid disease.
In line with the first aim of this review, and as described earlier, the first step in this mediation
model will be examined by combining all unadjusted estimates. It is known from previous
studies that the hypothesised mediators are all associated with smoking history, and that they
all independently predict prognosis (see section 5.2) thus establishing the second and third step
outlined above.[31, 39, 41, 57, 60, 275–277] In order to establish the fourth step, it is necessary
to demonstrate that controlling for the mediating factor leads to a reduction in magnitude of the
association between smoking history and prognosis.
In addition to indicating modification of risk, findings from sub-group analyses could also ful-
fil the fourth step of the mediation analysis . Sub-grouping by the presence or absence of a
mediating factor is, in effect, controlling for that factor. If sub-grouping for surgical treatment
resulted in an abolishing of the risk between those with a smoking history and those without
that was found when both levels of this factor were combined (i.e. surgical and non-surgical
treated patient studies combined), this would indicate that the risk associated with smoking
history was mediated through reduced eligibility for surgical treatment. In this case, smoking
history would not be of prognostic significance after treatment, and there would not be value in
further investigating the prognostic role of smoking for surgical patients. However, if surgical
patients with a smoking history remained at an increased risk, it was hypothesised that this risk
may be mediated through pathways that were either related to (i.e. later stage at presentation,
more aggressive histology of primary tumour) or not related to (i.e co-morbidity) cancer.
A second way of investigating mediation is to investigate the effect of adjustment on the size of
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association. If available, the best way to test this would be to compare unadjusted estimates to
those individually adjusted for potential mediating factors within a single study. For example,
smoking may causes poorer prognosis because smokers present at a later stage in their disease
course. If this is true, and in the absence of confounding, studies that examine the association
between smoking history and prognosis will have a unadjusted hazard ratio greater than one. On
adjustment for stage, this will decrease to one.[281] Thus, all other things being equal, a meta-
analysis of unadjusted study estimates will show an elevated hazard ratio and a meta-analysis
of study estimates adjusted for stage will show a hazard ratio around one. Although this is an
appealing idea, in practice both estimates are subject to sampling variation and residual con-
founding. Also, often intermediate adjusted models are not presented, and only a fully adjusted
model given. Therefore, depending on what evidence is available, it may not be possible to
tease out the effect of adjustment for individual potential modifiers using this method.
A third way to test for mediation is the effect of adjustment across studies. This has been done
by comparing studies that adjusted for each of these variables with studies that had not adjusted
for them using a dummy variable defining adjustment as an explanatory variable in a meta-
regression model. The justification for this analysis is the same as for testing for modifying
factors, except instead of participants or clinical characteristics being used to subgroup studies,
adjustment/or no adjustment for either stage, histology or co morbidity were the sub group-
ing factors. Again, as with comparing estimates from within study adjustment, the ability to
tease out the effect of controlling for individual potential mediators will be dependent on what
multivariable models are presented within included studies.
Outside of the four step model for investigating mediation, an additional indicator that risk is
mediated through pathways that are either related to or not related to cancer is the association
between smoking history and different prognostic outcomes. If mediated through the first, an
increased risk in both all cause mortality and also cancer related prognostic outcomes would
be expected in patients with a smoking history. However, if risk is mediated through the latter,
only an increase in all cause mortality would be expected.
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5.3 Methods
5.3.1 Database searches
After scoping the literature to check that no relevant systematic review had previously been
published, search strategies were constructed based on study inclusion criteria (see table 5.1).
I searched CINAHL (from 1981), EMBASE (from 1980), MEDLINE (from 1966), Web of
science (from 1966) and CENTRAL (from 1977)4 to December 2008 (search strategies can be
found in appendix B.1 - B.5). Search strategies included exploded MeSH terms and also text
words relating to smoking and lung cancer. At the time of conducting the search, there was no
widely accepted search strategy to identify prognostic studies.[273] However, due to the large
volume of studies identified using only disease and smoking related terms, search returns were
filtered in EMBASE and MEDLINE using ‘prognosis-specificity’ database specific filters, and
in Web of Science using text words relating to the study design. All searches were combined
in a reference manager database and duplicates removed. I also searched the reference lists of
included studies for additional studies that may contain relevant data that had not been identified
in the search.
5.3.2 Inclusion criteria
The inclusion criteria were broad in order to capture all relevant data (see table 5.1). Longitu-
dinal studies were chosen for inclusion as this study methodology represents the most robust
design available. No exclusions were made on the basis of clinical or demographic characteris-
tics of the study population (e.g. tumour histology, tumour stage, co-morbidities, treatment) so
that all possible sub-groups could be explored, if data allowed. Studies that presented any data
regarding the association between smoking and prognostic outcome were included regardless
of description and method of calculation.
4This systematic search was also used to identify studies for the review reported in chapter 6. Data relevant to
this second review could potentially be generated by an RCT, therefore CENTRAL was also searched
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Table 5.1: Inclusion criteria - systematic review of the association between smoking history and lung
cancer prognosis
Study design Observational cohort study (prospective or retrospective)
Population Patients diagnosed with a lung tumour
Exposure Presence of smoking history (ever, never)
Recency of smoking history (current, former, former/never, never) or
Heaviness of smoking history (Pack/years)
Outcome All cause mortality
Cancer specific mortality
Development of second primary
Development of recurrence
5.3.3 Data extraction
Studies were identified for inclusion by applying the inclusion criteria to the title, abstract and
full text article. This was performed by myself in parallel with one other reviewer. Any dif-
ferences were resolved through discussion. Data were dual extracted and cross checked for
inaccuracies. Papers in languages other than English were translated. Study authors were con-
tacted to request data if estimates could not be extracted or calculated from presented data.
Studies were excluded if data were not provided upon request. Data were extracted regarding:
1. Number of participants included in the study;
2. Details of study design (prospective/retrospective, length of follow up, country of study);
3. Baseline characteristics of study participants (age, gender, histology, stage, treatment,
co-morbidity);
4. Definition of smoking exposure groups and number of participants in each group; and
5. Prognostic outcomes (all cause mortality, cancer specific mortality, development of sec-
ond primary, recurrence) for smoking exposure comparisons.
Adjusted and unadjusted estimates of the association between smoking exposure and prognostic
outcomes were extracted as a hazard ratio (HRs) with 95% confidence intervals (CI) where
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available. If studies had given more than one adjusted model, these were extracted. When HR
and 95% CIs were not presented, I followed methods described by Parmar to calculate them
from Kaplan Meier (KM) curves, p values, or percentage survival (e.g. five-year survival).[296]
Most studies compared risk between ever, current or former smokers and never smokers. In
order to assess if risk reduced over time of quitting before diagnosis, the risk in current smokers
was compared to former using indirect comparison.
An indirect comparison compares the risk in two groups which have both been independently
compared to a common comparator. Methods outlined by Bucher were used to calculate the
indirect comparisons.[297] In order to calculate the indirect hazard ratio, one hazard ratio is
divided by the other. For example, to compare the risk associated with current smokers to that
of former smokers, the current/never smoker hazard ratio would be divided by the former/never
hazard ratio. The variance of this is the sum of the variances of each hazard ratio that are being
indirectly compared. This is calculated in the log scale. Data were also extracted regarding the
risk of prognostic outcomes for categories or continuous measures of pack years. Where pack
year data were presented as a continuous variable, risk estimates were converted into a per 10
pack year unit as an arbitrary amount using the log values of the HR and confidence intervals.
5.3.4 Assessment of study quality
Appraisal of the quality of studies in a systematic review is needed to assess risk of bias, and
to check that findings are valid.[298] There is scant empirical evidence demonstrating which
aspects of prognostic studies affect validity, and there is not a general consensus regarding how
best to rate quality.[299] However, Altman proposed a framework for assessing quality of prog-
nostic studies based on indirect evidence of factors that have the potential to introduce bias, and
this has been used to assess quality for studies in this review.[300] Studies could score a max-
imum of 22 points based on description of the cohort and study methodology. Studies scored
highly if the inclusion/exclusion criteria were well defined, if the characteristics of the patient
sample were described including distribution of important confounders and prognostic factors
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between smoking exposure groups, if treatment and smoking status were clearly described and
if patients were followed prospectively for more than five years. The details of scoring is sum-
marised in table 5.2.
5.3.5 Exploration of the association between smoking history and
prognosis
5.3.5.1 Risk of all-cause mortality
Clinical heterogeneity Unadjusted hazard ratios comparing the risk of all cause mortality
between ever smokers and never smokers were combined using a random effects inverse vari-
ance meta-analysis model. This was performed in STATA10, using the ‘metan’ command suite.
Statistical heterogeneity was measured using the I2 statistic.[291] It was hypothesised that sig-
nificant heterogeneity would be detected between study estimates, and that in particular risk
would be modified by curative treatment. To investigate this, unadjusted estimates from studies
in which all received surgical treatment were compared to estimates from studies that included
patients that had received non-surgical treatment. Differences between sub-groups were tested
using random effects meta-regression.
Methodological heterogeneity and publication bias Using sub-group analysis, estimates
that were presented as HR (95%CI) were compared with those that were calculated from data
provided such as survival curves or percentage survival. In addition, sensitivity analyses were
conducted to investigate if association between smoking history and prognosis was affected by
the exclusion of low quality studies. The median score (8/22) for quality was determined for all
studies included in the review. Studies that scored lower than the median score were considered
to be of low quality. Funnel plots were constructed and visually inspected for evidence of
publication bias. Plots were constructed using all available unadjusted estimates and for sub-
groups based on findings of clinical and methodological heterogeneity.
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Mediation by histology, stage and co-morbidity In order to investigate mediation of risk as-
sociated with smoking history in surgical patients, three approaches were taken using data from
studies that included surgical patients only. First, where possible, sub-group analyses were con-
ducted based on histology and stage characteristics of patients in each study, using unadjusted
estimates only. Second, using both unadjusted and adjusted estimates, three binary dummy
variables were created that defined whether an estimate did (defined as 1) or did not (defined as
0) control for either histology, stage or co-morbidity. Studies that provided both an unadjusted
estimate and an adjusted estimate for one of these potential mediators were identified. Adjusted
and unadjusted estimates were combined separately, and the effect of adjustment on the HR was
observed. Third, in order to use all available data, one estimate was used from each study, with
preference given to an adjusted estimate if studies provided both unadjusted and adjusted esti-
mates. Dummy variables defining adjustment for histology, stage or co-morbidity were added
separately and then together into a random effects meta-regression model in order to explore
the effect on the size of association.
Other analyses In order to investigate if recency of smoking at diagnosis was important in
determining the association between smoking history and prognosis, the above analyses were
repeated comparing current or former smokers with never smokers, current with former smokers
and also current with former/never smokers. Some studies also presented estimates for smoking
exposure measured in pack years, indicating the importance of heaviness of smoking history
in determining risk. Most studies compared two or more pack year categories, and cut-offs
varied between most studies. Where possible, meta analyses were performed for both recency
and heaviness of smoking comparisons. If this was not possible, estimates were presented
individually in tabular form.
5.3.5.2 Risk of cancer-related prognostic outcomes
To investigate if smoking history was associated with prognosis by increasing the risk of cancer
progression, all of the above analyses were repeated to estimate the risk of developing a second
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primary tumour, recurrence or cancer related mortality. Again, if there was sufficient data,
estimates were combined, otherwise they were presented individually in tabulated form.
5.4 Results
Searches of bibliographic databases returned 6466 potentially relevant study titles for screening.
Full text articles were obtained for 268 papers and 78 individual studies were identified for
inclusion in the review (figure 5.4).
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Records identified through 
database searching 
(n = 8122) 
Additional records identified 
through handsearches 
(n =  23) 
Records after duplicates removed 
(n = 6466) 
Records screened 
(n =6466) 
Records excluded 
(n = 6198) 
Full-text articles assessed 
for eligibility 
(n = 268) 
Full-text articles excluded 
(n= 190) 
 
n = 24 duplicates/ 
reporting from cohorts 
already included  
 
n= 14 not primary lung 
cancer 
 
n= 136 did not measured 
smoking and/or outcomes 
required 
 
n=16 contacted author for 
data, no response 
Studies included in 
qualitative synthesis  
(n =  43) 
 
(see section 5.4.4 and 
5.45, tables 5.11 -5.14, 
B.11 and B.12 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 56) 
 
(see section 5.42 and 
5.4.3, figures 5.5 – 5.13, 
C1-C9, tables 5.6-5.10) 
Total number of studies 
included 
(n = 78) 
Figure 5.4: PRISMA flow diagram of study selection and use. [301] (N.B. Twenty-one studies
contributed to both qualitative and quantitative syntheses [62, 137, 302–320])
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5.4.1 Characteristics of included studies
Study design characteristics Most included studies focused on prognostic factors other than
smoking, but had included data on smoking to assess potential confounding. Twenty two stud-
ies prospectively followed participants, and the remaining 56 studies retrospectively extracted
data from hospital records at the time that the study was conducted. The earliest year that cohort
studies began was 1952, and latest 2002. The median year of cohort inception was 1987. Sev-
enty five studies reported maximum follow up which ranged from 2-24 years (median 10yrs).
Twenty nine studies reported median follow up which ranged from 1-9 years (median 4.6yrs).
Most studies (55%) were conducted in Asia, with the remaining studies originating from Eu-
rope, North and South America. A summary of the study characteristics of all included studies
is presented in appendix B.6.
The majority of studies estimated the association between smoking history and risk of all cause
mortality (74 studies), and a minority of studies reported risk of cancer specific mortality (11
studies), second primary (5 studies) or recurrence (12 studies). Some studies compared a num-
ber of different smoking exposure categories, and for different outcomes. However, the major-
ity of studies presented estimates of the risk of all cause mortality in ever smokers compared to
never smokers.
Table 5.4 reports a breakdown of the number of unadjusted and adjusted estimates available, as
well as the number of studies presenting within study adjustments, by smoking exposure com-
parison and outcome. Adjusted estimates were extracted from 57 studies. No studies presented
intermediate models of adjustment, but only the final ‘best fit’ adjusted model. Most studies
adjusted for both confounders and more than one mediator and a summary of these adjusted
models is provided in table 5.3.
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Characteristics of all participants in included studies Gender was reported in all but two
studies.[315, 321] Studies were conducted in a mixture of male and female participants, apart
from two that solely recruited female participants.[322, 323] Of the mixed gender studies, a
range of 28-93% of participants were male, with a median of 77%. Age was reported in all but
6 studies.[307, 308, 315, 321, 324, 325] Average age ranged from 60-70 years in 64 studies,
was over 70 in three studies [304, 326, 327] and below 60 in five studies.[309, 328–331]
Five studies were conducted on participants diagnosed with SCLC only (all included patients
received non-surgical treatment), [331–335] 12 studies were conducted on a mixture of partic-
ipants with NSCLC and SCLC (SCLC = 3-21% of participant sample) [274, 322, 323, 325,
336–343] and the remaining studies were conducted on participants with NSCLC only. Of
the NSCLC studies, 51/62 reported the proportion of patients diagnosed at stage I-IIIa which
ranged from 19-100% with a median of 95%. Of the SCLC studies, 4/5 reported the proportion
of patients diagnosed with limited stage which ranged from 38-100% with a median of 79%.
Treatment regimes varied between studies. In 51 studies, all participants had undergone surgery
and some had received adjuvant therapy, patients received either surgery or chemoradiotherapy
in 11 studies,[302, 303, 309, 322, 327, 339, 341, 344–347] and eight studies included no pa-
tients that had received surgical treatment.[304, 331–335, 348, 349] In 8 studies, treatment was
not reported.[312, 323, 338, 340, 343, 350–352] However, these studies all included patients
diagnosed at a range of stages that were both eligible (Stage 1-3a) and ineligible (stage 3b-4)
for surgery so it was assumed that patients would have received either surgery or chemoradio-
therapy. Studies in which some or all patients did not receive surgery were compared to studies
in which all patients received surgery or surgery with adjuvant treatment to investigate moder-
ation by surgical treatment. These will be referred to as ‘surgical’ and ‘non-surgical’ studies,
respectively. A summary of participant characteristics for all included studies is presented in
appendix B.6.
Characteristics of participants by smoking exposure group Sixteen studies [137, 304, 305,
307, 311, 314, 315, 320, 328, 340, 343, 351–355] described baseline characteristics by smoking
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status. Balance of age and gender was assessed due to the confounding potential of these factors
(see table 5.5). In all studies, a greater proportion of smoking exposure groups were male, and
most ‘never smokers’ were female. Most studies found a significant difference in mean age at
diagnosis between smoking and non-smoking groups. However, the difference was not more
that 5 years, and this is unlikely to be clinically significant. Three studies reported detail of
ethnicity by smoking exposure, but grouped in different ways, and no pattern emerged. No
study reported socio-economic status.
Study quality Scores for study quality ranged from five to 11 out of a possible total of 22
points, with a median score of 8. Most studies lost points due to a retrospective study design,
a poor description of inclusion criteria and lack of description of participant baseline charac-
teristics by exposure group. Five of the 78 included studies described co-morbidity at baseline,
and it was not possible to tell if participants in other studies did not have co-morbid disease or
if it had simply not been measured. Smoking exposure was most often assigned based on retro-
spective assessment of clinical notes, and was split into two groups. Ever smokers and former
smokers were poorly described in terms of the distribution of current smoking and of years of
quitting before diagnosis. Finally, treatment and length of follow up was not described in eight
and five studies respectively resulting in further losses of quality points.
5.4.2 Risk of all cause mortality associated with presence of a smoking
history
Ever smokers were at a 41% increased risk of death compared to never smokers but as was ex-
pected, there was significant heterogeneity (unadjusted HR 1.41 (95% CI 1.12, 1.63), 17 studies,
I2 = 77%; figure 5.5; table 5.6). When studies were combined based on surgical treatment sub-
group, the findings suggested that treatment modified risk rather than mediated it. Risk was
higher for patients that had received curative surgical treatment and was reduced when com-
bining studies that included non-surgically treated patients (surgical HR 1.69 (95% CI 1.29,
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2.22), 13 studies, I2 = 80%; non-surgical HR 1.12 (95% CI 1.06, 1.18), 5 studies, I2 = 0%;
figure 5.5). This difference in risk approached statistical significance when tested using meta-
regression (p = 0.09). Heterogeneity remained high for surgical patients but was not detected
between estimates from studies including non-surgically treated patients.
Figure 5.5: Risk of all cause mortality in ever compared to never smokers: sub-group analysis by
treatment (all received surgery v none or some received surgery only)
Sensitivity analysis based on methodological characteristics of studies in surgically treated
patients The robustness of the finding that risk of death is elevated for surgical patients with a
smoking history compared to patients without a smoking history was investigated through sub-
group analysis based on methodological characteristics. Estimates that were calculated from
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data provided (i.e survival curves, percentage survival etc.) were found to be smaller than pre-
sented HR (95% CI) (presented HR 2.14 (95%CI 1.64, 2.79), 6 studies, I2 = 0%; calculated HR
1.38 (95%CI 0.98, 1.95), 7 studies, I2 = 85%; see figure C.1 in appendix B). Heterogeneity was
high for calculated estimates. In contrast, no heterogeneity was detected between presented es-
timates. Difference between groups approached significance when tested using meta-regression
(p= 0.07) and the prediction interval did not include 1 for presented estimates, but ranged from
0.49 to 3.94 for calculated estimates. This gives some evidence that larger and more precise es-
timates were more likely to be presented as HR (95% CI), whereas less certain estimates were
generally present in other ways e.g. survival curve, percentage survival.
All other study characteristics that may increase the risk of bias were incorporated into the
quality assessment. When confining the analysis to high quality studies only, the size of the
associated risk was strengthened and there was no heterogeneity detected (surgical patients HR
2.27 (95% CI 1.87, 2.75), 5 studies, I2 = 0%; see figure C.2 in appendix B). However, it should
be noted that four out of five high quality estimates from surgical studies were presented as
HRs, whereas five out of seven estimates from low quality studies were calculated from other
data.
Publication bias It is possible that large or significant estimates of risk associated with smok-
ing history were more likely to be published or reported in adjusted models. To test for publica-
tion bias, funnel plots were constructed and visually inspected. As previous analyses indicated
that treatment, mode of estimate presentation and study quality moderated risk, these groups
were assessed separately. Funnel plots of estimates demonstrated an asymmetrical pattern, with
a greater number of estimates congregating on the right hand side of the summary effect line
(figure 5.6a). This remained when considering only those studies conducted in surgical patients
(figure 5.6b). However, little asymmetry was detected when considering sub-groups based on
mode of presentation or study quality (figure 5.6d - 5.6f). These findings suggest that publica-
tion bias may be affecting the results of the meta-analyses for clinical sub-groups. However,
although the size and precision of estimate appeared to influence the way in which estimates
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were presented, there was no publication bias within mode of presentation.
(a) All estimates (b) Surgery only
(c) High quality studies (d) Low quality studies
(e) Presented estimates (f) Calculated estimates
Figure 5.6: Exploration of publication bias in studies with surgical patients: funnel plots of ever
compared to never smoking estimates
5.4.2.1 Exploration of mediation by histology, stage and co-morbidity in surgically
treated patents
Method 1: sub-group analysis Data allowed sub-grouping of studies based on histology
only, as all studies included a mixture of stages and co-morbidity was not reliably reported.
Two sub-group analyses were conducted by histology. First, studies including both SCLC and
NSCLC patients were compared to studies that included only NSCLC. Second, studies in ade-
nocarcinoma patients were compared with studies that included a number of different NSCLC
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histotypes. No evidence of difference was found in the size of associated risk for ever smokers
compared to never smokers for either of these analyses (see table 5.7). Forest plots are found in
appendices C.3 and C.4.)
Table 5.7: Risk of all cause mortality in ever smokers compared to never smokers: sub-group analyses
HR (95%CI) Prediction
interval
number of
studies
I2 p
All estimates 1.41 (1.12, 1.63) 0.87, 2.28 17 77 n/a
Surgical treatment 1.69 (1.29, 2.22) 0.70, 4.12 13 80
Non surgical treatment 1.12 (1.06, 1.18) 1.00, 4.12 5 0 0.09
Surgery only:
NSCLC only 1.86 (1.24, 2.79) 0.51, 6.74 9 85
NSCLC and SCLC 1.43 (1.01, 2.02) 0.39, 5.19 4 49 0.52
Adenocarcinoma 1.86 (0.99, 3.51) 0.26, 13.41 5 58
mixed NSCLC 1.76 (1.07, 2.88) 0.61, 4.61 5 91 0.83
Method 2: within study adjustment Eight studies provided within study adjustments. These
estimates are presented in table 5.8 stratified by adjustment for histology, stage and/or co-
morbidity. Other factors that were included in these adjusted models are also presented. The
findings of these analyses need to be interpreted with caution as the study quality varied but
more importantly, adjusted models varied. Some models included gender and age, which were
considered key confounding factors. However, others did not. The effect of adjusting for bi-
ological or genetic markers is unknown. However, assuming that adjustment for these other
factors does not affect the estimate, there was some evidence that adjustment for histology de-
creased the size of associated risk, adjustment for stage made no difference, and adjustment for
co-morbidity strengthened the estimated risk (see table 5.8).
Method 3: between study adjustment Finally, dummy variables that coded for adjustment
for histology or comorbidity between studies showed similar results to within study adjustment
when added to a random effects meta regression model. However, the co-efficients were non-
significant (histology unadjusted HR 1.79, adjusted HR 1.28, p= 0.18; co-morbidity unadjusted
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HR 1.49, adjusted HR 2.01, p = 0.59). Unlike after adjustment within study, a non-significant
increase was observed after adjusting for stage (unadjusted HR 1.36, adjusted HR 1.60, p =
0.57). The co-efficient for adding all three variables simultaneously was not significant (p =
0.5).
5.4.3 Risk of all cause mortality associated with recency of smoking
history
Risk of all cause mortality was compared between current, former, former/never and never
smokers in order to investigate if risk of death was lower in people who stopped smoking be-
fore diagnosis. When combining studies, regardless of patient treatment, current and former
smokers were at a 54% and 56% increased risk of death compared to never smokers, respec-
tively (current v never HR 1.54 (95% CI 1.21, 1.94), 11 studies, I2 = 73%; former v never HR
1.56 (95% 1.12, 2.18), 8 studies, I2 = 53%; figure 5.7). Comparing current and former smokers
indirectly confirmed a similar magnitude of risk in these two groups (current v former HR 1.04
(95% 0.79, 1.28), 8 studies, I2 = 0%; figure 5.8). Four studies compared current smokers to
a group of both former and never smokers. The risk in this comparison fell between that seen
for current smokers when compared to former smokers and when compared to never smokers
(current v former/never HR 1.31 (95% CI 1.17, 1.46), 4 studies, I2 = 0%; figure 5.8). Again,
this is consistent with the finding that both current and former smokers were at increased risk
compared with never smokers. No heterogeneity was detected between studies comparing cur-
rent with former or former/never smokers. However, heterogeneity was high between estimates
of both current and former smokers compared with never smokers. For characteristics of the
patients included in the studies in these analyses see appendices B.11 and B.12.
As with ever compared with never smokers, there was evidence that risk was modified by treat-
ment. Risk was strengthened when combining studies in surgical patients only for both current
and former smokers compared to never smokers, and heterogeneity was reduced (surgical cur-
rent v never HR 2.03 (95% CI 1.56, 2.64), 7 studies, I2 = 11%; surgical former v never HR 1.80
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Figure 5.7: Unadjusted risk estimate of all cause mortality comparing different categories of smoking
history
(95% CI 1.18, 2.73), 6 studies, I2 = 27% figure 5.9). Conversely, risk was reduced for current
and former smokers who had not received surgical treatment (non surgical current v never HR
1.13 (95% CI 0.93, 1.38), 4 studies, I2 = 65%; non surgical former v never HR 1.29 (95% CI
0.72, 2.32), 2 studies, I2 = 81%; figure 5.9).
Risk significantly differed between treatment sub-groups for current smokers, but not former
smokers, compared with never smokers (current v never p = 0.002, former v never p = 0.36).
Also, prediction intervals were significant for current smokers treated surgically compared to
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Figure 5.8: Unadjusted risk estimate of all cause mortality comparing different categories of smoking
history
never smokers, but were non-significant for surgically treated former smokers. This indicates
that for surgical patients, current smoking at diagnosis may be a stronger prognostic factor, and
that risk may decrease over time. For both surgical patients and non surgical patients, there
was no significant difference in risk detected between current and former smokers. However,
although not significant, risk estimates indicated that currently smoking surgical patients may
have an increased risk of death compared to former smokers (surgical current v former HR
1.21 (95% CI 0.81, 1.82), 6 studies, I2 = 0%; non surgical current v former HR 0.98 (95%
CI 0.76, 1.25), 2 studies, I2 = 0%; figure 5.10). Risk was similar for current compared with
former/never smokers (surgical only current v former/never HR 1.11 (95% 0.55, 2.26), 2 studies,
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Figure 5.9: Unadjusted risk estimate of all cause mortality comparing current or former smokers with
never smokers: sub-group analysis by treatment (surgical patients only v non surgical patients)
54% I2 = 54%; non surgical current v former/never HR 1.29 (95% 1.14, 1.47), 2 studies, 0%;
figure 5.10).
Sensitivity analysis based on methodological characteristics of studies in surgically treated
patients The robustness of the finding that risk of death is elevated for current and possi-
bly also former smokers treated with surgery compared with never smokers was investigated
through sub-group analysis based on methodological characteristics. There was some indica-
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Figure 5.10: Unadjusted risk estimate of all cause mortality comparing current with former or
former/never smokers: sub-group analysis by treatment (surgical patients only v non surgical patients)
tion that presented estimates were larger and more precise than those that were calculated from
other data (e.g. survival curves, % survival) when comparing current or former smokers with
never smokers (current v never presented HR 2.37 (95% CI 1.66, 3.38), 3 studies, I2 = 0%;
current v never calculated HR 1.93 (95% CI 1.20, 3.12), 4 studies, I2 = 23%; former v never
presented HR 2.39 (95% CI 1.40, 4.07), 2 studies, I2 = 13%; former v never calculated 1.44
(95% CI 1.01, 2.06), 4 studies, I2= 4%; see figure C.5 in appendix B). Presented estimates were
also larger than calculated estimates when comparing current smokers to former/never smokers,
although there was only one study in each of these sub-groups. All current compared with for-
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mer estimates were calculated and so it was not possible to investigate differences within this
comparison.
The risk of all cause mortality for both current and former smokers compared with never smok-
ers strengthened after removal of low quality studies. Current smokers were at over two and a
half fold increased risk of death compared with never smokers, and the risk was more than two
fold for former smokers (current v never high quality HR 2.53 (95% CI 1.82, 3.52), 5 studies,
I2 = 0%; former v never high quality 2.12 (95% CI 1.38, 3.26), I2 = 11%; see figure C.6 in
appendix B). Estimates from all studies of low quality were calculated, whereas both presented
and calculated HRs were extracted from high quality studies. Removing low quality studies
from the comparison of current with former or with former/never smokers did not change the
findings for these groups (see figure C.7 in appendix B).
Publication bias There was evidence of publication bias of estimates comparing current or
former with never smokers. Funnel plots showed an asymmetrical pattern when all estimates
were included and only those from studies of surgical patients (figure 5.11a to 5.11d). However,
no asymmetry was detected for current compared with former/never smokers (figure 5.11e and
5.11e).
5.4.3.1 Exploration of mediation by histology, stage and co-morbidity in surgically
treated patents
Method 1: sub-group analysis Data allowed comparison between surgically treated patients
with stage I disease and those diagnosed in a mixture of stages. Risk was greater in current
and former smokers compared to never smokers diagnosed in stage I and heterogeneity was
eliminated (current v never stage I HR 2.81 (95% CI 1.70, 4.66), 3 studies, I2 = 0%; current v
never mixed stage HR 1.90 (95% CI 1.30, 2.78), 3 studies, I2 = 39%; former v never stage 1
HR 2.12 (95% CI 1.25, 3.58), 3 studies, I2 = 0%; former v never mixed stage HR 1.69 (95%
CI 0.96, 2.97), 3 studies, I2 = 53%; see table 5.9 and figure C.8 in appendix B). No significant
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(a) CvN all estimates (b) CvN surgery only
(c) FvN all estimates (d) FvN surgery only
(e) CvFN all estimates (f) CvFN surgery only
Figure 5.11: Exploration of publication bias in studies with surgical patients: funnel plots of ever
compared to never smoking estimates
difference was detected between risk in current and former smokers in each stage sub-group
(current v former stage I HR 1.34 (95% CI 0.65, 2.78, 3 studies, I2 = 0%; current v former
mixed stage 1.14 (95% CI 0.65, 1.92), 2 studies, I2 = 54%; see table 5.9 and figure C.8 in
appendix B). All studies estimating risk for current compared with former/never smokers were
conducted in patients of mixed stage and therefore no sub-group analysis could be carried out
for this comparison.
It was not possible to conduct sub-group analyses by histology or co-morbidity. All studies
included a mixture of different types of NSCLC, and co-morbidity was not reliably reported.
Table 5.9 summarises the risk of all cause mortality between current, former, never and for-
282
CHAPTER 5. SYSTEMATIC REVIEW WITH META ANALYSIS AND META
REGRESSION: SMOKING HISTORY AND PROGNOSIS
mer/never smokers from sub-group analyses.
Table 5.9: Summary of findings for all studies and sub-groups based on surgery and stage
HR (95%CI) Prediction interval number of studies heterogeneity p
Current v never
All estimates 1.54 (1.21, 1.94) 0.75, 3.16 11 73 n/a
Surgical treatment 2.03 (1.56, 2.64) 1.28, 3.22 7 11 0.002
Non surgical treatment 1.13 (0.93, 1.38) 0.50, 2.55 4 65
Surgery only:
Stage 1 only 2.81 (1.70, 4.66) 0.11, 73, 83 3 0 n/a
Mixed stage 1.81 (1.36, 2.42) 0.84, 3.88 4 0
Former v never
All estimates 1.56 (1.12, 2.18) 0.65, 3.75 8 53 n/a
Surgical treatment 1.80 (1.18, 2.73) 0.69, 4.66 6 27 0.36
Non surgical treatment 1.29 (0.72, 2.32) n/a 2 81
Surgery only:
Stage only 1 2.12 (1.25, 3.58) 0.07, 64.10 3 0 n/a
Mixed stage 1.69 (0.96, 2.97) 0.00, 649.90 3 53
Current v former
All estimates 1.04 (0.84, 1.28) 0.79, 1.35 8 0 n/a
Surgical treatment 1.21 (0.81, 1.82) 0.68, 2.16 6 0 n/a
Non surgical treatment 0.98 (0.76, 1.25 n/a 2 0
Surgery only:
Stage 1 only 1.34 (0.65, 2.78) 0.01, 153.24 3 0 n/a
Mixed stage 1.16 (0.65, 2.78) 0.01, 28.16 3 0
Current v former/never
All estimates 1.31 (1.17, 1.46) 1.02, 1.67 4 0 n/a
Surgical treatment 1.11 (0.55, 2.26) n/a 2 54 n/a
Non surgical treatment 1.29 (1.14, 1.47) n/a 2 0
Surgery only:
Mixed stage 1.11 (0.55, 2.26) n/a 2 54 n/a
Method 2: within study adjustment Two studies provided estimates before and after adjust-
ment for both histology and stage in surgical patients, comparing risk between current, former
and never smokers. One study was conducted in stage 1 patients and also adjusted for treat-
ment, the other was conducted in a mixture of patients with stage 1-3a disease and also adjusted
for gender. Combined risk estimates were similar before and after adjustment (see figure 5.12).
One additional study[356] provided within study adjustment for current smokers compared with
former/never smokers. The adjustment model included stage in addition to age, and adjustment
had no effect on the size of risk (current v former/never unadjusted HR 1.28 (95% 1.12, 1.48),
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1 study; current v former/never adjusted CvFN HR 1.25 (95% 1.08, 1.46), 1 study).
Figure 5.12: Risk of all cause mortality and recency of smoking in surgical patients only: adjustment
within study for histology
Method 3: between study adjustment When using all available estimates to compare risk
before and after adjustment between studies, the size of risk reduced after adjustment for histol-
ogy although the change was not significant. Similar non-significant reductions were observed
after adjustment for stage, apart from when comparing current smokers to former/never smokers
when risk increased after adjustment. One study adjusted for co-morbidity, and compared risk
in current to former/never smokers only. Adjusting for this factor non significantly increased
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the risk of all cause mortality (see table 5.10).
Table 5.10: Risk of all cause mortality and recency of quitting: adjustment for histology, stage and
co-morbidity using meta regression
Histology
Unadjusted HR Adjusted HR p-value
Current v never 1.80 1.52 0.59
Current v former 1.16 1.01 0.72
Current v former/never 1.55 1.40 0.90
Former v never 2.05 1.68 0.42
Stage
Unadjusted HR Adjusted HR p-value
Current v never 1.93 1.62 0.58
Current v former 1.13 1.01 0.81
Current v former/never 0.64 1.58 0.37
Former v never 2.12 1.72 0.42
Co-morbidity
Unadjusted HR Adjusted HR p-value
Current v never N/R N/R N/R
Current v former N/R N/R N/R
Current v former/never 1.36 1.88 0.73
Former v never N/R N/R N/R
All factors
Unadjusted Adjusted p-value for
adding all terms
Current v never 2.01 1.51 0.77
Current v former 3.32 2.97 0.92
Current v former/never 0.64 0.00 0.79
Former v never 2.12 1.68 0.68
5.4.4 Risk of all cause mortality associated with heaviness of smoking
Three studies provided unadjusted estimates of the risk of all cause mortality associated with
a unit increase change in pack years.[62, 339, 357] Each of these studies were conducted in
surgical patients only. When converted to represent the risk associated with ten pack years of
smoking, no difference was found (per 10 yr increase in pack year HR 1.03 (95% CI 1.00, 1.05),
3 studies, I2 = 89.3%).
Twenty three studies compared 2 or more categories of pack year history in mixed NSCLC,
adenocarcinoma or SCLC patients (table 5.11 and 5.12).[302, 303, 305, 307, 309, 314–316,
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318, 319, 331, 344–347, 353, 354, 358–363] Three studies [307, 316, 318] compared surgical
patients with under 20 pack year history to those who had 20 or more years and a fourth study
[303] compared less than 19 pack years to 19 or more pack years in surgical patients. Combining
these estimates showed a non-significant increased risk for patients with a heavier pack year
history (<20 PY v ≥20 PY HR 1.26 (95% CI 0.76, 2.07), 4 studies, I2 = 70%; see figure C.9
in appendix B). Two studies conducted in surgical patients compared risk in patients with a
pack year history greater than 30 to those less than 30. Those with a heavier pack year history
showed a significant increase in risk (<30 PY v≥30 PY HR 1.44 (95% CI 1.12, 1.84), 2 studies,
I2 = 0%; see figure C.9 in appendix B). It was not possible to combine any other estimates
to explore if risk was associated with heaviness of smoking history due to the differences in
exposure category classification. In general, a greater pack year history was associated with a
higher risk of all cause mortality. However, no discernible trend was observed in risk with pack
year history when comparing individual estimates. In addition, the effect of adjustment did not
have a consistent effect across studies, with some showing an increase in risk whilst in other
studies adjustment lead to a decrease in risk (see tables 5.11 and 5.12).
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5.4.5 Risk of disease progression and cancer-related death associated
with smoking history
Twenty four studies reported on cancer specific outcomes. [62, 137, 304–308, 310, 312–314,
317, 318, 320, 323, 333, 335, 343, 349, 353, 359, 364–366] Due to low numbers of studies
in each comparison of smoking exposure, no meta-analyses were possible for cancer specific
mortality or risk of second primary. These data are presented in table 5.13. One study [323]
reported a significantly increased risk of cancer specific mortality in ever smokers compared to
never smokers. Adjustment for age, stage and histology reduced the risk and it became non-
significant. A second study [312] found no difference in risk when comparing current and never
smokers. Both of these studies included patients that had received either surgical or non-curative
treatment. A third study [314] found an increased risk of cancer specific mortality associated
with current smoking at diagnosis compared to being a former smoker. However, confidence
intervals were very wide. Seven studies report the risk of cancer specific mortality associated
with different categories of pack year history, and two studies reported the risk of pack year
history as a continuous variable. In general, a greater pack year history was associated with a
higher risk of cancer specific mortality, although it was not possible to discern if there was a
linear trend. Similarly, it was not possible to unpick the effect of adjustment on risk (see table
5.13).
Risk of developing a second primary was reported by five studies (see table 5.13). [313, 333–
335, 367] Similar to observations with all cause mortality outcomes, unadjusted estimates sug-
gested an increased risk of similar size for current and former smokers compared to never smok-
ers in surgical patients. However, estimates were not significant. Adjustment for treatment,
stage, histology and treatment by smoking status changed the magnitude of the risk in opposite
directions, but remained non-significant.[313] One additional study [334] conducted in SCLC
patients who received non-surgical firstline treatment found no difference in risk of developing
a second primary for current smokers at diagnosis compared with former smokers (table 5.13).
Three studies found there was no significant association between pack year history and risk of
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second primary.[333, 335, 367]
A more coherent pattern emerged regarding the risk of developing tumour recurrence. Three
studies provided unadjusted estimates that compared current or former smokers to never smok-
ers, and current to former smokers.[306, 313, 320] All of these studies were conducted in
NSCLC patients who had received surgical treatment, and two studies included stage 1 patients
only. Similar to the observations for all cause mortality and risk of second primary, when com-
bining estimates there was an indication that both current and former smokers were associated
with increased risk of a similar size compared with never smokers (current v never unadjusted
HR 1.75 (95%CI 0.98, 3.12), 3 studies, I2 = 52%; former v never unadjusted HR 1.86 (95%CI
0.52, 6.67), 2 studies, I2 = 70%; figure 5.13), whereas there was no difference between current
and former smokers (CvF unadjusted HR 1.04 (95%CI 0.51, 2.08), 2 studies, I2 = 0%; figure
5.13). In addition, three studies found a significant increase in risk of recurrence per pack year
increase of smoking history (see table 5.14). Adjustment appeared to effect the estimate of risk
of recurrence in most studies. However, it is difficult to interpret the meaning of this finding as
adjusted models varied (table 5.13).
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Figure 5.13: Risk of developing tumour recurrence associated with recency of smoking at diagnosis
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5.5 Discussion
The purpose of this discussion is to consolidate and interpret findings of the review in the context
of past literature. This will first include a discussion of findings regarding the association be-
tween smoking history and all cause mortality, including the evidence that smoking history has
prognostic significance for surgically treated patients. Second, the potential pathways through
which smoking history may influence prognosis in surgical patients will be discussed, along
with the evidence found from this review regarding these pathways. Next, the strengths and
weaknesses of the data are discussed, including the risk that findings may be a reflection of
bias or confounding. Finally, the implications of the findings and recommendations for future
research are summarised.
5.5.1 Risk of all cause mortality associated with smoking history and
prognostic significance for surgically treated patients
This review has found consistent evidence of an association between smoking history and prog-
nosis in lung cancer. Risk of all cause mortality was increased by around 50% in current,
former or ever smokers when compared with patients that had never smoked. When conduct-
ing sub-group analyses based on treatment, risk was strengthened for patients treated surgically
whereas the size of risk was smaller for patients treated non-surgically. If risk of death had
been completely explained (or mediated) by receipt of curative treatment, no difference in risk
between patients with a smoking history and those without would be detected when confining
analysis to surgical patients only. This supports the hypothesis that curative surgical treatment
modifies rather than mediates risk, and that smoking history is of prognostic significance for
surgical patients. Contrary to the initial hypothesis, there was some evidence from sub-group
analysis in current and former smokers compared with never smokers that stage also modifies
risk. In high quality studies, risk strengthened to a 2-3 fold increase in current, former or ever
smokers treated with surgery for stage I NSCLC compared with never smokers (see table 5.9).
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This indicates that the prognostic significance of smoking history is strongest for patients who
have greatest survival advantage. In other words, for those who have a poor prognosis, the
risk associated with smoking history does not have a sufficient time window to operate. How-
ever, for those with surgically removed early stage tumours, the time window is greater for the
prognostic disadvantage of smoking history to emerge.
Recency of smoking history Taking together the findings of relevant analyses, there was an
indication that more recent smoking at diagnosis was associated with a higher risk of all cause
mortality. There was a largely consistent pattern of higher risk associated with current smok-
ers than with former smokers when compared to never smokers. In surgical stage I NSCLC
patients, current smokers were associated with more than a two and a half fold increased risk
whereas former smokers were at a two fold increased risk when combining high quality studies.
In addition, prediction intervals did not include 1 for current smokers, but did for patients who
had quit before diagnosis. Although this suggests that risk may be different in these two groups,
the best method to test difference in risk is to directly compare these two group. Most studies
did not provide this comparison, so current and former smokers were indirectly compared us-
ing methods described by Song.[368] No difference was observed between current and former
smokers using this method. However, in clinical sub-groups for which smoking history was a
stronger prognosticator, the estimate suggested that current smoking carried greater risk.
Most studies did not describe how they defined former smoking. It is possible that former
smokers included a mixture of patients who had quit within a year before diagnosis with pa-
tients who had quit decades before diagnosis. If a risk reduction is seen only after a number of
years, including those who had quit shortly before diagnosis would limit the ability to detect a
difference between current and former smokers. One study [320] only in surgical patients that
was included in this review described the length of quitting before diagnosis in former smok-
ers. Patients were recruited consecutively and were not selected on the basis of their smoking
history, therefore it is likely that the distribution in time since quitting would be comparable
to other random samples. These authors reported that a third of former smokers quit within
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9 years of diagnosis, a further third quit between 9 and 17 years and the remaining third quit
18 or more years before diagnosis. A significant reduction in risk was found for each period
of recent quitting compared to current smokers, further indicating that risk may be reduced in
former smokers and that it reduces over a number of many years.
Intensity of smoking history Evidence regarding the importance of pack year history was
difficult to interpret as studies often categorised this exposure differently. Individual estimates
did not reveal a discernible pattern of risk. However, where it was possible to combine esti-
mates, there was an indication that a heavier smoking history may be associated with greater
risk. There was an significant increase in risk for those with a greater than 30 pack year history,
compared to those with less than 30 pack year history, and risk was also raised when 20 pack
years was used to dichotomise groups, but non-significantly. A small non-significant increase
per 10 pack years was also observed.
Pack year history is calculated by multiplying the number of years smoked by the number
of cigarette packs containing 20 cigarettes smoked per day. Thus, a patient that smoked 20
cigarettes per day (cpd) for 20 years will have a 20 pack year history, whereas a smoker of
40/cpd for 20 years will have a 40 pack year history. As most people begin smoking between
ages 18-25, and based on the assumption that the number of cigarettes smoked per day by most
lung cancer patients is similar, it is likely that a greater pack year history reflects more recent
smoking at the time of diagnosis. If these assumptions are correct, this would lend further
weight to the interpretation that greater risk is associated with more recent smoking. However,
it is also possible that increased risk is due to a higher dose of toxins due to a larger number of
cigarettes smoked each day.
It was not possible to tell with the data available in this review if there was a true association
between pack years and risk of death, and whether any increased risk associated with pack
years was due to recency or dose. Understanding the influence of recency or dose on risk
is important not only for patient counseling, but also for risk stratification in health care and
clinical trials.[273] More studies are needed which examine the risk associated with length
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of quitting in detail, and the risk associated with pack years adjusted for years of quitting, to
confirm or refute the gradual reduction in risk with increasing years of quitting before diagnosis
and the significance of dose.
5.5.2 Possible mechanisms of increased risk associated with smoking
history in surgical lung cancer patients
Assuming the relationship found between smoking history and all cause mortality in surgical
lung cancer patients is causal, this may be mediated through pathways that are related or unre-
lated to cancer. Risk of cancer related outcomes, and mediation by tumour histology, stage or
co-morbidity were investigated in this review in order to understand mediation of risk through
these pathways. I will now discuss these two potential pathways in turn, considering relevant
findings from this review in addition to other published studies.
5.5.2.1 Cancer related mechanisms of increased risk of death in patients with a smoking
history
It is possible that smoking exposure leads to increased risk of disease progression and cancer
related death in surgical patients. Unfortunately, this review found limited data to investigate
this. Most studies reported risk of all cause mortality rather than cancer specific outcomes,
and within study adjustments for stage and histology were not always available. In surgical
patients, risk of cancer specific mortality or development of a second primary tumour was non-
significantly elevated for both current or former smokers compared with never smokers, and risk
did not differ when comparing current and former smokers directly. These findings were based
on data from two studies.[313, 314] Within study adjustment for stage and histology generally
increased the size of the estimate and differences remained non-significant, apart from in one
study where confidence intervals were very wide.[314]
Surgical stage I-IIIa NSCLC current and former smokers were both at a non-significant in-
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creased risk of recurrence compared with never smokers, based on unadjusted estimates from
three studies.[306, 313, 320] Again, when comparing the risk in current smokers with formers
smokers, the estimate was close to 1 and not significant. Within study adjustment for histology
and stage appeared to reduce the risk associated with current and former smokers, but did not
completely abolish it. Two studies gave adjusted estimates only for risk of recurrence, compar-
ing ever smokers with never smokers. Both studies were conducted in stage I NSCLC surgical
patients and found that risk was elevated in patients with a smoking history independent of age,
gender, histology and stage. Increased risk was statistically significant in one of these studies.
Although estimates often did not reach statistical significance, the size of summary estimates
indicate that smoking history does increase the risk of second primary, recurrence, and cancer-
related death and that the risk is greater for current smokers than former smokers. In addition,
adjustment for stage and histology gave no reliable indication of mediation by these factors.
However, the evidence is very weak and further studies are needed to assess cancer related
mediation pathways and risk associated with smoking history.
Potential mechanisms If it is true that a smoking history increases the risk of cancer-related
death there are a few potential mechanisms by which this could occur. The goal of curative
surgical treatment is complete resection of the tumour. The International Association for the
Study of Lung Cancer (IASLC) Staging Committee published a definition of complete resec-
tion in 2005.[369] Resection is considered to be complete when resected tumour margins are
found to be free from cancer cells after microscopic investigation. In addition, there should
be systematic resection of local lymph nodes, and the highest mediastinal lymph node to be re-
moved should be negative, including no extracapsular extension of tumour cells. However, even
after apparent complete resection, solid tumours recur locally in up to two third of cases in the
absence of adjuvant treatment.[370, 371] Adjuvant therapy may reduce the risk of recurrence
and development of second primaries, but this still occurs in lung cancer[372–377] and other
tumours. [378–383]
The reasons for the development of second primary and recurrent tumours after complete re-
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section are not fully understood, but a few possible mechanisms have been cited.[370] One
possibility is ‘field cancerisation’, a concept that was first described over 50 years ago in the
context of oral cancer.[384] Field cancerisation is present when multiple genetic and pheno-
typic alterations are present within an area that has been exposed to the same carcinogen (e.g.
smoking, asbestos, human papillomavirus). These pre-neoplastic lesions are not apparent on
microscopic investigation, but can be detected with molecular analysis.[384] The existence of
field cancerisation has been described for a number of tumours,[370, 385, 386], and multiple
alterations have been found throughout the lungs of smokers and patients with both NSCLC
and SCLC.[387–390] It is possible that these changes would also been detected in other regions
of the body exposed to carcinogens from cigarette smoke. Therefore, exposure to smoking may
increase risk of recurrence or second primary due to increased burden of pre-neoplastic lesions
which remain after complete lung tumour resection and go on to develop into new tumours.[370]
Although lung cancer risk reduces after smoking cessation, it never returns to baseline.[388] If
risk is operating through this pathway, it is likely that a decrease in risk would be seen for those
who have quit smoking years before diagnosis but that risk would still be elevated. In addition,
there would be little evidence of mediation through tumour stage or histology as risk would
not be conferred by the nature of the primary tumour but the burden of mutation and pheno-
typic changes. The findings of this review are consistent with this mechanism of increased risk.
However, given the limitation of the data regarding reduction in risk over time, cancer related
outcome and mediation by stage and histology, it is not possible to conclude that risk may be
mediated through this pathway with any certainty.
A second possible mechanism by which progression of cancer may occur is dissemination of
occult primary tumour cells, or micro-metastasis.[370] In addition to spread of cancer cells
into the lymphatic system and bone marrow,[391] haematogenous tumour cell dissemination,
or ‘seeding’ of cells from the primary tumour into the blood stream, has been demonstrated
in both mice and humans.[370, 392, 393] Circulating tumour cells have been detected in lung
cancer patients.[394, 395] Traditionally, cancer progression is divided into initial phases where
the tumour grows and later phases in which cancer cells acquire the ability to disseminate and
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colonise new environments (see section 1.2).[396] However, recent research has shown that
dissemination may start early in tumour development[391, 397–400].
In addition, it has been demonstrated that surgical resection via either thoracotomy or video
assisted thoracic surgery (VATS) can promote haematogenous dissemination of lung cancer
cells.[371, 401] Detection of cancer cells in the blood after resection has been associated with
poorer prognosis in a number of tumours, including lung cancer.[371, 402–404] Many tumour
recurrences occur at the site of the surgical wound,[405] and it has been hypothesised that
circulating tumour cells may be responsible.[370] Surgical wounding precipitates an inflam-
matory response to aid cellular repair and angiogenesis,[406, 407] and biological markers of
inflammation are increased after thoracotomy[408] and to a lesser degree after VATS for lung
resection.[232] Inflammation creates a micro-environment that is tumour promoting,[409–412]
and infiltration of inflammatory cells into a tumour micro-environment is correlated with poorer
prognosis.[413–415] Such an environment may promote the development of unresected micro-
metatases in the location of the primary tumour, or reinfiltration and development of circulating
tumour cells.[370, 397]
It is possible that risk of re-infiltration and development of disseminated cells is higher in later
stages due to a higher burden of circulating cells. If increased risk associated with smoking was
operating through these mechanisms, evidence of mediation through tumour histology and stage
would be expected. Recency of smoking would influence risk in as much as it was associated
with development of more aggressive tumours and presentation at later stages. There was little
evidence of mediation by stage and histology in this review. However, it is not possible to rule
this mechanism out given the limitations in the data. Further research is needed to investigate
if smoking history increased the risk of cancer progression, and through which pathway this
operates.
An additional point to consider is that smoking itself increases expression of inflammatory
cytokines in lung and other tissue. [319] It is possible that a number of current smokers at
diagnosis continue to smoke, and that increased risk of cancer development is due to smoking
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induced inflammation in continuing smoking. Association of risk with continued smoking after
diagnosis has not been assessed in this review, but is the subject of the second review of this
thesis which can be found in chapter 6.
5.5.2.2 Non-cancer related mechanisms of increased risk of death in patients with a
smoking history
Within cancer literature there has been little attention paid to co-morbid conditions in terms of
prevalence, impact on care needs or influence on prognosis.[127, 416] Indeed, if co-morbidities
are acknowledged, it is normally as an exclusion criterion for clinical trials.[417] Given the
association of lung cancer with both smoking and older age,[14, 21, 39] it is likely that preva-
lence of smoking related disease is high in this patient group. Some studies have reported that
the prevalence of co-morbid cardiovascular or respiratory disease may be as high as 50% in
lung cancer populations (see section 1.5.3). Although presence of co-morbidity may reduce a
persons chance of receiving curative treatment, patients with co-morbid disease may still un-
dergo surgery, and it is possible that difference in survival rates in surgical patients are partly
explained by co-morbid disease. One previous study in surgically treated stage I NSCLC found
co-morbidity to be an independent predictor of prognosis as measured by the Kaplan-Feinstein
Index.[60] This measure classifies co-morbidity as absent, mild, moderate or severe based on
the number of individual diseases present and the extent to which the disease is advanced. Af-
ter adjustment for age, sex, tumour stage and tumour histology those with moderate or severe
co-morbidity were at a significantly increased risk of death compared to patients in whom co-
morbid disease was absent.
Although co-morbid disease may contribute to the increased risk of death of surgical lung cancer
patients as a whole, it is unknown if patients with a smoking history are at a greater risk of death
due to co-morbid disease compared to those with no smoking history. No known study has
looked at the distribution of co-morbid conditions between surgical patients based on smoking
history. In the studies included in this review, co-morbidity was often not described. In studies
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that did describe this patient characteristic, it was given for all patients in the study rather than by
smoking history. One study included co-morbidity in a multivariable regression analysis which
considered the risk of all cause mortality in ever smokers compared with never smokers.[326]
Co-morbidity was measured using the Charlston Comorbidity Index (CCI), which gives a score
based on the presence or absence of 19 conditions, weighted by relative mortality risk.[418]
If an increased risk of death was operating through this mechanism only, controlling for co-
morbidity should abolish the association between smoking history and prognosis. However,
risk was found to increase after adjustment rather than decrease.
Based on this study alone it is not possible to dismiss the possibility that association between
smoking history and prognosis is mediated through co-morbidity. Caution should be taken in
interpretation as the adjusted model also included both histology, stage and other factors. Future
studies are needed to more adequately describe the prevalence of co-morbidities on surgical lung
cancer patients, and to ascertain if smoking history increases risk of death after surgery due to
co-morbid disease.
5.5.3 The relationship between smoking history and prognosis in other
tumours
Decreased survival in patients with a smoking history has been reported for a number of other
solid tumours, including breast,[419–421] colorectal,[422, 423] head and neck,[424, 425] kid-
ney,[426–429] and prostate tumours.[421, 430–434] However, other studies have also found
no significant association between smoking and survival for these tumours.[435–438] As was
found in this review, studies have generally compared risk in current, former or ever smokers
with never smokers, and the length of time since quitting in the ever and former smokers groups
is poorly described.
A systematic review has previously been conducted in breast and bladder cancer only.[419, 439]
Aveyard[439] identified fifteen studies that investigated the relationship between smoking and
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prognosis in patients with bladder cancer. All included studies used a longitudinal cohort design
and most included patients with superficial tumours. No study found an increased risk of all
cause mortality associated with smoking history. However, most studies included both incident
and prevalent cases of bladder cancer and were of a low quality which limited the ability to draw
conclusions from the data, and data were not pooled. Braithwaite[419] reviewed eight longi-
tudinal cohort studies conducted in breast cancer patients. All patients had received surgery in
addition to either chemotherapy and/or radiotherapy. There was evidence that smoking history
was associated with an increased risk of all cause mortality, and risk of death was increased in
current and former smokers when compared to never smokers. However, the definition of both
current and former smokers was not described.
Concurrent to investigations of this thesis, I have been leading a systematic review examin-
ing the association between smoking history and prognosis in head and neck cancer. Searches
found 50 observational studies with data on overall survival, cancer specific survival and recur-
rence/second primaries in relation to smoking history. Briefly, studies provided 75 estimates
comparing risk of all cause mortality between various smoking exposures. Exposure was as-
sociated with an increased risk of death in 69 out of the 75 estimates, 27 were statistically
significant and the median HR was 1.59. A further 43 estimates of risk of cancer progression
or cancer specific mortality were extracted. Forty three showed an increase in risk associated
with smoking, 12 were statistically significant and the median HR was 1.5. Although a thor-
ough analysis of these data are yet to be completed, this brief analysis indicates that findings in
head and neck cancer may be consistent with the findings of this review; that smoking history
is associated with a less favourable prognosis.
5.5.4 Strengths and limitations
An important strength of this review is the exhaustive search for relevant studies. In addition,
broad inclusion criteria were applied and if possible, data not presented in the form of HR
(95% CI) were used to calculate this measure. This enabled all relevant and available data
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to be captured and used, increasing the power of sub-group analysis. However, as data were
observational, it is not possible to conclude that associations were causal, which is an impor-
tant limitation. Unadjusted estimates were used as adjusted estimates were considered to have
intractable difficulties in terms of interpretation, as many studies controlled for both potential
mediators/modifiers in addition to potential confounders . Non-randomised, unadjusted esti-
mates may be subject to confounding, and this is a possible interpretation of the findings of this
review.
By definition, for a variable to act as a confounder within the context of this review, it would
need to predict the risk of a person smoking and therefore ‘pre-date’ the smoking behaviour of
a patient, and also independently predict prognosis. Age and gender are the two main candidate
factors that may act as confounders. It is known from national population statistics that smoking
prevalence differs within sub-groups of these demographics.[283] Smoking prevalence has also
changed over time.[283] Most of the studies in this review were conducted in past decades, and
samples are likely to reflect underlying population demographic structures of smoking preva-
lence at the time of the study. Many of the included studies were also conducted in Asia where
the ‘smoking epidemic’ is in an earlier stage than seen in the western world.[32] Even so, in
these countries, certain demographic sub-groups are at a higher risk of smoking.
In terms of gender, it was considered that males were more likely to have a smoking history
than females. In Asia, smoking prevalence is higher in men.[32] Even though in the western
world the prevalence of smoking has decreased more rapidly in men over the past years, in
the time frame that included studies were conducted, men were more likely to smoke.[283] In
all 15 studies included in this review that reported gender by smoking exposure group, ever,
current and former smokers had a higher proportion of men than never smokers, and a higher
proportion of men were in heavier compared to lighter pack year history groups (see table 5.5).
Gender differences in lung cancer survival rates have also been reported in a number of previous
studies.[284, 285] In particular, women have been found to have higher survival rates than men,
regardless of stage. This has recently been demonstrated in the US, based on analysis of the
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SEER database[286], a large cohort from the Mayo Clinic[440] and in a Japanese study with
stage I-IIIa NSCLC treated with surgery.[441] However, these past studies have generally found
that the survival benefit of female gender can be explained by higher rates of adenocarcinoma,
earlier stage at presentation and low rates of co-morbid disease. Therefore, it is highly likely
that males have a worse prognosis because of a higher rate of smoking, which leads to increased
risk of death via the cancer dependent or cancer independent pathways considered in this review.
If this is the case, gender would not be acting as a confounder, but would rather be an antecedent
factor on the causal pathway between smoking and prognosis.
Although some of the 12 studies that described age by exposure group found a significant differ-
ence at baseline, no difference was greater than 5 years (see table 5.5). There have been mixed
reports of the prognostic significance of age for surgical lung cancer patients. One previous
study compared patients who were younger than 50 to those who were older than 50 at diagno-
sis. Younger patients were more likely to be diagnosed with adenocarcinoma, but there was no
difference in stage at presentation between the two group or in rates of survival.[442] A second
study compared patients diagnosed younger than 45 to those diagnosed older than 45 and found
that survival was worse for younger patients. The authors concluded that this was likely to be
because younger patients delayed seeking treatment.[328] A third study compared patients di-
agnosed before age 65 with those who were 65 or older at diagnosis and found that older age
was an independent predictor of risk of disease recurrence and all cause mortality.[287] Even
if age does predict a worse prognostic outcome, it is unlikely that this would be an important
confounder if on average non-smokers are diagnosed roughly 5 years younger than those with a
smoking history. Thus, overall, it was considered unlikely that the findings of this review could
be attributed to confounding.
In addition to potential confounding, there are a few other considerations that should taken
into account when interpreting these data. First, sub-groups were formed within the constraints
of available data, and compromises had to be made. For example, treatment varied both be-
tween studies and between individuals within a study. Although there were studies in which
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all received surgery or all did not receive surgery, treatment was not uniform within groups.
Also, often studies did not explicitly confirm that resection was complete. However, there is
no reason to assume that this would be systematically more likely for those with a smoking
history compared to those without. Including patients with incomplete resection would likely
reduce the size of association between smoking history and prognosis to a similar size as pa-
tients treated non-curatively. There were other studies that included both patients that had been
treated with curative intent and those that had not. This third group was combined with the
studies of patients treated non-surgically in order not to ‘dilute’ the surgical group. However,
this would have underestimated the difference in prognostic significance between patients who
were treated with surgery and those who were treated non-surgically.
Second, quality was assessed based on criteria proposed by Altman,[300] and studies were
found to be of low to moderate quality gaining between 23 and 50% of the total score. It is
therefore possible that the findings are subject to bias addressed by this score. In particular,
smoking exposure was mostly obtained in retrospect and poorly defined. If smokers were sys-
tematically more likely to be assigned as non-smokers, or vice versa, this would create assign-
ment bias. However, when analyses were restricted to high quality studies only, the strength of
the estimate increased, indicating the bias was obscuring the true effect size. It is worthy of note
that there was methodological heterogeneity based on mode of estimate extraction (i.e. hazard
ratios that were presented compared with those that were calculated from other data such as
percentage survival or Kaplan-Meier plots). Presented estimates were larger and more precise
than those calculated from other data, and more likely to be the chosen mode of presentation
in high quality studies. As has been found by others reviewing prognostic studies,[300] this
review also found strong evidence of publication bias. Studies were missing from the lower
left quadrant of funnel plots, and this asymmetry remained when confining these analyses to
sub-groups. This suggests that small, negative estimates have not been published which may
lead to an over-estimation of the risk. It is possible that bias was introduced in low quality
studies or due to publication bias. However, study quality and publication bias affected the es-
timate in opposite ways, with low quality studies (high risk of methodological bias) obscuring
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the association and publication bias falsely inflating it.
5.6 Conclusion
This review has found consistent evidence that smoking history is associated with increased risk
of all cause mortality in lung cancer patients. Findings suggested that risk was not explained by
reducing eligibility for surgery, as surgery modified the risk. Risk appeared to be elevated for
both surgical patients who were smokers at diagnosis and those who had quit before diagnosis,
and there was an indication that risk decreased with increased time since quitting. This is an
important finding as although a minority of patients are currently smoking when diagnosed,
most have a history of smoking.
Lack of data prevented strong conclusions to be drawn regarding mediation pathways. Few stud-
ies reported cancer specific prognostic outcomes. In addition, no models adjusted for individual
potential mediators were available, and it was difficult to interpret the effect of adjustment for
multiple factors. Most studies that reported risk of developing a second primary, recurrence or
of cancer specific death found an increased risk although often this was not statistically signif-
icant and it was often not possible to combine data. However, this indicates that risk may be
operating through cancer related mechanisms, although mediation through co-morbidity can-
not be ruled out. It is biologically plausible that smoking history may affect prognosis through
cancer related risk, even after surgery has completely removed the tumour. A prevailing hy-
pothesis that fits with tentative conclusions of this review is that of field cancerisation; in other
words, multiple pre-neoplastic lesions remaining after successful surgery are responsible for
development of second primaries and increased risk of death. However, further work is needed
to confirm this as data were limited and it is not possible to rule out bias or confounding as an
explanation for the findings.
Taken together, this review indicates that smoking history may be an important prognostic fac-
tor in surgical patients. Currently, little attention is paid to smoking history either in clinical
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practice or in cancer clinical trials. If it was confirmed that smoking history is an independent
prognostic factor, more careful detailing of a patients’ smoking history would need to be taken
at diagnosis as this would have implications for identifying those are greater risk of disease
progression. In addition, future prognostic studies would need to address this as a potential
confounding factor.[300] Despite the limited ability to draw a strong conclusion regarding the
prognostic significance of smoking history for surgical patients, this constitutes moderate evi-
dence of an association and warrants further investigation. Given the difficulties encountered
using study level estimates, it is most likely that investigation of these questions will be best
answered using individual patient data.
5.6.1 Identified research priorities
The following is a list of research questions that have been identified based on the findings of
this study:
1. What is the prevalence of current and former smoking at diagnosis in lung cancer surgical
patients.
2. What is the distribution of length of time of quitting before diagnosis in former smokers
treated with surgery.
3. Using propensity score matched individual level surgical lung cancer patient data, the
following questions need to be investigated:
(a) Is there evidence of a causal relationship between presence of a smoking history and
all cause mortality, development of a second primary, tumour recurrence or cancer
specific mortality and what is the size of risk, controlling for the effect of continuing
smoking after diagnosis and key confounders.
(b) Is the relationship mediated by surgical stage, histology, pre-neoplastic lesion bur-
den, inflammatory markers or co-morbidity
(c) Does the magnitude of risk decrease with increasing time since quitting.
(d) Does intensity of smoking history predict risk after controlling for recency of smok-
ing.
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CHAPTER
SIX
INVESTIGATION OF THE ASSOCIATION BETWEEN
CONTINUED SMOKING AFTER LUNG CANCER
DIAGNOSIS AND PROGNOSIS: SYSTEMATIC REVIEW
AND META-ANALYSIS
6.1 Review question
1. What is the association between continued smoking after a diagnosis of lung cancer and
the risk of all cause mortality, cancer specific mortality, development of a second primary
tumour or tumour recurrence in lung cancer patients?
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6.2 Introduction
This chapter reports a second systematic review that investigates the association between smok-
ing and prognosis, in particular focusing on the prognostic significance of continued smoking
after a lung cancer diagnosis. This review has been published by the BMJ, and a copy of the
full text publication can be found in appendix C. For clarity, the review presented in chapter 5
will be referred to as the smoking history review and the review presented in this chapter will
be referred to as the post-diagnosis smoking review.
Past studies have estimated that a significant minority of patients are current smokers at diag-
nosis, and many continue to smoke (see section 1.6.1). As with smoking history, it was hypoth-
esised that continued smoking may affect prognosis either through pathways that are related or
unrelated to cancer. Patients who continue to smoke and those who quit smoking are likely to
have a similar smoking history, as both groups are current smokers at diagnosis. Therefore, any
increased risk of disease progression and cancer related death is not likely to operate through
the same mechanisms hypothesised for smoking history e.g. later stage at diagnosis, more ag-
gressive tumour histology or presence of pre-malignant lesions (see section 5.5.2). However,
there are other possible mechanisms by which continued smoking may increase the risk of dis-
ease progression and cancer related death. It is possible that carcinogens in cigarette smoke
not only act as genetic inducers of tumour development but exposure to tobacco smoke may
also promote progression of the disease.[319, 443] For example, inflammation has been shown
to create a micro-environment that supports tumour development,[409, 410, 412] and smoking
causes inflammation.[444–446] As well as potentially increasing the risk of cancer related mor-
bidity and mortality, continued at diagnosis may also increase overall mortality by increasing
risk of death from co-morbid disease.[31, 447]
It is possible that the difficulty and discomfort of smoking cessation would mean that many
patients with advanced lung cancer choose to continue to smoke.[138] However, curative treat-
ment has good survival ratings, with up to 78% of patients surviving for 5 years after diagno-
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sis,[41] and it is possible that smoking cessation may be worthwhile in this group. Patients who
are still smoking at diagnosis may be given brief advice to stop but delivery of or signposting
to specialist smoking cessation support is not a standard component of cancer care. A recent
survey of 1 500 lung cancer clinicians who were members of the International Association for
the Study of Lung Cancer (IASLC) showed that although more than 90% believed that smoking
cessation support should be a routine part of care, only 39% routinely offered assistance with
quitting smoking.[248]
The Cancer Reform Strategy highlighted the need for development of tailored services to sup-
port cancer patients after diagnosis and treatment, and new care pathways are being developed
and tested (see section 1.7.2). In the future, these services for lung cancer patients may include
smoking cessation interventions.[186, 448] The qualitative interview study that was presented
in chapters 2 - 4 of this thesis found that most surgical lung cancer patients who were smoking
at diagnosis had a desire to be a non-smoker, and were open to offers of support to quit. Adop-
tion of smoking cessation support into standard care should be based on robust evidence that
quitting smoking improves outcomes. A systematic search of the literature was performed to
assess if there was evidence that continued smoking after diagnosis is associated with prognosis
in lung cancer patients, and to understand if risk is elevated through pathways that are related
or unrelated to cancer.
6.2.1 Methodological considerations
The question posed by this review could possibly be answered using a randomised controlled
trial (RCT) design. However, no RCTs testing smoking cessation interventions and reporting
both smoking cessation and prognostic outcomes were found from searches of the literature.
Therefore, this review is based on study level data from observational cohort studies. The
methodological considerations of using this type of data have been discussed at length in chap-
ter 5. The most important consideration for this review is the possibility of uncontrolled con-
founding. As smoking cessation would occur after diagnosis with a tumour and development
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of co-morbid disease, it is not possible for these factors to act as mediators of the relation-
ship between quitting and prognosis. In order to investigate confounding, comparison between
unadjusted and adjusted estimates were used as a basis of this review. This review found an
equal number of studies conducted in NSCLC and SCLC patients. Given the difference in
disease course and treatment approach, studies in non-small cell lung cancer were considered
separately to small cell lung cancer.
6.3 Methods
Relevant studies were identified from the same search conducted for the smoking history review
(for search methods see section 5.3.1). Inclusion criteria were also similar, but differed for the
exposure and also study design (see table 6.1). Studies were included if they estimated the
difference in risk for those who continued smoking after diagnosis compared with patients who
quit smoking. As it was possible that data may be derived from RCTs, this study design was
also included in the criteria.
Table 6.1: Inclusion criteria – systematic review of the association between smoking cessation after
diagnosis and lung cancer prognosis
Study design RCTs
Observational cohort study (prospective or retrospective)
Population Patients diagnosed with a lung tumour regardless of stage, histology and
treatment
Exposure Continued smoking after diagnosis compared with quitting at diagnosis
Outcome All cause mortality
Cancer specific mortality
Development of second primary
Development of recurrence
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6.3.1 Data extraction and study quality
Data were extracted using the same methods reported for the smoking history review (see sec-
tion 5.3.3). Unadjusted and adjusted estimates were extracted as a hazard ratio (HR) with 95%
confidence interval (CI) and methods described by Parmar were used to calculate HR (se) from
Kaplan Meier curves, p values or percentage survival when this was not presented.[296] In some
studies, observed risk was presented as a proportion of expected risk calculated using Poisson
regression modelling with general population data. In these cases, the HR was calculated by
indirect comparison.[368]
Study quality was assessed using the same scoring system as used for the smoking history
review which was based on a framework proposed by Altman for the assessment of prognostic
studies.[273] Studies could score a maximum of 22 points based on description of the cohort
and study methodology. Studies scored highly if the inclusion/exclusion criteria were well
defined, if the characteristics of the patient sample were described including distribution of
important confounders and prognostic factors between smoking exposure groups, if treatment
and smoking status were clearly described and if patients were followed prospectively for more
than five years. The scoring system is summarised in table 5.2 in chapter 5.
6.3.2 Exploration of the association between smoking cessation and
prognosis
Extracted HRs were combined using a random effects inverse variance model in STATA10, as
clinical and methodological heterogeneity was high. It was decided to report the results for
non-small cell lung cancer and small cell lung cancer studies separately given the difference in
disease course and treatment of these histological types. Statistical heterogeneity was assessed
using the I2 test. Where possible, sub-group analysis was conducted by receipt of surgical
treatment, and publication bias was assessed using funnel plots.
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Assuming the findings of the review reflected a causal relationship between smoking cessation
and risk of all cause mortality, I further investigated the data by constructing life tables for a
hypothetical group of one hundred 65 year old early stage lung cancer patients to estimate how
many deaths would be prevented by smoking cessation within the NSCLC and SCLC popu-
lation during five years. The number of patients who continued to smoke after diagnosis that
would survive for 5 years was estimated using the average risk of death reported for continuing
smoking from two high quality studies included in this review.[137, 449] Five year survival in
quitters at diagnosis was estimated by applying the continuing smoker death rate multiplied by
the reciprocal of the adjusted HR for risk all cause mortality presented in this review.
To investigate if reduction in risk associated with quitting smoking could be explained by a
reduced risk in death due to other smoking related diseases, I estimated the expected number of
cardiovascular and respiratory (CR) diseases that would be prevented due to smoking cessation
in the general population using life tables as above. The number of 65-69 year olds and number
that died of cardiorespiratory causes were estimated from ONS data from 2009, thus giving
the risk of cardiorespiratory death for this age group.[450] It was assumed this mortality rate
was approximately that of the non-smoking population because around 12% of this age group
smoke.[246] This rate was multiplied by the relative risk of death from CR causes in lifelong
smokers to estimate the number of deaths that would be expected over 5 years from CR causes
in the smoking 65 year old general population.[31] The risk reduction from cessation was then
applied to estimate the number of deaths that would be prevented, which was then compared to
the risk reduction from cessation in NSCLC and SCLC populations estimated in this review.[31]
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6.4 Results
Full text articles were obtained for 268 papers from which 10 individual cohort studies [137,
315, 333, 335, 366, 367, 449, 451–453] were included in the review (figure 6.1).
6.4.1 Characteristics of included studies
Five included studies estimated the association of smoking cessation with all cause mortality (4
NSCLC, 2 SCLC), four studies with the development of second primaries (1 NSCLC, 3 SCLC)
and two studies with recurrence of the primary tumour (1 NSCLC, 1 SCLC). In eight studies
that reported gender, most participants were male, ranging from 55-86%. Stage of disease was
reported in all studies. Nine of the studies were conducted on a patient sample with over 75%
presenting with early stage disease (stage 1-3a NSCLC or with limited stage SCLC). In three
studies in NSCLC, all patients received surgery and in the remaining two studies patients were
included that received surgery or chemo/radiotherapy. For studies in SCLC, all patients receive
radiotherapy and/or chemotherapy.
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Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 9) 
Total number of studies 
included  
(n =  10) 
Figure 6.1: PRISMA flow diagram of study selection and use. [301] (N.B. Three studies contributed to
both qualitative and quantitative syntheses [137, 333, 453])
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Overall study quality scores ranged from 13 to 18 points out of a maximum of 22 points. Four
studies reported the distribution of potential confounding factors by smoking exposure group
(see table 6.4). Quitting status was based on follow up 6 months or greater in five studies,
[333, 335, 366, 367, 449] but smoking was only measured at the time of treatment in four [137,
451–453]. Follow up was not defined in one study.[315] Reporting of smoking exposure varied
between studies. The best evidence for smoking status would be a prospectively collected mea-
sure with biochemical verification.[146] However, often there was ambiguity in the reporting
of the method used to obtain smoking status, or else it was not described. Two studies defined
quitting as continuous abstinence within six months of treatment initiation to longest follow
up[333, 367] and one study defined quitting as continuous abstinence during and subsequent to
treatment.[451] The remaining studies did not give a definition of quitting. In three studies,[333,
335, 366] patients were included in the analysis if they had survived two years disease free and
one study [367] only included patients that had been disease free for three years (Table 6.3).
Table 6.4: Balance of potential confounders between quitters and continuers
Gender Age Histology Stage
Baser, 2006 NSCLC Balanced Balanced N/R Balanced
Nia, 2005 NSCLC Balanced Balanced Balanced Balanced
Johnstone-Early, 1980 SCLC N/R N/R Balanced Unbalanced
Videtic, 2003 SCLC Unbalanced Balanced Balanced Balanced
6.4.2 The association between continued smoking after diagnosis and
prognostic outcomes
Non-small cell lung cancer - All cause mortality, occurrence of second primary and recur-
rence Four studies reported estimates of the association between continued smoking with all
cause mortality, one study with occurrence of a second primary, and one study with recurrence
in non-small cell lung cancer (figure 6.2). Estimates were derived from patient samples where
at least 80% were diagnosed with a stage 1-3a tumour. Three studies were conducted in sur-
gical patients, and one study[449] included patients who had not received surgery. Unadjusted
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estimates suggested that continued smoking was associated with a non-significant increased
risk of all cause mortality of 19% when compared to quitters. When considering only sur-
gical patients, a strengthening of risk to 71% increase was observed although this remained
non-significant (surgical patients HR 1.71 (95% CI 0.75, 3.93). On adjustment for potential
confounding variables there was an almost three fold increase in risk of all cause mortality for
continuing smokers compared to quitters (unadjusted HR 1.19 (95% CI 0.91, 1.54), 4 studies,
I2 = 0%; adjusted HR 2.94, (95% CI 1.15, 7.54), 1 study; 6.2).
There was no significant increase in the occurrence of second primaries before or after ad-
justment although confidence intervals were wide (unadjusted HR 0.35, (95% CI 0.06, 2.06), 1
study; adjusted HR 2.29 (95% CI 0.50, 10.58, 1 study; figure 6.2). One study reported an almost
two fold increase in unadjusted risk for continuing smokers of tumour recurrence (adjusted HR
1.86 (95% CI 1.01-3.41), 1 study; figure 6.2). Given the small number of studies, it was not
possible to conduct sensitivity analyses by study quality and the ability to assess publication
bias was limited. Unadjusted estimates of all cause mortality showed no evidence of funnel plot
asymmetry.
Small cell lung cancer - All cause mortality, occurrence of second primary and recurrence
All cause mortality in continuing smokers with small cell lung cancer was significantly in-
creased before and after adjustment, with adjustment strengthening the association (unadjusted
HR 1.18 (95% CI 1.03-1.36), 2 studies, I2 = 0%; adjusted HR 1.86 (95% CI 1.33-2.59), 1
study; figure 6.3). In each of these studies, patients were treated with either radiotherapy and/or
chemotherapy. Estimates were derived from patient populations where at least 79% were di-
agnosed with limited stage disease apart from one study where 29% of patients presented with
limited stage disease.[451] There was no heterogeneity between unadjusted scores despite there
being a marked difference between the patient populations in terms of stage at presentation.
Unadjusted estimates suggested an 86% increase in risk of developing a second primary, which
was strengthened to a fourfold increase in risk after adjustment for continuing smokers com-
pared to those who quit at diagnosis (unadjusted HR 1.86 (95% CI 0.96, 3.60), 3 studies,
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Figure 6.2: The association of continued smoking in early stage non-small cell with risk of all cause
mortality, second primary and recurrence compared with quitting at diagnosis
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Figure 6.3: The association of continued smoking in small cell lung cancer with all cause mortality,
development of a second primary or recurrence compared to in quitting at diagnosis
I2 = 0%; adjusted HR 4.31 (95% CI 1.09-16.98), 1 study; figure 6.3) although confidence
intervals were wide. One study reported an unadjusted estimate for the association between
continued smoking on recurrence that was statistically significant (unadjusted HR 1.26 (95%
CI 1.06-1.50)). Given the small number of studies, it was not possible to conduct sensitivity
analyses by study quality or assess publication bias.
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6.4.3 Contribution of cardiovascular and respiratory mortality to
reduced mortality rates in lung cancer patients who quit.
The life table analysis was based on a notional cohort of 65 year old smokers diagnosed with
early stage NSCLC or limited stage SCLC. Assuming a causal relationship between smoking
cessation and all cause mortality, the estimated five year survival rates were 41% in continuing
smokers and 75% in quitters for NSCLC and 36% in continuing smokers and 68% in quit-
ters for SCLC. In life table analyses based on general population data, five year survival from
cardiorespiratory deaths was estimated at 91% in smokers and 94% in quitters.
6.5 Discussion
This review included 10 observational studies, all of which showed some evidence that con-
tinued smoking after a diagnosis of early stage lung cancer is associated with elevated risk of
recurrence, second primary, or all-cause mortality compared to quitting at the time of diagnosis.
Although unadjusted estimates suggest that the associated risk of continuing (or the benefits of
cessation) may be modest, within study adjustment for key confounders suggested a doubling of
risk of mortality for SCLC and tripling of the risk for NSCLC. Across study assessment of the
effect of adjustment also suggested a strengthening in the risk of mortality, and this remained
when limiting the analysis to patients who had been treated with surgery.
Potential mechanisms of increased risk Assuming that the association between smoking
cessation and risk of all cause mortality represents a causal relationship and is not due to bias
or confounding, two possible explanations were hypothesised. Firstly, continued smoking may
increase the risk of death due to other smoking related causes such as cardiorespiratory dis-
eases. If this was the case, it would be expected that continued smoking would be associated
with an increased risk of all cause mortality, but no increase in cancer specific prognostic out-
comes would be found. Secondly, it is possible that continued smoking may increase the risk of
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disease progression and cancer death. In both early stage NSCLC and limited stage SCLC, this
study found evidence of a significant association between continued smoking and recurrence
of the primary tumour. There was additional evidence in limited stage SCLC of a significant
elevation in the incidence of a second primary tumour. Adjustment within study and across
studies strengthened the association between continued smoking and these cancer outcomes.
Thus, although data were limited, it indicated that continued smoking increased risk through
cancer related mechanisms.
Life table modelling estimated that smoking cessation in the general population would lead
to increased five year survival by 3% in absolute terms due to reduction in cardiorespiratory
deaths, whereas smoking cessation after diagnosis of early stage NSCLC and limited stage
SCLC increased five year survival by 34% and 32% respectively. This exercise was based
on assumptions that are likely to underestimate the possible mortality benefit from smoking
cessation. For the 65-69 year old general population, the baseline cardiorespiratory death rate
estimate was based on an assumption that the population were non-smokers. However, although
the prevalence of smoking is only around 12% many will be ex-smokers, conferring a greater
baseline risk for cardiovascular death than a completely non-smoking population. On the other
hand, the higher prevalence of pre-existing cardiorespiratory disease in lung cancer patients
means the absolute mortality gains seen in a general population are probably lower than in
lung cancer patients. Neither assumption seems sufficiently inaccurate to challenge the data
suggesting the major benefit from smoking cessation would be conferred by a reduction in
cancer-specific risk, if the reduced risk seen in this review was caused by smoking cessation,
but no studies reported cancer specific mortality rates to confirm this.
It is known that the risk of cardiovascular related illness and death decreases after smoking
cessation in patients with coronary heart disease,[454] reducing dramatically over the first three
years.[455] However, it generally takes longer for the risk of developing lung cancer to reduce
after smoking cessation,[31, 455, 456] It is noteworthy that this review has found evidence that
after lung cancer has been diagnosed, reductions in risk of developing a second primary or
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recurrence were associated with quitting within at least four years of follow up, suggesting that
the mechanism of increased risk acts in the short term and, even at diagnosis, it may be possible
to improve the prognostic outlook by smoking cessation.
There are a few potential mechanisms by which continued smoking may increase the risk of
disease progression and cancer death, acting in the short term. It is possible that continued
smoking may reduce the effectiveness of adjuvant treatment.[457, 458] Although little has been
done to assess the interaction between smoking and treatment on outcome, some studies in other
tumours have indicated that smoking during radiotherapy may effect the outcome. For example,
one study in 115 head and neck cancer patients reported that response rate was significantly
lower (45% vs 74%, p=0.008) and also 2 year survival was significantly lower (39% vs 66%,
p=0.005) in patients that continued to smoke during treatment compared to those who quit at
diagnosis or before.[459] Two case-control studies conducted in breast cancer patients found
that radiation to the chest in combination with smoking was a risk factor for developing a
second primary tumour in the lung. In one of these studies, radiotherapy alone was not found to
increase risk and in the second study radiotherapy and smoking were found to be a multiplicative
risk.[460, 461]
Smoking may also affect response to chemotherapy as it is a potent inducer of the cytochrome
P450 enzymes which is responsible for metabolism of a number of difference drugs in the
liver.[462] Several chemotherapeutic agents are metabolised by this enzyme system, and there-
fore smoking could potentially increase the rate of metabolism, leading to lower levels in the
blood and tissues.[457] No studies have investigated the effect of continued smoking on re-
sponse to chemotherapy, but one study showed that clearance of erlotinib (a epidermal growth
factor receptor tyrosine kinase inhibitor monoclonal antibody used to treat patients with ad-
vanced disease) to be 24% higher in patients who smoked compared to non-smokers.[463]
In addition to leading to worse treatment outcomes, constituents of tobacco smoke may also
alter the biological behaviour of lung cancer or aid processes that support tumour progres-
sion.[319, 457, 458] Smoking causes inflammation and, particularly over the past 10-15 years,
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evidence has been mounting for the critical role of ‘smouldering inflammation’ for both the
development and progression of tumours.[6, 410, 412] The mechanisms by which smoking, in-
flammation and lung cancer are linked are complex and not completely understood. However,
inflammatory cells and mediators have been found to be highly expressed in the lung tissue of
smokers, in precursor lung lesions and in established lung tumours.[446] Cigarettes smoke con-
tains many potential irritants and is a strong inflammatory stimulus, inducing pro-inflammatory
cytokines such as IL-6 and TNF∝. In addition, COPD, for which smoking is an important risk
factor,[464] is characterised by deregulated inflammation.[465] Chronic exposure to tobacco
smoke is associated with mutations that lead to the loss of p53 tumour suppressor gene function
and mutation of the KRAS oncogene, and presence of these mutations has also been linked to
increased inflammation, cell proliferation and angiogenesis.[446]
In addition to the potential tumour-promoting effects of smoking-induced inflammation, nico-
tine itself has also been shown to suppress apoptosis, stimulate cell proliferation and promote
angiogenesis in vivo.[466, 467] Thus, although the details of mediating pathways are yet to
be confirmed, evidence is mounting of plausible biological mechanisms by which continued
smoking after surgery may help create an environment that stimulates and support growth of
unresected pre-neoplastic lesions or unresected tumour cells.
Strengths and limitations An important strength of this review is the exhaustive search for
relevant studies. Five of the ten studies were ostensibly about the relationship of other potential
prognostic variables with outcome, but happened to present data on smoking status as a potential
confounder of those associations. Such a strategy mitigates concern about publication bias
because the decision to publish was unrelated to the findings on smoking status and cancer
outcome. However, it is still possible that reporting of factors included in an adjusted model
may be biased towards those that were statistically significant. No asymmetry was detected in
funnel plots to suggest such reporting bias, but it is possible that bias was not detected given the
small number of studies.
An important limitation of the data in this review is that it is derived from observation studies,
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and therefore no causal inferences can be made. A major challenge with systematic reviews of
observational studies is the possibility of uncontrolled confounding.[273] It was considered that
in the context of this review, the main potential confounders were age, gender, tumour histol-
ogy, tumour stage at diagnosis and co-morbidity. If, in general, potential confounding variables
were not associated with quitting status, the ratio of unadjusted to adjusted HRs within stud-
ies should be randomly distributed about one. For those studies that presented unadjusted and
adjusted HRs, these ratios were lower than one, with adjustment revealing a strengthening of
the association.[137, 333, 453] This suggests that smokers with unfavourable prognostic factors
were the most likely to give up smoking and therefore unadjusted estimates underestimated the
benefits of quitting. Four out of the ten included studies presented data on the baseline distri-
bution of potential confounders split by quitting status.[137, 449, 451, 453] One study[453] re-
ported a significantly higher proportion of men in the quitter than continuer smoking group, and
a further study reported that more patients with extensive stage SCLC quit smoking than con-
tinued to smoke through treatment.[451] Both male gender and more advanced stage have been
demonstrated as independent predictors of a worse prognosis. None of these studies measured
co-morbidity and therefore it was not possible to assess if this factor was unevenly distributed
between continuers and quitters.
Quality was assessed based on criteria proposed by Altman,[300] and studies were found to
be of moderate quality gaining between 59 and 81% of the total score. Generally, smoking
abstinence definitions were poor and only five of the 10 studies assigned patients to smoking
categories based on smoking status recorded at 6 months or greater after diagnosis. As a result,
the proportion of current smokers at diagnosis who continued to smoke based on the definitions
used for included studies ranged from 6-83%. There are conflicting reports in the literature of
the proportion of lung cancer patients who continue to smoke after diagnosis, with estimates
ranging from 13-60%,[132, 254, 468] There may be true variation in prevalence of continued
smoking based on differences in the clinical characteristics of study populations or course of
treatment for instance.[469] However, it is likely that much of the variation seen in included
studies resulted from heterogeneity in the classification of continued smoking. This may have
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led to a mixing of true exposure status. However, this is likely to have underestimated the ben-
efits of cessation as it is more likely that those who were counted as quitters went on to relapse
than vice versa.[258] Future studies in this area need to use accepted standards for measurement
of smoking abstinence in order for gain a more accurate estimate of the relationship between
continued smoking and prognosis.[146]
6.6 Conclusion
This study has found evidence that continued smoking after a diagnosis of early stage non-
small cell or small cell lung cancer is associated with a worse prognosis. Life table modelling
indicated that risk of continued smoking (or benefit of smoking cessation) was much larger than
would have been expected due to cardiovascular deaths only. Coupled with evidence that risk
of recurrence or development of a second primary was significantly elevated, this supports the
hypothesis that continue smoking increases risk through cancer-related pathways. Given the
limitations of the data, these findings must be considered preliminary. However, they are of
sufficient strength to warrant further investigation, including a randomised trial of a smoking
cessation intervention to examine questions of effect on smoking behaviour, health outcomes
and cost-effectiveness. Establishing the role of cigarette smoke in cancer progression will not
only produce the necessary evidence for implementing smoking cessation interventions, but
may also help to further understanding of the biological behaviour of lung cancer.
6.6.1 Identified research priorities
The following is a list of research questions that have been identified based on the findings of
this study:
1. What is the prevalence of continued smoking in surgical lung cancer patients?
2. What is the effectiveness of a smoking cessation programme for lung cancer patients in
terms of smoking abstinence and also prognostic outcomes.
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CHAPTER
SEVEN
OVERARCHING CONCLUSIONS AND
RECOMMENDATIONS FOR FURTHER RESEARCH
The research presented in this thesis aimed to investigate key health and supportive care issues
for surgical lung cancer patients in order to increase the evidence base for future developments
in supportive care for this patient group. Each individual research study, documented in chapters
2 - 6, contains a detailed discussion of the findings in the context of past published research,
considers the strengths and limitations of the study, draws conclusions from the findings and
makes specific recommendations for further research. Important design components of a
tailored rehabilitation programme for surgical lung cancer patients to take forward for testing
are described in section 4.1.4. The main findings from each individual study of this thesis, as
discussed within relevant chapters, along with identified research priorities are summarised in
table 7.1. The purpose of this final chapter is to summarise the overarching conclusions to be
drawn from this doctoral study and indicate their relevance to the ongoing developments within
cancer research and care.
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7.1 Many lung cancer patients experience a difficult and
protracted recovery after surgery, and their needs are
not being met
During the lifetime of this doctoral study, the NCSI has developed a new model of follow up
care for cancer patients. This features a risk stratified approach which is based on ongoing as-
sessment of patients’ needs. Patients who are largely well after treatment will be given the tools
they need to self-manage, whereas other patients may need additional support from secondary
and/or primary care and will be managed using the ‘shared care’ model. Finally, those who
have complex ongoing health care needs will receive consultant-led care (complex care). The
NCSI estimated that 15%, 60% and 25% of lung cancer patients will require self-management,
shared care or complex care, respectively.[181] This estimate is for lung cancer patients as a
whole rather than being specific for surgical lung cancer patients.
Qualitative investigations conducted as part of this doctoral study found that most participants
were affected by health challenges as a results of their treatment, although to different extents.
Most participants had improved over time but many were not yet back to normal at the time
of interview and were limited in their normal daily activities due to health challenges. In the
most extreme cases, participants continued to find activities of daily living difficult and were
largely housebound due to their health. Whilst some participants felt prepared for what to
expect with regards to surgery and recovery, many participants who underwent thoracotomy
expressed concern that they had not realised the extent to which they would be affected by
health challenges as a consequence of surgery.
Participants who were mildly affected by health challenges reported being able to manage their
health without additional support from primary or secondary care. Participants that demon-
strated this had generally undergone VATS, although a minority of participants who had under-
gone thoracotomy felt their needs had been met and were satisfied with standard care. In con-
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trast, most participants who underwent thoracotomy were moderately or severely affected by
health challenges, felt abandoned at discharge and expressed the need for additional supportive
care. Interviews took place with a purposeful sample of patients, and therefore the proportions
of patients that reported being mildly, moderately or severely affected by health challenges dur-
ing recovery may not reflect surgical lung cancer patients as a whole. However, QOL studies
in random samples of surgical patients also indicate that many continue to experience health
challenges and limitations in function for at least 3 months, and often up to 12 months. Taken
together, these data show that although some patients may be able to manage their recovery af-
ter surgery without additional support, many are in need of additional supportive care i.e. either
shared care or complex care.
7.2 Well developed treatments and services that are widely
available to other patients may potentially improve
quality of life and health outcomes after lung cancer
surgery
Breathlessness and pain were reported to be dominant health challenges during the first year
after surgery, and in addition some participants reported loss of appetite and weight, disturbed
sleep and general fatigue. There is a danger that poor overall survival rates for lung cancer and
the lack of research funding or studies for this tumour group may mean that the needs of surgical
patients (for whom survival rates are much improved) may continue to get overlooked.[261]
Although lung cancer patients were included in the considerations of earlier phases of the work
carried out by the NCSI, testing and implementing improved survivorship care pathways is now
focusing on breast, prostate and colorectal cancer patients only.[182] A recent announcement of
a new research alliance for lung cancer, uniting the expertise of leading research hospitals and
academic institutes in London, promises to increase funding available and research attention on
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lung cancer.[470] However, it is not clear whether supportive care needs will be prioritised.
This doctoral study concludes that the needs of lung cancer patients after surgery could be met
by accessing services and treatments (both pharmacological and non-pharmacological) that are
already available to other patients, and are well established. In particular, there is a strong
rationale for testing the benefit of pharmacological treatment of reversible breathlessness and
also pulmonary rehabilitation for this patient group. Participants that had enrolled on a COPD
rehabilitation-based programme being piloted at the time of the interview study were highly
satisfied with the level of supportive care they received, and this seems a promising template
on which to base additional supportive care for lung cancer patients after surgery. Based on
needs and preferences expressed by participants, and building on this rehabilitation programme,
important components of a tailored rehabilitation programme have been identified (see sec-
tion 4.1.4). Assessment and referral for support to manage pain, nutrition, anxiety/depression,
smoking cessation and mobility were also identified as potentially relevant to this patient group.
These findings support and extend the stratified pathway of care developed for lung cancer pa-
tients that was developed by the NCSI (see figure 7.1). In addition to the clinical support
services that are identified by this pathways as relevant to this patient group, investigations of
this thesis highlight that pain management and smoking cessation support are also important.
Further research to assess the effectiveness of these treatment and services for improving quality
of life and health outcomes is warranted.
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7.3 Measurement of smoking behaviour and support for
smoking cessation should take a more central role within
research and health care for surgical lung cancer
patients
Despite wide recognition of the causal role of smoking in the development of lung cancer,
the potential for smoking behaviour to determine cancer outcomes is largely overlooked in
cancer care and research. This is a cyclical problem. Without evidence that smoking is an
independent prognostic factor, past or present smoking behaviour is not adequately recorded
in patients’ clinical notes but inadequate recording also undermines studies investigating the
relationship between smoking behaviour with prognostic outcome. Few studies have overcome
this problem by recruiting patients at the time of diagnosis and obtaining a detailed description
of smoking behaviour for study purposes. Most studies identified by the systematic reviews
reported in this thesis were of poor quality, and due to limitations in the data conclusions are
preliminary. However, there was consistent evidence of an association between both smoking
history and continued smoking after diagnosis with prognosis. It is biologically plausible that
smoking history or smoking after diagnosis may increase the risk of cancer progression, and
although a limited number of studies reported cancer-specific prognostic outcomes there was
some indication that smoking was associated with an elevated cancer-specific risk.
There are a few commonly cited barriers to routinely offering smoking cessation support to
patients with cancer.[254, 256, 257] A particular concern has been that patients will not be
receptive to intervention, and that tackling smoking cessation at such a difficult time may be
unwelcome. However, there was no evidence that this was the case when patients’ attitudes
towards smoking and smoking cessation were explored in the qualitative study reported in
this thesis. On the contrary, many participants expressed a strong desire to be offered help.
An expressed caveat to this desire was that health professional approached the subject with a
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non-judgemental attitude, demonstrating an understanding of the difficulty of quitting smoking.
Previously published studies suggest that continued smoking may be associated with worse
short term outcome (e.g. elevated pain, increased risk of post-surgical complication, reduced
QOL)[134–136] and there is evidence that smoking cessation at least 4 weeks before surgery
leads to reduced risk of post-surgical complications.[169] Evidence indicating that health out-
comes may be improved, coupled with the finding that patients would prefer to receive support
to quit, constitutes a strong rationale for incorporating smoking cessation into standard care for
this patients group. Indeed, this has been advocated by leaders in the field for a number of
years.[143, 254, 457, 471–474] Taken together, findings of this thesis highlight the importance
of routine recording of smoking behaviour in clinical practice and indicate that further investi-
gation of the prognostic significance of smoking history is warranted. On the basis of patient
preference and gathering evidence for the short and long term health benefits of quitting, smok-
ing cessation support should be embedded within lung cancer care pathways. However, further
investigations to test the optimum intervention and length of support, and to confirm prognostic
benefits are needed.
7.4 Cancer-related inflammation: a unifying feature that
may underpin quality of life and prognostic outcome for
surgical lung cancer patients
This thesis began by outlining six hallmarks of cancer proposed by Hanahan and Weiberg in
2000, which are critical capabilities a tumour must develop in order to survive, develop and
invade new tissue (see section 1.2).[8] Over the past 10-15 years, the role of the environment
in which tumour formation is initiated, develops and gains the ability to metastasise has come
under increasing attention. New understandings have revealed that in addition to changes that
occur within cancer cells themselves, non-cancerous stromal cells forming the so called ‘tu-
mour micro-environment’ play a critical role in the neoplastic process.[410] In particular, excit-
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ing new developments have shown how cells of the innate immune system such as macrophages
and neutrophils may have an integral role in cancer,[409, 475–477] and in 2009 Colotta and col-
leagues proposed that ‘cancer-related inflammation’ should be regarded as a seventh hallmark
of cancer.[6]
The first known link between inflammation and cancer was made in 1863 by Virchow, a German
polymath, who noted leukocytes to be present in neoplastic tissue.[412] He hypothesised that
‘lymphoreticular infiltrate’ was responsible for the development of cancer at sites of chronic in-
flammation.[412] The developments of the past 10-15 years represent a renaissance of the idea
that cancer and inflammation are linked, and several lines of scientific enquiry are supporting
Virchow’s original hypothesis.[409, 412, 478] The risk of cancer is known to be increased at
sites of chronic inflammation, such as that caused by disease (e.g. inflammatory bowel disease,
COPD),[479, 480] by chronic infection (e.g. HPV, hepatitis, Helicobacter pilori)[481–483] and
by chronic irritation (e.g. cigarette smoke, asbestos).[15, 27, 31] This has been referred to as
‘smouldering inflammation’ which represent extrinsic causes of cancer-related inflammation
(CRI). It has also been established that CRI can arise from intrinsic pathways within cancer
cells, where mutations in oncogenes and tumour suppressor genes activate expression of in-
flammatory programmes which further build the inflammatory tumour micro-environment.[409,
477]
A common overarching theme that repeatedly emerged during this doctoral study was the poten-
tial for presence of pulmonary inflammation in surgically treated lung cancer patients. Through-
out this thesis, evidence from previous studies has been discussed showing that inflammation
is triggered in response to cigarette smoking, surgical wounding and also in the presence of
pre-neoplastic lesions. Prevalence of co-morbid inflammatory conditions, particularly COPD,
is high in this patient group.[465] It is known that many cases of mild COPD remain undi-
agnosed, and it is possible that the prevalence of this ‘smouldering inflammation’ is higher
than studies have shown.[484] Breathlessness and pain, the health challenges that dominated
the experience of patients during the first months after surgery, are both symptoms of inflam-
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mation.[228, 231, 485] Breathlessness and pain have other non-inflammatory causes and the
cause of these symptoms in surgical lung cancer patients are yet to be fully understood.[102,
111] However, if inflammation is involved due to some of the reasons above, it is possible that
anti-inflammatory treatment may partially or substantially reverse these symptoms leading to an
improvement in quality of life. In addition, given the evolving evidence base that inflammation
is critical to the neoplastic process, it is plausible that anti-inflammatory treatment may also
effect prognostic outcome in these patients.
Inflammation is a term that refers to a complex cascade of inter-related pathways that may be
mediated by a number of difference cells and a myriad chemicals.[486] One inflammatory me-
diator that has received much attention is the cyclooxygenase-2 (COX-2) enzyme,[487] which
catalyses the rate-limiting step for the production of prostaglandins and thromboxanes from
arachidonic acid.[487] COX-2 enzymes are inhibited by non-steroidal anti-inflammatory drugs
(NSAIDs) such as aspirin and ibuprofen, in addition to more recently developed drugs such as
celecoxib which is indicated for osteoarthritis, rheumatoid arthritis and ankylosing spondyli-
tis.[488] There are several reasons why this inflammatory mediator may have an important role
to play in CRI in surgical lung cancer patients. Oncogenic K-ras and EGFR signalling has
been demonstrated to correlate with COX-2 expression,[487, 489–491] and it is possible that
this signal remains after tumour resection due to the presence of unresected pre-neoplastic le-
sions or ‘field cancerisation’. Post-surgical pain can also be successfully treated using NSAID
and COX-2 specific inhibitors, suggesting that COX-2 has a role to play in surgery-related in-
flammation.[119, 485] Prostaglandin E2 (PGE2), which is produced in the presence of COX-2,
is a pro-inflammatory mediator and has been implicated in roles crucial to development and
progression of a tumour, including resistance to apoptosis, angiogenesis, enhanced invasion,
metastasis and suppression of anti-tumour immunity.[487, 492, 493] A number of studies have
demonstrated a chemopreventative effect of long term low dose aspirin and other NSAIDS
in both colorectal cancer [494–497] and in lung cancer.[498] In line with this, COX-2 over-
expression has also been associated with a decreased survival in lung cancer[499, 500] and
other tumours.[493, 501–503] Treatment of inflammation using COX-2 inhibitors (NSAIDs)
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has previously been highlighted for use as a potential chemopreventative and treatment drug in
lung cancer.[487]
This doctoral study has shown that many lung cancer patients have ongoing needs after surgery,
including management of breathlessness, pain and smoking cessation. In addition to the fur-
ther research that has already been suggested throughout this thesis, the presence and role of
pulmonary inflammation warrants further investigation. Further epidemiological studies are
needed to confirm the link between anti-inflammatory treatment and prognosis, and to test the
effectiveness of treatment on quality of life and prognostic outcomes.
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Figure A.1: McGill Pain Questionnaire
Figure A.2: Confirmation of funding by the National School of Primary Care Research (NSPCR)
Figure A.3: University of Birmingham to act as sponsor
Figure A.4: Ethical approval for interview study (11th March, 2009)
Figure A.5: Ethical approval for interview study - substantial amendment 1 (21th Sept, 2009)
Figure A.6: Ethical approval for interview study - substantial amendment 2 (16th May, 2011)
Figure A.7: Letter of access to Birmingham Heartlands Hospital
Figure A.8: Letter of access to University Hospital Birmingham
Figure A.9: Consent form for interview study
Figure A.10: Patient information sheet for interview study
Figure A.11: Information given to participants after interview to signpost information and support
Figure A.12: Ethical approval for healthtalkonline interviews
Figure A.13: Letter of access to Birmingham Heartlands Hospital for healthtalkonline interviews
Figure A.14: Consent form for healthtalkonline interviews
Figure A.15: Patient information sheet for healthtalkonline interviews
Figure A.16: Interview script, version 1
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Figure A.17: Nvivo queries
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Figure A.1: McGill Pain Questionnaire
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Figure A.3: University of Birmingham to act as sponsor
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Figure A.4: Ethical approval for interview study (11th March, 2009)
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Figure A.5: Ethical approval for interview study - substantial amendment 1 (21th Sept, 2009)
359
APPENDIX A. SUPPLEMENTARY MATERIAL FOR THE QUALITATIVE INTERVIEW
STUDY (CHAPTERS 2–4)
360
APPENDIX A. SUPPLEMENTARY MATERIAL FOR THE QUALITATIVE INTERVIEW
STUDY (CHAPTERS 2–4)
Figure A.6: Ethical approval for interview study - substantial amendment 2 (16th May, 2011)
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Figure A.7: Letter of access to Birmingham Heartlands Hospital
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Figure A.8: Letter of access to University Hospital Birmingham
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Figure A.9: Consent form for interview study
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Figure A.10: Patient information sheet for interview study
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Figure A.11: Information given to participants after interview to signpost information and support
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Figure A.12: Ethical approval for healthtalkonline interviews
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Figure A.13: Letter of access to Birmingham Heartlands Hospital for healthtalkonline interviews
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Figure A.14: Consent form for healthtalkonline interviews
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Figure A.15: Patient information sheet for healthtalkonline interviews
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Figure A.16: Interview script, version 1
• Thank the participant for allowing us to interview him/her.
• Reiterate the purpose of the interview:
“The purpose of this interview is to talk to you about your experiences as
somebody who has been diagnosed and treated with lung cancer. We know that
after treatment has ended people can find they have been left with difficulties
in many different areas of their lives and we particularly want to talk to you
about how being a patient with lung cancer has affected your physical and
psychological health. Some ways to help your health and hopefully improve
your quality of life might be to exercise and eat well as well as not smoke. We
are looking at how best to help you with these things. In order for us to improve
the services offered to cancer patients we want to talk to patients themselves
to find out what you think and what your experiences have been. During this
interview I’m going to ask you questions about your health, what things you
may already be doing yourself to be healthy and we are going to talk about
what you think about some ways in which the health service can help you to
be as well as possible.”
• Reiterate what the participant can expect to happen during the interview
– will last no longer than 1.5 hrs
– ask if it is ok to record
– explain that the interviewer will ask questions but they are permitted to decline to
answer
– information recorded will be kept confidentially and not traceable to them person-
ally.
– Can completely withdraw at any time. If they do withdraw we will ask participant
at that point if they are happy for us to use the data we have already collected.
• Gain written consent
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Background information (10mins)
• Background information about diagnosis and treatment
– To start off with, can you tell me when you first realised there was something wrong
and went to see the doctor?
– What happened after that?
– What were you told was wrong with you?
– What happened after that? What treatments did you get?
– How long has it been since you finished treatment?
Day to day post operative physical and mental health (10 mins)
• Briefly find out about their current day to day physical and mental health as related to the
long term impacts of cancer
– How healthy do you feel on a day to day basis?
– What are the main ways you feel healthy?
– What are the main ways that you feel unhealthy?
– What are some of the worries that you feel you have been left with as a result of
having cancer?
– Do you think that people need help with their health after being treated with cancer?
What help would you want? Why? What about depression? What about anxiety?
What about smoking? What about diet?
Attitudes towards effects of health behaviours on health (10 mins)
• Have a general discussion about patients attitudes towards improving health behaviours
(it may be that this section needs to be integrated into the in depth section below). “A
rehabilitation programme might include things like an exercise programme to help your
lungs recover and general fitness, or eating healthily and/or support to give up smoking.”
– Has having cancer changed the way you think about smoking, your diet or exercise?
– Do you feel that changing you diet, doing more exercise or cutting out smoking
could help your health on a day to day basis or to reduce the risk of the cancer
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coming back?
Attitudes towards and experiences of health behaviour management (30 mins)
• More in depth discussion about health behaviours and management
– If you were planning a rehabilitation programme for lung cancer patients, what do
you think would be the main things you would address? (investigate topic areas
raised by the patients, in particular probe as below)
For patients with smoking history only:
• First of all I want to talk to you a bit about your smoking. When did you start smoking?
• Have you ever tried to give up smoking? When was that? What made you decide to try
to give up smoking then? How did you find it?
• Did the doctors or nurses that you saw speak to you about your smoking and about giving
up? What did they say?
• How did you feel about the advice to give up/the prospect of giving up?
• CURRENT SMOKER
– Did you try to give up? What happened?
– Was it difficult to talk to the doctors and nurses about your smoking?
– How do you feel about smoking now? What are the good things about it and what
are the bad things?
– Would you like to be able to give up smoking?
• QUIT AT DIAGNOSIS
– When did you quit smoking?
– Did you get any help?
– What was it like? Do you think that it helped or hindered you physically/mentally
whilst going through the treatment or now?
– Was it easier/harder in comparison to other quit attempts you may have made earlier
in your life? Why?
– Do you feel healthier for giving up smoking?
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– Would you have liked some support?
• RELAPSED FROM FORMER SMOKER/QUIT AT DIAGNOSIS
– When did you start smoking again?
– What led you to start smoking again?
– How did you feel about your smoking? How do you feel now? What are the good
things and what are the bad things?
– Did you receive any help to stop smoking?
For all interviewees
• Have you tried to do anything to improve your health (other than giving up smoking for
smokers)? What have you done? What was helpful? What was unhelpful?
• Were you advised by doctors or nurses to change your diet or increase the amount of
exercise that you do?
• Do you think it would be hard or easy to change you diet and increase exercise..?
• Do you think that changing your diet or exercise would be helpful? Why?
• Is there anything else that you think might help?
Attitudes towards health service intervention to help improve health behaviours and views
about delivery (20 mins)
• Views on services available to help people give up smoking
– PATIENTS WITH SMOKING HISTORY ONLY - When do you think is the best
time to give up smoking, before or after treatment? (We need to probe a bit here
because suppose they say after, we could and should perhaps bring up the idea that
it would help their recovery from surgery, reduce the chance of them getting wound
infections or chest infections and does that change their mind? Why do they suggest
that.)
– Do you think it would be good to cut out cigarettes all at once or gradually?
– Would you like to take medications that we know help people to give up? Do you
think that taking nicotine replacement for a long time would help you?
386
APPENDIX A. SUPPLEMENTARY MATERIAL FOR THE QUALITATIVE INTERVIEW
STUDY (CHAPTERS 2–4)
– ALL PATIENTS - Would you be interested in enrolling in a programme that not only
helps you with your smoking but also gives you an exercise programme tailored to
your needs and encouragement to do more exercise and improve your diet?
– When do you think is the best time to address these things?
– How would other types of rehabilitation discussed in this interview best be deliv-
ered?
– Would you like help in the form of a group or individually?
– Would you prefer to go to the normal services i.e. NHS stop smoking services, for
treatment or to see someone who knows about your cancer and the treatment that
you have received for that?
– How long do you think it would be helpful to have support?
– How often would you like to attend such a programme, once a week/month..?
• Any other interesting topics raised during the interview (10 mins)
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Figure A.17: Nvivo queries
The following queries were used to identify interview text that was potentially relevant to
the themes in bold:
Breathlessness
breath*
Pain
pain* OR sore* OR heal* OR wound* OR numb*
Appetite or weight loss
diet OR appetite OR weigh* OR eat* OR food
Fatigue and sleep
tired* OR sleep* OR exhaust* OR fatigue OR
energy OR weak* OR weary OR effort
Smoking
smok* OR quit*
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Table B.1: Medline search strategy
Table B.2: Embase search strategy
Table B.3: Web of science search strategy
Table B.4: CINAHL search strategy
Table B.5: COCHRANE search strategy (CENTRAL)
Table B.6: Study characteristics of included studies
Table B.7: Participant characteristics of included studies: stage 1 surgical patients
Table B.8: Participant characteristics of included studies: mixed stage surgical patients
Table B.9: Participant characteristics of included studies: non-surgical patients
Table B.10: Quality scores for included studies
Table B.11: Patient characteristics for studies included in current v never and former v never comparison
Table B.12: Patient characteristics for studies included in current v former and current v former never
comparison
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Table B.1: Medline search strategy
1 lung neoplasms/
2 carcinoma, non-small-cell lung/
3 adenocarcinoma/
4 carcinoma, squamous cell/
5 lung.mp.
6 3 and 5
7 4 and 5
8 (lung adj2 (cancer or carcinoma$ or neoplasm$)).mp.
9 1 or 2 or 6 or 7 or 8
10 smoking/
11 smoking cessation/
12 tobacco/
13 (smoking or smoke or smoker$ or tobacco or cigarette).mp.
14 10 or 11 or 12 or 13
15 9 and 14
16 limit 15 to “prognosis (specificity)”
17 limit 15 to “etiology (specificity)”
18 16 or 17
19 Clinical Trials/
20 15 and 20
21 18 or 20
Table B.2: Embase search strategy
1 exp lung tumor/
2 (lung adj2 (cancer or carcinoma$ or neoplasm$)).mp.
3 1 or 2
4 smoking/
5 smoking cessation/
6 tobacco/
7 Tobacco Smoke/
8 TOBACCO DEPENDENCE/
9 (smoking or smoke or smoker$ or tobacco or cigarette).mp.
10 4 or 5 or 6 or 7 or 8 or 9
11 3 and 10
12 limit 11 to “prognosis (specificity)”
13 limit 11 to “causation-etiology (specificity)”
14 12 or 13
15 Clinical Trials/
16 11 and 15
17 14 or 16
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Table B.3: Web of science search strategy
#1 TS=(lung SAME neoplasm*)
#2 TS=(lung SAME cancer)
#3 TS=(non SAME small SAME cell SAME lung SAME cancer)
#4 TS=(adenocarcinoma AND lung)
#5 TS=(squamous cell AND lung)
#6 TS=((small SAME cell) AND lung)
#7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
#8 TS=(smoking)
#9 TS=(smoking cessation)
#10 TS=(tobacco)
#11 TS=(cigarette*)
#12 #11 OR #10 OR #9 OR #8
#13 #12 AND #7
#14 TS=((cohort OR prognos* OR (relative SAME risk) OR surviv*))
#15 #13 AND #14
#16 TS=(control* SAME trial)
#17 #13 AND #16
#18 #15 or #17
Table B.4: CINAHL search strategy
1 lung neoplasms/
2 carcinoma, non-small-cell lung/
3 adenocarcinoma/
4 carcinoma, squamous cell/
5 lung.mp.
6 3 and 5
7 4 and 5
8 (lung adj2 (cancer or carcinoma$ or neoplasm$)).mp.
9 1 or 2 or 6 or 7 or 8
10 exp smoking/
11 tobacco/
12 (smoking or smoke or smoker$ or tobacco or cigarette).mp.
13 10 or 11 or 12
14 9 and 13
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Table B.5: COCHRANE search strategy (CENTRAL)
#1 lung neoplasms
#2 non small cell lung cancer
#3 adenocarcinoma
#4 squamous cell carcinoma
#5 lung
#6 #3 AND #5
#7 #4 AND #5
#8 #1 OR #2 OR #6 OR #7
#9 smoking
#10 smoking cessation
#11 tobacco
#12 #9 OR #10 OR #11
#13 #8 AND #12
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Table B.7: Participant characteristics of included studies: stage 1 surgical patients (** = 100% NSCLC).
Author Male
(%)
Average age
mean
(SD or range)
Squamous
(%)
SCLC
(%)
Stage Co-morbidity
Chatkin, 2004 70 62.9 (9.3) 46 0 1 N/R
Gail, 1984 73 62 48 0 1 N/R
Haga, 2003 64 62 65 0 1 N/R
Hung, 2007 76.2 65.5 (9.4) 32.6 0 1 N/R
Isobue, 1994 43 62 (45-73) 0 0 1 N/R
Iyoda, 2006 55.5 63 (36-83) 19.4 3.3 1a N/R
Kobayashi, 2007 55 64 (30-84) 16 0 1a N/R
Matsugama, 2008 61.3 65 (35- 85) 25 0 1 N/R
Rice, 2003 57 63.4 N/R 0 1 N/R
Sawabata, 2006 89 65.5 (10) 100** 0 1 N/R
Tsai, 2006 69.1 65.13 (24-86) 20.8 0 1a N/R
Wu, 2003 85.7 63 (8) 49.2 0 1 N/R
Table B.8: Participant characteristics of included studies: mixed stage surgical patients. (* = stage 1–3.
** = 100% NSCLC. *** = 100% adenocarinoma)
Author Male
(%)
Average age
mean
(SD or range)
Squamous
(%)
SCLC
(%)
Stage 1-3a
Limited
(%)
Co-morbidity
Battifora, 1992 74 62 56 4 N/R N/R
Birim, 2003 81 70+ 47 0 95 80
Bryant, 2007 69 59.9 (21-85 ) 40 0 93* N/R
Fujisawa, 1999 66 62.2 (34-87) 38 0 100 N/R
Furak, 2003 55 60.5 (41-79) 0 0 88 N/R
Hanagiri, 2008 86.5 N/R 28 0 85 N/R
Harpole, 1995 63 63 (8) 34 0 100 N/R
Hendricks, 1996 86 62.5 (8) 52 0 95 N/R
Jiang, 2005 52.3 N/R 45.4 0 100 N/R
Kawaguchi 81 61 (34-80) 48 0 100 N/R
Kawai, 2005 61 63 (10.2) 27 0 100 N/R
Kikuchi, 2006 [504] 68 N/R 42 0 n/r N/R
Kosaka, 2009 51 64 (29-89) 0 0 97 N/R
Lee, 1995 72 N/R 36 4 79 N/R
Maeda, 2006 70.7 64.0 +- 9.7 39 0 95 N/R
Maeshima, 2008 61 60 (26-84) 100*** 0 89* N/R
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Table B.8: cont
Author Male
(%)
Average age
mean
(SD or range)
Squamous
(%)
SCLC
(%)
Stage 1-3a
Limited
(%)
Co-morbidity
Marsit, 2005 60 64-70 44 0 78 N/R
Mitsudomi, 1989 73 61-62 35 0 85.4 N/R
Moro-Sibilot, 2005 89 62.7 (33-86) 62 0 100 53
Myrdal, 2002 65 60-69 46 0 100 N/R
Nakamura, 2008 64 64.8 (35-81) 29 0 100 N/R
Nia, 2005 86 65 47 0 92.1 N/R
Okada, 2004 64 64.6 +/- 9.9 27 0 89 N/R
Ramnath, 2007 64.5 57.1( 11.2) 54 0 85 N/R
Rui, 2006 67 63 (52- 84) 36.7 20 100* N/R
Saito-Nakaya, 2006 60.9 62.4 (10.4) 21 0 81 40
Sakao, 2008 49 64 (35-82 ) 100** 0 n/r N/R
Sekine, 1997 68 60-69 64 0 86 N/R
Shiba, 2000 72 62.4 (8.8) 59 0 100 N/R
Sioris, 2000 83 median 65 58 0 91 N/R
Sobue, 1991 66 60-69 0 0 90 N/R
Sun, 2006 58 66 28 0 64 N/R
Suzuki 63 64 (23-85) 26 0 90 N/R
Takeshita, 2008 64 67 ( 41-84) 26 0 99 N/R
Tammemagi, 2000 44 68 (9.5) 39 0 100 N/R
Tang, 2006 72 59 (30-78) 50 0 87 N/R
Tsurutani, 2007 37 65 (38-84) 100*** 0 76* N/R
Yoshino, 2006 N/R N/R 40 0 N/R N/R
Zhou, 2006 51 67 (31-89 ) 29 0 100 N/R
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Table B.9: Participant characteristics of included studies: non-surgical patients (* = stage 1–3. ** =
100% NSCLC. *** = 100% adenocarinoma)
Author Male
(%)
Average age
mean
(SD or range)
Squamous
(%)
SCLC
(%)
Stage 1-3a
Limited
(%)
Co-morbidity
Ademuyiua, 2007 66 median 60-70 100** 0 39.4 N/R
Blanchon, 2006 84 64.1 (11.5) 47 0 54 N/R
Buccheri, 1993 93 64 (38-88) 100 0 50 N/R
Demeter, 2003 55 66.5 (11) 23 17 28 N/R
Fox, 2004 56 70 37 0 54 N/R
Goodman, 1990 69 64 28 14 64 N/R
Hinds, 1982 0 50-64 17 16 55 N/R
Holli,1999 88 65 (9) 59 21 n/r N/R
Hotta, 2009 60 63 (29-85) 0 0 40 N/R
Kato, 1990 74 60-69 24 9 N/R N/R
Kawahara N/R N/R 0 100 N/R N/R
Kim, 2005 58.5 59.8 100*** 0 61.3 N/R
Liang, 2003 78.2 60 (33-77) 32.7 0 47.3 N/R
Martins, 1999 76 60-70 51 0 33 N/R
Mulligan, 2006 62 median 66 31 0 50 N/R
Nordquist, 2004 41 56-65 0 0 44 N/R
Rades, 2008 78 median 65 55 0 100* N/R
Song, 2004 71.7 58 (22-76) 0 100 45 N/R
Subramanian, 2007 28 median 70 8.8 0 60.9 N/R
Tammemagi, 2004 59 67 (10.6) 26 12 63 61
Tan, 2003 0 65 (23-93) 16.6 7.7 45.7 N/R
Toh, 2004 66 62.4 (11.8) 22 0 19 52
Tucker, 1997 55 61 0 100 79 N/R
Usuda, 1994 70.7 67 (33-86) 38.5 4 90.8 N/R
Wolf, 1991 85 50-60 0 100 38 N/R
Yoshida, 1996 80.3 61 (37-79) 0 100 85 N/R
Zhang, 2008 81.1 77 (70-94) 38.5 0 49 N/R
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APPENDIX
C
SUPPLEMENTARY FIGURES FOR THE SMOKING
HISTORY SYSTEMATIC REVIEW (CHAPTER 5)
Figure C.1: Risk of all cause mortality in ever compared to never smokers treated with surgery:
sensitivity analysis by HR estimation (presented v calculated from other data)
Figure C.2: Risk of all cause mortality in ever compared to never smokers treated with surgery:
sensitivity analysis by study quality (high v low)
Figure C.3: Risk of all cause mortality in ever compared to never smokers treated with surgery: sub
group analysis by histology (NSCLC v NSCLC and SCLC)
Figure C.4: Risk of all cause mortality in ever compared to never smokers who have received surgical
treatment for NSCLC only: sub group analysis by histology (Mixed NSCLC histology v
adenocarcinoma only)
Figure C.5: Risk of all cause mortality between current or former smokers and never smokers treated
with surgery: Sensitivity analysis, presented v calculated
Figure C.6: Risk of all cause mortality in current or former smokers compared to never smokers treated
with surgery: sensitivity analysis by study quality (high v low)
Figure C.7: Risk of all cause mortality in current compared with former smokers and current with
former/never smokers treated with surgery: sensitivity analysis by study quality (high v low)
Figure C.8: Risk of all cause mortality and recency of smoking in surgical patients only: sub group
analysis by stage (stage 1 v mixed stage)
Figure C.9: Risk of all cause mortality in patients with heavier compared to lighter pack year history
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Figure C.1: Risk of all cause mortality in ever compared to never smokers treated with surgery:
sensitivity analysis by HR estimation (presented v calculated from other data)
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Figure C.2: Risk of all cause mortality in ever compared to never smokers treated with surgery:
sensitivity analysis by study quality (high v low)
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Figure C.3: Risk of all cause mortality in ever compared to never smokers treated with surgery: sub
group analysis by histology (NSCLC v NSCLC and SCLC)
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Figure C.4: Risk of all cause mortality in ever compared to never smokers who have received surgical
treatment for NSCLC only: sub group analysis by histology (Mixed NSCLC histology v
adenocarcinoma only)
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Figure C.5: Risk of all cause mortality between current or former smokers and never smokers treated
with surgery: Sensitivity analysis, presented v calculated
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Figure C.6: Risk of all cause mortality in current or former smokers compared to never smokers treated
with surgery: sensitivity analysis by study quality (high v low)
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Figure C.7: Risk of all cause mortality in current compared with former smokers and current with
former/never smokers treated with surgery: sensitivity analysis by study quality (high v low)
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Figure C.8: Risk of all cause mortality and recency of smoking in surgical patients only: sub group
analysis by stage (stage 1 v mixed stage)
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Figure C.9: Risk of all cause mortality in patients with heavier compared to lighter pack year history
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PUBLICATION OF THE POST DIAGNOSIS
SYSTEMATIC REVIEW (CHAPTER 6)
Figure D.1: BMJ Publication
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